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Abstract 
 
My thesis is focussed on using new and existing molecular technologies to survey immune 
system (i.e. HLA, KIR and MICA), blood group and HPA genes in Polynesian and Maori 
subjects.  I have compiled large datasets for these individuals including first ever molecular 
typing blood group, HPA and MICA.  I have also compared my data with those from 
previous genetic studies of KIR and HLA for the four Polynesian sub-populations and HLA 
for Maori.  Combined with previous information in a small scale meta-analysis, the results 
presented here were interpreted for the first time in the light of new theories about the hybrid 
origin of Proto-Polynesians via gender-biased gene flow between Austronesian-speaking 
Mongoloids and Papuan-speaking Australoids. Phylogenetic and principal 
component/coordinate analyses show that Polynesian sub-populations are closer to each other 
and are end populations of the great Austronesian Diaspora.  Estimation based on HLA class 
I and II allele frequencies show a wide range (55:45 to 90:10) of ASM:P-SA ancestral 
fractions in Maori and other Polynesians.  The same phenomenon was observed for blood 
group, HPA and KIR data.  Thus, findings from the present study generally support the 
account deduced from Y-chromosome, mtDNA and genome wide SNP data, and are in 
accord with the emergent picture from linguistics and archaeology studies.   
 
The data collected bear more or less directly on questions of health including tissue matching 
for transfusion and transplant surgery, disease resistance and the relative incidence of 
autoimmune disease in these ethnic groups.  Tissue matching of HLA, MICA, KIR, blood 
group and HPA is a fundamental element in transfusion and transplant surgery and it is vital 
that these technologies take accurate account of the ethnic origins of both donors and 
recipients.  This is important due to significant differences between Polynesians and people 
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of European origin, who form the majority segment of the modern day multi-ethnic country 
of New Zealand.  The prevalence of HLA, MICA, KIR, blood group and HPA and their 
potential influence on the health of modern day Maori and Polynesians were also discussed.   
 
This study was intentionally designed to validate new molecular blood group and HPA typing 
methods in Polynesian and Maori populations.  Scores for the other loci are based on the 
application of pre-existing technologies.  Validation using three different blood group and 
HPA genotyping methods (i.e. PCR-SSP, SBT and SNP assay) gave 100% concordance and 
thus reflects the accuracy of the new DNA-based methods.  Overall, molecular genotyping 
does seem to offer the opportunity to improve the efficiency of high quality transfusion 
services, but should include all known variants that are associated with serological 
expression.   
 
In conclusion, the present molecular genetics study has successfully compiled new HLA, 
MICA, blood groups, HPA and KIR datasets for Polynesians and Maori, used the datasets for 
dual analyses of ancestry and health, and demonstrated the reliability of current genotyping 
platforms that would suit well the needs of transfusion and transplantation centres.  In 
general, this thesis has strongly endorsed the indigenous biomedicine approach, and 
particularly will be valuable to Asia-Pacific populations of Austronesian peoples.   
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General Introduction 
 
Genetics has always been an implicit part of medicine and has now become explicit.  Taking 
family histories guided practitioners for centuries, but genetic factors have only become main 
stream in the last 100 years basis for inheritance has become better understood.  This era start 
with Archibald Garrod and inborn errors of metabolism and developed through case studies 
such as the role variants in beta-globin gene variants of sickle cell anaemia.  The DNA era 
began using terminal restriction fragment length polymorphism (T-RFLP) to track markers 
that are associated with conditions such as Huntington‟s disease and cystic fibrosis.  In more 
recent times, genome wide association studies (GWAS) are able to map out complex 
multifactorial diseases and there is now the possibility of universal genome scans for 
individuals.  This thesis devoted to use new DNA-based technology in two areas which have 
seen particularly significant advances in 20
th
 century; transplantation and transfusion 
medicine. 
 
 
1.1 Transplantation medicine 
 
Transplantation is the transfer of a graft (cell, tissue or organ) either from one part of the 
body to another (autograft) or between a donor and recipient pair of same species (allograft).  
Successful allograft transplantation depends on having the requisite level of genetic 
compatibility between donor and recipient, particularly for ABO blood groups and human 
leukocyte antigens (HLA).  For HLA, rejection episodes are significantly reduced with 
decreasing numbers of allelic mismatched loci particularly for HLA-A, -B and -DRB1, and 
this requirement is extended to HLA-C and HLA-DQB1 in unrelated bone marrow 
transplants (Kalwak et al., 2006, Sheldon and Poulton, 2006 and Doxiadis et al., 2006).   
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Typically, there are three different phases of rejection; hyperacute, acute and chronic.  
Hyperacute rejection usually occurs within minutes to hours immediately following 
transplantation and is due to circulating preformed antibodies (i.e. humoral immunity) against 
donor ABO and/or HLA.  The pre-existing antibodies in the recipient can be produced by a 
previous transplantation, blood transfusion and pregnancy (Hopkins, 2006).  Therefore, 
serological cross-matching between donor and recipient using panels of reactive antibodies 
prior to transplatation is of particular importance to avoid hyperacute rejection of the graft 
(Lydyard et al., 2004).   
 
Acute and chronic rejections may occur later due to HLA incompatibily between donor and 
recipient. Acute rejection is a form of cell-mediated immunity which takes place within 
weeks of engraftment (Wise and Carter, 2002 and Lydyard et al., 2004).  Two main 
mechanisms are involved during acute rejection; direct and indirect allorecognition by 
circulating T cells, respectively.  Direct allorecognition involves T cell recognition of HLA 
molecules on donor antigen processing cells (APC), while indirect allorecognition involves 
antigenic presentation by HLA class I and II to CD4
+
 and CD8
+
 T cells, respectively (see 
Elgert, 2009, Pathak and Palan, 2005 and  sub-section 1.6.1 of this chapter for more details). 
The allorereactivity remains in chronic rejection and is further impaired by the development 
of alloantibodies against the graft.  This will be followed by graft loss over months to years 
after transplantation (Wise and Carter, 2002, Plant and Wood, 2009 and Hopkins, 2006).  
 
The reverse situation occurs in allogenic bone marrow transplantation where the incompatible 
recipient tissue is attacked by donor immunocompetent T cells (aka graft versus host disease; 
GVHD).  In bone marrow transplantation, patients usually undergo preparative treatments 
which include chemotheraphy and irradiation.  These treatments not only eradicate residual 
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cancer/diseased cells, but also paralyse patient cell-mediated responses (Elgert, 2009).  This 
condition will lead to direct allorecognition of grafted immunocompetent lymphocytes 
againts the genetically incompatible host.  
 
In addition to HLA, the polymorphic major histocompatibility complex class I chain-related 
gene A (MICA) and killer cell immunoglobulin-like receptor (KIR) genes have also been 
shown to be clinically and practically important in transplantation.  The MICA system 
produces stress-induced antigens expressed on the surface of keratinocytes, endothelial cells 
and monocytes.  These antigens are recognized by NKG2D, an activating receptor for 
cytotoxic natural killer (NK) and CD8
+
 T cells (see Bauer et al., 1999 and Zwirner et al., 
1999 and sub-section 1.6.2).  Therefore, MICA is capable of stimulating cellular immunity 
againts transplanted grafts and/or able to trigger graft versus host reaction against 
mismatched MICA antigens possessed by donors and recipients (Zou and Stastny, 2010).  In 
contrast, KIRs are not markers of tissue identity, but they do mediate self-recognition by NK 
cells through their interaction with HLA class I ligands (see sub-section 1.6.5 for details).  
For example, interaction of inhibitory KIR2DL1 and HLA-C group 1 allotypes provide 
tolerance to NK cells, while interaction between stimulatory KIR2DS1 and HLA-C group 1 
ligands induce NK alloreactivity.  The same mechanism occurs in allogenic transplantation, 
where allografts lacking compatible HLA ligands for inhibitory KIRs are attacked by the 
recipient‟s NK cells (Ludajic et al., 2009 and Rajalingam and Gebel, 2011).  Nonetheless, 
missing ligands for KIR were shown to have beneficial in hematopoietic stem cell 
transplantation, including significantly reduced leukemia relapse and graft rejection (aka anti-
leukemia effect).  This was observed in HLA haplotype-mismatched (haplo-identical) 
transplants where recipient‟s leukemia cells are recognized (i.e. receptor-ligand mismatched) 
as foreign by the alloreactive donor‟s NK cells (Ruggeri et al., 2002).    
Chapter 1 
 
4 
 
Overall, correct matching for blood group and HLA markers and more recently, for MICA 
and KIR variants will determine success rates in allogenic transplantation.  Compared with 
blood group and HLA, the role of MICA and KIR is considered as a new development in the 
field of immunogenetics, as well as in transplantation (Bach and Amos, 1967, Moretta et al., 
1993, Bahram et al., 1994). Future studies will fill some of the remaining gaps in our present 
understanding of the biological function of these markers and their synergy in transplantation 
medicine.   
 
1.2 Transfusion medicine 
 
Transfusion medicine is an area of multidisciplinary expertise; management of blood 
donation, blood component preparation, blood cell serology and blood transfusion therapy. It 
is the most common and successful form of tissue transplantation (Davenport and Mintz, 
2007 and Elgert, 2009).  Unlike other types of transplantation, blood contains little or no 
HLA class I (Elgert, 2009).  However, blood does contain various types of other significant 
polymorphic antigens.  These include the highly immunogenic ABO antigens, which cause 
hyperacute rejection of vascularised grafts such kidney and heart.  Others including Rhesus, 
Kell, Dombrock, Kidd, MNS and platelet antigens can also be important (Anstee, 2009, 
Chinen and Bukley, 2011 and Brown and Navarrete, 2011).  Routine serological matching is 
only required for ABO and RhD antigens (Blann, 2006 and Brown and Navarrete, 2011).  
But, in certain cases (e.g. refractoriness to platelet transfusion and transfused related acute 
lung injury), patients may require compatibility testing for these other blood group antigens 
(particularly Kell and Duffy) and may even extend to HLA and HPA matching for 
transfusion of blood component products (see Brown and Navarrete, 2011 and Chapter 3.4 
for further details). 
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1.3 Genetic testing in transplantation and transfusion medicine 
 
The major barriers to transplantation and transfusion are HLA and blood group antigens, 
although others, e.g. MICA, HPA and KIR can also contribute towards immunological 
reaction following transfusion and transplantation (see Chapters 3.2 to 3.5 for further details).   
The HLA and blood group antigens are targets of the immune system.  Transplantation and 
transfusion success both rely on the level of compatibility between donor and recipient for 
these markers.  Therefore, prior genetic testing plays a critical role for the matching process 
and this can be done using serological or molecular techniques.   
 
Serological procedures (i.e. combination of HLA/blood phenotyping, antibody screening and 
crossmatching) still remain as fundamental elements in transplantation and transfusion 
medicine (see Doxiadis et al., 2006 and Higgins, 2007).  Nonetheless, molecular approaches 
are now being widely used for HLA and blood group genotyping and are already considered 
superior to serology-based techniques in several circumstances; e.g. genotyping of weakly 
expressed antigens and determination of blood groups and HLA types in multi-transfused and 
multi-transplanted patients (see Middleton, 2005, Sheldon and Poulton, 2006, Avent et al., 
2009 and Hustinx et al., 2009).  In addition, the advent of molecular methods has improved 
resolution of HLA and blood group polymorphisms to a precision that could not be achieved 
using serology alone (see Patnaik et al., 2012 and Robinson et al., 2013).  Most of the HLA 
and blood group antigens are now defined at allelic levels, which are difficult to detect 
serologically.  Often there are limited supplies of monoclonal antibody or perhaps none at all 
(Middleton et al., 1988 and Schonitzer, 2009).  The efficiency and accuracy of molecular 
genotyping is supported by the higher survival rates for unrelated transplantation with 
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matching at the allelic level, compared with serologically matched pairs (Sheldon and 
Poulton, 2006).  
 
Overall, there is compelling evidence for the wider application of molecular approaches in 
transplantation and transfusion. The most accurate and reliable molecular technique is 
sequence based typing (SBT) as it shows exact variations in particular genes.  In fact, SBT is 
now a „gold standard‟ in several transplantation centres (Oliviera et al., 2012).  However, 
certain clinical circumstances require rapid and high throughput genotyping platforms; e.g. 
for heart and lung transplantation.  Currently, hybridization SNP assays (e.g. Luminex and 
BLOODchip) seem set to become the accepted platforms for transfusion and transplantation 
services (reviewed by Veldhuisen et al., 2009 and Wu and Csako, 2006).  
 
1.4 Donor recruitment and applications of population data 
 
Successful transplantations and transfusions also rely on the efficiency of pre-operative 
treatment and donor recruitment, plus post-operative care. Although post-
transplantation/transfusion complications can be managed by immunosuppressive therapy 
(e.g. corticosteroids and cyclosporin), this strategy is usually associated with long term 
adverse effects, such as infection and drug-specific toxicity (Lawson, 2006 and Higgins, 
2007).   Therefore, careful donor recruitment seems to be the best way to avoid such 
complications.    
 
Bone Marrow Donors Worldwide (BMDW) is a good example of an international 
collaboration that organizes recruitement of HLA-typed donors for unrelated hematopoietic 
stem cell transplantation.  The BMDW database consists of 20,966,656 volunteer stem cell 
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donors and 569,598 units of cord blood are available for transplantation (www.BMDW.org, 
accessed 14 April 2013).  However, majority of the donors recruited are of European origin.  
This was demonstrated by finding lower hit rate for New Zealand (NZ) Maori and 
Polynesians than for European patients when the database was searched for HLA-A, -B and -
DRB1 matches (Zlatibor and Carter, 1999).  Therefore, it has become a policy of the NZ 
Bone Marrow Registry (NZBMDR) to recruit increased numbers of of Maori and Polynesian 
donors as they are presently under-represented in BMDW (Dunn et al., 2012).  In addition, 
the feasibility of finding suitable donors for particular patients is enhanced by identification, 
characterization and compilation of population data for medically important and highly 
polymorphic genes such as HLA, MICA, blood groups, HPA and KIR.  This is because 
geographically or historically related populations tend to share common and unique 
alleles/haplotypes.  For example, it is difficult to find a donor for a patient with a HLA-
A*02:12-C*07:02-B*39:05-DRB1*08:02-DQA1*04:01-DQB1*04:02 haplotype in New 
Zealand, but it is quite widely distributed among Indigenous Americans.  The presence of this 
haplotype in Polynesian patients is associated with the South American slave trade which 
operated across the Pacific during the 1800s (see Thorsby, 2012 and Chapter 3.2 for further 
details).   This shows how population survey data can be used to narrow down the scope of 
searches for alleles/haplotypes that are not common in particular populations, but may be so 
in others. 
 
Donor and recipient matching will remain as a fundamental element in transplantation and 
transfusion.  Nonetheless, recent advances in molecular biology, immune therapy (e.g. gene 
transfer and immune suppressive drugs) and bio-engineering may one day provide better 
solutions (see Lawson, 2006 and Song et al., 2013). 
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1.5 Overview of the thesis layout  
 
Many infectious and autoimmune diseases have now been directly linked to human genes 
(e.g. see Pleasance et al., 2010).  Molecular approaches point to genetic alterations due to 
mutation, failure of recombination processes or cellular repair mechanisms. These changes 
may influence individual susceptibility or resistance towards particular diseases.  In 
particular, modern molecular methods offer unprecedented insights into human genomic 
regions.  Hence, such investigation should become a priority area for biomedical research.  
 
My PhD study involves molecular screening of HLA, MICA, blood groups, HPA and KIR 
loci using Victoria University of Wellington (VUW) DNA Bank samples (see Fig. 1 for the 
chromosal locations of these markers).  The study has two major components; a bioinformatic 
study of HLA and MICA data and laboratory based analyses of blood groups, HPA and KIR 
(see Chapter 2 for further details).  Only one molecular genetic study  of HLA variation in 
New Zealand Maori has previously been carried out by Tracey (2007).  Molecular scoring of 
HLA and KIR for the four Pacific Island sub-populations has been reported by Velickovic 
(2001) and Velickovic et al. (2006), respectively.  The data provided from these three studies 
are informative but only in a preliminary sense. Further work still needs to be done in order to 
provide more extensive and reliable data for the Polynesians and Maori (e.g. regarding the 
effects of European admixture).  Nonetheless, earlier data on the Polynesian and Maori sub-
populations can be re-interpreted and combined with those from the present study, making 
larger databases (see Chapter 3.1 and 3.2 for further details).  All prior studies on blood 
groups on Maori and Polynesians have been done via serological typing alone and thus 
provide an interesting basis for comparisons.  This study will also validate and establish the 
application of high-throughput blood group and HPA typing (i.e. BLOODChip) in NZ 
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subjects by comparing those results with similar ones obtained using a polymerase chain 
reaction-sequence specific primer (PCR-SSP) assay and SBT.  Thus, the present study will be 
a stepping stone for the introduction of molecular approaches for HLA, MICA, blood group, 
HPA and KIR typing in New Zealand.  Several other features also distinguish the present 
work.  My survey uses DNA samples that have been classified according to admixture based 
on self-declared ancestry and interview.  Hence, this new work allows one to examine 
participants that can be clearly identified as lacking genetic input from European ancestors.  
Therefore, population data provided by the present survey can not only be used as a base line 
medical reference standard but also for other advantages (see below).  Overall, it is expected 
to give a better perspective regarding the distribution of HLA, MICA, blood group, HPA and 
KIR in Maori and Polynesians; e.g. as a guide when searching for donor and health 
assessments based on diseases known to be associated with specific HLA, MICA, blood 
group, HPA and KIR. 
 
Population data for highly polymorphic genes such as HLA, MICA, blood groups, HPA and 
KIR also have significant values for ancestry studies.  This complements previous mtDNA, 
Y-chromosome haplotype scoring and microsatellite DNA analysis of VUW DNA Bank 
samples.  Our presently emergent picture of Polynesian origins is captured by the extended 
version (Chambers and Edinur, 2013) of the „Synthetic Total Evidence Model (STEM)‟ see 
Box 1 for other competing models.  According to STEM, the distal sources of populations 
that contribute to the settlement of Remote Oceania can be divided into at least 2 groups; first 
an ancient Papuan-speaking Australoid lineage (P-SA; ancestors of Australian Aborigines, 
ex-coastal Melanesia, hill tribes of Papua New Guinea, Andaman Islanders and Negritos) 
moved South from Asia 40,000-70,000 yrs ago and the second group of  Austronesian-
speaking Mongoloids (A-SM) who first occupied Taiwan around 4-6,000 years ago (see Fig. 
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2). The A-SM people migrated to Island South East Asia (ISEA), coastal Papua New Guinea 
and Island Melanesia between 5000 to 3,500 years ago (Bellwood et al., 2011 and Chambers 
and Edinur, 2013).  In coastal settlements around northern mainland Papua New Guinea and 
the neighbouring islands, matrilineal marriage meant that numerous P-SA men were recruited 
by the A-SM voyagers and contributed towards a gender-biased genetic admixture process; 
see Chambers and Edinur (2013) for further details. The newly formed hybrid population 
(Proto Polynesians) was then moved outwards to Remote Oceania (Polynesia) and eventually 
occupied New Zealand from 650 ybp.  Genetic admixture continues today as Maori and 
Polynesian people intermarry with the descendant of Europeans who arrived in New Zealand 
over the last 150 years.  These historical events have left a „genetic trail‟ that stretches from 
Taiwan to New Zealand, Hawaii and Easter Islands.  Many studies have contributed to this 
account including mitochondrial DNA, Y-STR and other autosomal loci (see Chambers, 2008, 
Kayser et al, 2008 and Belwood et al., 2011).  The present study on HLA, MICA, blood 
group, HPA and KIR loci adds to this story and also informs their medical significance (see 
the following Chapters). 
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Fig. 1: Chromosomal locations of genetic markers used in the present study.  Figure is modified from 
Logdberg et al. (2005) and Oberti et al. (2004). 
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Box 1: Models of population expansion to Oceania 
 
 
 
Model  Descriptions 
   
The Express Train to 
Polynesia model by 
Diamond (1988) 
 
Based on the „Out of Taiwan‟ archaeological hypothesis proposed 
by Bellwood (1985).  According to this hypothesis, common 
Austronesian ancestors are hill tribe aboriginal people of Taiwan 
who migrated southwards via the Batanes Islands, Philippines to 
Remote Oceania without measurable pause in Near Oceania. 
   
The Slow Boat Model 
by Oppenheimer and 
Richards (2001) 
 
This model suggested Island of Southeast Asia as the origin of 
Polynesians, which is in marked conflict with archaeological 
chronology. 
   
The Synthetic Total 
Evidence Model 
(STEM) by  Chambers 
(2006) 
 
This model embraces all pattern and process elements including 
Out of Taiwan, gender-biased reticulated admixture process in 
Near Oceania and genepool refinement via bottlenecks and founder 
effects. 
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Fig. 2: Migration patterns of A-SM in Island South East Asia, Near and Remote Oceania based on archaeological dating.  The directions of movements are inferred from 
sequential chronology and lingusitic evidence. Abbreviations: A-SM (Austronesian-speaking Mongoloid), P-SA (Papuan-speaking Australoid) and E (Europeans).  This 
figure is reproduced after Chambers (2008).  
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1.6 Genetic markers   
 
1.6.1 Human leukocyte antigen (HLA) 
 
The major histocompatibility complex (MHC) lies on the short arm of human chromosome 6 
and encodes a number of immune genes, including human leukocyte antigen (HLA) class I 
and II.  The HLA class I antigens consist of non-covalently associated of α-chain 
glycoprotein and β2-microglobulin (Eren and Travers, 2000).  The α-chain glycoprotein 
determines HLA class specificities (i.e. HLA-A, -C and -B) and is coded for by the highly 
polymorphic HLA-A, -C and -B genes, located within the classical class I sub-region of MHC 
complex (Milner et al., 2000).  In contrast, the β2-microglobulin is non-polymorphic and 
encoded by a single gene on chromosome 15 (Goodfellow et al., 1975).  The HLA class II 
antigens are heterodimers of α- and β-chain glycoproteins which are encoded by three pairs 
of genes on HLA-D region of chromosome 6 (Trowsdale, 1987).  This region codes for the 
three types of HLA class II antigens, HLA-DP, -DQ and -DR.  
 
The HLA class I antigens are present on all nucleated cells and play role in endogenous 
antigenic peptide presentation to CD8
+
 T cell (see Fig. 3).  The peptide binding clefts of 
newly synthesized HLA class I molecules bind to endogenously synthesized antigens in the 
cytosol of the cell. The antigenic peptides associated with HLA class I molecules are then 
moved out to the cell surface and form a ligand for T-cell receptors (TCRs) of CD8
+
 T 
cytotoxic cell recognition (Thorsby, 1999).  In contrast, HLA class II are usually expressed 
on the surface of antigen presenting cells and are involved in presentation of exogenous 
peptides to CD4
+
 T cells (see Fig. 3).  The class II ligands are mainly derived from 
endocytosed plasma membrane proteins and extracellular fluid proteins. The HLA class II-
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peptide complexes are then transported to the cell surface for CD4
+
 T helper cell recognition 
(Crumpton, 1987, Strominger, 1987 and Davies, 1997).  Generally, HLA molecules are 
involved in recognition of foreign (non-self) peptides, which is crucial for disease resistance.  
However, certain foreign materials also contain components that resemble those expressed by 
human cells and cause predisposing HLA molecules to bind and present apparent auto-
antigens to T-cells.  This process is known as molecular mimicry and may trigger 
autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, narcolepsy and 
coeliac disease (see Sinha et al., 1990 and Thorsby and Lie, 2005). 
 
Serological and molecular studies have revealed marked differences in levels of variation 
between α- and β-chains of HLA class II antigens. For example, α-chain is constant between 
individuals for HLA-DR, but are polymorphic for HLA-DQ (Trowsdale, 1987).  Mutation 
and shuffling of closely linked HLA loci by recombinantion mechanism can account for the 
extensive diversity of HLA loci (Bodmer and Thomson, 1977). There are more than 1800, 
2400, 1300, and 1000 of HLA-A, -B, -C and -DRB1 alleles (respectively) have been reported 
and compiled in public HLA database; www.allelefrequencies.net (Gonzalez-Galarza et al., 
2011).  The HLA class I and II polymorphism in Polynesian and Maori populations together 
with their applications in population genetics and modern day health are explained and 
discussed in more details in Chapters 3.1 and 3.2.  
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Fig. 3: Schematic diagram of HLA class I and II antigenic peptide presentation to CD8+ T and  
CD4+ T cells, respectively.  This figure is modified from Thorsby and Lie (2005). 
 
 
1.6.2 Major histocompatibility complex class I chain-related gene A (MICA) 
 
The major histocompatibility complex class I chain-related gene A (MICA) molecule is 
encoded by a highly polymorphic gene located within the classical class I sub-region on the 
chromosome 6 (Horton et al., 2004).   Structurally, the MICA molecule is similar to HLA 
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class I, but not associated with β2-microglobulin and is not involved in antigenic peptide 
presentation (Groh et al., 1996 and Stephens, 2001).  Instead, MICA molecules are expressed 
by keratinocytes, fibroblasts, endothelial cells, monocytes, epithelial cells in response to 
cellular stress (Bauer et al., 1999). The MICA molecules expressed by these cells stimulate 
cytotoxic activity of natural killer and CD8
+
 T (αβ and γδ) cells (Bahram et al., 1994, Bauer 
et al., 1999, Zwirner et al., 1999).  
 
Currently, there are 83 MICA SNP alleles that have been characterized that give rise to 67 
protein variants (Robinson et al., 2010).  The high diversity of the MICA gene is thus due to 
both synonymous and non-synonymous mutation in exons 2, 3 and 4, which code for the 
three (α1-3) extracellular domains (Perez-Rodriguez et al., 2002). In addition, transmembrane 
domain of MICA encoded by exon 5 also shows a unique number of repetitive polyalanine 
motif, but is shared with a number of MICA alleles (Robinson et al., 2001).  Roles and 
functions of MICA as well as their associations with HLA alleles are discussed in the 
following section (i.e. Chapter 3.2). 
 
1.6.3 Blood group 
 
The ABO system is the first blood group identified in the early 20
th
 century.  Since then, 
many more systems have been characterized. Currently, there are 30 blood group systems 
documented in public databases (Patnaik et al., 2012).  The following ones are involved in 
the present study (see Table 1). 
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Table 1: List of blood groups involved in this study and their molecular bases 
 
 
Abbreviations: TM: transmembrane proteins, GPI: proteins anchored to the membrane by an glycosylphosphatidylinositol tail. Table was adapted from Daniels (2009) and 
Veldhuisen et al. (2009).
System  Chromosome  Protein  Polymorphism  Molecular basis  Amino acid change 
 
 
 
 
 
 
 
 
 
 
 
ABO  9  Transferase   A→B  526C>G, 703G>A, 796C>A, 803G>C  R176G, G235S, L266M, G268A 
 
 
 
 -  A→O  ∆261G  Truncated glycosyltransferase 
 
 
 
 
 
 
 
   
 
MNS  4  TM   M→N  59C>T, 71G>A, 72T>G  S20L, G24E  
 
 
 
 TM   s→S  143C>T  T48M  
 
 
 
 
 
 
 
   
 
Rhesus  1  TM   D→variant D  Deletion//hybrid/SNPs  partial, weak and D-negative 
 
 
 
 TM   C→c  48C>G, 178A>C, 203G>A, 307T>C  C16W, I60L, S68N, S103P 
 
 
 
 TM  e→E  676G>C  A226P 
 
 
 
 
 
 
 
   
 
Lutheran  19  TM   Lua→Lub  230G>A  R77H 
 
 
 
 
 
 
 
   
 
Kell  7  TM   k→K  578C>T  T193M 
 
 
 
 
 
 
 
   
 
Duffy  1  TM  Fya→Fyb  125G>A  G42D 
 
 
 
 -  Fyb→Fy  _67T>C (GATA-1)  Not coding 
 
 
 
 
 
 
 
   
 
Kidd 
 
18 
 
TM  
 
Jka→Jkb 
 
838G>A 
 
D280N 
 
 
 
 
 
 
 
   
 
Diego  17  TM   Dia→Dib  2561C>T  P854L 
 
 
 
 
 
 
 
   
 
Dombrock 
 
12 
 
GPI 
 
Dob→Doa 
 
793A>G 
 
D265N 
 
 
 
 
 
 
 
   
 
Colton  7  TM  Coa→Cob  134C>T  A45V 
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1.6.3.1 ABO 
 
The precursor for ABO blood group is the H antigen, encoded by the H gene on chromosome 
19.  The H antigen is then converted to A or B antigens by α1,3-N-
acetylgalactosaminyltransferase and α1,3-D-galactosyltransferase, encoded by the ABO gene 
complex on chromosome 9, respectively (see Harmening and Firestone, 2005 and Table 1 for 
more details).  Therefore, the A and B antigens are the end products of the acting of A- and B-
glycosyltransferases on H antigen.  In contrast, the O allele contains a deletion (∆261G) in 
exon 6 of ABO gene resulting in loss of enzymatic activity and H antigen remains unchanged 
(Olsson and Chester, 2001 and Daniels, 2009).  Together, combinations of A, B and O alleles 
produce four phenotypes; A, B, AB and O.  In addition, inactivating mutations in H gene 
produce the very rare autosomal recessive phenotype (Oh or Bombay phenotype) and carriers 
develop isoantibodies toward A, B and H antigens (Cooling, 2008).   
 
1.6.3.2 Rhesus 
 
The Rh blood group is clinically important in blood transfusion and gestation (Ridgwell et al., 
1992).  The Rh blood group system consists of 5 antigens; D, C, c, E, and e.  The D antigen is 
encoded by RHD gene while the other antigens are encoded by RHCE gene (see Table 1).  
These two genes are closely linked and located on chromosome 1p34.3-p36.1 (Hemker et al., 
1999).   Individuals will either be D-positive or D-negative (aka Rhesus-positive and negative, 
respectively) no matter which RHCE antigens they carry.  The D-negative occurred due to 
mutation in RHD gene as well as genetic exchange between the highly homologous RHD and 
RHCE genes (Arce et al., 1993 and Daniels, 2005).  The same mechanism is also generated 
other variants of D antigen such as „weak D‟ and „partial D‟, which are at low incidence in 
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the world populations (Westhoff, 2008).  The most common occurring Rhesus phenotypes are 
DCcee in White, Dccee in Black and DCCee in Asians (Grunbaum et al., 1980). 
 
1.6.3.3 MNS 
 
MNS antigens are integral membrane proteins encoded by two homologous glycophorin gene 
family, GYPA and GYPB located on long arm of chromosome 4 (Huang et al., 1993 and 
Velliquette et al., 2010).  The GYPA gene codes for M and N blood group antigens while 
GYPB gene codes for the S and s blood group antigens.  These two pairs of polymorphic 
antithetical and co-dominant antigens are differ by three (59C>T, 71G>A, 72T>G) and one 
(143C>T) SNPs, respectively (see Table 1).  Nonetheless, deletions, misalignment during 
meiosis and gene conversion between the closely linked and homologous GYPA and GYPB 
genes give rise to low incidence MNS variants such as  En(a-), S-s-U-, M
k
 and Miltenberger  
(Poole et al., 1999 and Leger and Calhoun, 2005).   
 
1.6.3.4 Kell 
 
The Kell blood group antigens are 93-kDa type II glycoproteins that are linked by a single 
disulfide bond to an integral membrane protein, Kx (Lee et al., 2001).  The Kell and Kx 
antigens are encoded by separate genes, KELL and XK located on chromosome 7q33 and 
Xp21.1, respectively (Reid and Lomas-Francis, 2004).  There are epistatic interactions 
between these two gene products as the absence in the KX protein of XK blood group system 
will reduce expression of Kell antigens (in McLeod syndrome; see Daniels, 2002).  The weak 
expression of Kell antigens can also be seen in the Kmod RBC phenotype which is associated 
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with a missense mutation (1208G>A) in exon 10 of the Kell blood group gene (Lee et al., 
2003).    
 
Overall, the Kell blood group system comprises more than 34 serologically defined antigens, 
including three sets of antigens; K and k, Kp
a
, Kp
b
 and Kp
c
 and Js
a
 and Js
b 
(Patnaik et al., 
2012).  The K and its antithetical antigen, k allele only differ by 578T>C nucleotide 
substitution which led to Thr193Met amino acid exchange, respectively (Lee et al., 1995).  
The Kp
b
 allele is the most common in all populations and only differs from Kp
a
 and Kp
c
 by a 
single amino acid substitution at codon 281 of exon 8.  The Kp
a 
codon
 
codes for tryptophan 
(TGG),
 
Kp
b 
for arginine (CGG)
  
and 
 
glutamine (CAG) for Kp
c
. Equally, Pro597Leu 
substitution differentiates between the Js
a
 and Js
b 
alleles, respectively (Daniels, 2005 and Lee, 
2007).  
 
1.6.3.5 Kidd 
 
The JK or SLC14A1 (solute carrier family 14, member 1) gene located on chromosome 
18q11-q12 codes for the Kidd antigens.  Variants of this locus, the JKA and JKB
 
alleles, code 
for the two co-dominant Kidd antigens, Jka and Jkb, respectively (Daniels, 2002).  The 
JKA/JKB
 
polymorphism involves a nucleotide transition (838G>A) and define three 
phenotype: Jk(a+b-) , Jk(a-b+)  and Jk(a+b+) (Olives et al., 1997).  
 
The occurrence of Jknull phenotype or Jk(a-b-) has been observed in Polynesian and Finnish 
populations (Irshaid et al., 2000).  The Jknull phenotype occurs due to a mutation in the 3‟-
acceptor splice site of intron 5 (IVS5-1G>A) and 5‟- splice site of intron 7 of JKB alleles 
which lead to either skipping of exon 6 (Jk∆6 mutation) and exon 7 (Jk∆7 mutation), 
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respectively (Lucien et al., 1998 and Lin and Yu, 2008).  In addition, single nucleotide 
polymorphism (202C>T, 222C>A, 582C>G, 871T>C, 896G>A, 956C>T), 723delA, deletion 
of intron 3 to intron 5 also contributed towards a Jknull phenotype (Lucien et al., 1998; Irshaid 
et al., 2000; Wester et al., 2008; Liu et al., 2009).  
 
1.6.3.6 Duffy 
 
The Duffy antigen chemokine receptor (DARC) gene located on the long arm of chromosome 
1q22-q23 (Reid and Lomas-Francis, 2004).  There are two alleles; FY*A and FY*B, which 
code for Fya and Fyb antigens, respectively that are expressed on red blood cell (RBC), 
endothelium, brain, colon and kidney.  They are identified as receptors for Plasmodiium vivax 
and Plasmodium knowlesi (Tournamille et al., 1995 and Leger and Calhoun, 2005). The 
FY*A and FY*B alleles differ by a point mutation at nucleotide 125 (125G>A) that encode 
glycine and aspartic acid, respectively (Estalote et al., 2005).  These alleles determine three 
of five known phenotypes: Fy (a+b-), Fy (a-b+) and Fy (a+b+).  
 
The fourth phenotype, Fy (a-b-) or Fyb
Es
 (erythroid silent) has resulted from a 67T>C point 
mutation in the GATA-1 binding motif of the FY*B promoter (Tournamille et al., 1995 and 
Rios et al., 2000).  Despite having Fyb
Es
 phenotype, several individuals do express weak Fyb 
antigens (Fya-b
weak
) which are associated with FY*X allele.  The FY*X allele is caused by 
Arg89Cys substitution (286C>T) in the background of FY*B allele (Tournamille et al., 
1998). 
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1.6.3.7 Dombrock 
 
Dombrock antigens, Do
a 
and Do
b
 are glycoproteins encoded by the DO gene, located on 
chromosome 12p13.2-p12.1 (Reid and Lomas-Francis, 2004).  These antigens are attached to 
RBC membrane by glycosylphosphatidylinositol (GPI) and incompatibility can cause a 
transfusion reaction (Daniels, 2008 and Costa et al., 2010).  Multiple single nucleotide 
polymorphisms in exon 2 of the DO gene: 378C>T, 624T>C and 793A>G differentiate the 
Do
a 
and Do
b
 alleles (Storry et al., 2003).  While the first two SNPs are silent transitions, the 
last ones causes an amino acid change at position 265 from asparagine for Do
a  
to aspartic for 
the Do
b
 antigen (Costa et al., 2010).  
 
1.6.3.8 Colton 
 
Colton antigens (Co
a
 and Co
b
) are encoded by a gene on chromosomal 7p14 (Daniels, 2002 
and Reid and Lomas-Francis, 2004).  The Co
a
 and Co
b
 antigens are produced by single 
nucleotide polymorphism (C>T) at nucleotide position 134 resulting in an alanine to valine 
change (Arnaud et al., 2010).  Alloantibodies against Co
a
 and Co
b
 antigens can cause 
haemolytic transfusion reaction and haemolytic disease of the fetus and newborn (Daniels, 
2008). 
 
1.6.3.9 Diego 
 
Diego antigens (Di
a
 and Di
b
) are located on the anion exchanger 1 of red cell membrane 
glycoprotein, products of SLC4A1 gene (solute carrier family 4, anion exchanger, member 1) 
on chromosome 17q12-q21 (Daniels, 2002).  A single nucleotide polymorphism (2561C>T) 
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in exon 9 causes an amino acid substitution (Lys658Glu) and differentiates these two 
antigens (Reid and Lomas-Francis, 2004). The Di
a 
antigen is very rare among Africans and 
Europeans, but slightly higher among Asians and Indigenous Americans (Daniels, 2008). 
 
1.6.4 Human platelet antigens (HPA) 
 
Human platelet antigens (HPA) are glycoproteins on the surface of anucleate platelets and 
play major role in haemostasis.  Here, platelet aggregation takes place through interaction of 
HPAs with other vascular endothelium and plasma proteins (Norton et al., 2004).  The 
molecular bases of no less than 27 HPA systems have been assigned and approved according 
to guidelines set up by The Platelet Nomenclature Committee (Metcalfe et al., 2003).  
According to HPA nomenclature, each HPA system is represented by „a‟ and „b‟ alleles.  The 
taq „w‟ (workshop) is added after the antigen only if antibody against the „a‟ antigen has been 
reported.  See Table 2 for the molecular basis of HPA alleles and Chapter 3.4 for further 
details of HPA work in Polynesian and Maori populations.  
 
Table 2:  Molecular basis of HPA systems involved in this study 
Antigen  Glycoprotein  Chromosome  Nucleotide Change  Protein 
HPA-1 
HPA-2 
HPA-3 
HPA-4 
HPA-5 
HPA-6w 
HPA-7w 
HPA-8w 
HPA-9w 
HPA-10w 
HPA-11w 
HPA-15 
 
GPIIIa 
GPIba 
GPIIb 
GPIIIa 
GPIa 
GPIIIa 
GPIIIa 
GPIIIa 
GPIIb 
GPIIIa 
GPIIIa 
CD109 
 
17 
17 
17 
17 
5 
17 
17 
17 
17 
17 
17 
6 
 
176T>C 
482C>T 
2621T>G 
506G>A 
1600A>G 
1544G>A 
1297C>G 
1984C>T 
2602G>A 
263G>A 
1976G>A 
2108C>A 
 
L33P 
T145M 
I843S 
R143Q 
E505K 
R489Q 
P407A 
R636C 
V837M 
R62Q 
R633H 
S703Y 
 
Nucleotide substitutions are shown as changes from a to b alleles. Adapted from IPD database (Metcalfe et al., 
2003).   
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1.6.5 Killer cell immunoglobulin-like receptor (KIR) 
 
Natural killer (NK) cells are large granule lymphocytes involved in cytotoxicity response 
toward infected and tumour cells.  Recognition of healthy and unhealthy cells by NK cells are 
assisted by various combinations of NK receptors and their ligands (e.g. HLA and MIC).  The 
NK receptors are either immunoglobulin-like or lectin-like structure, encoded by leukocyte 
receptor complex (LRC) of chromosome 19 and natural killer complex of  chromosome 12, 
respectively (see Yokoyama and Plougastel, 2003 and Martin et al., 2002).  Killer cell 
immunoglobulin-like receptors (KIRs) are among the receptors encoded by the LRC complex.  
The KIRs are highly diverse and evolve rapidly, compared with the lectin-like receptor genes 
which are quite well conserved in humans.  For this reason, KIRs have become attractive 
markers in immunogenetic and population studies (see Robinson et al., 2010 and Gonzalez-
Galarza et al., 2011). 
 
The name given to KIR antigens are based on their extracellular immunoglobulin domains (2 
domains or 3 domains) and the length of cytoplasmic domain (Long: L or Short: S). The KIR 
proteins with long cytoplasmic domains transmit inhibitory signals via an immune receptor 
tyrosine-based inhibitory motifs (ITIMs) while the KIR proteins with short cytoplasmic 
domain lack an ITIM and are activating receptors.  The KIR2DL1, KIR2DL3, KIR3DL1, 
KIR3DL3 and KIR2DL5 genes code for inhibitory receptor whereas KIR2DS4, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1 genes code for stimulatory receptors.  The 
KIR2DL4 gene has both, stimulatory and inhibitory potential (Robinson et al., 2010).  The 
KIR genes can also be divided into two haplotype groups (see Fig. 3): 
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a. Haplotype A: KIR2DL1, KIR2DL3, KIR3DL1, KIR3DL3, KIR2DS4, KIR2DP1, KIR3DP1, 
KIR3DL2  and KIR2DL4 
b. Haplotype B: Any combination other KIR genes including those assigned for haplotype A 
 
A given KIR haplotype may have variable number of KIR genes, as there are variations in the 
presence or absent of KIR genes, except for the framework loci (KIR3DL3, 3DP1, 2DL4 and 
3DL2), which are common to all haplotypes (Middleton et al., 2002).  This form of 
polymorphism is not limited to gene content but also extends to allelic level.    
 
Currently, more than 600 alleles have been reported across all 16 of the KIR loci (see 
Robinson et al., 2010 and Gonzalez-Galarza et al., 2011).  In this respect, the complexity of 
KIR system reflects to that observed for HLA class I, which is also a ligand for KIRs (see 
Table 3).  The extreme diversity of KIR and HLA class I loci are also thought to be co-
evolutionary with distinct KIR-HLA combinations providing varying degrees of protection 
toward diseases (see Single et al., 2007 and Chapter 3.5 for further details).  Nevertheless, 
those KIRs without HLA ligands might also engage in vital part in phato-physiological 
functions with ligands other than HLA (Parham et al., 2012 and VandenBussche et al., 2009).   
 
Chapter 1 
 
27 
 
 
Fig. 4: Schematic diagram of KIR haplotype A and B. Figure is modified from Parham et al. (2012). 
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Table 3: List of KIRs and their ligands 
KIR 
 
Alleles 
 
Protein variants 
 
HLA ligands 
       
2DL1 
2DL2 
2DL3 
2DL4 
2DL5 
2DS1 
2DS2 
2DS3 
2DS4 
2DS5 
3DL1 
3DS1 
3DL2 
3DL3 
3DP1 
2DP1 
 
43 
28 
34 
46 
41 
15 
22 
14 
30 
16 
73 
16 
84 
107 
22 
23 
 
24 
11 
17 
22 
17 
7 
8 
5 
13 
11 
58 
12 
61 
55 
0 
0 
 
C2 
C1,C2 
C1,C2 
G 
unknown 
C2 
unknown 
unknown 
A*11, some C 
unknown 
Bw4 
unknown 
A*03,-11 
unknown 
0 
0 
       
 
C1 = HLA-C allotypes with serine and asparagines at position 77 and 80 of α1 domain, respectively C2 = HLA-
C allotypes with  asparagines and lysine at position 77 and 80 of α1 domain, respectively and Bw4 = HLA-B 
allotypes with isoleucine or threonine at position 80 of  α1 domain. Adapted from Robinson et al. (2010) and 
Parham et al. (2012). 
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1.7 Summary of experimental objectives  
 
Objectives of these projects are: 
A. To compile new HLA, MICA, blood group, HPA and KIR data set for Polynesian and 
Maori subjects 
B. To compare our data from all these systems with those from previous studies 
C. To use data from this study for: 
i.       Tracing Polynesian ancestry and migration pattern 
ii.       Showing old and new genetic admixture events 
iii.    Examining the potential influence of these variants on Maori and Polynesian     
health 
D. To evaluate new molecular blood group and HPA genotyping methods using: 
i. Sequence specific primer-based typing (BAGene DNA-SSP; BAG Health 
Care GmbH, Lich, Germany) 
ii. Chip hybridization SNP assay (BLOODchip® v2.0; Progenika Biopharma 
S.A., Spain) 
iii. Sequence based typing as a quality assurance check  
    
The work described here in pursuit of these objectives and allows one to test a range of 
competing ideas about the significance of HLA, MICA, KIR, blood groups and HPA 
diversities in Polynesians.  These are listed in the next section (sub-section 1.8). 
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1.8 Hypotheses 
 
In the following chapters, we tested these specific hypotheses: 
 
Chapter 3.1: that HLA data will provide a way to test the claim of the STEM model that 
Polynesians have unequal genetic contributions from A-SM and P-SA ancestors. 
 
Chapter 3.2: that high resolution HLA and MICA data will help to explain differences in the 
rates of occurrence of auto-immune diseases and infection diseases between that Polynesians 
and Europeans. 
 
Chapter 3.3: that molecular techniques provide a reliable alternative technology for 
determining  blood groups in Polynesian subjects. 
 
Chapter 3.4: that Maori and Polynesians will show difference in HPA allelic distribution 
from Europeans due to population history. 
 
Chapter 3.5: that Polynesians will display a unique repertoire of KIR haplotypes and 
different from those previously reported in Europeans. 
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Extended information on Materials and Methods 
 
Individual experimental protocols are given in each result section (Chapter 3.1 - 3.5).  The 
following paragraphs provide further details regarding materials and general laboratory 
methods. 
 
2.1 Banked DNA sample 
 
Frozen-preserved DNA samples obtained from unrelated Polynesian (TP: Total Polynesians) 
and Maori (TM: Total Maori) individuals were obtained from the Victoria University of 
Wellington (VUW) DNA bank. They are all local volunteer participants who provided 
doubly de-identified blood samples with informed consent and were recruited via the 
Wellington Blood Service.  These volunteers have varying degrees of admixture with 
Europeans.  They are divided based on self-reported pedigree at interview into full ancestry 
(PFA: Polynesians with Full Ancestry and MFA: Maori with Full Ancestry) for those with 
four grandparents and no family ancestral knowledge of members from other ethnic groups 
vs. admixed history (PAH: Polynesians with Admixed History and MAH: Maori with 
Admixed History) for those with 3 or fewer full grandparents.  Ethical approvals were 
obtained from the New Zealand Central Region Ethic Committee and Victoria University 
Human Ethics Committee – see Hamilton (1993) and Marshall (1994) for details of collection, 
interview questions and information sheet given to participants. 
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2.2 General laboratory practice 
 
All plasticware, glassware, deionized water and pipette tips were sterilized by autoclave at 20 
psi (121
o
C) for 20 minutes.  A new set of disposable plastic gloves was used for each reaction 
set-up.  In order to avoid cross contamination, different working areas were designated for 
sample preparation, PCR setup and handling of post-PCR activities.  
 
2.3 DNA quantification 
 
Quantity of DNA in extraction and PCR products was estimated using NanoPhotometer
TM
 
Pearl (IMPLEN).  The photometer was calibrated using distilled water (3-5 µl).  An amount 
of 3-5 µl of sample was used for DNA quantification and the reading was given in ng/µl. 
 
2.4 Low resolution typing of HLA, MICA and KIR loci 
 
Polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) using Luminex 
(LABType
®
 One Lambda
®
, CA, USA) was used to genotype HLA-A, -B, -C, -DRB1, -
DQA1, -DQB1, MICA and KIR loci.  The target regions were amplified using biotinylated 
locus-specific primers. Amplicons were then hybridized to complementary bead-bound 
oligonucleotide probes following denaturation and neutralization procedures. The hybrids 
were then detected using R-Phycoerythrin-conjugated Streptavidin (SAPE) and fluorescence 
intensities were read by flow analyzer (LABScan
TM 
100).  Allele/gene scores were assigned 
based on reaction patterns of reference standards.   
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2.5 High resolution typing of HLA loci 
 
Sequencing was performed for high resolution HLA typing. High resolution HLA-DRB1 
typing was either performed by DNA sequencing using the method described by Kotsch et al. 
(1999) or by using High Resolution Luminex beads (High Definition beads, test performed 
by Peter Brescia, One Lambda).  Unambiguous class I sequencing (HLA-A, B and C) was 
performed by DNA sequencing.  Group-specific amplification separated the two genes at 
each locus by PCR and each was sequenced separately (Dunn et al., 2003). The PCR was 
performed using Expand High Fidelity PCR System (Roche Diagnostics Deutschland 
GmbH).  The amplicons were purified using AMPure magnetic beads (Agencourt Bioscience 
Corporation) and then subjected to cycle sequencing using BigDye™ terminators (Life 
Technologies Corporation). Generally, 6-8 cycle sequencing reactions were performed to 
obtain DNA sequences (both strands) of exons 2-4 (HLA-A, -B) or exons 2-7 (HLA-C).  
Unincorporated fluourescent dyes were removed using CleanSEQ beads (Agencourt 
Bioscience Corporation) and sequencing reaction products were then separated by capillary 
electrophoresis using a 3130XL Genetic Analyser (Life Technologies).  DNA sequences were 
compiled, analysed and assigned using SBTengine (GenDx, Utrecht, Netherlands). 
 
2.6 PCR-SSP typing of ABO, Rhesus, MNS Kell, Kidd, Duffy and HPA 
 
Commercial DNA-SSP kits (BAG Health Care GmbH, Lich, Germany) were used to 
genotype ABO (ABO-TYPE variant), Rhesus (RH-TYPE), MNS (MNS-TYPE), Kell, Kidd 
and Duffy (KKD-TYPE) and human platelet (HPA-TYPE) loci.  Each reaction tube contains 
a prealiquoted and dried reaction mixture of oligonucleotide primer pairs (allele specific and 
internal control for human growth hormone) and deoxynucleotides.  The full reaction mixture 
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(10 ul) was then make up by adding with 1 ul of 10x PCR master mix (BAG Health Care 
GmbH, Lich, Germany), 1ul of DNA (50-100 ng/ul), 8 ul distilled water and 0.08 ul of Taq 
DNA Polymerase (5 U/ul, Roche Diagnostics Deutschland GmbH).  Each tube was closed 
with the provided lid and amplified using GeneAmp
®
 PCR System 2700 (Applied 
Biosystems).  Thermal cycling regime is according to the manufacturer‟s instruction. 
 
Agarose gel electrophoresis was used to to detect the presence of specific PCR products of 
known size. A 2% agarose gel was prepared by adding 3 g of agarose powder (AppliChem 
GmbH, Germany) into 150 ml of 0.5X TBE buffer (Roche Diagnostic, GmbH, Germany) and 
ethidium bromide (0.5 µg/ml) stain (2 µl per 100 ml gel solution).  A total volume of 10 µl of 
the PCR products was loaded into each well. A small volume, 5 µl of 100 bp DNA size 
standard ladder (250 µg/ml) was loaded on each sample row containing PCR amplified 
products. Electrophoresis was carried out at 80 V for 45 minutes. The product band was 
visualized and recorded by using image analyzer (UVITEC, Cambridge).  The presence of 
specific PCR products was interpreted by using BAGenotype evaluation software version 1.4.  
 
2.7 Sequence based typing of Kell, Duffy, JKnull  and HPA-6  
 
Genotyping protocols for Kell, Duffy and JKnull (i.e. g>a mutation at the 3‟ acceptor splice 
site of intron 5) were described in detail in Chapter 3.3 (i.e. Table S2).  The HPA-6 locus was 
genotyped using forward (5'-CTGGCTGGCTGGGATCCCAGTG-3) and reverse (5'-
CCCTGCAGTTCTCCTCACCTGAG-3) primers and amplified using a PCR protocol 
previously described by Tanaka et al. (1996).  Briefly, target DNA loci was amplified using a 
thermo cycler (GeneAmp PCR System 9700, Applied Biosystems, Foster City, CA, USA) in 
a 50 µl mixture containing 4 ul of 15 ng/ul genomic DNA, 2 ul of each forward and reverse 
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primers (10 uM each), 25 ul of MyTaqTM Red Mix (Bioline) and 17 ul of distilled water. 
The PCR conditions were as follows: 28 cycles at 95
o
C for 1 minute, 70
o
C for 1 minute, 72
o
C 
for 1 minute, with an initial denaturation at 95
o
C for 3 minutes and a final extension at 72
o
C 
for 5 minutes.  The amplified products were purified using DNA Clean & Concentrator
TM
-5 
(Zymo Research Corporation) and sequenced using multi-color fluorescence-based 
technology on ABI3730 DNA Analyzer (Applied Biosystems) at Massey University, New 
Zealand (Massey Genome Service). 
 
2.8 Blood group and HPA genotyping using chip hybridization SNP assay 
 
High-throughput molecular blood group genotyping was performed using hybridization SNP 
assay (BLOODchip
®
 v2.0) service provided by Progenika Biopharma S.A., Spain 
(http://www.progenika.com).  Briefly, a total of 45 specific regions of genomic DNA (≥ 2 µg, 
50 ng/µl) were amplified and labelled using 3 different master mixes. The labelled amplicons 
were then allowed to hybridize with complementary oligonucleotide probes spotted on glass 
slides.  The oligonucleotide probes are designed to detect 128 SNPs that belong to 9 blood 
group (ABO, Rhesus, MNS, Kell, Kidd, Duffy, Colton, Dombrock and Diego) and 12 platelet 
antigen (HPA-1 to -11 and -15) loci.  After a washing procedure to remove excess amplicons, 
the fluorescently labelled amplicon-oligonucleotide complex were measured using a scanner 
and the presence of specific SNPs are interpreted by the BLOODchip® v2.0 software. 
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2.9 Statistical analysis 
 
2.9.1 Allele, gene and carrier frequencies 
 
Allele and carrier frequencies were obtained by direct counting. Gene frequency (GF) for 
KIR was calculated using the formula  where F is observed carrier 
frequency. 
 
2.9.2 Haplotype frequency 
 
Haplotypes are unknown when individuals are heterozygous for more than one locus. In this 
study, an expectation-maximization (EM) algorithm integrated in the Arlequin software 
package was used to estimate haplotypes from genotypic data with unknown gametic phase.  
Estimation of linkage disequilibrium (D) between alleles at 2 and 3 different loci and their 
level of significance (p) is described in Chapter 3.1. 
 
2.9.3 Exact tests for Hardy-Weinberg equilibrium 
 
The exact tests were carried out on an extended two-by-two contingency table of arbitrary 
size (Arlequin) or by chi-squared tests (SPSS Inc., Chicago, IL) and were used to test for 
Hardy-Weinberg equilibrium (HWE).   Deviation from HWE is considered significant at the 
p-value of < 0.05, with 1 degree of freedom. 
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2.9.4 Linkage disequilibrium             
 
Determination of linkage disequilibrium (LD) between pairs of loci was done by using exact 
tests under the null-hypothesis of no association between the two tested loci (Excoffier et al., 
2006).  Cramer‟s V statistic (i.e. Pearson´s correlation) was also used to estimate LD between 
pairs of KIR loci (after Single et al., 2008).  The correlation coefficient (r) is equivalent to 
Wn and has a range from -1 (negative association) to +1 (positive association).  The 
significant association (p < 0.05) of LD between two loci was then estimated using Fisher‟s 
exact test.   
 
2.9.5 Testing for natural selection 
 
2.9.5.1 Deviation from HWE 
 
According to the HWE model, gene variant frequencies in the genepool of an infinitely large 
and randomly breeding population remains constant throughtout generations provided there is 
no influence from natural selection, genetic drift, mutation, gene flow and non-random 
mating.  This model is represented by the equations below: 
                                                      p + q = 1 
where p and q is frequencies of a gene with two alleles, f(A) and f(B):   
                                                  AA (p
2
) = f(A)● f(A) 
                                   AB and BA (2pq) = 2 f(A)● f(B) 
                                                   BB (q
2
) = f(B)● f(B) 
Thus, genotype frequencies are equal to: 
                                          p
2
 + 2pq + q
2
 = 1 
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where observed genotypic data can be compared with expectation via a chi-squared test with 
one degree of freedom.  
 
Deviation from HWE (as heterozygote excess or deficiency) can arise either from violation of 
one of the assumption of the model or by natural selection. However, deviation for 
expectation do not indicate either the direction or intensity of selection. 
 
2.9.5.2 The Ewens-Watterson neutrality test 
 
The Ewens-Watterson neutrality test was performed to test hypothesis for neutral evolution 
against either balancing or directional selection.  This test is based on Ewens‟ sampling 
theory and the Infinites Alleles Model of neutral theory. The test uses the observed allele 
frequency spectrum against that expected using the model. The action of natural selection in 
the population is considered significant if having p-value < 0.05 (see Chapter 3.2 for details). 
 
2.9.5.3 T-test  
 
Selection was tested for pairs of KIR and HLA ligands using a T-test with a total of 10,000 
permutations.  The p-value (i.e. of the Pearson correlation co-efficient) was calculated as a 
percentage of the 10,000 correlation estimation (see Chapter 3.5 for details). 
         
2.9.5.4 Ancestral fraction scaling test 
 
This is a novel method developed in Chapter 3.1 of this thesis.  Pricipal coordinate (PCO) 
analysis was also used to search for evidence of natural selection in Polynesian sub-
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populations.  Ancestral fractions in these populations were estimated by using set of reference 
A-SM and P-SA genepools (see Chapter 3.1 for details).  The relative ancestral fraction in 
test population was estimated by projecting the test population onto the line joining the two 
reference pools.  Loci that showed large shifted towards one or other ancestral population 
were interpreted as having under gene selection favouring alleles that were more common in 
that ancestor. 
 
2.9.6 Exact test of population differentiation 
 
Homogeneity and heterogeneity between datasets were evaluated using exact or chi-squared 
(with Yate‟s continuity correction) tests performed using Arlequin (Excoffiler et al., 2006) 
and Graphpad (http://www.graphpad.com) software, respectively. Two datasets are 
considered significantly different if the return p-value is < 0.05. 
 
2.9.7 Phylogenetic analysis 
 
Phylogenetic analysis was achieved using programs included in PHYLIP version 3.6 
(Felsenstein, 2004).  Bootstrap and genetic distance analyses were performed by Seqboot and 
Gendist programs, respectively. The neighbour-joining routine was used to construct 
evolutionary trees and a single consensus bootstrapped tree was obtained with Consense 
program (Felsenstein, 2004).  Topology of the consensus tree was visualized with TreeView 
program (Page, 1996).  
 
Phylogenetic analysis summarizes similarities and differences in a single diagram under the 
null assumption that they were generated by a strictly tree-like process.  Organisms that share 
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a common ancestor are expected to evolve and show hierarchial clustering.  If this natural 
hierarchical distribution is violated or erased, e.g. due to admixture and hybridization, then 
phylogenetic analysis may not resolve relationships reliably and yield trees with branches 
supported by low bootstrap values.   
 
2.9.8 Principal coordinate and component analysis  
 
Principle coordinate (PCO) and component analyses (PCA) were carry out by using 
Multivariate Statistical Package 3 (MVSP3) (Kovach Computing Services, UK; 
http://www.kovcomp.com/mvsp).  The PCO and PCA transform dissimilarity and similarity 
matrixes (respectively) into uncorrelated variables called principal coordinates/components 
(respectively). The PCO/PCA methods collapse genetic variability in several axes and the 
two most informative were usually represented in a two-dimensional plot. Each population is 
plotted as a 2-dimentional scatter graph and the distance between populations demonstrates 
their genetic relationship.  Pairs of populations with closer genetic relationship will be plotted 
together, while those which are distinct will be separated.   
 
2.9.9 Probability of an exact match 
 
Probability of finding a phenotype match between randomly selected donors and recipients 
was calculated according to the following formula (after Badjie et al., 2011): 
 
Probability of an exact match =   (frequency of donor‟s AA X frequency of recipient‟s AA) +          
(frequency of donor‟s BB X frequency of recipient‟s BB) + 
(frequency of donor‟s AB X frequency of recipient‟s AB) 
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where                          A and B = antigens of particular locus 
                                            AA = homozygote for A antigen 
                                            AB = heterozygote for A and B antigens 
                                            BB = homozygote for B antigen 
 
2.9.10 Probability of alloimmunization 
 
Probabilities of transfusion and pregnancy alloimmunization were calculated according to the 
following formula (after De La Vega Elena et al., 2008): 
 
i. Probability of transfusion alloimmunization  = (1 - pp)
2
 - (2pd - pd
2
) 
where                                                             pp = gene frequency of patient‟s population 
                                                                       pd = gene frequency of donor‟s population 
ii. Probability of pregnancy alloimmunization   = (1 - pm)
2
 X 2pp  
where                                                             pm = gene frequency of mother‟s population 
                                                                        pp = gene frequency of father‟s population 
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Abstract 
 
Human Leukocyte Antigens (HLA) are important genetic markers of tissue identity and 
accurately reflect ancestral history.  The work reported in this paper provides a detailed 
description of HLA polymorphism in Polynesian and Maori individuals in relation to other 
populations.  Our study concerns HLA class I and II antigens in Polynesian (N = 36) and 
Maori (N = 114) subjects genotyped at 2 digit resolution by New Zealand Blood Service 
Laboratory in Auckland using PCR-SSO Luminex and PCR-SSP technologies.  We have also 
compared our data with those from other Austronesian-speaking Mongoloid and Papuan-
speaking Australoid populations in order to test previously published account of the origin of 
Proto-Polynesians via gender-biased gene flow between these two ancestral populations.  We 
use principal coordinate (PCO) analysis for this purpose, arguing this approach to be superior 
to tree-based methods, due to factors associated with population history and admixture.  Our 
data are in general agreement with earlier work and reflect received wisdom on the dual 
origin of Proto-Polynesians.  They also show the way in which the genetic make up of 
Polynesian and Maori subjects is changing due to intermarriage with Europeans. 
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Introduction 
 
Austronesian-speaking Mongoloids (A-SM) from East Asia (Taiwan) first migrated to South 
East Asia (SEA), coastal New Guinea and Island Melanesia between 5000 to 3,500 years ago, 
intermixed with Papuan-speaking Australoid (P-SA) residents (1). Their descendants moved 
outwards to cross the Pacific basin Remote Oceania and occupied New Zealand from 650 
ybp. On the route to New Zealand, the genepool ultimately inherited by Polynesians and local 
Maori people was repeatedly refined by founder effects due to multiple re-settlements; aka 
the „Genetic bottleneck in Polynesia‟ and see (2) for more details.  This means that 
Polynesian and Maori people are on average more closely related to one another than the 
members of large outbred populations; say those in Asia or Europe, would be.  The recent 
period has seen the beginning of a further phase of gene flow as Polynesian and Maori people 
intermarry with Europeans.  
 
Studies on immune system loci have played a leading part in the development of genetic 
evidence that underpins the present account (3-30).  Our present study examines HLA 
markers in DNA samples that have been classified according to reported admixture.  Hence, 
this new work includes the only individuals ever examined where some participants can be 
clearly identified as lacking genetic input from European ancestors.  This design allows 
comparisons that were not previously possible.  This work represents an independent re-
sampling of these populations, and thus has comparative value too.  However, these new data 
can be combined with previous data on Polynesians and Maori in a small scale meta-analysis.  
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In the present study, our historical reconstructions compared principal coordinate analysis 
(PCO) and neighbour-joining (NJ) methodologies.  The HLA data generated from this study 
will be tested under the Total Synthetic Evidence Model of Pacific settlement and specifically 
allowing for recent admixture.  They will also be interpreted for the first time in the light of 
new knowledge about Polynesians genetics including tests for historical geneflow with a 
70:30 ratio (A-SM:P-SA) as a null hypothesis based on the SNP data (31) and tested versus 
values calculated from (32).  Wider comparisons have also been made in a new and more 
appropriate context recognising other Austronesian populations (e.g. Malay and Taiwanese 
Aboriginals) as being distinct from Polynesians and as representing ancestral type 
Austronesian-speaking Mongoloid lineages.  In making these last comparisons we have also 
critically scrutinised population labels applied in previous reports for authentic content; e.g. 
does „Taiwan‟ really mean Han Chinese vs. Atayal, Bunun and Paiwan etc.  Overall, we 
believe that our compilation and comparison of HLA class I and II in this study and previous 
works fill some of the gaps left in our present understanding of Polynesian immunogenetics.  
 
Materials and Methods 
Samples, HLA genotyping and ethical clearance 
DNA samples were obtained from the Victoria University of Wellington DNA Bank and 
comprise Total Polynesians (TP: N = 36) and Total Maori (TM: N = 114) groups.  Each 
individual was assigned into one of two sub-groups based on their self-reported pedigree: TP 
= Polynesians with Full Ancestry (PFA: N = 24) + Polynesians with Admixed History (PAH: 
N = 12) and TM = Maori with Full Ancestry (MFA: N = 49) + Maori with Admixed History 
(MAH: N = 65).  Ethical approvals were obtained from the New Zealand Central Region 
Ethic Committee and Victoria University Human Ethics Committee (HEC).  The HLA class I 
and II alleles were typed using polymerase chain reaction-sequence specific oligonucleotide 
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(PCR-SSO) using Luminex (LABType
®
 One Lambda
®
, CA, USA) and ambiguities were 
resolved by using Life Technologies AllSet
TM
 Gold HLA low resolution SSP kits. 
Statistical analysis 
Allele frequencies were obtained by the direct counting method. Direct gene counting could 
be applied because no typing ambiguities were found. Individuals are considered 
homozygotes if only one type of allele group detected at particular HLA locus. Arlequin 
software version 3.1 (33) was used to estimate allele and haplotype frequencies, to test for 
Hardy-Weinberg equilibrium and linkage disequilibrium between pairs of HLA loci and carry 
out exact test of population differentiation.  Linkage disequilibrium (D) between two alleles 
at two different loci and level of significance (p-value = 0.05) were calculated using Arlequin 
software (33).  The generated linkage disequilibrium (D) values were then used to calculate 
linkage disequilibrium (D) between three alleles at three different loci. Formula for 
calculating 3-locus disequilibrium and their level of significance (p-value = 0.05) are Dkri  = 
Pkri - qiDkr -  yrDki - pkDri -pk . yr . qi and χ2  = 2N(Dkri)2 ÷  pk(1-pk) yr(1-yr) qi(1-qi), 
respectively  (34,35). The Dkri  is the linkage desequilibrium (D) of the haplotype kri, Pkri  is 
the frequency of the haplotype kri, qi is frequency of the allele i, yr = the frequency of the 
allele r, pk = is the frequency of the allele k, Dkr = the linkage desiquilibrium (D) of the 
haplotype kr, Dki = the linkage desiquilibrium (D) of the haplotype ki, Dri  = the linkage 
desiquilibrium (D) of the haplotype ri and N = the number of samples. Phylogenetic trees 
were constructed using PHYLIP software package, version 3.6 (36) and the TreeView 
programme (37).  Principal coordinate (PCO) plots were constructed using Multivariate 
Statistical software package 3 (Kovach Computing Services, UK; 
http://www.kovcomp.com/mvsp). Proportions of A-SM:PSA genepools in Polynesian and 
Maori populations were estimated by using set of simulations blending representative of two 
individuals A-SM  and P-SA  populations (e.g. Ami vs. Goroko and Ami vs. Rangers) in 
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various combinations with a range of proportions 50:50 to 90:10 A-SM:P-SA.  The A-SM:P-
SA combinations were then compared with Polynesian and Mori datasets using X
2 
goodness 
of fit (SPSS Inc., Chicago, IL) and exact test of population differentiation (Arlequin software 
version 3.1 – ref 33).  Admixture coefficient in Polynesian and Maori populations were also 
estimated by plotting a full range simulated proportions (0:100 to 100:0) of average genetic 
profiles of two broad groups, A-SM:P-SA genepools on PCO plots. 
 
 Results  
 
Name and frequency of HLA alleles (based on two digit allele groups) identified across the 
class I and II loci in our Polynesian and Maori study groups and sub-groups are shown in 
Table 1.  There is no significant deviation from Hardy-Weinberg equilibrium at any of the six 
loci (Table S1) and tests for pairwise linkage disequilibrium were significant except for the 
HLA-A-B and HLA-A-C pairs in PAH (Table S2). The 2- and 3-locus class I and II 
haplotypes with significant associations between alleles at different loci estimated for 
Polynesians and Maori in our new survey are listed in Table 2. 
 
Our new HLA class I and II data for PFA closely resemble those from four different 
Polynesian populations (Cook Islands – CI, Tokelau – TOK, Tonga – TON and Samoa – SA) 
previously collected (3,4), but which have not previously appeared in the primary literature – 
see Table 1.  This observation holds for both total numbers and types of alleles found.  Exact 
tests of population differentiation on the HLA class I and II data show few significant 
differences between the four populations except to differentiate Cook Islands and Tonga in 
HLA class II comparisons (see Table S3).  We took these observations as justification for  
combining these four populations into a larger unified group; VTP (Velickovic Total 
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Polynesians), see Table 1 for comparison with our newly collected data for Polynesians.  
Exact tests using HLA class I, II or combined of class I and II allele frequencies (see Table 
S3) shows that the PFA sub-group is most similar to VTP and that PFA is only significantly 
different from Tokelau (p-value < 0.05), one of the four individual sub-groups that make up 
VTP. Hence, we judge it legitimate to combine PFA with VTP into PMD (Polynesian Meta 
Dataset – see Table 1) for comparisons with other (ancestral) populations (see later). The 
statistically significant differences observed between PFA and PAH may be attributed to 
recent admixture with Europeans and this is the subject of the next set of analyses with 
reference European populations – see later.  
 
The 2- and 3-locus haplotypes associations found for Polynesians in our new survey also 
compare well with those with those previously obtained (3,4) – see Table S4. Although 
haplotype frequencies do sometimes show quite marked differences among the four Island 
groups, the combined VTP data set matches PFA fairly closely, particularly with respect to 
the more common associations discussed above.  Hence, we created a haplotype metadata 
group (PMD) by combining them two.  
 
We also compared the HLA allele frequency scores of our Maori study group with those from 
a previous study (5,6) on Maori (TTM). In summary, HLA data for MFA and TTM are 
similar in terms of the most frequent alleles observed. Many alleles which are not detected in 
MFA were recorded for TTM, e.g.  HLA-A*29, -B*35, -B*37, -B*58 and -C*16.  All of these 
are present in MAH.  This suggests TTM is more similar to either our MAH sub-group or the 
wider TM group which contain alleles due to admixture with Europeans.  Therefore, we ran 
exact tests using MFA, MAH and TTM datasets and all comparisons were significantly 
different from one another (see Table S3). 
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In contrast to Polynesians, where VTP is equivalent to PFA in terms of un-admixed 
Polynesian gene content, here we have shown TTM most closely resembles MAH and 
suggests greater degree of admixture in (5,6) datasets than (3,4).  To best illustrate these 
comparisons, we have plotted HLA class I and II allele frequency spectra for the various 
Maori (Figs. 1 and 2) and Polynesian (not shown) datasets against the two reference 
European populations, ELAN (class I-ref 7) and ENG (class II-ref 8).  In all of the graphs, 
vertical allele frequency bars plotted for PAH, MAH and TTM are intermediate between 
values represented by PFA/MFA and ELAN/ENG or shared just with the latter.  Hence, we 
judge it to be optimal to use PMD and MFA as reference groups for studying Polynesian and  
Maori genealogy.  Our original plan to create the largest possible Polynesian and Maori meta 
datasets by combining TP and VTP and TM and TTM had to be rejected due to extensive 
European contributions in both, PAH and TTM/MAH, respectively. Therefore, HLA data 
from the earlier work on TTM is specifically excluded from Tables 1 and S4 due to 
admixture. 
  
Next, we asked if Maori is typical of other Polynesian populations.  The HLA data from 
MFA are then compared with other Polynesian datasets (see Table 1). In general, the most 
common alleles in MFA are also typical for the other Polynesians; except for HLA-B*56, -
DQA1*03 and -DRB1*04 which are less frequent in MFA compared to other Polynesian 
populations.  Similar patterns can be seen with the distributions of HLA class I and II 
haplotypes, but with a few minor exceptions such as; HLA-DRB1*08-DQB1*05 is only 
detected in MFA and CI while HLA-DRB1*08-DQA1*01-DQB1*05 is only observed in 
MFA.  Overall, the new data collected for MFA are consistent with those from other 
Polynesians, although allele and haplotype frequencies do show some slight differences 
between sub-populations.  
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It is obvious that variations will arise between individual populations due to their history and 
the widely accepted way to examine their genetic relationships is by using Neighbour-Joining 
(NJ) phylogenetic trees and PCO plots. Here we show only those from the latter (Figs. 3 and 
4 and Figs. S1 and S2) but note that the NJ trees (not shown) were broadly congruent. We 
argue in discussion that the PCO method is a superior tool when admixture is a feature of 
population history. The HLA-A, -B and -C and HLA-DRB1 and -DQB1 PCO diagrams 
constructed using information obtained from axis 1 and 2 (Figs. 3 and 4, respectively) are 
perhaps more informative and show clear separation of A-SM and P-SA than those 
constructed using axis 1 and 3 (Figs. S1 and S2).  In Figs. 3 and 4, Polynesians fall as 
intermediate between cumulative of A-SM and P-SA genepools and Cook Islanders are closer 
to MFA compared with the other Polynesian populations.  Nevertheless, our admixed groups 
(MAH and TM) as well as TTM are plotted as displaced toward European datasets, ELAN 
and ENG in the HLA-A, -B and -C and HLA-DRB1 and -DQB1 plots, respectively. We state 
here that there are no marked differences between PCO plots constructed for combined and 
original populations from those based only on the original populations (for example see Fig. 
S3 compared with Fig. 3). 
 
Because comparative genotypic data were not available for wider P-SA and A-SM groups, 
we were unable to carry out STRUCTURE analysis and apportion the genepool of our 
Polynesian and Maori subjects between their ancestral groups, cf. (31) and (32) studies using 
SNP data.  Therefore, we ran an extensive set of simulations blending representative of two 
individual P-SA and A-SM (e.g. Ami vs. Goroko) populations in various combinations with a 
range of proportions 50:50 to 90:10 A-SM:P-SA.  We then carried out X
2 
goodness of fit 
analysis and exact tests of population differentiation comparing PFA, VTP and PMD to each 
of these.  All proved to be significantly different (p-values = 0, e.g. see Table S5).  We 
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therefore resorted to plotting a full range of simulated proportions (0:100 to 100:0) of A-
SM:P-SA genepools on the PCO plots and estimating admixture by projecting the individual 
points for PMD, VTP etc. on to the line joining the simulated points (see Figs. S4 to S8).  For 
Polynesians, these gave intersections around 60:40 for HLA-A (Fig. S4) and 40:60 for HLA-
C (Fig. S6) loci but values fell in the 90:10 to 100:0 intervals for HLA-B (Fig. S5) and may 
reflect past episodes of natural selection (see Discussion).  The only locus for which there are 
sufficient data to attempt calculation of admixture proportions from HLA class II is HLA-
DRB1, since there are no data for Taiwan aborigines for the other class II loci.  Here, all 
Polynesian populations including PFA and the composites VTP and PMD fell close to 100:0 
proportion of A-SM:P-SA genepools (Fig. S7).  Our estimations show that they are around 
30:70 for HLA-A and -C, and 100:0 for HLA-B and -DRB1 (see Figs. S4-S7) proportion of 
A-SM:P-SA ancestral fractions in Maori. Overall, our simulation using a combined HLA-A, -
B, -C and –DRB1 allele frequencies show that there is around a 60:40 genetic proportion of 
ASM:P-SA ancestral fractions in Maori and other Polynesians (see Fig. S8). 
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Table 1: HLA class I and II allele frequencies for Polynesian and Maori datasets.  
 
Datasets (N) TP (36) PFA (24) PAH (12) TM (114) MFA (49) MAH (65) CI (50) TOK (50) TON (50) SA (50) VTP (200) PMD (224) TTM (§)  MMD (§) 
HLA-A* 
              01 
02 
03 
11 
23 
24 
25 
26 
29 
30 
31 
32 
33 
34 
43 
66 
68 
0.06 
0.22 
- 
0.11 
- 
0.40 
- 
0.03 
0.01 
- 
- 
- 
- 
0.17 
- 
- 
- 
0.02 
0.21 
- 
0.15 
- 
0.39 
- 
0.04 
- 
- 
- 
- 
- 
0.19 
- 
- 
- 
0.13 
0.25 
- 
0.04 
- 
0.42 
- 
0- 
0.04 
- 
- 
- 
- 
0.13 
- 
- 
- 
0.07 
0.33 
0.04 
0.18 
- 
0.27 
0.01 
0.01 
- 
0.00 
0.00 
0.00 
0.00 
0.07 
- 
- 
0.01 
0.05 
0.36 
- 
0.16 
- 
0.38 
- 
- 
- 
- 
- 
- 
- 
0.05 
- 
- 
- 
0.08 
0.31 
0.07 
0.18 
- 
0.19 
0.02 
0.02 
- 
0.01 
0.01 
0.01 
0.01 
0.08 
- 
- 
0.02 
0.01 
0.22 
0.01 
0.11 
- 
0.48 
- 
0.02 
- 
0.01 
- 
- 
- 
0.13 
- 
- 
0.01 
0.01 
0.17 
- 
0.16 
- 
0.56 
- 
0.01 
- 
- 
0.01 
- 
- 
0.08 
- 
- 
- 
- 
0.12 
- 
0.21 
- 
0.50 
- 
0.06 
- 
- 
- 
- 
- 
0.11 
- 
- 
- 
0.01 
0.34 
- 
0.11 
- 
0.46 
0.01 
- 
- 
- 
- 
- 
- 
0.07 
- 
- 
- 
0.01 
0.21 
0.00 
0.14 
0 
0.50 
0.00 
0.03 
0 
0.00 
0.00 
- 
- 
0.10 
- 
- 
0.00 
0.01 
0.21 
0.00 
0.14 
- 
0.49 
0.00 
0.03 
- 
0.00 
0.00 
- 
- 
0.11 
- 
- 
0.00 
0.05 
0.34 
0.06 
0.17 
0.00 
0.23 
0.00 
0.01 
0.01 
0.00 
0.01 
0.01 
0.00 
0.08 
0.00 
0.00 
0.01 
0.06 
0.34 
0.05 
0.17 
0.00 
0.25 
0.01 
0.01 
0.01 
0.00 
0.01 
0.01 
0.00 
0.08 
0.00 
0.00 
0.01 
k 7 6 6 13 5 13 9 7 5 6 11 11 17 17 
HLA-B* 
              07 
08 
13 
14 
15 
18 
27 
35 
37 
38 
0.01 
0.01 
0.06 
- 
0.06 
0.01 
0.01 
- 
- 
- 
- 
- 
0.06 
- 
0.02 
- 
0.02 
- 
- 
- 
0.04 
0.04 
0.04 
- 
0.13 
0.04 
- 
- 
- 
- 
0.05 
0.03 
0.02 
0.02 
0.04 
0.01 
0.01 
0.00 
0.00 
0.00 
0.02 
0.02 
0.04 
- 
0.01 
- 
0.01 
- 
- 
- 
0.07 
0.04 
- 
0.04 
0.05 
0.02 
0.01 
0.01 
0.01 
0.01 
- 
0.01 
0.06 
- 
0.03 
- 
0.02 
- 
- 
- 
- 
- 
0.04 
- 
0.08 
- 
0.01 
- 
- 
- 
- 
- 
0.03 
- 
0.05 
- 
0.02 
- 
- 
- 
0.03 
0.01 
0.06 
- 
0.04 
- 
- 
- 
- 
- 
0.01 
0.01 
0.05 
- 
0.05 
- 
0.01 
- 
- 
- 
0.01 
0.00 
0.05 
- 
0.05 
- 
0.00 
- 
- 
- 
0.13 
0.02 
0.04 
0.00 
0.04 
- 
- 
0.02 
0.01 
- 
0.10 
0.03 
0.03 
0.01 
0.04 
0.00 
0.00 
0.02 
0.01 
0.00 
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Table 1 cont. 
 
Datasets (N) TP (36) PFA (24) PAH (12) TM (114) MFA (49) MAH (65) CI (50) TOK (50) TON (50) SA (50) VTP (200) PMD (224) TTM (§)  MMD (§) 
HLA-B* 
              39 
40 
44 
45 
47 
48 
50 
51 
52 
54 
55 
56 
57 
58 
67 
81 
Blank 
0.06 
0.32 
0.04 
- 
0 
0.07 
- 
- 
- 
- 
0.18 
0.15 
0.01 
- 
- 
- 
- 
0.06 
0.42 
0.02 
- 
- 
0.10 
- 
- 
- 
- 
0.15 
0.13 
0.02 
- 
- 
- 
- 
0.04 
0.13 
0.08 
- 
- 
- 
- 
- 
- 
- 
0.25 
0.21 
- 
- 
- 
- 
- 
0.11 
0.18 
0.05 
0.00 
0.00 
0.12 
0.01 
0.00 
- 
0.00 
0.25 
0.06 
0.00 
0.01 
- 
- 
0.01 
0.09 
0.20 
0.02 
- 
- 
0.14 
- 
- 
- 
- 
0.37 
0.07 
- 
- 
- 
- 
- 
0.12 
0.16 
0.08 
0.01 
0.01 
0.10 
0.02 
0.01 
- 
0.01 
0.16 
0.05 
0.01 
0.02 
- 
- 
0.02 
0.12 
0.19 
- 
- 
- 
0.11 
- 
0.02 
- 
- 
0.22 
0.20 
- 
- 
- 
- 
- 
0.06 
0.51 
- 
- 
- 
0.01 
- 
- 
- 
- 
0.19 
0.09 
- 
- 
- 
- 
- 
0.03 
0.35 
- 
- 
- 
0.11 
- 
- 
- 
- 
0.07 
0.34 
- 
- 
- 
- 
- 
0.06 
0.41 
- 
- 
- 
0.11 
- 
- 
- 
- 
0.12 
0.16 
- 
- 
- 
- 
- 
0.07 
0.37 
- 
- 
- 
0.09 
- 
0.01 
- 
- 
0.15 
0.20 
- 
- 
- 
- 
- 
0.07 
0.38 
0.00 
- 
- 
0.09 
- 
0.01 
- 
- 
0.15 
0.19 
0.00 
- 
- 
- 
- 
0.05 
0.18 
0.01 
- 
- 
0.17 
0.01 
0.01 
0.00 
0.02 
0.21 
0.03 
0.02 
- 
0.01 
0.02 
- 
0.07 
0.18 
0.03 
0.00 
0.00 
0.15 
0.01 
0.01 
0.00 
0.01 
0.22 
0.04 
0.01 
0.00 
0.00 
0.01 
0.00 
k 13 10 10 23 11 22 10 8 8 9 11 13 20 26 
HLA-C* 
              01 
02 
03 
04 
05 
06 
07 
08 
12 
14 
0.33 
- 
0.13 
0.18 
0.03 
0.01 
0.11 
0.07 
0.06 
- 
0.27 
- 
0.15 
0.21 
0.02 
0.02 
0.08 
0.10 
0.06 
- 
0.46 
- 
0.08 
0.13 
0.04 
- 
0.17 
- 
0.04 
- 
0.30 
- 
0.04 
0.12 
0.05 
0.03 
0.20 
0.15 
0.03 
- 
0.45 
- 
0.02 
0.17 
0.01 
- 
0.14 
0.13 
0.04 
- 
0.18 
- 
0.06 
0.08 
0.08 
0.05 
0.24 
0.16 
0.02 
- 
0.40 
- 
0.03 
0.13 
0.01 
0.01 
0.16 
0.11 
0.04 
0.02 
0.25 
- 
0.01 
0.46 
0.01 
- 
0.07 
0.01 
0.12 
- 
0.35 
- 
0.12 
0.20 
- 
- 
0.08 
0.12 
0.06 
- 
0.24 
- 
0.25 
0.17 
- 
- 
0.12 
0.11 
0.03 
- 
0.31 
- 
0.10 
0.24 
0.01 
0.00 
0.11 
0.09 
0.06 
0.01 
0.31 
- 
0.11 
0.22 
0.01 
0.00 
0.11 
0.09 
0.06 
0.01 
0.25 
0.00 
0.04 
0.17 
0.04 
0.02 
0.19 
0.11 
0.03 
0.00 
0.27 
0.00 
0.04 
0.15 
0.05 
0.02 
0.19 
0.13 
0.03 
0.00 
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Table 1 cont. 
 
Datasets (N) TP (36) PFA (24) PAH (12) TM (114) MFA (49) MAH (65) CI (50) TOK (50) TON (50) SA (50) VTP (200) PMD (224) TTM (§)  MMD (§) 
HLA-C* 
              15 
16 
18 
Blank 
0.07 
0.01 
- 
- 
0.08 
- 
- 
- 
0.04 
0.04 
- 
- 
0.06 
0.00 
- 
0.02 
0.03 
- 
- 
- 
0.08 
0.01 
- 
0.03 
0.09 
- 
- 
- 
0.07 
- 
- 
- 
0.07 
- 
- 
- 
0.08 
- 
- 
- 
0.08 
- 
- 
- 
0.08 
- 
- 
- 
0.08 
0.04 
0.03 
- 
0.07 
0.02 
0.01 
0.01 
k 10 9 8 10 8 10 10 8 7 7 10 10 13 13 
HLA-DQA1* 
              01 
02 
03 
04 
05 
Blank 
0.36 
- 
0.38 
0.01 
0.22 
0.03 
0.35 
- 
0.44 
0.02 
0.19 
0 
0.38 
- 
0.25 
- 
0.29 
0.08 
0.29 
0.04 
0.21 
0.02 
0.41 
0.03 
0.26 
- 
0.27 
0 
0.48 
0 
0.32 
0.07 
0.17 
0.04 
0.36 
0.05 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
k 4 4 3 5 3 5 
        
HLA-DQB1* 
              02 
03 
04 
05 
06 
Blank 
0.01 
0.54 
0.06 
0.15 
0.21 
0.03 
- 
0.56 
0.08 
0.17 
0.19 
- 
0.04 
0.50 
- 
0.13 
0.25 
0.08 
0.07 
0.58 
0.04 
0.15 
0.14 
0.03 
0.02 
0.68 
0.04 
0.12 
0.13 
- 
0.10 
0.50 
0.04 
0.17 
0.15 
- 
0.02 
0.64 
0.03 
0.22 
0.09 
- 
- 
0.66 
0.08 
0.10 
0.16 
- 
- 
0.56 
0.05 
0.18 
0.21 
- 
- 
0.58 
0.11 
0.14 
0.17 
- 
0.01 
0.61 
0.07 
0.16 
0.16 
- 
0.00 
0.60 
0.07 
0.16 
0.16 
- 
0.10 
0.52 
0.01 
0.20 
0.18 
- 
0.08 
0.54 
0.02 
0.18 
0.17 
0.01 
k 5 4 4 5 5 5 5 4 4 4 5 5 5 5 
HLA-DRB1* 
              01 
03 
04 
07 
08 
0.03 
0.01 
0.22 
- 
0.10 
0.02 
- 
0.25 
- 
0.10 
0.04 
0.04 
0.17 
- 
0.08 
0.04 
0.04 
0.15 
0.04 
0.13 
0.01 
0.02 
0.16 
- 
0.18 
0.05 
0.06 
0.14 
0.07 
0.09 
0.01 
0.01 
0.28 
0.01 
0.10 
- 
- 
0.46 
- 
0.12 
- 
- 
0.22 
- 
0.13 
- 
0.02 
0.25 
0.01 
0.12 
0.00 
0.01 
0.30 
0.01 
0.12 
0.00 
0.01 
0.29 
0.00 
0.12 
0.03 
0.04 
0.18 
0.05 
0.10 
0.03 
0.04 
0.17 
0.05 
0.11 
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Table 1 cont. 
 
Datasets (N) TP (36) PFA (24) PAH (12) TM (114) MFA (49) MAH (65) CI (50) TOK (50) TON (50) SA (50) VTP (200) PMD (224) TTM (§)  MMD (§) 
HLA-DRB1* 
              09 
11 
12 
13 
14 
15 
16 
Blank 
0.15 
0.07 
0.14 
0.04 
0.14 
0.10 
- 
- 
0.19 
0.06 
0.13 
0.02 
0.15 
0.08 
- 
- 
0.08 
0.08 
0.17 
0.08 
0.13 
0.13 
- 
- 
0.06 
0.16 
0.21 
0.03 
0.09 
0.04 
- 
0.01 
0.10 
0.18 
0.28 
- 
0.05 
0.01 
- 
- 
0.03 
0.15 
0.16 
0.05 
0.12 
0.05 
- 
0.02 
0.08 
0.12 
0.17 
0.01 
0.14 
0.07 
- 
- 
0.04 
- 
0.22 
0.03 
0.07 
0.06 
- 
- 
0.16 
0.16 
0.08 
- 
0.12 
0.13 
- 
- 
0.25 
0.08 
0.08 
- 
0.09 
0.10 
- 
- 
0.13 
0.09 
0.14 
0.01 
0.11 
0.09 
- 
- 
0.14 
0.09 
0.14 
0.01 
0.11 
0.09 
- 
- 
0.04 
0.15 
0.22 
0.03 
0.10 
0.06 
0.01 
- 
0.05 
0.16 
0.22 
0.03 
0.10 
0.05 
0.00 
0.00 
k 10 9 10 11 9 11 11 7 7 9 11 11 12 12 
 
N = total number of individuals, k = total number of observed alleles, 0=not observed, 0.00 = <0.01, TP: Total Polynesians, PFA: Polynesians with Full Ancestry, PAH: 
Polynesians with Admixed History, TM= Total Maori, MFA = Maori with Full Ancestry,  MAH: Maori with Admixed History, CI: Cook Islands (3,4), TOK: Tokelau (3,4), 
TON: Tonga (3,4), SA: Samoa (3,4), VTP: Velickovic Total Polynesians (CI+TOK+TON+SA), PMD: Polynesian Meta Dataset (PFA+VTP), TTM:  Tracey Total Maori 
(5,6), MMD: Maori Meta Dataset (TM+TTM), §: total number of individuals for TTM and MMD at HLA-A* (176 and 290, respectively), -B* (171 and 285, respectively), -
C*(124 and 238, respectively), -DQB1 (187 and 301, respectively) and -DRB1* (200 and 314, respectively) loci.   
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Table 2: List of the most common (frequencies ≥ 0.06) class I and II haplotypes with 
respective value of linkage disequilibrium (D) and their level of significance (p).
HLA-A*-C* Freq ≥ 0.06 D p-value 
TP (N=36) 
   02-01 
11-04 
34-15 
0.15 
0.07 
0.07 
0.06 
0.05 
0.0579 
0.01 
0.01 
0 
PFA (N=24) 
   02-01 
11-04 
34-15 
0.19 
0.08 
0.08 
0.13 
0.05 
0.07 
0 
0.01 
0 
PAH (N=12) 
   01-07 0.08 0.06 0.01 
TM (N=114) 
   02-01 
11-04 
11-08 
24-07 
34-15 
0.20 
0.06 
0.08 
0.08 
0.05 
0.11 
0.04 
0.05 
0.02 
0.04 
0 
0 
0 
0.04 
0 
MFA (N=49) 
   02-01 
11-04 
11-08 
24-07 
0.33 
0.09 
0.10 
0.10 
0.16 
0.06 
0.03 
0.05 
0 
0 
0.01 
0.01 
MAH (N=65) 
   02-01 
11-08 
34-15 
0.13 
0.09 
0.07 
0.07 
0.06 
0.06 
0 
0 
0 
HLA-C*-B* Freq ≥ 0.06 D p-value 
TP (N=36) 
   01-55 
01-56 
03-40 
04-40 
04-15 
07-39 
08-48 
15-40 
0.18 
0.13 
0.11 
0.14 
0.04 
0.06 
0.07 
0.07 
0.12 
0.07 
0.07 
0.08 
0.03 
0.05 
0.06 
0.05 
0 
0 
0 
0 
0 
0 
0 
0 
PFA (N=24) 
   01-55 
01-56 
03-40 
04-40 
07- 39 
08-48 
15-40 
0.15 
0.10 
0.15 
0.19 
0.06 
0.1 
0.08 
0.11 
0.07 
0.09 
0.10 
0.06 
0.09 
0.05 
0 
0 
0 
0 
0 
0 
0.01 
PAH (N=12) 
   01-56 0.21 0.12 0 
TM (N=114) 
   01-55 
01-56 
04-40 
07-39 
08-48 
0.25 
0.15 
0.12 
0.09 
0.12 
0.18 
0.02 
0.10 
0.08 
0.10 
0 
0.01 
0 
0 
0 
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Table 2 cont. 
HLA-C*-B* Freq ≥ 0.06 D p-value 
    
MFA (N=49) 
   01-55 
01-56 
04-40 
07-39 
08-48 
0.37 
0.06 
0.17 
0.09 
0.13 
0.20 
0.02 
0.14 
0.08 
0.11 
0 
0.02 
0 
0 
0 
    
MAH (N=65) 
   01-55 
04-40 
05-44 
07-07 
07-39 
08-48 
15-40 
0.16 
0.08 
0.06 
0.06 
0.10 
0.10 
0.07 
-0.03 
0.06 
0.06 
0.05 
0.06 
0.07 
0.06 
0 
0 
0 
0 
0 
0 
0 
    
HLA-A*-C*-B* Freq ≥ 0.06 D p-value 
TP (N=36) 
   02-01-55 
11-04-40 
24-01-55 
24-01-56 
24-03-40 
24-04-44 
34-15-40 
0.08 
0.07 
0.09 
0.12 
0.07 
0.08 
0.07 
-0.15 
0.03 
-0.31 
-0.28 
0.03 
0.04 
0.04 
<0.01 
<0.01 
<0.01 
<0.01 
<0.02 
<0.01 
<0.01 
    
PFA (N=24) 
   02-01-55 
24-08-48 
34-15-40 
0.12 
0.06 
0.08 
0.05 
0.02 
0.04 
<0.01 
<0.01 
<0.01 
    
TM (N=114) 
   02-01-55 
11-04-40 
11-08-48 
24-07-39 
0.19 
0.06 
0.07 
0.08 
0.09 
0.03 
0.03 
0.03 
<0.01 
<0.01 
<0.01 
<0.01 
    
MFA (N=49) 
   02-01-55 
11-04-40 
24-01-56 
24-07-39 
24-08-48 
0.29 
0.09 
0.06 
0.09 
0.08 
0.03 
0.04 
0.02 
0.04 
0.02 
<0.05 
<0.01 
<0.02 
<0.01 
<0.01 
    
MAH (N=65) 
   02-01-55 
11-08-48 
24-07-39 
34-15-40 
0.11 
0.08 
0.07 
0.07 
0.05 
0.04 
0.03 
0.05 
<0.01 
<0.01 
<0.01 
<0.01 
    
HLA-DRB1*-DQB1* Freq ≥ 0.06 D p-value 
TP (N=36) 
   04-03 
08-06 
09-03 
11-03 
12-03 
14-05 
15-06 
0.18 
0.08 
0.15 
0.07 
0.14 
0.13 
0.10 
0.06 
0.06 
0.07 
0.03 
0.06 
0.11 
0.08 
0.02 
0 
0 
0.04 
0 
0 
0 
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Table 2 cont. 
 
 
 
HLA-DRB1*-DQB1* Freq ≥ 0.06 D p-value 
    PFA (N=24) 
   04-04 
08-06 
09-03 
12-03 
14-05 
15-06 
0.06 
0.08 
0.19 
0.13 
0.15 
0.08 
0.04 
0.06 
0.08 
0.05 
0.12 
0.07 
0.02 
0 
0 
0.02 
0 
0 
    PAH (N=12) 
   04-03 
08-06 
12-03 
14-05 
15-06 
0.17 
0.08 
0.17 
0.08 
0.13 
0.08 
0.07 
0.08 
0.08 
0.10 
0.04 
0.02 
0.04 
0 
0 
    TM (N=114) 
   04-03 
08-06 
09-03 
11-03 
12-03 
13-06 
14-05 
0.13 
0.07 
0.06 
0.15 
0.21 
0.03 
0.09 
0.04 
0.06 
0.03 
0.06 
0.09 
0.03 
0.08 
0 
0 
0 
0 
0 
0 
0 
    MFA (N=49) 
   04-04 
08-05 
08-06 
09-03 
11-03 
12-03 
0.04 
0.06 
0.12 
0.10 
0.18 
0.28 
0.03 
0.04 
0.91 
1.00 
0.06 
0.09 
0 
0 
0 
0.02 
0 
0 
    MAH (N=65) 
   04-03 
11-03 
14-05 
0.14 
0.13 
0.12 
0.08 
0.11 
0.13 
0 
0 
0 
    HLA-DRB1*-DQA1*-DQB1* Freq ≥ 0.06 D p-value 
    TP (N=36) 
   08-01-06 
11-05-03 
12-05-03 
13-01-06 
14-01-05 
15-01-06 
0.08 
0.07 
0.14 
0.15 
0.13 
0.10 
0.03 
0.02 
0.03 
0.13 
0.05 
0.04 
<0.01 
<0.02 
<0.01 
<0.01 
<0.01 
<0.01 
    PFA (N=24) 
   08-01-06 
12-05-03 
13-01-06 
15-01-06 
0.08 
0.13 
0.19 
0.08 
0.03 
0.03 
0.18 
0.03 
<0.01 
<0.01 
<0.01 
<0.01 
    PAH (N=12) 
   04-03-03 
13-01-06 
0.17 
0.08 
0.04 
0.04 
<0.05 
<0.05 
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Table 2 cont. 
 
 
N = total number of individuals, TP: Total Polynesians, PFA: Polynesians with Full Ancestry, PAH: 
Polynesians with Admixed History, TM= Total Maori, MFA = Maori with Full Ancestry, MAH: Maori with 
Admixed History. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-DRB1*-DQA1*-DQB1* Freq ≥ 0.06 D p-value 
TM (N=114) 
   04-03-03 
08-01-06 
09-03-03 
11-05-03 
12-05-03 
14-01-05 
0.13 
0.07 
0.06 
0.15 
0.21 
0.09 
0.08 
0.03 
0.02 
0.03 
0.02 
0.04 
<0.01 
<0.01 
<0.01 
<0.01 
<0.02 
<0.01 
    MFA (N=49) 
   08-01-06 
09-03-03 
11-05-03 
12-05-03 
0.12 
0.10 
0.18 
0.28 
0.05 
0.02 
0.04 
2.43 
<0.01 
<0.02 
<0.01 
<0.01 
    MAH (N=65) 
   04-03-03 
14-01-05 
0.14 
0.12 
0.05 
0.05 
<0.01 
<0.01 
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Fig. 1: Distributions of HLA class I alleles in our study group and sub-groups in comparison with TTM from previous study (5) and European population (ELAN-ref 7); (a) 
HLA-A, (b) HLA-B and (c) HLA-C. Abbreviations: MFA = Maori with Full Ancestry, TM = Total Maori, TTM = Tracey Total Maori, MAH = Maori with Admixed History, 
ELAN = England Lancaster. 
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Fig. 2: Graphs constructed using (a) HLA-DQA1, (b) HLA-DQB1 and (c) HLA-DRB1 allele frequencies show 
European admixtures in our admixed sub-group (MAH) and previous study on Maori (TTM-ref 6), in 
comparison to our full ancestry Maori sub-group (MFA) and typical European (ENG-ref 8) population. 
Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, 
TTM = Tracey Total Maori, ENG = England. 
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Fig. 3: PCO plots (axis 1 and 2) constructed using HLA-A, -B and -C allele frequencies. Reference populations obtained from (3,5,7,11,14,15).  Abbreviations: TM = Total 
Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, PAH = Polynesians with 
Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta Dataset (VTP + PFA), TTM = Tracey Total 
Maori, PNG = Papua New Guinea. 
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Fig. 4: Genetic relationships between Polynesians and other Asia Pacific populations (4,6,7,14,16,18,25) were probed using HLA-DRB1 and -DQB1 allele frequencies PCO 
plots (axis 1 and 2). Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians 
with Full Ancestry, PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta 
Dataset (VTP + PFA), TTM = Tracey Total Maori, PNG = Papua New Guinea, ENG = England.  
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Discussion 
 
The data presentation and analysis in the present study were specifically designed to trace the 
origin of Polynesians and Maori based on multidisciplinary perspectives of Proto-Polynesian 
diffusion to Remote Oceania, including recent admixture with Europeans (1,38,39).  For this 
reason, our new survey on HLA from full ancestry and admixed history sub-groups was 
carefully scrutinized and compared with existing data on Polynesians (3,4), Maori (5,6) and 
the European reference populations (7,8).   
 
The most common HLA genes observed in Polynesians are HLA-A*02, -A*24, -B*40,-B*56, 
-C*01, -DQB1*03 and -DRB1*04 (see Table 1).  The predominance of HLA-A*02, -A*24, -
B*40, -B*55, -DQB1*03 and -DRB1*04 genes in Polynesia can be traced back to Asia as 
these allele groups combinations are common among Taiwan aborigines and other A-SM 
populations (7,9,10-13,18,20,22,24-27).  The HLA-A*24 is also commonly seen among P-SA, 
where it may have also been passed to Proto-Polynesians via this route (see 7,10,11). In 
contrast, high frequencies of HLA-B*56 and -C*01 among Polynesians may reflect geneflow 
from P-SA, as these alleles are also common among Austronesian speaking groups in 
Melanesia and other Australoids, respectively (7,11).  
 
The HLA-B*55 and -DQA1*03 alleles are not common in either putative ancestral population 
(i.e. P-SA and A-SM).  A detailed search of the Allele Frequency Net Database (7) shows 
Taiwan aborigines and Chinese to have the highest frequency of the HLA-B*55 allele in 
worldwide populations.  Hence, the presence HLA-B*55 in Polynesia may be taken as a 
faithful pointer to Taiwanese ancestors.  The HLA-DQA1 allele frequency distributions 
among Polynesians are generally inconsistent, where both HLA-DQA1*03 and -DQA1*05 
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have been reported to be the most common alleles in these people (7,18).  Because HLA-
B*55 and -DQA1*03 allele groups are not the most frequent HLA-B and -DQA1 allele 
groups in either of A-SM and P-SA peoples, it might be that natural selection or other 
evolutionary mechanisms have elevated the frequency of this allele in Polynesia (as 
discovered by others for HLA loci – see 40).   
 
Overall, there is agreement between the new HLA data for PFA and those previously 
obtained (3,4) – see Table 1.  This view is supported by the exact tests of population 
differentiation (see Table S3). Although individual Polynesian (Cook Islands, Tokelau, 
Tonga and Samoa) may well be significantly different from each other, their combined 
genepool as VTP is not significantly different from PFA. The differences between individual 
Polynesian populations might be due to genetic refinement via founder effects (aka The 
Genetic Bottleneck in Polynesia) during multiple re-settlements and also due to selection 
during long periods of isolation. The latter will further investigated using high resolution 
HLA data.  In particular, the close similarity of VTP to PFA rather than TP shows that 
subjects recruited for the previous studies probably have relatively little admixture.  Hence, 
we combined VTP and PFA to gain PMD for wider phylogenetic and PCO comparison 
(later). In doing so, we consciously rejected the opportunity to increase the overall sample 
size by combining TP and VTP.  We recognized that this sacrificed genuine Polynesian 
signal present in the TP group, but would increase noise due to inclusion of European genetic 
component in PAH.  
 
Genetic fractions in Polynesians are arguably best demonstrated by their HLA haplotype 
distributions.  The haplotype analysis increases statistical power by combining multiple loci 
as a single unit of inheritance.  Our estimation of haplotype frequencies might be slightly 
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affected by the inability of the Arlequin software to account of the presence of very small 
number of blank in the present study. The most frequent haplotypes detected in our PFA and 
other Polynesians (see Tables 2 and S4) can all be traced back to Asia and Melanesia.  For 
example,  HLA-A*02-C*01, HLA-C*01-B*56, HLA-C*04-B*40 and HLA-A*02-C*01-B*55 
associations are recorded from Taiwan, Philippines, Papua New Guinea Great Britain Rabaul, 
Cook Islands and Tokelau (refer 3,7,10,11,15,22) while HLA-DRB1*09-DQB1*03 is 
relatively common among Chinese, Japanese, Filipinos, Trobriand Islanders, PNG Roro 
(22,26,29,30).  Thus, the most frequent haplotypes represented by PFA and those previously  
reported (3,4) can be detected, all along the diffusion route of A-SM to Remote Oceania, as 
inferred from multidisciplinary perspectives (1). The potential influence of P-SA ancestors on 
the Polynesian genepool is supported by the presence of HLA-DRB1*15-DQA1*01-
DQB1*06 haplotype in the PFA (Table 2).  This is commonly reported as the most frequent 
haplotype among P-SA populations (see 17,19), but does also occur at relatively high 
frequency among Japanese, Chinese and Koreans (7).  Others (19) used high resolution HLA 
data to show differences between A-SM and P-SA.  Their P-SA populations included 
Australian aborigines have high frequencies of the HLA-DRB1*15:02-DQA1*01:02-
DQB1*06:01 haplotype while HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 is the more 
common type among their Asian populations: refer also to The Allele Frequency Net website 
(7) for wider population coverage.  Interestingly, the P-SA haplotype is more frequent among 
Polynesians (19).  Therefore, Polynesians seem to have inherited both haplotypes.  The HLA 
data generated from our present study does show the need for high resolution analysis in 
future in order to better distinguish level of ancestral contributions to the Polynesian 
genepool, because the current data are insufficient to trace origins and migration patterns in 
fine detail.  
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Existing HLA class I (5) and class II (6) data on Maori (TTM) provide the possibility of 
creating a larger unified group of Maori by combining MFA and TTM.  In general, HLA 
class I and II data for MFA and TTM do have general similarity in terms of the most frequent 
alleles observed.  Nonetheless, there are number of alleles reported in TTM that are absent in 
MFA, but often detected in MAH and our reference European populations, ELAN (7) and 
ENG (8).  We interpret this as showing European input in both, TTM and MAH. This view is 
further supported by the absence of nearly all of these alleles among the two ancestors, A-SM 
and P-SA, of modern Polynesian populations.  This recent European admixture effect is 
demonstrated clearly in Figs. 1 and 2. Although the more common alleles (e.g. HLA-A*02, -
C*01 and -DRB1*04) in MAH and TTM show quite similar frequencies to MFA, the MAH 
and TTM frequency bars for other alleles are only shared with ELAN/ENG or are 
intermediate in frequencies between MFA and ELAN.  This situation mirrors those observed 
in admixed Polynesians (PAH) at both, class I and II loci. 
 
The admixture effects in MAH and TTM are also shown, e.g. by both noting the reduced 
frequencies of some haplotypes (e.g. HLA-A*24-C*01 and HLA-A*24-C*04) which are quite 
common in MFA.  This might due to the presence of alleles in MAH and TTM which are 
common to Europeans and lead to the presence of additional haplotypes, which are not 
otherwise common among Polynesians.  For example, the HLA-A*02-C*05-B*44, HLA-
DRB1*07-DQB1*02 and HLA-DRB1*13-DQB1*06 haplotypes observed in MAH and TTM 
are almost exclusively European types (7).  
 
We conclude that our class I and II HLA data from MFA could be the best reference to use 
for genealogical comparisons while those belonging to TTM as reported by (5,6) and from 
our TM group should be treated as admixed groups and best represent the present-day Maori 
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genepool.  So, we take TTM plus TM together as MMD to best represent Maori presently 
living in New Zealand. In contrast, the previous Polynesian data (3,4) appears to be relatively 
free of admixture.  Thus, the data we collected for PAH and MAH are entirely novel in our 
experience and show the effect of recent admixture following the arrival of Europeans settlers 
in New Zealand from 1840 onwards.  In our view, recent admixture with Europeans has had 
significant impact on the genepool of Polynesians and Maori in New Zealand today. This is 
evident from both, the distributions of HLA alleles and haplotypes.  This conclusion is 
potentially of particular importance for genetic studies with medical applications and is the 
subject of the future high resolution analysis of these samples via sequence based typing (to 
be reported later). 
 
Next, we compared HLA data between Polynesians and Maori.  The predominant HLA class 
I alleles (see Table 1) observed in Polynesians such as HLA-A*02, -A*24, -B40, -B55 and -
C*01 are also the most common in MFA, except for HLA-B*56 which is slightly reduced in 
MFA.  As discussed earlier, HLA-A*02, -B*40 and -B*55 link Polynesians to A-SM 
populations, -C*01 and -B*56 to P-SA and -A*24 is in both (3,7,9-15).  There are only slight 
differences in distribution of HLA class II alleles between MFA and other Polynesians (see 
Table 1).  Besides the general inconsistency of HLA-DQA1 loci among Polynesians as 
previously noted, MFA has HLA-DRB1*12 as the most common allele while HLA-DRB1*04 
is predominant among other Polynesians.  However, both alleles can be traced back to their 
A-SM ancestors.  The HLA-DRB1*04 allele is the most common form among east coast 
Taiwanese Ami tribe (0.56) while two central mountain Taiwanese tribes (Taiwan Bunun: 
0.27 and and Rukai: 0.33) have HLA-DRB1*12 as their most common form (see 9).  
Nonetheless, differences at HLA-DQA1 and -DRB1 between Maori and other Polynesians 
may be attributed to a combination of historical and local selection forces (40).  This view 
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will be the subject of our next analysis using high resolution data (Dunn and Edinur 
unpublished). Overall, the distribution of HLA class I and II alleles shows the greater 
representation of A-SM ancestry in the Maori genepool, where HLA-A*24 and -C*01 are the 
only alleles that can be traced back to P-SA populations.   
 
The same can be seen regarding the distribution of HLA class I haplotypes where those that 
are typical of Polynesians, link them to A-SM populations and are particularly common in 
MFA (see Table 1 and Table S1).  Nevertheless, there is marked difference for class II 
haplotypes (see Table 1) where Maori have higher frequencies of HLA-DRB1*12- and HLA-
DRB1*12-DQA1*05- related haplotypes (e.g. HLA-DRB1*12-DQB1*03 and HLA-DRB1*12-
DQA1*05-DQB1*03).   Conversely, HLA-DRB1*04 and HLA-DRB1*04-DQA1*03-related 
haplotypes are more common among Polynesians (e.g. HLA-DRB1*04-DQB1*03 and HLA-
DRB1*04-DQA1*03-DQB1*03).  These haplotype combinations are consistent with the 
differences between Maori and other Polynesians at HLA-DRB1 and -DQA1 discussed 
above. However, HLA-DRB1*12- and HLA-DRB1*12-DQA1*05- related haplotypes 
associations, which are common in MFA, can also be traced back to Melanesian and Asian 
populations and indicate genetic affinities between Asia-Pacific populations (4,7,14,25,29).   
 
We used NJ phylogenetic tree (figure not shown) and PCO plots (Figs. 3-4 and Figs. S1-S2) 
to examine genetic affinities between Polynesian populations and their positions in a wider 
geographical context, particularly within the Asia-Pacific region.  As noted in the results 
section, geographically related populations tend to cluster in both data mapping/procedures. 
The NJ analysis does not, however, resolve the wider pattern of relationships as effectively as 
PCO.  We believe the latter to be a superior methodology in that it is empirical cf. theory-
based.  The NJ algorithm can only return a faithful representation of an evolutionary pattern 
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if the underlying population level process that generates it, is itself tree-like. When this 
assumption is violated, e.g. as here due to full or partial reticulation arising from dual origin 
and gene flow, then the method may not resolve the tree reliably.  The PCO method is based 
only on relative similarity and excludes them from this constraint.  Our PCO plots 
constructed using information from axis 1 and 2 (Figs. 3 and 4) show more clear separation 
of populations than those constructed using information from axis 1 and 3 (Figs. S1 and S2) 
and this finding is associated with greater relative amount of genetic information captured by 
axis 2 compared with axis 3. The PCO plots in Figs. 3 and 4 show that Polynesians are 
distinct from other Austronesian-speaking groups (Taiwanese and Malays) and their position 
reflects degree of shared ancestry with the P-SA populations (Australian aboriginals and 
PNG).  The distance between the two Austronesian groups (Taiwan aboriginals and Malays) 
reflect the diverse genepool of A-SM populations (41) and may be attributed to differences in 
allele frequency arising from founder effects during migration and/or natural selection 
associated with disease resistance.  This is supported by X
2 
goodness of fit analyses and exact 
tests of population differentiation where all the simulated of A-SM:P-SA populations are 
significantly different (p-value = 0) from Polynesians, regardless of mixing ratio.  We 
interpret this to mean that the test is too powerful for its intended purpose, i.e. it simply 
shows that allele frequencies differ between the test groups rather than pointing to the best 
match. 
   
Therefore, we used PCO plots to estimate genetic fractions of A-SM and P-SA in Polynesian 
and Maori genepools. Overall, we estimate approximate 60:40 genetic proportions of 
ASM:P-SA ancestral fractions in Maori and other Polynesians (see Figs. S4 to S8) compared 
with 70:30 and 85:15 proposed earlier by (31) and (32), respectively.  There is a fairly wide 
range across all loci (55:45 to 90:10).  Nonetheless, our estimation based on HLA-A, -B, -C 
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and -DRB1 allele frequencies and those proposed above (31,32) do lead to just one 
conclusion, the A-SM/P-SA dual origin of Polynesians.  Our corresponding estimates for 
Melanesians are 30:70 (range 24:76 to 50:50) compared with the previously reported value 
45:55, but ours are based on far fewer data.  Hence, this other value must be rated as more 
reliable as it is based on many SNP loci.  However, the general correspondence (i.e. with 
respect to both rank order and magnitude) between our calculated values and theirs is 
encouraging and supports the idea of genetic differentiation between Melanesians and 
Polynesians due to much higher P-SA content in the genepool of the former. 
 
Analysis of the two-digit resolution HLA class I and II data in this series point out the need 
for high resolution data to better resolve outstanding ambiguities and also to better determine 
A-SM/P-SA ancestral fractions.  Therefore, this will be now part of the subject matter in our 
next study using high resolution HLA class I and II data, besides the primary focus to look 
deeper at evolutionary processes such as bottlenecks, natural selection and, more significantly, 
the implications for health.  Finally, placements of admixed sub-groups (e.g. MAH, TM and 
PAH) toward European population (ELAN and ENG) in Figs. 3 and 4 are evidence for 
significant contemporary geneflow from Europeans.  In our view, full understanding of these 
admixed sub-groups should be a primary focus in any new developments in domestic health 
policies as these emerging lineages corresponds to present day Polynesian and Maori living 
in New Zealand. 
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Supplementary information 
 
Table S1: Exact test of Hardy-Weinberg equilibrium (p-values) for the studied population 
groups and sub-groups.  
 
Deviation from HWE is considered significant at p-value < 0.05. Abbreviations: TP: Total Polynesians, PFA: 
Polynesians with Full Ancestry, PAH: Polynesians with Admixed History, TM= Total Maori, MFA = Maori 
with Full Ancestry, MAH: Maori with Admixed History. 
 
 
 
 
 
Table S2: Likelihood-ratio test of linkage disequilibrium (p-values) between pairs of HLA 
loci in the studied population groups and sub-groups.  
 
HLA-
A*-C* 
HLA-
A*-B* 
HLA-C*-
B* 
DRB1*-
DQA1* 
HLA-DRB1-
DQB1* 
HLA-DQA1-
DQB1* 
TP 0 0 0 0 0 0 
PFA 0 0.04 0 0 0 0 
PAH 0.47 0.23 0.01 0 0 0 
TM 0 0 0 0 0 0 
MFA 0 0 0 0 0 0 
MAH 0 0 0 0 0 0 
 
Linkage between pairs of loci is considered significant at p-value < 0.05. Abbreviations: TP: Total Polynesians, 
PFA: Polynesians with Full Ancestry, PAH: Polynesians with Admixed History, TM= Total Maori, MFA = 
Maori with Full Ancestry, MAH: Maori with Admixed History. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HLA-A* HLA-C*  HLA-B* HLA-DRB1* HLA-DQA1* HLA-DQB1* 
 
 
 
 
 
  
 
 
TP 
PFA 
PAH 
TM 
MFA 
MAH 
 0.65 
0.32 
0.92 
0.28 
0.69 
0.16 
0.43 
0.22 
0.69 
0.68 
0.77 
0.51 
 0.38 
0.14 
0.23 
0.62 
0.83 
0.77 
0.56 
0.46 
1 
0.11 
0.47 
0.43 
0.75 
0.14 
0.56 
0.47 
0.24 
0.78 
0.30 
0.79 
0.79 
0.37 
0.99 
0.32 
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Table S3: Exact test of population differentiation (p-values) between pairs of Polynesian and 
Maori datasets 
 
The two populations are considered significantly different if having p-value < 0.05. Abbreviations: TP: Total 
Polynesians, PFA: Polynesians with Full Ancestry, PAH: Polynesians with Admixed History, CI: Cook Islands 
(3,4), TOK: Tokelau (3,4), TON: Tonga (3,4), SA: Samoa (3,4), VTP: Velickovic Total Polynesians 
(CI+TOK+TON+SA) and PMD: Polynesian Meta Dataset (PFA+VTP), TM= Total Maori, MFA = Maori with 
Full Ancestry,  MAH: Maori with Admixed History, TTM: Tracey Total Maori  (5,6). 
 
Exact tests class I (p-values) 
 
TP PFA PAH CI TOK TON SA VTP PMD TM MFA MAH TTM 
TP 
PFA 
PAH 
CI 
TOK 
TON 
SA 
VTP 
PMD 
TM 
MFA 
MAH 
TTM 
~ 
1 
0.52 
0.25 
0 
0.02 
0.13 
0.01 
0.12 
0.03 
0.01 
0 
0 
~ 
0.02 
0.35 
0 
0.27 
0.44 
0.45 
0.91 
0.05 
0 
0 
0 
~ 
0.02 
0 
0 
0 
0 
0 
0.08 
0 
0.04 
0.01 
~ 
0 
0 
0 
0 
0.01 
0 
0.04 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0.46 
0.42 
0 
0 
0 
0 
 
~ 
0.04 
0.21 
0 
0 
0 
0 
~ 
1 
0 
0 
0 
0 
~ 
0 
0 
0 
0 
 
~ 
0.48 
0.93 
0 
~ 
0 
0 
~ 
0 
 
~ 
              Exact tests class II (p-values) 
              
 
TP PFA PAH CI TOK TON SA VTP PMD TM MFA MAH TTM 
TP 
PFA 
PAH 
CI 
TOK 
TON 
SA 
VTP 
PMD 
TM 
MFA 
MAH 
TTM 
~ 
1 
0.96 
0.35 
0 
0.34 
0 
0.12 
0.12 
0.03 
0 
0.01 
0 
~ 
0.49 
0.62 
0.01 
0.73 
0.03 
0.91 
0.96 
0.04 
0.01 
0.01 
0 
 
~ 
0.09 
0 
0.02 
0 
0 
0 
0.59 
0.01 
0.92 
0.10 
~ 
0 
0.08 
0 
0.36 
0.30 
0.04 
0.03 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0.36 
0.38 
0 
0 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
~ 
1 
0 
0 
0 
0 
 
~ 
0 
0 
0 
0 
~ 
0.13 
0.69 
0 
~ 
0 
0 
~ 
0.01 ~ 
              Exact tests class I and II (p-values) 
                            
 
TP PFA PAH CI TOK TON SA VTP PMD TM MFA MAH TTM 
 ~ 
1 
0.85 
0.33 
0 
0.05 
0 
0 
0.09 
0.01 
0 
0 
0 
~ 
0.04 
0.48 
0 
0.55 
0.12 
0.75 
0.99 
0.01 
0 
0 
0 
~ 
0.01 
0 
0 
0 
0 
0 
0.14 
0 
0.17 
0.01 
~ 
0 
0 
0 
0.01 
0.01 
0 
0.01 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0.50 
0.42 
0 
0 
0 
0 
 
~ 
0 
0 
0 
0 
0 
0 
~ 
1 
0 
0 
0 
0 
 
~ 
0 
0 
0 
0 
~ 
0.28 
0.97 
0 
~ 
0 
0 
~ 
0 
 
~ 
TP 
PFA 
PAH 
CI 
TOK 
TON 
SA 
VTP 
PMD 
TM 
MFA 
MAH 
TTM 
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Table S4: List of HLA class I and II haplotypes in Maori and Polynesian datasets.  
Datasets  
(N) 
TP 
(36) 
PFA 
(24) 
PAH 
(12) 
TM 
(114) 
MFA 
(49) 
MAH 
(65) 
CI 
(50) 
TON 
(50) 
TOK 
(50) 
SA 
(50) 
VTP 
(200) 
PMD 
(224) 
HLA-A*-C* 
            
             02-01 
02-03 
02-05 
02-07 
11-01 
11-04 
11-08 
24-01 
24-03 
24-04 
24-07 
24-08 
24-12 
34-01 
34-15 
0.15 
0 
0.03 
0 
0 
0.07 
0 
0.16 
0.08 
0.10 
0 
0.04 
0.06 
0.03 
0.07 
0.19 
0 
0 
0 
0 
0.08 
0.04 
0.06 
0.10 
0.10 
0.04 
0.06 
0.06 
0.02 
0.08 
0.13 
0.04 
0.04 
0.04 
0 
0.04 
0 
0.29 
0 
0.08 
0.04 
0 
0.04 
0.04 
0.04 
0.20 
0.01 
0.03 
0.06 
0 
0.06 
0.08 
0.09 
0 
0.05 
0.08 
0.05 
0 
0 
0.05 
0.33 
0 
0.01 
0 
0 
0.09 
0.10 
0.12 
0 
0.09 
0.10 
0.07 
0 
0 
0.02 
0.13 
0.01 
0.05 
0.11 
0 
0.05 
0.09 
0.05 
0.01 
0.02 
0.07 
0.03 
0 
0 
0.07 
0.14 
0 
0 
0 
0 
0 
0.04 
0.21 
0 
0.05 
0.11 
0.05 
0.08 
0.05 
0.06 
0.06 
0 
0 
0 
0.06 
0 
0.07 
0.21 
0 
0.11 
0.05 
0.05 
0 
0 
0.05 
0.09 
0 
0 
0.05 
0 
0.12 
0 
0.12 
0 
0.28 
0 
0 
0 
0 
0.04 
0.11 
0.15 
0 
0 
0 
0 
0 
0.12 
0.09 
0.07 
0.09 
0.04 
0 
0 
0.04 
0.10 
0.04 
0 
0 
0.02 
0.05 
0.04 
0.17 
0.04 
0.13 
0.06 
0.04 
0.02 
0 
0.05 
0.11 
0.04 
0 
0 
0.02 
0.05 
0.04 
0.16 
0.05 
0.13 
0.06 
0.04 
0.02 
0 
0.05 
             HLA-C*-B* 
            
             01-55 
01-56 
03-40 
04-15 
04-40 
04-55 
05-44 
07-07 
07-39 
07-56 
08-48 
12-15 
15-40 
0.18 
0.13 
0.11 
0.04 
0.14 
0 
0.03 
0.01 
0.06 
0.01 
0.07 
0 
0.07 
0.15 
0.10 
0.15 
0.02 
0.19 
0 
0.02 
0 
0.06 
0.02 
0.10 
0 
0.08 
0.19 
0.21 
0.04 
0 
0.04 
0 
0 
0.04 
0.04 
0 
0 
0 
0 
0.25 
0.15 
0.01 
0 
0.12 
0 
0.03 
0.03 
0.09 
0.02 
0.12 
0 
0.05 
0.37 
0.06 
0.01 
0 
0.17 
0 
0.01 
0.01 
0.09 
0.01 
0.13 
0 
0.02 
0.16 
0.02 
0.01 
0.01 
0.08 
0 
0.06 
0.06 
0.10 
0.02 
0.10 
0 
0.07 
0.22 
0.15 
0 
0 
0.09 
0 
0 
0 
0.10 
0.04 
0.10 
0 
0.07 
0.07 
0.26 
0.08 
0.04 
0.14 
0 
0 
0 
0.03 
0.04 
0.11 
0 
0.07 
0.18 
0.07 
0 
0 
0.43 
0 
0 
0 
0.04 
0 
0 
0.05 
0.04 
0.10 
0.12 
0.21 
0.04 
0.10 
0 
0 
0.03 
0.04 
0 
0.10 
0 
0.07 
0.14 
0.15 
0.07 
0.02 
0.19 
0 
0 
0 
0.05 
0.02 
0.08 
0.01 
0.06 
0.14 
0.14 
0.08 
0.02 
0.19 
0 
0 
0.03 
0.05 
0.02 
0.08 
0.01 
0.06 
                          HLA-A*-C*-B* 
             01-07-08 
02-01-55 
02-03-40 
02-05-44 
02-07-07 
11-01-56 
11-04-40 
11-08-48 
24-01-55 
24-01-56 
24-03-40 
24-04-15 
24-04-40 
24-07-39 
24-07-56 
24-08-48 
24-12-15 
34-01-55 
34-15- 40 
0.01 
0.08 
0 
0 
0 
0.04 
0.07 
0 
0.09 
0.12 
0.07 
0 
0.04 
0 
0 
0.04 
0 
0 
0.07 
0 
0.12 
0 
0 
0 
0 
0.08 
0.04 
0 
0.06 
0.10 
0 
0.08 
0.04 
0 
0.06 
0 
0 
0.08 
0.04 
0.08 
0.04 
0 
0 
0.04 
0.04 
0 
0.17 
0.13 
0 
0 
0 
0 
0 
0 
0 
0 
0.04 
0.03 
0.19 
0 
0.03 
0.03 
0 
0.06 
0.07 
0.05 
0.03 
0 
0 
0.04 
0.08 
0 
0.05 
0 
0 
0.05 
0.02 
0.29 
0 
0 
0.01 
0 
0.09 
0.05 
0.07 
0.06 
0 
0 
0.06 
0.09 
0 
0.08 
0 
0 
0.02 
0.04 
0.11 
0.01 
0.05 
0.04 
0 
0.05 
0.08 
0.04 
0.02 
0 
0 
0.02 
0.07 
0 
0.02 
0 
0 
0.07 
0 
0.13 
0 
0 
0 
0 
0 
0.04 
0.05 
0.11 
0 
0 
0.05 
0.09 
0 
0.05 
0 
0.04 
0.06 
0 
0.04 
0 
0 
0 
0.05 
0 
0.07 
0 
0.19 
0 
0.04 
0.04 
0 
0.04 
0.04 
0 
0 
0.05 
0 
0.09 
0 
0 
0 
0 
0.12 
0 
0.08 
0 
0 
0 
0.27 
0 
0 
0 
0.06 
0 
0 
0 
0.05 
0.15 
0 
0 
0 
0 
0 
0 
0.08 
0.05 
0 
0.09 
0 
0 
0.06 
0 
0 
0.04 
0 
0.08 
0.04 
0 
0 
0 
0 
0 
0.04 
0.10 
0 
0 
0.11 
0 
0 
0.04 
0 
0 
0.04 
0 
0.08 
0.04 
0 
0 
0 
0.01 
0 
0.04 
0.10 
0.01 
0 
0.11 
0 
0 
0.04 
0 
0 
0.04 
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Table S4 cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TP: Total Polynesians, PFA: Polynesians with Full Ancestry, PAH: Polynesians with Admixed 
History, TM= Total Maori, MFA = Maori with Full Ancestry,  MAH: Maori with Admixed History, CI: Cook 
Islands (3,4), TOK: Tokelau (3,4), TON: Tonga(3,4), SA: Samoa (3,4), VTP: Velickovic Total Polynesians 
(CI+TOK+TON+SA) and PMD: Polynesian Meta Dataset (PFA+VTP) 
 
 
 
 
 
 
 
 
 
 
 
 
Datasets  
(N) 
TP 
(36) 
PFA 
(24) 
PAH 
(12) 
TM 
(114) 
MFA 
(49) 
MAH 
(65) 
CI 
(50) 
TON 
(50) 
TOK 
(50) 
SA 
(50) 
VTP 
(200) 
PMD 
(224) 
HLA-DRB1*-DQB1* 
 01-05 
03-02 
04-02 
04-03 
04-04 
07-02 
07-03 
08-05 
08-06 
09-03 
11-03 
12-02 
12-03 
13-06 
14-05 
15-05 
15-06 
0.03 
0.01 
0 
0.18 
0.04 
0 
0 
0 
0.08 
0.15 
0.07 
0 
0.14 
0.03 
0.13 
0 
0.10 
0.02 
0 
0 
0.19 
0.06 
0 
0 
0 
0.08 
0.19 
0.06 
0 
0.13 
0.01 
0.15 
0 
0.08 
0.04 
0.04 
0 
0.17 
0 
0 
0 
0 
0.08 
0.08 
0.08 
0 
0.17 
0.04 
0.08 
0 
0.13 
0.03 
0.03 
0 
0.13 
0.02 
0.02 
0.01 
0.02 
0.07 
0.06 
0.15 
0 
0.21 
0.03 
0.09 
0 
0.03 
0.01 
0.02 
0 
0.12 
0.04 
0 
0 
0.06 
0.12 
0.10 
0.18 
0 
0.28 
0 
0.05 
0 
0.01 
0.04 
0.05 
0 
0.14 
0 
0.04 
0.02 
0 
0.03 
0.03 
0.13 
0 
0.01 
0.05 
0.12 
0 
0.05 
- 
- 
- 
0.24 
0 
- 
- 
0.03 
0.03 
0.09 
0.11 
- 
0.16 
- 
0.13 
0 
0.03 
- 
- 
- 
0.17 
0.03 
- 
- 
0 
0.11 
0.15 
0.16 
- 
0.06 
- 
0.11 
0.03 
0.07 
- 
- 
- 
0.36 
0.06 
- 
- 
0 
0.07 
0.04 
0 
- 
0.22 
- 
0.07 
0 
0.06 
- 
- 
- 
0.15 
0.08 
- 
- 
0 
0.07 
0.25 
0.07 
- 
0.08 
- 
0.08 
0 
0.08 
- 
- 
- 
0.23 
0.04 
- 
- 
0.01 
0.07 
0.13 
0.09 
- 
0.13 
- 
0.10 
0.01 
0.06 
- 
- 
- 
0.21 
0.05 
- 
- 
0 
0.08 
0.16 
0.07 
- 
0.13 
- 
0.12 
0 
0.07 
             HLA-DRB1*-DQA1*-DQB1* 
 01-05-01 
03-02-05 
04-03-03 
07-02-02 
08-05-01 
08-06-01 
09-03-03 
11-03-05 
12-05-03 
13-06-01 
14-01-05 
15-01-06 
0.03 
0.01 
0.18 
0 
0 
0.08 
0.15 
0.07 
0.14 
0.15 
0.13 
0.10 
0.02 
0 
0.19 
0 
0 
0.08 
0.19 
0.06 
0.13 
0.19 
0.15 
0.08 
0.04 
0.04 
0.17 
0 
0 
0.08 
0.03 
0.08 
0.17 
0.08 
0.08 
0.13 
0.03 
0.03 
0.13 
0.03 
0.03 
0.07 
0.06 
0.15 
0.21 
0.03 
0.09 
0.03 
0.01 
0.02 
0.12 
0 
0.06 
0.12 
0.10 
0.18 
0.28 
0 
0.05 
0.01 
0.05 
0.05 
0.14 
0.05 
0 
0.04 
0.03 
0.13 
0.16 
0.05 
0.12 
0.05 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
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Table S5: Exact tests of population differentiation of HLA class I data from Polynesian, Maori and combination genepool of Taiwan Ami (A) 
and Papua New Guinea Goroko (G).  
 
Exact tests class I (p-values)  
 
PFA MFA CI TOK TON SA VTP PMD A G 50A:50G 60A:40G 70A:30G 80A:20G 90A:10G 
PFA 
MFA 
CI 
TOK 
TON 
SA 
VTP 
PMD 
A 
G 
50A:50G 
60A:40G 
70A:30G 
80A:20G 
90A:10G 
~ 
0 
0.29 
0 
0.29 
0.41 
0.43 
0.92 
0 
0 
0 
0 
0 
0 
0 
~ 
0.03 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
~ 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0.46 
0.47 
0 
0 
0 
0 
0 
0 
0 
~ 
0.06 
0.19 
0 
0 
0 
0 
0 
0 
0 
~ 
1 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0 
0 
0 
0 
0 
0 
~ 
0 
0 
0 
0.06 
0.74 
1 
~ 
0 
0 
0 
0 
0 
 
~ 
1 
0.69 
0.01 
0 
~ 
1 
0.66 
0.01 
 
~ 
1 
0.59 
 
~ 
1 
 
~ 
 
The two populations are considered significantly different if having p-value < 0.05. Abbreviations: PFA: Polynesians with Full Ancestry, MFA = Maori with Full Ancestry, 
CI: Cook Islands (3), TOK: Tokelau (3), TON: Tonga (3), SA: Samoa (3), VTP: Velickovic Total Polynesians (CI+TOK+TON+SA) and PMD: Polynesian Meta Dataset 
(PFA+VTP), A: Taiwan Ami (7,15) and G: Papua New Guinea Goroko (11). 
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Fig. S1: PCO plots (axis 1 and 3) constructed using HLA-A, -B and -C allele frequencies. Reference populations obtained from (3,5,7,11,14,15).  Abbreviations: TM = Total 
Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, PAH = Polynesians with 
Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians meta dataset (VTP + PFA), TTM = Tracey Total 
Maori, PNG = Papua New Guinea.  
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Fig. S2: PCO plots in Fig. 4 were re-construct using genetic percentage represent by axis 1 and 3.  References populations obtained from (4,6,7,14,16,18,25). Abbreviations: 
TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, PAH = 
Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians meta dataset (VTP + PFA), TTM 
= Tracey Total Maori, PNG = Papua New Guinea, ENG = England.  
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Fig. S3: Here, we demonstrate that there are no marked differences between PCO plots constructed using HLA-A, -B and -C allele frequencies (axis 1 and 2) for just the 
original populations and from those constructed together with combined populations (Fig. 3). Reference populations obtained from (3,5,7,11,14,15). Abbreviations: TM = 
Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, PAH = Polynesians 
with Admixed History, TTM = Tracey Total Mori, PNG = Papua New Guinea.  
Chapter 3.1 
 
105 
 
 
 
Fig. S4: HLA-A allele frequencies PCO plots used to estimate genetic fractions of Maori and Polynesian populations based on simulated proportions of A-SM (Taiwan Ami, 
Atayal, Paiwan, Rukai, Puyuma and Tsou) and P-SA (Papua New Guinea Goroko and West Schrader Ranges)  genepools. References populations obtained from 
(3,5,7,11,15).  Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with 
Full Ancestry, PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta 
Dataset (VTP + PFA), TTM = Tracey Total Maori, A-SM = Austronesian-speaking Mongoloids, P-SA = Papuan-speaking Australoids.  
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Fig. S5: HLA-B allele frequencies PCO plots used to estimate genetic fractions in Maori and Polynesian populations based on simulated proportions of A-SM (Taiwan Ami, 
Atayal, Paiwan, Rukai, Puyuma and Tsou) and P-SA (Papua New Guinea Goroko and West Schrader Ranges) genepools. Reference populations obtained from (3,5,7,11,15). 
Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, 
PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta Dataset (VTP + 
PFA), TTM = Tracey Total Maori, A-SM = Austronesian-speaking Mongoloids, P-SA = Papuan-speaking Australoids.  
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Fig. S6: HLA-C allele frequencies PCO plots used to estimate genetic fractions in Maori and Polynesian populations based on simulated proportions of A-SM (Taiwan Ami, 
Atayal, Paiwan, Rukai, Puyuma and Tsou) and P-SA (Papua New Guinea Goroko and West Schrader Ranges) genepools. Reference populations obtained from (3,5,7,11,15). 
Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, 
PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta Dataset (VTP + 
PFA), TTM = Tracey Total Maori, A-SM = Austronesian-speaking Mongoloids, P-SA = Papuan-speaking Australoids.  
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Fig. S7: HLA-DRB1 allele frequencies PCO plots used to estimate genetic fractions in Maori and Polynesian populations based on simulated proportions of A-SM (Taiwan 
Ami, Atayal, Paiwan, Rukai, Puyuma and Tsou) and P-SA (Australian Aborigine Yuendemu, Kimberly, Cape York Peninsula and Papua New Guinea Goroko) genepools. 
References population obtained from (4,6,7,11,15). Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with Admixed History, TP = Total 
Polynesians, PFA = Polynesians with Full Ancestry, PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook Islands + Tokelau + Tonga + 
Samoa), PMD = Polynesians Meta Dataset (VTP + PFA), TTM = Tracey Total Maori, A-SM = Austronesian-speaking Mongoloids, P-SA = Papuan-speaking Australoids.  
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Fig. S8: Combination of HLA-A, -B, -C and –DRB1 allele frequencies PCO plots used to estimate genetic fractions in Maori and Polynesian populations based on simulated 
proportions of A-SM (Taiwan Ami, Atayal, Paiwan, Rukai, Puyuma and Tsou) and P-SA (Australian Aborigine Yuendemu, Kimberly, Cape York Peninsula and Papua New 
Guinea Goroko) genepools. Reference populations obtained from (3-7,11,15). Abbreviations: TM = Total Maori, MFA = Maori with Full Ancestry, MAH = Maori with 
Admixed History, TP = Total Polynesians, PFA = Polynesians with Full Ancestry, PAH = Polynesians with Admixed History, VTP = Velickovic Total Polynesians (Cook 
Islands + Tokelau + Tonga + Samoa), PMD = Polynesians Meta Dataset (VTP + PFA), TTM = Tracey Total Maori, A-SM = Austronesian-speaking Mongoloids, P-SA = 
Papuan-speaking Australoids. 
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ABSTRACT 
 
Data from HLA typing studies have made significant contributions to genetic theories about 
the Austronesian diaspora and the health of descendant populations. To help further unravel 
pattern and process elements, we have typed HLA and MICA loci at high resolution in DNA 
samples from well defined groups of Maori and Polynesian individuals.  Our results show a 
restricted set of HLA class I alleles compared with other well characterised populations.  In 
contrast, the class II HLA-DRB1 locus seems to be diverse in Maori and Polynesians and 
both groups show high frequencies of HLA-DRB1*04:03, -DRB1*08:03, -DRB1*09:01 and -
DRB1*12:01.  Our survey also provides the first ever MICA datasets for Polynesians and 
reveal unusual distributions and associations with the HLA-B locus.  Overall, our data 
provide further support for a hybrid origin for Maori and Polynesians.  One novel feature of 
our study is the finding that the gene sequence of the HLA-B*40:10 allele in Polynesians is a 
recombinant of HLA-B*55:02 and -B*40:01.  HLA-B*40:10 is in close association with HLA-
C*04:03, an allele identified as a hybrid of HLA-C*04 and -C*02.  In this respect, our data 
resemble those reports on Amerindian tribes where inter-allele recombination has been a 
common means of generating diversity.  However, we emphasize that Amerindian gene 
content per se is only a very minor element of the overall Polynesian genepool.  The wider 
significance of HLA and MICA allele frequencies across the Pacific for modern day health is 
also discussed in terms of the frequency relative to reference populations of disease known to 
be associated with specific HLA and MICA markers. Thus, Polynesians and Maori are 
largely unaffected by “European autoimmune diseases” such as ankylosing spondylitis, 
uveitis and coeliac disease, yet there are several Maori- and Polynesian-specific autoimmune 
diseases where the HLA and MICA associations are still to be determined. 
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1. Introduction 
 
     The structurally homologous classical HLA (human leukocyte antigen) and MICA (major 
histocompatibility complex class I chain-related gene A) molecules are encoded by the 
closely-linked genes located on the short arm of human chromosome 6.  The HLA and MICA 
genes are highly polymorphic, reflecting their roles in the adaptive immune system [1-3].  
MICA, as HLA, is clinically relevant in organ transplantation [4] and may have a role in 
haematopoietic stem cell transplantation as it is a ligand for NKG2D which activates NK 
cells and T cells [5].  Pacific population data from HLA and MICA may also be viewed in the 
light of an uncontested archaeological chronology [6].  The present survey is the first study of 
MICA in Polynesian and Maori subjects, while population data generated from HLA studies 
have been of longstanding value in learning about the origins of Polynesians [7-13].  In 
general, they show close genetic similarities between Polynesian and Asian populations. 
Other work illustrates moderate gene flow between Austronesian-speaking Mongoloids (A-
SM) and Papuan-speaking Australoids (P-SA) in Melanesia before voyaging began to 
Remote Oceania; see [6,13] for further details.  The emerging picture is one, where both 
Polynesian and Melanesian people have a common hybrid origin, but that the former have 
retained relatively greater A-SM content in their genepool.  These features mirror conclusions 
based on SNP data [14,15].  Such findings are entirely consistent with earlier studies from 
tissue typing laboratories; blood groups and globin gene rearrangements [16-23].  Autosomal 
markers are thus in accord and show hybrid origin of Polynesians with strongest link to Asia. 
 
 Data from maternal and paternal specific markers, mtDNA and Y-chromosome,  
reveal details of the hybridisation phase – specifically  that it was gender-biased with 
relatively high proportions of  P-SA males and A-SM females involved in the  diffusion 
Chapter 3.2 
113 
 
process via Near Oceania and out to wider Polynesia.  Hence, mtDNA maps Polynesian 
origins back to Taiwan [24] while Y chromosome data show a predominantly „Melanesian‟ 
influence in the Polynesian paternal genepool [25,26].  These markers also show variation 
from West to East as voyaging progressed via repeated founder effects and were repeatedly 
subject to episodes of natural selection.  The same forces may well have shaped HLA and 
MICA allele frequencies and nature of variation at these loci may indicate the effect of 
particular types of selection pressure.  Cell surface antigens such as HLA and MICA are 
important in disease resistance and have been associated with a wide range of autoimmune 
disorders.  In this context, variations of HLA and MICA alleles in particular populations may 
also have consequences for contemporary health, as many studies have shown associations of 
HLA and MICA alleles with diseases; e.g. multiple sclerosis, rheumatoid arthritis, ankylosing 
spondylitis, Behcet‟s disease, type 1 diabetes etc. [2,27,28].  These loci are, therefore, 
exposed to natural selection and their patterns of allelic diversity can reveal features of 
significant events in population history. The HLA and MICA data generated from this survey 
and previous studies will now be used to provide further information about socio-cultural 
factors prevailing during initial occupancy of Near Oceania by Polynesian ancestors and 
extended to include the effects of recent admixture with Europeans and their contemporary 
medical significance. 
 
2. Materials and Methods 
 
2.1. Samples 
 
     Human genomic DNA samples from unrelated individuals were obtained from the 
Victoria University of Wellington DNA Bank and consist of Total Polynesian (TP) and Total 
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Maori (TM) groups.  The volunteers have varying degrees of admixture, particularly with 
Europeans.  We have divided them into Full Ancestry (i.e. Polynesians with Full Ancestry: 
PFA and Maori with Full Ancestry; MFA) sub-groups for those with four grandparents and 
no family ancestral knowledge of members from other ethnic groups.  All genetic materials 
were obtained with informed consent and ethical approvals were obtained from the New 
Zealand Central Region Ethic Committee and Victoria University Human Ethic Committee.   
 
2.2. HLA and MICA genotyping  
 
     Genetic variation at HLA-A, -B and -C loci were determined by high resolution DNA 
sequence based typing using a combination of locus- and allele-specific primers [29]. HLA-
DRB1 high resolution typing was also by sequence based typing (SBT) [29] or by using 
Luminex High Definition DRB1 beads („HD DR‟ One Lambda, Canooga Park, CA, USA).  
DNA sequences were compiled and assigned using SBTengine software (Genome 
Diagnostics, Utrecht Holland).  The HLA-DRB3, DRB4, DRB5, DQA1, DPA1, -DPB1 and 
MICA loci were genotyped using rSSOP Luminex beads (One Lambda, Canoga Park, CA, 
USA) at the Cleveland Clinic, Ohio.  To test for a MICA deletion [30], a multiplex PCR 
approach was utilized as previously described [31].  Briefly, DNA samples were sent to the 
Cleveland Clinic and interrogated for a possible MICA deletion using multiplex PCR carried 
out on a thermo cycler (GeneAmp PCR System 9700, Applied Biosystems, Foster City, CA, 
USA) in a 20 µl mixture containing 0.1 µg of genomic DNA, three primer pairs (0.5 µM 
each), 0.2 mM dNTP, 1.5 mM MgCl2, 5% DMSO, and 1.25 units of AmpliTaq Gold DNA 
polymerase (Applied Biosystems). The PCR conditions were as follows: 31 cycles at 95 ºC 
for 1 min, 61 ºC for 1 min, 72ºC for 1 min, with an initial denaturation at 95 ºC for 5 min and 
a final extension at 72ºC for 5 min. The MICA locus for Polynesian sub-populations Cook 
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Islands, Samoa, Tokelau and Tonga was genotyped using SBT as previously described 
[32,33]. The MICA deletion was not specifically confirmed in Polynesian sub-populations. 
DNA sequences were compiled and assigned using Match Tools and MT Navigator software 
(Applied Biosystems, Foster City, CA, USA)  
 
2.3. Statistical analyses 
 
     Allele frequencies were obtained by the direct counting method. Direct counting was 
applied because no typing ambiguities were observed and individuals are considered 
homozygotes if only one type of allele group detected at particular HLA and MICA locus, 
unless MICA deletion was detected for the latter.  Observed MICA allele frequencies were 
generated for Polynesian sub-populations (i.e. Cook Islands, Tokelau, Tonga and Samoa) 
including the blank allele as MICA deletion could not be excluded or confirmed (Velickovic, 
unpublished).  Haplotype frequencies estimation (i.e. Expectation-Maximization), test for 
Hardy-Weinberg equilibrium (HWE) and linkage disequilibrium (LD) between pairs of HLA 
loci, compute LD coefficients between pairs of alleles at different loci, exact test of 
population differentiation and Ewens-Watterson homozygosity (F) tests were carried out 
using algorithm included in Arlequin software version 3.1 [34].  The LD between three 
alleles at three different loci was calculated as described elsewhere in [13].  Multi-Variate 
Statistical Package version 3 (Kovach Computing Services; http://www.kovcomp.com/mvsp) 
was used to build PCO plots.  The heatmap plot was constructed using ggplots2 and 
RColorBrewer in R (http://www.r-project.org/). 
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3. Results  
 
     The numbers and frequencies of HLA and MICA alleles observed in our new survey on 
Polynesian and Maori individuals are listed in Table 1.  Our data for MICA are novel and the 
first reported for Polynesians and Maori.  Statistical tests on genotypic HLA and MICA data 
show that Polynesian and Maori study groups and sub-groups are in HWE except for HLA-C 
in PFA, HLA-DRB1, -DPB1 in TM, and MICA in both, TM and MFA.  There is significant 
linkage disequilibrium between pairs of HLA-A-C, HLA-C-B, HLA-DQA1-DRB1, HLA-
DQB1-DRB1, HLA-DPA1-DPB1 and HLA-B-MICA in both Maori and Polynesian study 
groups and sub-groups.  Ewens-Watterson homozygosity tests based on HLA and MICA 
allele frequencies (in Table 1) are shown in Table S1.  Together with our newly collected 
data in Table S1 are HLA data from other Polynesian populations [8,9,35-37] - see later for 
population comparison.  Overall, the homozygosity values for Polynesian and Maori datasets 
are around or below those expected under the assumption of neutrality with only Tonga 
(HLA-B, -DQB1 and -DRB1), Samoa (HLA-DQB1) and TM (HLA-DPA1) being 
significantly lower. 
 
     We have made every effort to compare our data with all of those available for related 
populations in other published sources.  This is often difficult because different studies 
examine different sets of loci having greater or lesser overlap with ours.  This means that for 
some loci that we tested, there are more sources with which we can make comparisons than 
for others.  We began with a detailed examination of our data and compared them with 
[8,9,35] as the closest comparable works on Polynesians (see Table S2).  For accuracy, 
comparisons were only made on HLA allele frequencies as MICA deletion was not 
specifically confirmed in the previous study of Polynesians (see Table S2 for reason to 
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exclude MICA).  The HLA allele frequencies do sometimes show significant differences at 
some loci among individual Polynesian populations in these earlier studies.  Nonetheless, we 
combined Cook Islands, Tokelau, Tonga and Samoa data into a larger unified group, VTP 
(Velickovic Total Polynesians).  This matches our PFA fairly closely at all of the six tested 
HLA loci (see Table S3).  Our TP group shows good internal agreement with PFA at all loci 
tested, but is differentiated from VTP at both, HLA-B (p = 0.02) and -DRB1 (p = 0.01).   
This is probably due to the inclusion of individuals who have admixture with Europeans as a 
component of TP group [see later and 13].  In contrast, the previous Polynesian datasets 
[8,9,35] exclusively comprise full ancestry Polynesian individuals.  Based on the statistical 
results, we decided to combine PFA with VTP as PMD (Polynesian meta dataset- see Table 
S2) for comparisons with other populations (see later).  In addition, the most common HLA 
class I and II haplotype combinations found for PFA match well with those for other 
Polynesians reported by [8,9,35] - see Table 2.  This provides further strong evidence for the 
value of using the PMD grouping in order to gain more confidence via greater statistical 
power when testing for Polynesian ancestry.  Our present survey also provides novel 2- and 
3-locus haplotype combinations for HLA-B*-DRB1*, HLA-A*-B*-DRB1* and HLA-B*-
MICA* for Polynesians and these are listed in Table 2.  
 
     Next, we compared our Maori data with those from a previous study on Maori (TTM), 
reported by [36,37].  Here, only 5 out of 7 tested loci are common to both datasets.  The most 
common HLA alleles in MFA are also predominant in TTM, but with slightly reduced 
frequencies; e.g. HLA-A*24:02 is 0.36 in MFA compared with 0.21 in TTM, HLA-B*55:02 is 
0.36 in MFA, but only 0.18 in TTM, HLA-C*01:02 is 0.45 in MFA vs. 0.21 in TTM and 
HLA-DRB1*12:01 is 0.24 in MFA, but only slightly lower (0.22) in TTM (see Table S2).  
The HLA data recorded for TTM have more alleles than MFA and some are missing also in 
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TM.  Both observations are probably due to undisclosed European admixture in TTM as 
previously recognized by [13].  In addition, statistical tests show some significant differences 
in allele frequencies between MFA and TTM except at HLA-A and -DPB1 (see Table S3).  It 
is clear that TTM resembles TM more closely than its MFA sub-group.  Our original plan to 
create a larger Maori study group by combining MFA with TTM had to be rejected (after ref 
13) due to admixture in the latter.  Hence, TTM and TM may be combined as a Maori meta 
dataset (MMD) representing present day Maori living in New Zealand.  In contrast, the HLA 
data from MFA will be used as a representative group for full ancestry Maori in historical 
reconstructions.  This contrasts with our findings and subsequent analysis in the study of 
HLA and MICA loci in TP, where the admixture is not too obvious because only a few of the 
individuals are known to have some European admixture compared with those in TM.  The 
most common haplotypes in our Maori study group and sub-group are also compared with 
those reported for TTM in Table 2.  Visual inspection shows the most frequent haplotypes 
recorded for MFA have slightly higher values than the corresponding haplotypes in TTM.   
For example; HLA-A*02:06-C*01:02 is 0.28 in MFA, but only 0.15 in TTM, HLA-C*01:02-
B*55:02 is much higher in MFA (0.36) compared with 0.05 in TTM [36].  Therefore, the 
distributions of haplotype frequencies further support our earlier claim [13] regarding 
unknown but significant levels of admixture in TTM and our decision to use MFA for the 
ancestry study of Maori. 
 
     We also examined genetic affinities between New Zealand Maori and other Polynesian 
populations.  Generally, the new data collected for MFA are consistent with those from other 
Polynesians (both, new and previous data) with only minor exceptions, most probably  at the 
HLA-A, -B and -DRB1 loci (see Tables 1 and S2).  These differences are due to relatively 
higher frequencies of HLA-A*02:06 (0.30 in MFA vs. 0.07-0.17 among Polynesians), -
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B*55:02 (0.36 in MFA vs. 0.07-0.22 among Polynesians) and -DRB1*12:01 (0.24 in MFA 
vs. 0.08-0.22 among Polynesians) in MFA.  We also compared the most common 2- and 3-
locus haplotype associations between MFA and Polynesians (see Table 2).  These datasets 
share similar allelic combinations where the most common ones observed in MFA, are also 
abundant in Polynesians, but with different frequencies (see Tables 2).  There are a few 
exceptions to this generality; HLA-A*24:02-C*03:04 is only detected as a significant 
association in Maori while HLA-B*40:01-DRB1*09:01 was only recorded in PFA.  Thus, 
minor differences between MFA and other Polynesians echo the previous observations on 
individual Polynesian populations [8,9,35] and may be attributed to a combination of 
historical and local selective forces - see later.  
 
     These are the first ever MICA reports for Polynesians.  Therefore, we provide a complete 
analysis of HLA-B-MICA associations for the combined Polynesian and Maori populations 
(i.e. TP and TM).  A heatmap of linkage disequilibrium values (r
2
) was constructed for all 
possible MICA-HLA-B associations possible in the combined Maori and Polynesian 
populations that were typed at HLA-B and MICA loci (see Fig. 1).  For haplotype 
frequencies ≥ 1%, statistically significant (Χ2 ≥ 6.64, p ≤ 0.01, 1 d.f.) linkage disequilibrium 
was observed for the following MICA*-HLA-B* haplotypes: 008-0801, 008-18:01, 008-
40:01, 008-48:01, 010-39:01, 012-40:10, 012-55:02, 045-39:01, del-48:01. 
 
     Influences of the presumed A-SM and P-SA ancestors in shaping the descendant 
Polynesian and Maori genepools were demonstrated by plotting the most common HLA and 
MICA alleles at each locus on bar diagrams (Fig. 2).  Several of the alleles can be linked to 
both A-SM and P-SA populations [38-40], but no simple correlation can be made to point to 
a single unique Polynesian origin.  We also compared the most common 2-locus haplotype 
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associations (see Table 2) observed in our Polynesians with A-SM and P-SA populations 
[38,40].  Most of the predominant haplotypes observed in Polynesians and Maori can be 
traced back to either A-SM or P-SA populations, but a few of them are unique only to 
Polynesians (e.g. HLA-A*34:01-C*12:03 and HLA-C*12:03-B*13:01 - see Table 2). 
 
     Finally, a PCO plot based on HLA-A, -B, -C and -DRB1 allele frequencies (Fig. 3) was 
used to examine genetic relationships between Polynesian populations and to place them in a 
wider Asia-Pacific context [8,9,35-40].  The PCO plot shows clear separation of A-SM, P-SA 
and Polynesian populations.  In the plot, Maori and other Polynesians appear to be closely 
related to one another and fall in between clusters representing A-SM and P-SA populations.  
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Table 1: Number and frequency of HLA and MICA alleles identified across HLA and MICA 
loci in our Polynesian and Maori study groups and sub-groups 
HLA-A* 
 
TP (N=29) 
 
PFA (N=22)  TM (N=114)  MFA (N=48) 
    
 
 
 
 
 
01:01 
02:01 
02:05 
02:06 
02:12 
02:119 
03:01 
11:01 
24:01 
24:02 
25:01 
26:01 
30:02 
31:01 
33:01 
34:01 
68:01 
 
0.05 
0.12 
- 
0.10 
- 
- 
- 
0.14 
- 
0.36 
- 
0.03 
- 
- 
- 
0.19 
- 
 
0.05 
0.09 
- 
0.09 
- 
- 
- 
0.18 
- 
0.34 
- 
0.05 
- 
- 
- 
0.21 
- 
 0.07 
0.08 
0.02 
0.22 
0.01 
0 
0.04 
0.18 
0 
0.27 
0.01 
0.01 
0 
0 
0 
0.07 
0.01 
 0.05 
0.03 
0.01 
0.30 
0.01 
- 
- 
0.17 
0.01 
0.37 
- 
- 
- 
- 
- 
0.05 
- 
k 
 
7 
 
7  17  9 
    
 
 
 
 
 
HLA-B* 
 
TP (N=29) 
 
PFA (N=22)  TM (N=114)  MFA (N=48) 
    
 
 
 
 
 
07:02 
07:05 
08:01 
13:01 
14:01 
14:02 
15:01 
15:06 
18:01 
27:04 
27:05 
35:03 
37:01 
38:01 
39:01 
39:05 
39:06 
40:01 
40:02 
40:10 
40:06 
44:02 
45:01 
47:01 
48:01 
50:01 
51:01 
54:01 
55:01 
55:02 
56:01 
56:02 
57:01 
58:01 
 
0.02 
- 
0.02 
0.05 
- 
- 
0.02 
0.05 
0.02 
- 
0.02 
- 
- 
- 
0.05 
- 
- 
0.19 
0.09 
0.07 
- 
0.05 
- 
- 
0.07 
- 
- 
- 
- 
0.12 
0.02 
0.14 
0.02 
- 
 
- 
- 
0.02 
0.07 
- 
- 
- 
0.02 
- 
- 
0.02 
- 
- 
- 
0.07 
- 
- 
0.23 
0.09 
0.09 
- 
0.02 
- 
- 
0.09 
- 
- 
- 
- 
0.09 
0.02 
0.14 
0.02 
- 
 0.04 
0 
0.03 
0.02 
0.01 
0.01 
0.03 
0 
0.02 
0 
0 
0 
0 
0 
0.08 
0.01 
0.01 
0.07 
0.05 
0.06 
0 
0 
0 
0 
0.14 
0.01 
0 
0 
0 
0.26 
0.02 
0.04 
0 
0.01 
 0.01 
0.01 
0.02 
0.04 
- 
- 
0.01 
- 
- 
0.01 
- 
- 
- 
- 
0.08 
- 
- 
0.10 
0.02 
0.08 
- 
0.02 
- 
- 
0.15 
- 
- 
- 
- 
0.37 
0.01 
0.06 
- 
- 
k 
 
17 14  34  15 
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Table 1 cont. 
 
 
 
HLA-C* 
 
TP (N=29)  PFA (N=22)  TM (N=107)  MFA (N=46) 
   
   
 
  
01:02 
03:03 
03:04 
04:01 
04:03 
05:01 
06:02 
07:01 
07:02 
07:04 
08:01 
08:02 
12:02 
12:03 
15:02 
15:05 
 
0.29 
0.02 
0.10 
0.03 
0.16 
0.03 
0.02 
0.03 
0.09 
- 
0.07 
- 
- 
0.05 
0.10 
-  
0.25 
0.02 
0.11 
0.05 
0.16 
0.02 
0.02 
0.02 
0.09 
- 
0.09 
- 
- 
0.07 
0.09 
- 
 0.31 
0.02 
0.01 
0.06 
0.07 
0.04 
0.03 
0.04 
0.16 
0.01 
0.13 
0.03 
0.01 
0.02 
0.06 
0.01 
 0.45 
- 
0.01 
0.10 
0.09 
0.01 
- 
0.02 
0.11 
0.01 
0.13 
- 
0.01 
0.03 
0.02 
0.01 
   
  
 
 
 
 
k  12  12  16  13 
     
 
 
 
 
HLA-DRB1*  TP (N=37)  PFA (N=26)  TM (N=114)  MFA (N=49) 
         
01:01 
01:02 
01:03 
03:01 
04:01 
04:03 
04:04 
04:05 
07:01 
08:01 
08:02 
08:03 
09:01 
11:01 
12:01 
13:01 
13:02 
13:04 
14:01 
14:04 
14:05 
14:08 
14:54 
15:01 
15:02  
0.03 
- 
- 
0.01 
0.03 
0.14 
- 
0.05 
- 
- 
0.01 
0.10 
0.16 
0.05 
0.15 
0.03 
0.01 
0.01 
- 
- 
0.01 
0.05 
0.05 
0.05 
0.04  
0.02 
- 
- 
0.02 
- 
0.15 
- 
0.08 
- 
- 
0.02 
0.12 
0.19 
0.06 
0.14 
0.02 
- 
- 
- 
- 
- 
0.04 
0.08 
0.04 
0.04 
 0.02 
0.01 
0 
0.04 
0.05 
0.08 
0 
0.02 
0.04 
0.01 
0.01 
0.11 
0.06 
0.17 
0.21 
0.02 
0.01 
- 
- 
0 
0 
0.04 
0.04 
0.04 
0  
0.01 
- 
- 
0.02 
0.03 
0.11 
- 
0.04 
- 
- 
- 
0.18 
0.10 
0.18 
0.25 
- 
- 
- 
0.01 
- 
- 
0.02 
0.02 
0.02 
- 
     
 
   
k  18  14  23  13 
         
HLA-DPA1*  TP (N=25)  PFA (N=17)  TM (N=114)  MFA (N=42) 
         
01:03 
01:05 
02:01 
02:01/02 
02:02 
 0.48 
0.02 
0.02 
0.02 
0.46  
0.47 
- 
- 
0.03 
0.50  
0.40 
- 
0.03 
0.01 
0.50  
0.32 
- 
0.02 
- 
0.66 
 
 
       
k  4  3  3  3 
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Table 1 cont. 
 
HLA-DPB1*  TP (N=25)  PFA (N=17) 
 
TM (N=91) 
 
MFA (N=42) 
 
 
   
    
01:01 
02:01 
02:02 
04:01 
04:01/134:01 
04:02 
05:01 
09:01 
10:01 
13:01/107:01 
14:01 
15:01 
15:01/74:01 
17:01 
20:01 
35:01 
 - 
0.16 
- 
0.08 
0.20 
0.06 
0.46 
- 
0.02 
- 
0.02 
- 
- 
- 
- 
-  
- 
0.18 
- 
0.06 
0.21 
0.03 
0.47 
- 
0.03 
- 
0.03 
- 
- 
- 
- 
- 
 
0.02 
0.17 
0.02 
0.04 
0.22 
0.01 
0.48 
0.01 
- 
0.01 
- 
0.01 
0.01 
0.01 
0.01 
0.01 
 
0.01 
0.11 
0.01 
0.02 
0.18 
- 
0.66 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
   
    
k  7  7 
 
14 
 
7 
 
 
   
    
MICA*  TP (N=25)  PFA (N=17) 
 
TM (N=91) 
 
MFA (N=42) 
 
    
    
001 
002 
007 
008 
009 
010 
011 
012 
017 
019 
033 
045 
del  
- 
- 
0.02 
0.44 
- 
0.02 
- 
0.36 
- 
0.02 
- 
0.08 
0.06  
- 
- 
0.03 
0.56 
- 
- 
- 
0.21 
- 
0.03 
- 
0.09 
0.09 
 
0.02 
0.04 
0.01 
0.34 
0.02 
0.04 
0.02 
0.43 
0.01 
0.01 
0.01 
0.03 
0.02 
 
- 
- 
- 
0.27 
0.02 
0.02 
- 
0.56 
- 
- 
0.02 
0.06 
0.04 
 
    
    
k  6  5  12  6 
 
Abbreviations: N= total number of individuals, k = total number of alleles observed, 0 = < 0.01, - = not 
observed, TM: Total Maori, MFA: Maori with Full Ancestry, TP: Total Polynesians, PFA: Polynesians with 
Full Ancestry 
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Table 2: List of 2-locus haplotypes in Polynesians and Maori in comparison with other Asia Pacific populations 
 
HLA-A*-C* 
 
TP (N=49) 
 
PFA (N=22)  TM (N=107)  MFA ( N=41) 
 
Polynesians  
 
Possible origins  
     
 
 
 
 
    
02:06-01:02 
11:01-04:03 
11:01-08:01 
24:02-01:02 
24:02-03:04 
24:02-04:01 
24:02-04:03 
24:02-07:02 
34:01-12:03 
34:01-15:02 
 
0.07 
0.09 
0.03 
0.15§ 
0.08§ 
0.02§ 
0.07§ 
- 
0.05 
0.08 
 
0.02§ 
0.11 
0.05§ 
0.20 
0.07§ 
0.02§ 
- 
- 
0.07 
0.09 
 0.19 
0.06 
0.08 
0.10 
- 
0.05 
- 
0.08 
0.01 
0.05 
 0.28 
0.09 
0.04§ 
0.16§ 
- 
0.06§ 
- 
0.09 
0.03 
0.02 
 
0.03-0.15[35,36] 
0.03-0.12[35,36] 
0.03-0.07[35,36] 
0.02-0.21[35,36] 
0.03-0.09[35] 
0.03-0.28[35,36] 
0.04-0.08[35,36] 
0.05-0.11[35,36] 
0.05[35] 
0.04-0.06[35] 
 
TA (0-0.07)[38] 
Filipinos (0.04)[38], TA (0.01-0.34)[38] 
TA  (0.01-0.06)[38] 
Filipinos  (0.01)[38],TA (0.01-0.11)[38] 
Filipinos (0.03)[38], TA (0.05-0.47)[38] 
Filipinos (0.04)[38], TA (0.01-0.16)[38] 
TA (0.01-0.06)[38] 
Filipinos (0.05)[38], TA (0.02-0.49)[38] 
(recombinant of A-SM-P-SA) 
Filipinos (0.07)[38] 
     
 
 
 
 
    
HLA-C*-B* 
 
TP (N=49) 
 
PFA (N=22)  TM (N=107)  MFA (N=41) 
 
Polynesians  
 
Possible origins  
     
 
 
 
 
    
01:02-55:02 
01:02-56:02 
03:04-40:01  
04:01-40:01  
04:03-40:10  
07:02-39:01  
08:01-48:01  
12:03-13:01  
15:02-40:02  
 
0.12 
0.14 
0.10 
0.03 
0.07 
0.05 
0.07 
0.05 
0.09 
 
0.09 
0.14 
0.11 
0.05 
0.09 
0.07 
0.09 
0.07 
0.09 
 0.25 
0.04 
0.01 
0.06 
0.07 
0.08 
0.13 
0.01 
0.05 
 0.36 
0.07 
0.01 
0.10 
0.09 
0.09 
0.13 
0.03 
0.02 
 
0.07-0.22[35,36] 
0.04-0.12[35] 
0.08-0.21[35] 
0.02-0.29[35,36] 
0.04-0.06[35] 
0.03-0.10[35] 
0.10-0.11[35] 
0.03[35] 
0.04-0.07[35] 
 
TA (0.02-0.13)[38] 
PNGH (>0.02)[40] 
Filipinos ( 0.08)[38],TA (0.02-0.23)[38]   
Filipinos ( 0.07)[38], TA(0.01-0.21)[38]   
USA Asian (0.06)[38] 
Filipinos (0.03)[38], TA (0.04-0.54)[38] 
Filipinos (0.04)[38], TA (0.04-0.26)[38] 
(recombinant of A-SM-PSA) 
PNGH (>0.02)[40] 
     
 
 
 
 
    
HLA-A*-C*-B* 
 
TP (N=29) 
 
PFA (N=22)  TM (N=107)  MFA (N=46) 
 
Polynesians  
 
Possible origins  
 
    
 
 
 
 
    
02:06-01:02-55:02 
11:01-04:03-40:10 
11:01-08:01-48:01 
24:02-01:02-55:02 
24:02-01:02-56:02 
24:02-04:01-40:01 
24:02-03:04-40:01 
24:02-04:03-15:06 
24:02-07:02-39:01 
24:02-08:01-48:01 
34:01-12:03-13:01 
34:01-15:02-40:02 
 
0.05 
0.05 
0.03 
0.07§ 
0.10 
0.02§ 
0.07 
0.05 
- 
0.03§ 
0.05 
0.09 
 
0.02§ 
0.07 
0.05 
0.07§ 
0.14 
0.02§ 
0.07§ 
- 
- 
0.05 
0.07 
0.09  
0.19 
0.06 
0.08 
0.05 
0.04 
0.06 
- 
- 
0.07 
0.04§ 
0.01 
0.05 
 0.26 
0.09 
0.04
§
 
0.09§ 
0.07 
0.06 
- 
- 
0.09 
0.08 
0.03 
0.02 
 0.04-0.13[35] 
0.05[35] 
0.04
[35]
 
0.03-0.08[35] 
0.03-0.11[35] 
0.05-0.27[35] 
0.05[35] 
0.04[35] 
0.03-0.09[35] 
0.04-0.06[35] 
- 
0.04-0.06[35] 
 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
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Table 2 cont. 
 
Abbreviations: N= total number of individuals, - = not observed, ● = not reported, TM: Total Maori, MFA: Maori with Full Ancestry, TP: Total Polynesians, PFA: 
Polynesians with Full Ancestry, § = alleles are not significantly associated (p-value>0.05), TA = Taiwan Aborigines, PNGH = Papua New Guinea Highlanders 
HLA-B*-DRB1* 
 
TP (N=27) 
 
PFA (N=21) 
 
TM (N=111)  MFA (N=48)  Polynesians  
 
Possible origins  
     
 
 
 
  
   
48:01-11:01  
55:02-12:01  
55:02-09:01  
40:01-11:01  
48:01-08:03  
40:01-09:01  
 
0.02 
0.07 
0.06§ 
- 
0.04 
0.09 
 
0.02 
0.05 
0.05§ 
- 
0.05 
0.12 
 
0.09 
0.18 
0.05 
0.05 
0.04 
- 
 0.06 
0.24 
0.09 
0.08 
0.08 
- 
 ● 
● 
● 
● 
● 
● 
 
Filipinos (0.03)[38],TA(0.02-0.07)[38] 
TA (0.03-0.04)[38] 
TA (0.02-0.03)[38] 
Filipinos (0.01)[38], TA (0.01-0.13)[38] 
TA (0-0.01)[38] 
Filipinos (0.01)[38], TA (0.01-0.08)[38] 
HLA-A*-B*-DRB1* 
 
TP (N=27) 
 
PFA (N=21) 
 
TM (N=111)  MFA (N=48)  Polynesians  
 
Possible origins  
      
 
 
 
 
   
02:06-55:02-12:01 
11:01-48:01-11:01 
24:02-40:01-09:01 
24:02-40:01-11:01 
24:02-48:01-08:03 
24:02-55:02-09:01 
24:02-56:02-04:03 
34:01-40:02-14:54 
 
0.06 
0.02 
0.06§ 
- 
0.02§ 
0.06 
0.04§ 
0.04 
 
- 
- 
0.10 
- 
0.02§ 
0.05 
0.05§ 
0.05 
 
0.18 
0.06 
- 
0.05 
0.02 
0.04 
0.02 
- 
 0.24 
0.04 
- 
0.08 
0.06 
0.06 
0.04§ 
- 
 ● 
● 
● 
● 
● 
● 
● 
● 
 
● 
● 
Asian populations[38] 
Taiwanese[38] 
● 
● 
● 
● 
HLA-DPA1*-DPB1* 
 
TP (25) 
 
PFA (17) 
 
TM (91)  MFA (42)  Polynesians  
 
Possible origins  
      
 
 
 
 
   
01:03-02:01  
01:03-04:01/134:01  
01:03-04:01  
02:02-05:01  
 
0.14 
0.16 
0.06§ 
0.46 
 
0.15 
0.18 
0.06§ 
0.47 
 
0.16 
0.21 
0.04 
0.48 
 0.11 
0.18 
0.02 
0.66 
 0.19-0.32[8] 
- 
0.19-0.39[8] 
0.26-0.56[8] 
 
PNGH (0.36)[38] 
● 
PNGH (0.37)[38] 
Japan (0.38)[38], PNGH (0.15)[38] 
HLA-B*-MICA* 
 
TP (N=20) 
 
PFA (N=15) 
 
TM (N=90)  MFA (N=42)  Polynesians  
 
Possible origins  
      
 
 
 
 
   
13:01-045  
39:01-008 
40:01-008 
40:02-008 
40:10-012  
48:01-del  
55:02-012  
56:02-012 
 
0.08 
0.03§ 
0.25 
0.08 
0.05 
0.08 
0.10 
0.13 
 
0.10 
0.03§ 
0.30 
0.10 
0.07§ 
0.10 
0.03§ 
0.10 
 
0.02 
0.08 
0.07 
0.06 
0.06 
0.02 
0.28 
0.04 
 0.05 
0.07 
0.11 
0.02 
0.08 
0.02 
0.38 
0.06 
 ● 
● 
● 
● 
● 
● 
● 
● 
 
China (0.08)[38], South Korea (0.03)[38] 
● 
China (0.12)[38] 
Thailand (0.03)[38] 
● 
● 
● 
● 
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Fig. 1: Linkage disequilibrium p-values for HLA-B*-MICA* associations in combined Polynesian and Maori 
populations (N=110).  
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Fig. 2:  Comparison of the most common HLA and MICA alleles in Polynesians (purple fill) and Maori (bright purple fill) to those in Austronesian-speaking Mongoloid (A-
SM)/Asia (blue fill) and Papuan-speaking Australoid (P-SA - red fill) populations.  Data for reference populations were obtained from [38-40].  Abbreviations; PMD: 
Polynesian meta dataset, MFA: Maori with Full Ancestry, AYA: Australian Yuendemu Aborigine, ACYPA: Australia Cape York Peninsula Aborigine, AKA: Australian 
Kimberly Aborigine, PNGH: Papua New Guinea Highland, *: the highest allele frequencies recorded in Allele Frequencies.net or observed in the present survey. 
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Fig. 3:  Relationships of Polynesian and Maori datasets shown in a wider Asia Pacific context. Reference populations were obtained from [8,9,35-40].  Abbreviations; PMD: 
Polynesians meta dataset, VTP: Velickovic Total Polynesians, TP: Total Polynesians, PFA: Polynesians with Full Ancestry, TM: Total Maori, MFA: Maori with Full 
Ancestry, PNG: Papua New Guinea, A-SM: Austronesian-speaking Mongoloids, P-SA: Papuan-speaking Australoids, TTM: Total Tracey Maori, MMD: Maori Meta dataset. 
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4. Discussion 
 
     Ethnic diversity in the New Zealand population provides valuable opportunities for 
genetic studies of ancestry and health.  The 4 millions living there today include of 
Europeans: 68%, Maori: 15%, Pacific people: 7%, Asians: 9% and others: 1%. The Pacific 
peoples principally include Samoans, Cook Islanders, Tongans, Fijian and Tokelauans 
(Statistics New Zealand; http://www.stats.govt.nz). Previously [13], we tested the expectation 
that both, Polynesians and Maori will be intermediate between A-SM and P-SA but closer to 
the former (minimally 70% according to the SNP data – see Introduction). We found that the 
HLA genepool may be up to 100% A-SM at some loci - e.g. HLA-B and -C.  Our previous 
findings thus generally support the account [6,41] deduced from Y-chromosome, mtDNA and 
genome wide SNP data [10,14,15,25], but may point to past locus-specific selection events.   
 
     Here, we have further characterized HLA and MICA loci using a combination of high 
resolution SBT and Luminex typing in the same subjects reported earlier [13].  In particular, 
statistically significant differences observed between our admixed groups (TP and TM) and 
full ancestry sub-groups (PFA and MFA) are associated with European admixture.  The same 
effects were observed in previous studies on Maori [36,37].  In contrast, slight differences 
between our full ancestry study sub-groups (PFA and MFA) and Polynesian sub-populations 
(Cook Islands, Tokelau, Tonga and Samoa) might be due to genetic refinement via selective 
pressure and longer-term bottlenecks as the genepool of Polynesian sub-populations were 
repeatedly refined by founder effects due to multiple re-settlements [8,9,35].  Overall, these 
have led us to the same conclusion regarding A-SM/P-SA hybrid ancestry of Polynesians and 
extensive European contributions in genepools of modern day Maori and Polynesians living 
in New Zealand (see Results and Fig. 3). Presently, we lack adequate comparative data from 
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A-SM and P-SA populations for the MICA locus.  However, allele frequencies for MICA in 
Polynesians and Maori are most similar to those observed in Asian populations, rather than 
being similar to Europeans, Africans or Amerindians [38,42-47].  Two subjects were 
homozygous for HLA-B*48:01 (one MFA and one PFA) and no MICA alleles were detected.  
In addition, 19 of the 20 individuals who carried HLA-B*48:01 and another HLA-B allele, 
had only one MICA allele detected. Interestingly, only two of the 19 subjects carrying the 
possible MICA deletion haplotypes were PFA and the remaining were Maori (8 MFA and 9 
admixed).  When we tested specifically using pairs of primers for detecting the MICA gene, 
the presence of MICA*del in Maori and Polynesians which is associated with two individuals 
who are homozygous for HLA-B*48:01 and is shown to be in significant LD with HLA-
B*48:01 (see Fig. 1).  There is one caveat regarding this conclusion because there are six 
samples which have not been able to re-analyse.  These include one MICA*008 homozygote 
and one MICA*012 homozygote.  Thus, it is still possible (albeit unlikely) that these conceal 
MICA-del.  In addition, we also provide the first ever HLA-B and MICA associations for 
Polynesian and Maori populations (see Table 2).  We would like to point out that our 
haplotype analysis (Table 2) for HLA and MICA should be regarded as suggestive and 
provisional rather that definitive.  This caveat is associated with less the use of extensive and 
sophisticated analysis and is due to several recombination hotsports present in between HLA 
and MICA loci that might harm haplotype predictions.   There was a high frequency of the 
HLA-B*55:02-MICA*012 and HLA-B*40:01-MICA*008 haplotypes.  We also observed 
potentially novel associations between HLA-B*39:01 and MICA*045 and HLA-B*39:01 and 
MICA*010.  However, these associations may only highlight the general lack of MICA data 
for Asia Pacific populations, particularly from A-SM and P-SA.  Frequencies of MICA 
alleles and B-MICA haplotypes are of clinical interest in the light of the literature suggesting 
that MICA antigens could be target for immune allorecognition with consequent antibody 
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mediated rejection in kidney, pancreas and heart transplantation and deleterious transplant 
outcomes [48-50]. 
 
     Our findings from this present survey conclusively exclude Amerindians as the first 
settlers in Polynesia [51].  However, we did detect common Amerindian alleles/haplotypes in 
two Maori individuals with admixed history and one Cook Island individual.  Their 
genotypes are HLA-A*02:12/11:01-C*07:02/15:02-B*39:05/40:06-DRB1*08:02/14:04-
DQA1*01GN/04MS-DQB1*04:02/05:03, HLA-A*02:12/03:01-C*06:02/07:02-
B*39:05/47:01-DRB1*01:03/08:02-DQA1*04MS/05EF-DQB1*04:02/03CJB and HLA-
A*02:12/34:01-C*07:02/12:03-B*13:01/39:05-DRB1*04:05/08:02-DQA1*03:01/04:01.  
The highlighted alleles are common in Amerindians; see [52-54] for details.  The HLA-
A*02:12 and -DRB1*08:02 alleles were also detected in our MFA and PFA groups, 
respectively, but these samples were observed to have allele/haplotype combinations which 
are not common in Amerindians.  However, we would not entirely exclude the possibility of 
a small amount of Amerindian admixture even among our self-proclaimed full ancestry 
Maori or Polynesian individuals.  An ad hoc query to the Tissue Typing Laboratory Histotrac 
(SystemLink, Chantilly, VA, USA) database  (New Zealand Blood Service) for either HLA-
A*02:12 or -B*39:05 or -DRB1*08:02 shows at least 10 patients or donors with the full 
Amerindian haplotype HLA-A*02:12-C*07:02-B*39:05-DRB1*08:02.  There may be more, 
because not all routine typing resolves to the allelic level (Paul Dunn, unpublished 
observations). The presence of an Amerindian haplotype in our data is most likely to be a 
historical signal due to a South American slave trade which operated across the Pacific before 
Europeans colonised New Zealand (Erik Thorsby, personal communication). 
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     Overall, the present study on Maori and Polynesians shows a restricted set of alleles for 
HLA class I and MICA loci, compared with the more diverse nature of HLA class II (i.e. 
HLA-DRB1).  Nonetheless, we propose that gene conversion involving a small number of 
HLA genes may be a mechanism of maintaining diversity at HLA class I protein level in 
Maori and Polynesians.  For example, HLA-B*40:10 allele really does look like a genuine 
hybrid between HLA-B*55 or -B*56 and -B*40:01.  The DNA sequence of the gene starts in 
the 5'UTR/promoter region exactly matching HLA-B*55 and -B*56 sequences and continues 
like this through exon 1 to the beginning of exon 2 (first 100 nucleotides), but then changes to 
match HLA-B*40:01 for all remaining exons and introns into 3'UTR (see Fig. 4).  Therefore, 
amino acid differences between the protein encoded by HLA-B*40:10 compared with that 
encoded by HLA-B*40:01 are in the peptide binding groove, an immensely important region 
for generating diversity.  The HLA-B*40:10 allele is almost absent from all other populations 
(see Fig. 4) and not reported anywhere for South American populations [38,55], but quite 
common among Polynesians (0.01-0.09). This suggests that HLA-B*40:10 was formed by 
gene conversion of ancestral (A-SM or P-SA) alleles.  This is a reasonable proposal because, 
HLA-B*55 is quite frequent among the A-SM populations [38,39] while HLA-B*56 is more 
common among P-SA [38,40].  HLA-B*40 is common in both, A-SM and P-SA populations 
[38-40] and observed here (see Table S2) as B60 protein (HLA-B*40:01 and -B*40:02 
alleles) and B61 (HLA-B*40:02 allele).  This same mechanism has been inferred in Papuan 
populations in generating HLA-C*04:03, which is a frequent HLA-C allele among 
Polynesians and thought to be a hybrid of HLA-C*04 and -C*02 alleles [56].  The HLA-
C*04:03 is also in associations with HLA-B*40:10 in Polynesian populations (see Table 2). 
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Fig. 4:  Recombinant structure of HLA-B*40:10 allele and its distribution in various populations. The allele 
frequency maps were adapted from [55].  
 
 
     We should now examine whether natural selection has played an important role in shaping 
of HLA and MICA allele distributions in Polynesians.  We would like to note that natural 
selection might be a reason for observed HWE deviation in PFA (HLA-C), TM (HLA-DRB1 
and -DPB1) and TM and MFA (MICA), although linkage between pairs of HLA loci, founder 
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effects and nature of our samples that make up our study groups and sub-groups might also 
be contributing factors. Homozygosity tests on HLA and MICA allele frequency spectra 
suggested that balancing selection is acting on these loci in Polynesian and Maori populations 
(see Table S1).  These findings reflect those apparent from other studies [11,12,55].   Thus 
natural selection can be considered as a factor for having elevated and/or maintain high 
frequencies of several HLA and MICA alleles (e.g. HLA-B*55:02 and MICA*012 in MFA 
and HLA-DRB1*04:03 in Tokelauans) among individual Polynesian population, compared 
with those in their A-SM and P-SA ancestors [38-40,43].  However, there is also possible 
evidence for directional selection acting on HLA-A in MFA, HLA-C in Tokelau, HLA-DPA1 
in Samoa, Tokelau and MFA and MICA in PFA (see Table S1).  These explanation arise 
from finding relatively high frequencies of several ancestral (A-SM and P-SA) alleles (e.g. 
HLA-A*02:06, -A*11:01 and -A*24:02 in MFA and HLA-C*01:02 and -C*04:01 in 
Tokelauans).  In our opinion, this apparent evidence of directional change on HLA loci in 
Polynesians might be better interpreted as due to founder effects, rather than directional 
selection.  In Tokelauns, this is most likely due to a massive depletion of genepool in the 
1800s, as a result of slave trade when ~95% of able bodied men were taken from the island in 
one year [57].  In addition, selective forces acting on particular Polynesian populations may 
well reflect the influence of more localised geographic factors on particular diseases, as these 
people are well scattered over the large Pacific basin in Remote Oceania.  
 
     Thus, it seems clear that maintenance of HLA and MICA diversity within Pacific 
populations is influenced by several factors which include both, local selective forces and 
founder effects.  It is widely accepted that susceptibility and resistance to disease are 
genetically linked, especially for HLA and MICA loci.  Ankylosing spondylitis (AS), uveitis 
(UV) and coeliac disease (CD) are autoimmune diseases strongly associated with tissue types 
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of European (CD) or European and Asian (AS and UV) origin.  AS and UV are usually 
associated with B*27:05 in Europeans and B*27:04 with Asians [58,59].  The HLA-B*27 
allele is at low frequency in Maori and Polynesians (0.01-0.02) populations characterized 
here and are probably only present at all due to European admixture.  Coeliac disease (CD), 
or gluten intolerance as it is also known, is another common (~0.01) autoimmune disease in 
populations from Europe, South America, Australasia and the USA [60,61].  The risk of 
coeliac disease is strongly associated with the DQ2.5 (HLA-DQB1*02-DQA1*05:01/05) 
heterodimer and to a lesser extent with the DQ8.1 (HLA-DQB1*0302-DQA1*0301) 
heterodimer [62].  In the Maori and Polynesian samples, there were a small number (0.06-
0.09) of DQ2.5 types, but many more (0.16-0.38) DQ8.1 haplotypes – see [13].  The low 
numbers of DQ2.5 haplotype may explain the low frequency of CD in Maori and 
Polynesians, but this is certainly not true for the DQ8.1 haplotype.  Therefore, we now 
question the importance of the DQ8.1 haplotype in diagnosis of CD particularly in these 
subjects.  The three HLA-associated diseases, namely CD, AS and UV, are not usually 
observed in Maori and Polynesians (Paul Dunn, unpublished observations).  In addition, 
increasing admixture with Europeans may mean that CD, AS and UV will perhaps become 
known as emerging “European autoimmune diseases” in the Maori and Polynesian 
populations of New Zealand.   
 
     The pathogenesis of rheumatoid arthritis is also associated with HLA; HLA-DRB1*04:01 
in Europeans and -DRB1*04:05 in Polynesians [63].  HLA-DRB1*04:05 was only seen in a 
small number of the Maori and Polynesian individuals studied here (0-0.09) and thus might 
reflect the low prevalence of rheumatoid arthritis in these populations.  However, HLA-
DRB1*04:03 is relatively common in our Maori and Polynesian populations, with 
frequencies from 0.08 in TM and up to 0.38 in the Tokelauans (see Table S2).  HLA-
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DRB1*04:03 is considered „not associated with‟, and possibly protective of Type 1 Diabetes 
(however, see further) and rheumatoid arthritis. Thus, selection in favour of HLA-
DRB1*04:03 might be thought of as a “health advantage” for Maori and Polynesians.  
Conversely, subacute cutaneous lupus erythematosus (SCLE) is much higher in Polynesians, 
compared with New Zealand Europeans [64].  The SCLE condition is thought to be 
genetically linked to the HLA-A1-B8-DR3 haplotype [65], which is relatively uncommon in 
Maori and Polynesians (see Tables 1 and S1).  Therefore, susceptibility factors to SCLE in 
Polynesians might involve other HLA antigens/candidate genes within MHC complex, as the 
effects of disease susceptibility genes may differ among ethnic groups [see 66].  
 
     Subcutaneous T cell paniculitis is a rare skin lymphoma found in various different ethnic 
populations.  In Maori and Polynesians, this condition is treated well with cyclosporine 
indicating T cell involvement (Hilary Blacklock, personal communication).  We have 
analysed the HLA types of 6 patients with this condition but have not observed an obvious 
association (Paul Dunn, unpublished observation).  There is also no clear HLA association 
with type II diabetes in Maori and Polynesians, although HLA-B22 and -B40 have been 
implicated with this form of diabetes [67,68].  Recently, we have identified six Polynesian 
adult patients with „late onset type I diabetes‟ - a hitherto unknown entity in Polynesians.  
Four of the five patients tested had HLA-DRB1-DQ haplotypes previously associated in 
European subjects with the latent autoimmune diabetes in adults (LADA) variant of type 1 
diabetes, [68]. Three of our subjects were HLA-DRB1*09:01-DQA1*03:01-DQB1*03:03 and 
one was HLA-DRB1*04:03-DQA1*03:01-DQB1*03:02. LADA may be more common in 
adult Polynesians than previously thought and this HLA information, in conjunction with 
anti-GAD antibody testing and C-peptide assay, could prove valuable in future diagnoses 
(Tangi Purea, Tim Cundy and Paul Dunn personal communication). 
Chapter 3.2 
137 
 
     The MICA locus is also associated with a number of autoimmune diseases and most of 
them are also HLA associated [1].  This might be due to composition of the MHC region 
itself which contains several categories of genes related to innate and adaptive immunity; 
antigen processing (e.g. HLA class I and II), stress response (e.g. MICA and MICB), the 
complement cascade (e.g. BF and C2), inflammation (e.g. ABCF1 and AIF1), 
immunoglobulin superfamily (e.g. AGER and BTN1A1) and immune regulation (NFKBIL1 
and RXRB) loci – see [70] for details.  It is noteworthy that two individuals were positive for 
MICA*007:01 (one MFA and one Polynesian with admixed history subjects), an allele that 
has been reported in association with T1D in Japanese [71], Kawasaki disease in Taiwanese 
[72], and seronegative spondylarthropathies in Japanese [73] and Europeans [74]. Both 
MICA*007:01 carrying individuals appear to carry the following probable extended 
haplotype HLA-A*02:01-C*01:02-B*27:05-MICA*007:01-DRB1*01:01-DQA1*01:01-
DQB1*05:01.  However, many of the previous MICA-HLA and disease association studies 
involved a repetitive GCT motif in exon 5, encoding the MICA transmembrane domain.  This 
appeared to be less informative as the repetitive polyalanine encoding motif is shared with a 
number of other well-characterized MICA alleles [3,75].  In our combined opinion, future 
studies should focus on association of HLA and MICA polymorphism with diseases, e.g. by 
looking at HLA and MICA alleles which are closely linked and crucial in immune responses 
[see 1,2,70].  In addition, HLA and MICA polymorphisms are also important in 
transplantation as the success rate of transplantation is dependent on the degree of HLA and 
MICA matching between donor and recipient [4,76,77].  The HLA and MICA data presented 
here suggest that the feasibility of finding suitable donors for Maori and Polynesian patients 
is within their own ethnic group(s), as they share a number of common and unique HLA and 
MICA alleles.   
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     The complex genepool of Polynesians as previously described (41) can now be better 
understood.  Re-interpretations of HLA and MICA data in the light of new scholarship [6] 
have brought a clearer picture of A-SM/P-SA ancestral fractions in these people, although 
HLA and MICA alleles do sometimes show slight differences between them in tracing their 
putative ancestors.  Our survey also points out significant European gene flow in our TP and 
TM groups, which are more typical of modern day Polynesians and Maori living in New 
Zealand, respectively.   This later phase of gene flow is medically significant as interaction 
between European and Polynesian genes might influence new patterns of disease resistance 
and vulnerability.  Therefore, we believe that the HLA and MICA data from this study could 
be used as a preliminary medical reference standard for Maori and Polynesians living in New 
Zealand, also helping to redefine the immunogenetics of autoimmune diseases such as coelics 
disease and Type 1 diabetes. 
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Supplementary information 
 
Table S1: Homozygosity (F) values for Maori and Polynesian datasets 
 
 
Abbreviations: TP: Total Polynesians, PFA: Polynesians with Full Ancestry, TM= Total Maori, MFA = Maori with Full Ancestry,  CI: Cook Islands [8,9,31], SA: Samoa 
[8,9,31], TOK: Tokelau [8,9,31], TON: Tonga [8,9,31], VTP: Velickovic Total Polynesians (CI+SA+TOK+TON), PMD: Polynesian Meta Dataset (PFA+VTP), TTM:  
Tracey Total Maori [32,33], MMD: Maori  Meta Dataset (TM+TTM), obs: observed, exp: expected, F = homozygosity,  p: significant level (<0.05), ● = not reported 
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0.34 
0.42 
 
0.21 
0.30 
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Table S2: HLA and MICA allele frequencies for Polynesian and Maori datasets 
HLA-
A* 
TP 
(29) 
PFA 
(22) 
CI 
50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(444) 
MFA 
(48) 
TM 
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MMD 
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0.19 
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0.09 
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0.09 
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0.18 
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0.01 
0.01 
- 
- 
0.01 
0.10 
0.01 
- 
- 
0.48 
- 
- 
- 
- 
0.02 
- 
- 
0.01 
- 
- 
- 
- 
- 
0.13 
- 
- 
- 
0.01 
0.01 
0.02 
- 
- 
0.15 
- 
- 
- 
- 
- 
- 
0.14 
0.02 
- 
- 
0.56 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
0.01 
- 
- 
- 
0.08 
- 
- 
- 
- 
0 
0.05 
- 
- 
0.07 
- 
- 
- 
- 
- 
- 
0.20 
0.01 
- 
- 
0.50 
- 
- 
- 
- 
0.05 
0.01 
- 
- 
- 
- 
- 
- 
- 
0.11 
- 
- 
- 
- 
0.01 
0.22 
- 
- 
0.12 
- 
- 
- 
- 
- 
- 
0.10 
0.01 
- 
- 
0.46 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
0.07 
- 
- 
- 
- 
0.01 
0.08 
- 
- 
0.13 
- 
0 
0 
- 
- 
0 
0.14 
0.01 
- 
- 
0.50 
- 
- 
- 
- 
0.02 
0 
- 
0 
- 
0 
- 
- 
- 
0.10 
- 
- 
- 
0 
0.01 
0.08 
- 
- 
0.12 
- 
0 
0 
- 
- 
0 
0.14 
0.01 
- 
- 
0.48 
- 
- 
- 
- 
0.02 
0 
- 
0 
- 
0 
- 
- 
- 
0.11 
- 
- 
- 
0 
0.05 
0.03 
- 
0.01 
0.30 
- 
0.01 
- 
- 
- 
- 
0.17 
- 
- 
0.01 
0.36 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.05 
- 
- 
- 
- 
0.07 
0.07 
- 
0.02 
0.22 
- 
0.01 
- 
- 
0 
0.04 
0.18 
- 
- 
0 
0.27 
- 
- 
- 
0.01 
0.01 
- 
- 
- 
0 
0 
- 
0 
- 
0.07 
- 
- 
0.01 
- 
0.05 
0.10 
0 
0.01 
0.22 
0.01 
0.01 
- 
0 
- 
0.06 
0.17 
0.01 
0 
- 
0.21 
0 
0 
0.01 
0 
0.01 
- 
0.01 
0 
- 
0.01 
0.01 
- 
0 
0.09 
0 
0 
0.01 
- 
0.06 
0.09 
0 
0.01 
0.22 
0 
0.01 
- 
0 
0 
0.05 
0.17 
0 
0 
0 
0.24 
0 
0 
0.01 
0.01 
0.01 
- 
0.01 
0 
0 
0.01 
0.01 
0 
0 
0.08 
0 
0 
0.01 
- 
k 7 7 13 9 8 8 15 15 9 17 27 31 
             HLA-
B* 
TP  
(29) 
PFA 
(22) 
CI 
(50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(444) 
MFA 
(48) 
TM 
(114) 
TTM 
(171) 
MMD 
(285) 
             07:02 
07:03 
07:04 
07:05 
07:06 
07:07 
07:10 
07:45 
08:01 
08:02 
13:01 
13:02 
14:01 
14:02 
15:01 
15:02 
15:03 
15:06 
0.02 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
0.05 
- 
- 
- 
0.02 
- 
- 
0.05 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
0.07 
- 
- 
- 
- 
- 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
0.04 
0.02 
- 
0.01 
- 
- 
- 
0.03 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.04 
- 
- 
- 
- 
- 
- 
0.07 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.03 
- 
- 
- 
- 
- 
- 
0.05 
0.03 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
0.06 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
0.04 
0.01 
- 
0 
- 
- 
- 
0.04 
0.01 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
0.05 
0 
- 
0 
- 
- 
- 
0.04 
0.01 
- 
- 
0.01 
- 
- 
- 
- 
0.02 
- 
0.04 
- 
- 
- 
0.01 
- 
- 
- 
0.04 
- 
- 
0 
- 
- 
- 
- 
0.03 
- 
0.02 
- 
0.01 
0.01 
0.03 
- 
- 
0 
0.08 
0 
0 
0.03 
0 
0 
0 
0.01 
0.02 
0 
- 
0.03 
- 
0 
0.02 
0 
0 
0.01 
0.06 
0 
0 
0.02 
0 
0 
0 
0 
0.02 
0 
0.01 
0.02 
0 
0.01 
0.02 
0 
0 
0.01 
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Table S2 cont. 
 
HLA-
B* 
TP  
(29) 
PFA 
(22) 
CI 
(50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(444) 
MFA 
(48) 
TM 
(114) 
TTM 
(171) 
MMD 
(285) 
             15:21 
15:28 
15:31 
15:33 
15:34 
18:01 
27:04 
27:05 
35:01 
35:03 
35:10 
35:60 
37:01 
37:02 
38:01 
39:01 
39:02 
39:05 
39:06 
39:10 
40:01 
40:02 
40:03 
40:06 
40:07 
40:10 
40:12 
40:33 
40:49 
44:02 
44:03 
44:23N 
45:01 
47:01 
48:01 
48:03 
48:05 
48:14 
50:01 
51:01 
51:02 
51:09 
52:01 
54:01 
55:01 
55:02 
55:13 
56:01 
56:02 
56:04 
57:01 
58:01 
67:01 
81:01 
- 
- 
- 
- 
- 
0.02 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
0.05 
- 
- 
- 
- 
0.19 
0.09 
- 
- 
- 
0.07 
- 
- 
- 
0.05 
- 
- 
- 
- 
0.07 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.12 
- 
0.02 
0.14 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
0.07 
- 
- 
- 
- 
0.23 
0.09 
- 
- 
- 
0.09 
- 
- 
- 
0.02 
- 
- 
- 
- 
0.09 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.09 
- 
0.02 
0.14 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
0.11 
- 
0.01 
- 
- 
0.07 
0.07 
- 
- 
0.01 
0.04 
- 
- 
- 
0.01 
- 
- 
- 
- 
0.11 
- 
- 
- 
- 
0.01 
0.01 
- 
- 
- 
- 
0.22 
- 
0.08 
0.11 
0.01 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
0.06 
- 
- 
- 
- 
0.42 
0.05 
- 
- 
- 
0.05 
- 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.19 
- 
0.04 
0.05 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
0.03 
- 
- 
- 
- 
0.17 
0.09 
- 
- 
- 
0.09 
- 
- 
- 
- 
- 
- 
- 
- 
0.11 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.07 
- 
0.15 
0.18 
0.01 
- 
- 
- 
- 
0.04 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.05 
- 
0.01 
- 
- 
0.32 
0.08 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
0.10 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.12 
- 
0.04 
0.11 
0.01 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
0.01 
0 
- 
- 
- 
- 
- 
- 
- 
0.06 
- 
0.01 
- 
- 
0.25 
0.07 
- 
- 
0 
0.05 
- 
- 
- 
0 
- 
- 
- 
- 
0.08 
0 
- 
- 
- 
0.01 
0 
- 
- 
- 
- 
0.15 
- 
0.08 
0.11 
0.01 
0 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
0.01 
0 
- 
- 
- 
- 
- 
- 
- 
0.06 
- 
0 
- 
- 
0.24 
0.07 
- 
- 
0 
0.05 
- 
- 
- 
0 
- 
- 
- 
- 
0.08 
0 
- 
- 
- 
0 
0 
- 
- 
- 
- 
0.14 
- 
0.07 
0.11 
0.01 
0 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
- 
- 
- 
0.08 
- 
- 
- 
- 
0.10 
0.02 
- 
- 
- 
0.08 
- 
- 
- 
0.02 
- 
- 
- 
- 
0.15 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.36 
- 
0.01 
0.06 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
0 
0 
- 
0 
- 
- 
0 
- 
0 
0.08 
- 
0.01 
0.01 
- 
0.07 
0.05 
- 
0 
- 
0.06 
- 
- 
- 
0.04 
- 
- 
0 
0 
0.14 
- 
- 
- 
0.01 
0 
- 
- 
- 
0 
0 
0.26 
- 
0.02 
0.04 
- 
0 
0.01 
- 
- 
- 
0 
0 
0 
0 
- 
- 
- 
0.01 
0.01 
0 
0 
- 
0.01 
- 
0.01 
0.02 
- 
0.02 
0 
0.12 
0.01 
0 
- 
0.02 
0.02 
0 
0 
0 
0.02 
0.01 
0 
- 
- 
0.14 
0.02 
0 
0 
0.01 
0.01 
- 
0 
0 
0.02 
0.02 
0.18 
0 
0.01 
0.02 
- 
0.02 
- 
0.01 
0.02 
- 
0 
0 
0 
0 
0.01 
0 
0 
0.01 
0.01 
0 
0 
0 
0 
0 
0.04 
0.01 
0 
0.01 
0 
0.10 
0.02 
0 
0 
0.01 
0.04 
0 
0 
0 
0.03 
0.01 
0 
0 
0 
0.14 
0.01 
0 
0 
0.01 
0.01 
- 
0 
0 
0.01 
0.01 
0.21 
0 
0.01 
0.03 
- 
0.01 
0 
0.01 
0.01 
k 17 14 20 12 12 15 23 25 15 34 57 69 
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Table S2 cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-
C* 
TP 
(29) 
PFA 
(22) 
CI 
(50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(444) 
MFA 
(46) 
TM 
(107) 
TTM 
(124) 
MMD 
(231) 
01:02 
01:03 
02:02 
03:02 
03:03 
03:04 
04:01 
04:03 
05:01 
06:02 
07:01 
07:02 
07:04 
07:05 
08:01 
08:02 
12:02 
12:03 
14:02 
15:02 
15:03 
15:04 
15:05 
16:01 
16:02 
18:01 
0.29 
- 
- 
- 
0.02 
0.10 
0.03 
0.16 
0.03 
0.02 
0.03 
0.09 
- 
- 
0.07 
- 
- 
0.05 
- 
0.10 
- 
- 
- 
- 
- 
- 
0.25 
- 
- 
- 
0.02 
0.11 
0.05 
0.16 
0.02 
0.02 
0.02 
0.09 
- 
- 
0.09 
- 
- 
0.07 
- 
0.09 
- 
- 
- 
- 
- 
- 
0.40 
- 
- 
- 
- 
0.03 
0.06 
0.07 
0.01 
0.01 
0.01 
0.15 
- 
- 
0.10 
0.01 
0.02 
0.02 
0.02 
0.09 
- 
- 
- 
- 
- 
- 
0.25 
- 
- 
- 
- 
0.01 
0.30 
0.16 
0.01 
0 
0 
0.07 
- 
- 
0.01 
- 
0.02 
0.10 
- 
0.07 
- 
- 
- 
- 
- 
- 
0.35 
- 
- 
- 
0.02 
0.10 
0.10 
0.10 
0 
0 
0 
0.08 
- 
- 
0.12 
- 
0.02 
0.04 
- 
0.07 
- 
- 
- 
- 
- 
- 
0.24 
- 
- 
- 
0.01 
0.24 
0.11 
0.06 
0 
0 
0.02 
0.10 
- 
- 
0.11 
- 
- 
0.03 
- 
0.07 
0.01 
- 
- 
- 
- 
- 
0.31 
- 
- 
- 
0.01 
0.10 
0.14 
0.10 
0.01 
0 
0.01 
0.10 
- 
- 
0.09 
0 
0.02 
0.05 
0.01 
0.08 
0 
- 
- 
- 
- 
- 
0.30 
- 
- 
- 
0.01 
0.10 
0.13 
0.10 
0.01 
0 
0.01 
0.10 
- 
- 
0.09 
0 
0.01 
0.05 
0 
0.08 
0 
- 
- 
- 
- 
- 
0.45 
- 
- 
- 
- 
0.01 
0.10 
0.09 
0.01 
- 
0.02 
0.11 
0.01 
- 
0.13 
- 
0.01 
0.03 
- 
0.02 
- 
- 
0.01 
- 
- 
- 
0.31 
- 
- 
- 
0.02 
0.01 
0.06 
0.07 
0.04 
0.03 
0.04 
0.16 
0.01 
- 
0.13 
0.03 
0 
0.02 
- 
0.06 
- 
- 
0 
- 
- 
- 
0.21 
0.03 
0 
0.02 
0.01 
0.01 
0.07 
0.11 
0.04 
0.02 
0.07 
0.11 
0 
0.01 
0.09 
0.02 
0.02 
0.01 
0 
0.06 
- 
0.02 
- 
0.03 
0 
0.03 
0.26 
0.02 
0 
0.01 
0.02 
0.01 
0.07 
0.09 
0.04 
0.02 
0.05 
0.14 
0.01 
0.01 
0.11 
0.03 
0.01 
0.02 
0 
0.06 
- 
0.01 
0 
0.02 
0 
0.02 
             k 12 12 14 10 10 11 16 16 13 16 24 25 
             HLA-
DQB1* TP  PFA  
CI 
(50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) PMD  MFA  TM  
TTM 
(187) MMD  
02:01 
02:02 
02:03 
03:01 
03:02 
03:03 
03:04 
04:01 
04:02 
05:01 
05:02 
05:03 
06:01 
06:02 
06:03 
06:04 
06:05 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
0.02 
- 
- 
0.30 
0.25 
0.09 
- 
- 
0.03 
0.01 
0.08 
0.13 
0.08 
0.01 
- 
- 
- 
- 
- 
- 
0.22 
0.38 
0.06 
- 
- 
0.08 
- 
- 
0.10 
0.14 
- 
0.02 
- 
- 
- 
- 
- 
0.23 
0.17 
0.16 
- 
- 
0.05 
- 
0.01 
0.17 
0.19 
0.02 
- 
- 
- 
- 
- 
- 
0.16 
0.16 
0.26 
- 
0.01 
0.10 
- 
0.03 
0.11 
0.14 
0.03 
- 
- 
- 
0.01 
- 
- 
0.23 
0.24 
0.14 
- 
0 
0.07 
- 
0.03 
0.13 
0.14 
0.02 
0.01 
- 
- 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
0.08 
0.02 
0 
0.30 
0.12 
0.06 
0.03 
- 
0.01 
0.04 
0.06 
0.11 
0.08 
0.06 
0.01 
0.02 
0 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
             k ● ● 10 7 8 9 12 ● ● ● 16 ● 
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Table S2 cont. 
 
HLA-
DRB1* 
TP 
(37) 
PFA 
(26) 
CI 
(50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(452) 
MFA 
(49) 
TM 
(114) 
TTM 
(200) 
MMD 
(314) 
             
01:01 
01:02 
01:03 
03:01 
03:07 
04:01 
04:03 
04:04 
04:05 
04:07 
04:10 
07:01 
08:01 
08:02 
08:03 
09:01 
11:01 
11:02 
11:03 
11:04 
11:11 
12:01 
12:02 
13:01 
13:02 
13:04 
13:05 
13:10 
13:12 
14:01 
14:04 
14:05 
14:07 
14:08 
14:23 
14:54 
15:01 
15:02 
16:01 
16:02 
0.03 
- 
- 
0.01 
- 
0.03 
0.14 
- 
0.05 
- 
- 
- 
- 
0.01 
0.09 
0.16 
0.05 
- 
- 
- 
- 
0.15 
- 
0.03 
0.01 
0.01 
- 
- 
- 
- 
- 
0.01 
- 
0.05 
- 
0.05 
0.05 
0.04 
- 
- 
0.02 
- 
- 
0.02 
- 
- 
0.15 
- 
0.08 
- 
- 
- 
- 
0.02 
0.12 
0.19 
0.06 
- 
- 
- 
- 
0.13 
- 
0.02 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.04 
- 
0.08 
0.04 
0.04 
- 
- 
0.01 
- 
- 
0.01 
- 
- 
0.26 
- 
0.03 
- 
- 
0.01 
- 
0.02 
0.08 
0.08 
0.12 
- 
- 
- 
- 
0.16 
0.01 
- 
- 
- 
- 
- 
0.01 
0.07 
- 
- 
- 
0.07 
- 
- 
0.01 
0.06 
- 
- 
- 
- 
- 
- 
- 
- 
0.38 
- 
0.07 
0.01 
- 
- 
- 
- 
0.12 
0.04 
- 
- 
- 
- 
- 
0.22 
- 
0.03 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.07 
- 
- 
- 
0.06 
- 
- 
- 
- 
- 
- 
- 
- 
0.17 
- 
0.04 
- 
0.01 
- 
0.01 
- 
0.12 
0.16 
0.16 
- 
- 
- 
- 
0.08 
- 
- 
- 
- 
- 
- 
- 
0.05 
- 
- 
- 
0.07 
- 
- 
0.03 
0.10 
- 
- 
- 
- 
- 
0.02 
- 
- 
0.16 
- 
0.09 
- 
- 
0.01 
- 
0.02 
0.10 
0.25 
0.08 
- 
- 
- 
- 
0.08 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
0.08 
- 
- 
0.03 
0.07 
- 
- 
0 
- 
- 
0.01 
- 
- 
0.24 
- 
0.06 
0 
0 
0.01 
0 
0.01 
0.11 
0.13 
0.09 
- 
- 
- 
- 
0.14 
0 
0.01 
- 
- 
- 
- 
0 
0.03 
- 
- 
- 
0.07 
- 
0 
0.02 
0.07 
- 
- 
0 
- 
- 
0.01 
- 
- 
0.23 
- 
0.06 
0 
0 
0 
0 
0.01 
0.11 
0.14 
0.09 
- 
- 
- 
- 
0.13 
0 
0.01 
- 
- 
- 
- 
0 
0.03 
- 
- 
- 
0.07 
- 
0.01 
0.02 
0.07 
- 
- 
0.01 
- 
- 
0.02 
- 
0.03 
0.11 
- 
0.04 
- 
- 
- 
- 
- 
0.18 
0.10 
0.18 
- 
- 
- 
- 
0.24 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
0.02 
- 
0.02 
0.02 
- 
- 
- 
0.02 
0.01 
0 
0.04 
- 
0.05 
0.08 
0 
0.02 
- 
- 
0.04 
0.01 
0.01 
0.11 
0.06 
0.17 
- 
- 
- 
- 
0.21 
- 
0.02 
0.01 
- 
- 
- 
- 
0 
0 
0 
- 
0.04 
- 
0.04 
0.04 
- 
- 
- 
0.03 
- 
- 
0.04 
0.01 
0.05 
0.11 
0.01 
0 
- 
0.01 
0.05 
0 
- 
0.09 
0.04 
0.14 
0 
0 
0 
0 
0.22 
0.01 
0.01 
0.01 
- 
0.01 
0 
- 
0.03 
- 
- 
0 
0.06 
0 
- 
0.05 
0.01 
0 
0 
0.03 
0 
0 
0.04 
0 
0.05 
0.10 
0 
0.01 
- 
0 
0.05 
0.01 
0 
0.10 
0.05 
0.15 
0 
0 
0 
0 
0.21 
0 
0.01 
0.01 
- 
0 
0 
- 
0.02 
0 
0 
0 
0.05 
0 
0.01 
0.05 
0.01 
0 
0 
             
k 18 14 16 9 12 13 20 21 13 23 31 37 
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Table S2 cont. 
 
 
 
 
 
 
 
 
 
 
HLA-
DPA1* 
TP 
(25) 
PFA 
(17) 
CI 
(N=50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(434) 
MFA 
(42) 
TM 
(114) TTM MMD 
             
01:03 
01:05 
02:01 
02:01/ 
02 
02:02 
04:01 
0.48 
0.02 
0.02 
 
0.02 
0.46 
- 
0.47 
- 
- 
 
0.03 
0.50 
- 
0.54 
- 
- 
 
- 
0.44 
0.02 
0.73 
- 
0.01 
 
- 
0.26 
- 
0.46 
- 
- 
 
- 
0.53 
0.01 
0.42 
- 
0.01 
 
- 
0.57 
0 
0.54 
- 
0.01 
 
- 
0.45 
0.01 
0.53 
- 
0 
 
0 
0.45 
0.01 
0.32 
- 
0.02 
 
- 
0.65 
- 
0.47 
- 
0.03 
 
0.01 
0.49 
- 
● 
● 
● 
 
● 
● 
● 
● 
● 
● 
 
● 
● 
● 
             
k 4 3 3 3 3 3 4 4 3 3 ● ● 
HLA-
DPB1* 
TP 
(25) 
PFA 
(17) CI (50) 
TOK 
(50) 
TON 
(50) 
SA 
(50) 
VTP 
(400) 
PMD 
(434) 
MFA 
(42) 
TM 
(91) 
TTM 
(199) 
MMD 
(290) 
             01:01 
02:01 
02:02 
03:01 
04:01 
04:01/ 
134:01 
04:02 
05:01 
06:01 
08:01 
09:01 
10:01 
11:01 
13:01 
13:01/ 
107:01 
14:01 
15:01 
15:01/ 
74:01 
16:01 
17:01 
20:01 
21:01 
23:01 
25:01 
28:01 
29:01 
31:01 
35:01 
65:01 
- 
0.16 
- 
- 
0.08 
0.20 
 
0.06 
0.46 
- 
- 
- 
0.02 
- 
- 
- 
 
0.02 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.18 
- 
- 
0.06 
0.21 
 
0.03 
0.47 
- 
- 
- 
0.03 
- 
- 
- 
 
0.03 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.26 
- 
0.02 
0.23 
- 
 
0.02 
0.44 
- 
- 
- 
- 
- 
0.01 
- 
 
- 
- 
- 
 
- 
- 
0.01 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
0.32 
- 
0.01 
0.39 
- 
 
0.01 
0.26 
- 
- 
- 
0.01 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.24 
- 
0.01 
0.19 
- 
 
0.01 
0.52 
- 
- 
- 
- 
- 
- 
- 
 
0.01 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
- 
- 
- 
0.19 
- 
- 
0.21 
- 
 
0.02 
0.56 
- 
- 
- 
- 
- 
- 
- 
 
0.01 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
0.25 
- 
0.01 
0.26 
- 
 
0.02 
0.45 
- 
- 
- 
0 
- 
0 
- 
 
0.01 
- 
- 
 
- 
- 
0 
- 
- 
- 
0 
0 
0.01 
- 
- 
- 
0.25 
- 
0.01 
0.24 
0.02 
 
0.02 
0.45 
- 
- 
- 
0 
- 
0 
- 
 
0.01 
- 
- 
 
- 
- 
0 
- 
- 
- 
0 
0 
0 
- 
- 
0.01 
0.11 
0.01 
- 
0.02 
0.18 
 
- 
0.65 
- 
- 
0.01 
- 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.02 
0.17 
0.02 
- 
0.04 
0.22 
 
0.01 
0.48 
- 
- 
0.01 
- 
- 
- 
0.01 
 
- 
0.01 
0.01 
 
- 
0.01 
0.01 
- 
- 
- 
- 
- 
- 
0.01 
- 
0.01 
0.16 
0.01 
0.02 
0.29 
- 
 
0.06 
0.40 
0 
0 
0 
0 
0.01 
0 
- 
 
- 
- 
- 
 
0.01 
0.01 
- 
0 
0.02 
0 
- 
- 
- 
- 
0 
0.01 
0.16 
0.01 
0.01 
0.21 
0.07 
 
0.04 
0.43 
0 
0 
0 
0 
0.01 
0 
0 
 
- 
0 
0 
 
0.01 
0.01 
0 
0 
0.01 
0 
- 
- 
- 
0 
0 
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Table S2 cont. 
 
 
HLA data for CI, TOK, TON and SA were obtained from [8,9,35 and Velickovic, unpublished] and from [36,37]  
for TTM. We considered creating PMD by adjusting allele frequency values in VTP assuming MICA*del = 0.09,  
as in  PFA.  We decided not to do so due to high blank values in various Polynesian sub-populations that make up  
VTP. Some of these might be authentic MICA-del homozygotes. Abbreviations: number in bracket = total number  
of individuals, k = total number of observed alleles, 0 = < 0.01, - = not observed), TP: Total Polynesians, PFA:  
Polynesians with Full Ancestry, TM= Total Maori, MFA = Maori with Full Ancestry,  CI: Cook Islands, TOK:  
Tokelau, TON: Tonga, SA: Samoa, VTP: Velickovic Total Polynesians (CI+TOK+TON+SA), PMD: Polynesian  
Meta Dataset (PFA+VTP), TTM:Tracey Total Maori, MMD: Maori  Meta Dataset (TM+TTM), ● = not reported 
 and  § = MICA allele frequencies were determined by direct counting (counting once for homozygotes) and blank 
 might include MICA-del. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICA* 
TP 
(25) 
PFA 
(17) 
CI
§
 
(43) 
TOK
§
 
(36) 
TON
§
 
(38) 
SA
§
 
(41) 
VTP
§
 
(158) PMD 
MFA 
(42) 
TM 
(91) TTM MMD 
             001 
002 
004 
006 
007 
008 
009 
010 
011 
012 
017 
019 
027 
033 
045 
del 
- 
- 
- 
- 
0.02 
0.44 
- 
0.02 
- 
0.36 
- 
0.02 
- 
- 
0.08 
0.06 
- 
- 
- 
- 
0.03 
0.56 
- 
- 
- 
0.21 
- 
0.03 
- 
- 
0.09 
0.09 
- 
- 
- 
0.01 
- 
0.20 
- 
- 
- 
0.38 
- 
0.01 
0.07 
0.02 
0.03 
- 
- 
- 
- 
- 
- 
0.38 
- 
- 
- 
0.23 
- 
0.08 
0.10 
0.01 
0.03 
- 
- 
- 
- 
- 
0.01 
0.18 
- 
- 
- 
0.34 
- 
0.07 
0.07 
0.01 
0.03 
- 
- 
- 
0.01 
- 
0.01 
0.34 
- 
- 
- 
0.22 
- 
0.04 
0.06 
- 
0.05 
- 
- 
- 
0.01 
0.01 
0.01 
0.27 
- 
- 
- 
0.30 
- 
0.04 
0.07 
0.01 
0.03 
- 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
- 
- 
- 
- 
- 
0.27 
0.02 
0.02 
- 
0.56 
- 
- 
- 
0.02 
0.06 
0.04 
0.02 
0.04 
- 
- 
0.01 
0.34 
0.02 
0.04 
0.02 
0.43 
0.01 
0.01 
- 
0.01 
0.03 
0.02 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
● 
blank - - 0.29 0.17 0.30 0.29 0.25 ● - - ● ● 
k 6 5 7 6 6 7 9 ● 6 12 ● ● 
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Table S3: Exact tests of population differentiation (p-values) on Polynesian and Maori 
datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-A 
           
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
TTM 
~ 
1.00 
0.19 
0.00 
0.16 
0.07 
0.01 
0.08 
0.15 
0.34 
0.32 
~ 
~ 
0.30 
0.01 
0.23 
0.03 
0.02 
0.25 
0.17 
0.38 
0.38 
~ 
~ 
~ 
0.58 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.36 
~ 
~ 
~ 
~ 
0.02 
0.00 
0.02 
0.00 
0.00 
0.00 
0.14 
~ 
~ 
~ 
~ 
~ 
0.00 
0.84 
0.12 
0.21 
0.32 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.13 
0.13 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.17 
0.54 
0.47 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.48 
0.56 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
1.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
           HLA-B 
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
TTM 
~ 
1.00 
0.07 
0.07 
0.10 
0.06 
0.01 
0.04 
0.02 
0.09 
0.00 
~ 
~ 
0.06 
0.01 
0.22 
0.29 
0.01 
0.18 
0.62 
0.62 
0.00 
~ 
~ 
~ 
0.94 
0.01 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
0.04 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.01 
0.02 
0.02 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.20 
0.24 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.13 
0.12 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.25 
0.32 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
1.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
           HLA-C 
           
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
TTM 
~ 
1.00 
0.08 
0.01 
0.18 
0.07 
0.00 
0.30 
0.09 
0.20 
0.09 
~ 
~ 
0.13 
0.03 
0.20 
0.26 
0.00 
0.49 
0.26 
0.43 
0.16 
~ 
~ 
~ 
0.20 
0.31 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
0.54 
0.00 
0.00 
0.11 
0.01 
0.01 
0.00 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.26 
0.06 
0.06 
0.01 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.19 
0.07 
0.09 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.97 
0.98 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
1.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
           HLA-DQB1 
           
 
TP PFA TM MFA CI SA TOK TON VTP ~ 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
TTM 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.28 
0.11 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.01 
0.04 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.75 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
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Table S3 cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TP: Total Polynesians, PFA: Polynesians with Full Ancestry, TM= Total Maori, MFA = Maori 
with Full Ancestry,  CI: Cook Islands [8,9,35], SA: Samoa [8,9,35], TOK: Tokelau [8,9,35], TON: Tonga 
[8,9,35], VTP: Velickovic Total Polynesians (CI+SA+TOK+TON), PMD: Polynesian Meta Dataset 
(PFA+VTP), TTM:  Tracey Total Maori [36,37], MMD: Maori  Meta Dataset (TM+TTM), p: significant level 
(<0.05). 
 
 
HLA-DRB1 
           
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
TTM 
~ 
1.00 
0.01 
0.02 
0.16 
0.22 
0.00 
0.10 
0.01 
0.02 
0.00 
~ 
~ 
0.01 
0.03 
0.44 
0.59 
0.00 
0.33 
0.43 
0.68 
0.00 
~ 
~ 
~ 
0.52 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
0.01 
0.00 
0.24 
0.63 
0.62 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.26 
0.28 
0.49 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.52 
0.59 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
1.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
           HLA-DPA1 
           
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
~ 
1.00 
0.25 
0.05 
0.38 
0.28 
0.00 
0.61 
0.15 
0.14 
~ 
~ 
1.00 
0.14 
0.69 
0.69 
0.01 
1.00 
0.59 
0.59 
~ 
~ 
~ 
0.03 
0.05 
0.54 
0.00 
0.52 
0.10 
0.13 
~ 
~ 
~ 
~ 
0.00 
0.22 
0.00 
0.06 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
0.06 
0.01 
0.45 
0.45 
0.36 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.57 
0.07 
0.07 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.32 
0.34 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.97 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
           HLA-DPB1 
           
 
TP PFA TM MFA CI SA TOK TON VTP PMD 
           TP 
PFA 
TM 
MFA 
CI 
SA 
TOK 
TON 
VTP 
PMD 
TTM 
~ 
0.98 
0.56 
0.08 
0.34 
0.35 
0.02 
0.22 
0.43 
0.52 
0.70 
~ 
~ 
0.51 
0.16 
0.46 
0.42 
0.05 
0.41 
0.37 
0.47 
0.58 
~ 
~ 
~ 
0.38 
0.38 
0.63 
0.00 
0.23 
0.01 
0.01 
0.05 
~ 
~ 
~ 
~ 
0.01 
0.33 
0.00 
0.06 
0.01 
0.01 
0.08 
~ 
~ 
~ 
~ 
~ 
0.20 
0.02 
0.54 
0.66 
0.60 
0.23 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.66 
0.52 
0.56 
0.19 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
0.03 
0.04 
0.09 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.60 
0.64 
0.05 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
1.00 
0.00 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
0.00 
           MICA 
           
 
TP PFA TM ~ ~ ~ ~ ~ ~ ~ 
           TP 
PFA 
TM 
MFA 
~ 
0.84 
0.61 
0.33 
~ 
~ 
0.11 
0.01 
~ 
~ 
~ 
0.62 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
~ 
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Summary 
 
In recent years with the application of genotyping technology, there has been a substantial 
increase in the number of reported blood group alleles.  The present survey was designed to 
evaluate new molecular blood group genotyping methods and compile reference blood group 
datasets for Polynesian and Maori subjects.  Subsequent analyses of these results were used 
to calculate probability of random match, to trace Polynesian ancestry and migration patterns 
and to reveal past and present episodes of genetic admixture.  Genomic DNA samples from 
Maori and Polynesian subjects were drawn from the Victoria University of Wellington DNA 
Bank and genotyped using combination of commercial PCR-SSP kits, hybridization SNP 
assay services or sequence based typing.  The present survey also involves compilation of 
serological ABO and Rhesus blood group data from RakaiPaaka Iwi Tribal members for 
comparison with those generated during our molecular blood group study.  We observed 
perfect consistency between results obtained from all molecular methods for blood group 
genotyping.  The A, O, DCcEe, DCCee, MNs, K-k+, Jk(a+b-), Jk(a+b+), Fy(a+b-), Fy(a+b+), 
Di(a+b-), Co(a+b-) and Do(a-b+) were predominant blood group phenotypes in both 
Polynesians and Maori.  Overall, our survey data show only small differences in distributions 
of blood group phenotypes between Polynesian and Maori groups and their sub-groups.  
These differences might be associated with selection, population history and gene flow from 
Europeans.   In each case, we estimate that patients with certain blood groups have a very low 
probability of an exact phenotypic match, even if the patients were randomly transfused with 
blood from donors of their own ethnicity.  The best way to avoid haemolytic transfusion 
reaction in such cases is to perform a pre-transfusion cross-match and recruit increased 
numbers of donors with rare phenotype profiles.  The conclusion of this study is that 
application of molecular method covering as many known variants as possible may help to 
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improve the accuracy blood group genotyping and potentially conserve the routine 
requirements of transfusion centres.   
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Introduction 
 
Blood group antigens are polymorphic genetic markers located on the surface of red blood 
cells.  Currently, substantial genetic variation, amounting to 1251 alleles belonging to 30 
blood group systems, has been documented (see Daniels and Reid, 2010; Patnaik et al., 
2012).  Following the elucidation of the molecular basis underpinning the structure of blood 
group antigens, a wide range of molecular techniques have been developed.  These range 
from simple polymerase chain reaction (PCR) techniques (e.g. PCR-fragment length 
polymorphism and sequence specific primer) to the rapid high-throughput SNP arrays 
(BeadChip and BLOODchip) genotyping platforms; see also Wu and Csako, (2006); Avent 
(2007); Hashmi et al. (2007); Veldhuisen et al. (2009) for reviews on blood group typing. 
 
    It is already well established that ABO, Rhesus and Kell blood group antigens are 
clinically important in transfusion compatibility and in certain cases are valuable as prenatal 
diagnostics in the management of hemolytic disease of the fetus and newborn (HDFN).   As 
well as ABO, Rhesus and Kell, there are other blood group antigens which can stimulate 
clinically significant antibodies and these include Dombrock, Kidd and MNS (Anstee, 2009).  
New Zealand comprises a unique population mixture and there are no recent blood group data 
available for any of its sub-ethnic groups.  This presents challenges and opportunities for 
molecular blood group screening.   The present survey of blood groups is a part of wider 
screening exercise (i.e. blood group and HPA loci; see Edinur et al., 2013 for details) and was 
designed to assess application of new molecular blood group typing methods in Polynesian 
and Maori populations.  This is because most of the molecular blood group platforms which 
have been tested have been used with subjects (e.g. Europeans and Africans), who might 
have differing „molecular‟ blood groups profiles compared with Polynesians.  Blood group 
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data generated from this survey can also be used for dual analysis of ancestry and health.  The 
data presented here will prove useful in the supply of „safe blood‟ to multi- or recently-
transfused patients, or to patients with pre-existing autoantibodies.  Overall, the blood group 
data presented here complement our recent studies of HLA and HPA genes, which are 
medically important genetic markers and reflect ancestral history (Edinur et al., 2012; Edinur 
et al., 2013).   
 
Materials and methods 
Serological data 
The present survey involves compilation of serological ABO and Rhesus blood group data 
for comparison with our new DNA-based blood group study in Maori and Polynesian 
subjects.  The serological data comprise information for 269 Te o Iwi RakaiPaaka members 
(Total RakaiPaaka: TR), one of Maori tribe living in New Zealand (NZ).  These data were 
generated during the Te Iwi o Rakaipaaka Health and Ancestry Study (RHAS), under permit 
from RHAS Management Team, NZ Multi-Regional Ethics Committee and Victoria 
University of Wellington (VUW) Human Ethics Committee (refer Eccles, 2011 for details). 
Data from those un-admixed individuals (i.e.  those with four grandparents and no family 
ancestral knowledge of members from other ethnic groups) in this collection were then 
grouped into a smaller sub-group; RakaiPaaka with Full Ancestry (RFA).    
Genomic DNA  
The molecular blood group study involved genomic DNA typing of Maori (Total Maori: TM) 
and Polynesian with Full Ancestry (PFA) subjects, drawn from the VUW DNA Bank.  We 
have selected a Full Ancestry (MFA) sub-group from the TM group containing for those with 
four grandparents and no familial knowledge ancestors from other ethnic groups by means of 
family history interview (see Box 1A). All genetic materials used in the present survey were 
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obtained with informed consent and full ethical approval (New Zealand Central Region 
Ethics Committee and VUW Human Ethics Committee).   
Blood group genotyping 
The blood group genotyping strategy for the present survey is shown in Fig. 1.  All subjects 
were genotyped using either commercial PCR-SSP kits (BAGene DNA-SSP ABO-TYPE 
variant, RH-TYPE, MNS-TYPE and KKD-TYPE kits; BAG Health Care GmbH, Lich, 
Germany) or by hybridization SNP assay (BLOODchip
®
 v2.0; Progenika Biopharma S.A., 
Spain) services (see Table S1 for details of variants covered by each genotyping platform).  
Nonetheless, we had to perform sequence based typing (SBT) for JKnull (i.e. g>a mutation at 
the 3‟ acceptor splice site of intron 5; Wester et al., 2008) which is not covered by the 
commercial PCR-SSP kits (see Table S2 for details of PCR and SBT protocols).  A total of 
10 samples were genotyped using both, PCR-SSP and BLOODchip, as cross-validation of the 
molecular methods used in this study.  As a further quality assurance measure, an additional 
30 samples were randomly selected for Kell (578T>C for Kell*A and Kell*B alleles, 
respectively) and Duffy (125G>A for FY*A and FY*B alleles, respectively) genotyping (see 
Table S2 for practical details and references) using SBT.  
Statistical analysis 
Phenotype frequencies were estimated by direct counting while the probability of finding a 
phenotype match between randomly selected donors and recipients was calculated according 
to Badjie et al. (2011).  Exact tests were performed using Arlequin, version 3.1 (Excoffier et 
al., 2005).  Neighbor-joining trees based on Nei‟s genetic distance were constructed using the 
PHYLIP software package, version 3.6 (Felsenstein, 2004) and visualized with the TreeView 
program (Page, 1996).  Principal coordinate (PCO) analysis was performed using Multi-
Variate Statistical Package, version 3 (MVSP3). 
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Box 1A: Note on study groups and sub-groups.  
We provide additional information about the identity and ancestry of our study groups and sub-groups (see 
Edinur et al., 2012 for further details). 
 
  
Population Description 
  
TR 
 
Member of Maori tribal group Te Iwi O RakaiPaaka. Majority are resident of the 
village of Nuhaka, New Zealand. 
  
TM 
 
Maori volunteers of mixed tribes from the Wellington region in New Zealand and 
whose genetic material form part of the VUW DNA Bank. 
  
PFA 
 
Pacific Islanders from different geographical sources (e.g. Tonga, Samoa and Cook 
Island) living in New Zealand. Only those with four grandparents and no family 
knowledge of members from other ethnic groups were included.  
  
RFA 
 
 
RFA is a sub-set of TR. The RFA sub-group consists of those with four 
grandparents and no family ancestral knowledge of members from other ethnic 
groups. 
  
MFA 
 
 
MFA is a sub-set of TM. The MFA sub-group consists of those with four 
grandparents and no family ancestral knowledge of members from other ethnic 
groups. 
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Fig. 1:  Schematic diagram of blood group genotyping strategy. Abbreviations are given in the Materials and methods section. Pooled data are shown in Table 2, except for 
HPA where have been reported elsewhere (Edinur et al., 2013).  
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Results 
 
Serologically determined blood group antigen frequencies collected from the RakaiPaaka Iwi 
are given in Table 1 and DNA-based blood group phenotype frequencies for VUW DNA 
Bank volunteers are listed in Table 2.   Included in Table 2 are reference European (Euro) 
populations obtained from Grunbaum et al. (1980) and Hashmi et al. (2007).  The present 
survey used two different molecular methods for predicting blood group phenotype 
frequency.  To ensure that we have covered all commonly reported variants that affect blood 
group antigen expression (see Table S1) and may be present in Polynesians, we also  
performed SBT for the Kidd g>a mutation at the 3‟ acceptor splice site of intron 5 (IVS5-
1g>a) (Irshaid et al.,  2000), which is not covered by the commercial PCR-SSP kits.  In 
addition, we note that several less well known blood group systems such as Diego, 
Dombrock, Colton, Kp
a
, Kp
b
 and Kp
c
 and Js
a
 and Js
b
, Kmod-1 and Gp.Mur can only be tested 
using BLOODchip (see Table S1).  These data are not included in Table 2 because almost all 
loci tested across 50 samples were found to be fixed; i.e. 100% are Di(a-b+), Co(a+b-), Kp
b
 
and Js
b
.  No samples were found with Kmod-1 and Gp.Mur phenotypes.  Only the Dombrock 
antigens were polymorphic and phenotype frequencies are given in Table 2.  Comparison of 
PCR-SSP and BLOODchip methods using 10 samples gave 100% agreement.  Our further 
validation using SBT on the 30 randomly selected individuals for Kell and Duffy blood 
groups showed results fully consistent with those obtained from PCR-SSP and BLOODchip 
(see Fig. 2 for examples).  In addition, Polynesian and Maori subjects were observed to have 
most common type variants at other SNPs in the region flanked by the sequencing primers 
(e.g 577A for Kell and 293G for Duffy blood groups; see Patnaik et al., 2012). 
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     The newly observed ABO and Rhesus blood group data for TM and MFA were compared 
to those collected from the RakaiPaaka Iwi study.  Exact tests show no significant differences 
between Maori sub-groups except for TM and RFA, for both, ABO and Rhesus (see Table 
S3).  We judge this might be due to admixture in TM (see later).  Next, we compared blood 
group data from MFA with Polynesians (i.e. PFA).  Visual examination shows surprisingly 
high frequencies of ABO B and Rhesus DCCee phenotype frequencies in PFA, compared 
with MFA (see Table 2).  Overall, statistical tests show that the MFA data are not generally 
different from PFA, except for the ABO, Rhesus and Kidd blood groups (refer Table S4).  
Blood group frequencies from Maori and Polynesian datasets were compared with reference 
European (Euro) populations.  Exact tests (Table S4) show significant differences between 
Maori/Polynesian and European datasets particularly for Rhesus, MNS and Duffy blood 
groups.   
 
     The blood group data listed in Table 2 were also used to estimate the probability of match 
between randomly selected donors and recipients.  The Diego and Colton blood groups are 
monomorphic and therefore have 100% matches between all datasets.  For the polymorphic 
loci, only the Kell blood type was observed to have a high probability of match between a 
randomly selected recipient and donor of similar ethnicity.  In every case, the probability 
values also suggested a lower chance of an exact match for Maori or Polynesians with blood 
sourced from European donors, compared with donor and recipient pairs of similar ethnicity. 
 
     Finally, a phylogenetic tree (Fig. 3) and PCO plot (Fig. 4) were constructed using ABO, 
Rhesus and MNS phenotype frequencies and used to examine genetic relationships between 
Polynesian populations and other populations including their putative A-SM and P-SA 
populations (see Box 1B for detailed description of these populations).  In the phylogenetic 
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tree, Maori datasets form a distinct branch while PFA and Tongan appear to be closely 
related and grouped together with A-SM population, including Filipinos - similar to that 
captured by the PCO plot.  Our admixed TM group and previous study on Maori (i.e. Maori 
NZ) are plotted closer to Mexico and European populations in the top hand corner of Figure 
4.   
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Table 1: ABO and Rhesus phenotype frequencies from the RakaiPaaka Iwi Study  
Blood group  TR (N=269) 
 
RFA (N=126) 
 
 
   
ABO  
   
 
 
   
A 
B 
AB 
O 
 0.54 
0.05 
0.04 
0.38 
 
0.54 
0.06 
0.02 
0.38 
 
 
   
Rhesus  
   
 
 
   
Rh+ 
Rh- 
 0.97 
0.03 
 
0.99 
0.01 
 
 
   
 
Abbreviations: TR: Total RakaiPaaka, RFA: RakaiPaaka with Full Ancestry, N = sample size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3.3 
 
169 
 
Table 2: Blood group phenotype frequencies and probability of match for European, Maori 
and Polynesian datasets  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABO  Euro (N=914) 
 
TM (N=65) 
 
MFA (N=45) 
 
PFA (N=25) 
 
 
       
A 
B 
AB 
O 
 0.41 
0.09 
0.05 
0.45 
 
0.48 
0.00 
0.05 
0.48 
 
0.53 
0.00 
0.02 
0.44 
 
0.36 
0.24 
0.00 
0.40 
 
 
       
PM  0.38 
 
0.46 
 
0.48 
 
0.35 
PM¶  
  
0.41 
 
0.42 
 
0.35 
 
 
       
Rhesus*  Euro (N=914) 
 
TM (N=65) 
 
MFA (N=45) 
 
PFA (N=24) 
 
 
       
DCCEe 
DCCee 
DCcEE 
DCcEe 
DccEE 
Dccee 
DCcee 
DccEe 
dccee 
dCcee 
dccEE 
dccEe 
 0.00 
0.17 
0.00 
0.13 
0.01 
0.04 
0.32 
0.12 
0.18 
0.01 
0.00 
0.01 
 
0.00 
0.18 
0.00 
0.42 
0.22 
0.00 
0.12 
0.00 
0.05 
0.02 
0.00 
0.00 
 
0.00 
0.16 
0.00 
0.47 
0.27 
0.00 
0.11 
0.00 
0.00 
0.00 
0.00 
0.00 
 
0.00 
0.58 
0.00 
0.21 
0.00 
0.00 
0.13 
0.04 
0.00 
0.00 
0.00 
0.04 
 
 
       
PM  0.20 
 
0.27 
 
0.33 
 
0.40 
PM¶  
  
0.14 
 
0.13 
 
0.17 
 
 
       
MNS  Euro (N=751) 
 
TM (N=65) 
 
MFA (N=45) 
 
PFA (N=25) 
 
 
       
MNSs 
MNS 
MNs 
MSs 
MS 
Ms 
NSs 
NS 
Ns 
 0.21 
0.04 
0.24 
0.15 
0.07 
0.11 
0.03 
0.01 
0.16 
 
0.09 
0.00 
0.45 
0.05 
0.00 
0.18 
0.06 
0.03 
0.14 
 
0.09 
0.00 
0.47 
0.04 
0.00 
0.18 
0.04 
0.04 
0.13 
 
0.08 
0.00 
0.44 
0.04 
0.00 
0.32 
0.00 
0.00 
0.12 
 
 
       
PM  0.16 
 
0.27 
 
0.28 
 
0.32 
PM¶  
  
0.18 
 
0.18 
 
0.18 
 
 
       
Kell  Euro (N=911) 
 
TM (N=74) 
 
MFA (N=45) 
 
PFA (N=25) 
 
 
       
K+k- 
K+k+ 
K-k+ 
 0.00 
0.09 
0.90 
 
0.00 
0.04 
0.96 
 
0.00 
0.04 
0.96 
 
0.00 
0.04 
0.96 
 
 
       
PM  0.83 
 
0.95 
 
0.96 
 
0.92 
PM¶  
  
0.88 
 
0.89 
 
0.87 
 
 
       
Kidd  Euro (N=514) 
 
TM (N=74) 
 
MFA (N=45) 
 
PFA (N=25) 
 
 
       
Jk (a+b-) 
Jk (a-b+) 
Jk (a+b+) 
 0.28 
0.25 
0.47 
 
0.62 
0.09 
0.28 
 
0.71 
0.02 
0.27 
 
0.44 
0.12 
0.44 
 
 
       
PM  0.36 
 
0.47 
 
0.58 
 
0.40 
PM¶  
  
0.33 
 
0.33 
 
0.36 
 
 
       
Chapter 3.3 
 
170 
 
Table 2, cont. 
 
Duffy  Euro (N=913) 
 
TM (N=74) 
 
MFA (N=45) 
 
PFA (N=25) 
 
 
       
Fy(a+b-) 
Fy(a-b+) 
Fy(a+b+) 
Fy(a-b-) 
 0.22 
0.32 
0.45 
0.01 
 
0.41 
0.16 
0.43 
0.00 
 
0.40 
0.16 
0.44 
0.00 
 
0.64 
0.00 
0.36 
0.00 
 
 
       
PM  0.35 
 
0.38 
 
0.38 
 
0.54 
PM¶  
  
0.33 
 
0.34 
 
0.30 
 
 
       
Dombrock  Euro (N=1243) 
 
TM (N=40) 
 
MFA (N=20) 
 
PFA (N=10) 
 
 
       
Do(a+b-) 
Do(a-b+) 
Do(a+b+) 
 0.13 
0.51 
0.36 
 
0.08 
0.75 
0.18 
 
0.00 
0.85 
0.15 
 
0.10 
0.60 
0.30 
 
 
       
PM  0.41 
 
0.60 
 
0.75 
 
0.46 
PM¶  
  
0.46 
 
0.49 
 
0.43 
 
 
       
 
Abbreviations: Euro = Europeans, TM =Total Maori, MFA= Maori with Full Ancestry, PFA = Polynesians with 
Full Ancestry, N = sample size, PM = probability of match between donor and recipient of similar ethnic 
background, PM¶ = probability of math between European donor and Maori/Polynesian datasets, * = individual 
with weak D is considered as donor and recipient D positive while individual with partial D is considered as 
donor D positive and recipient negative. Reference data for Europeans obtained from Grunbaum et al., 1980 
(ABO, Rhesus, MNS, Kell, Kidd and Duffy) and Hashmi et al., 2007 (Dombrock). Abbreviations: TM =Total 
Maori, MFA= Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, > = donor to receipient. 
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Fig. 2: Comparative screening of Kell, Kidd and Duffy blood group polymorphisms using combination  
of PCR-SSP and SBT. 
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Fig. 3:  NJ tree constructed using ABO, Rhesus and MNS phenotype frequencies. Reference populations for A-
SM (blue), P-SA (red), Polynesians (green) and others (black) were obtained from Gajdusek et al., 1978; Sanger 
et al., 1951; Lai and Bloom, 1982; Grunbaum et al., 1980; Stavely and Douglas, 1959; Woodfield et al., 1987; 
Windhof and Walter, 1983; Nakajima et al., 1971; Chen et al., 1985. 
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Fig. 4:  Position of Maori and Polynesian datasets in the PCO plots compared to those probed in Fig. 3. 
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Box 1B: Note on nomenclature of Asian and Pacific peoples.  
We have adopted the system below to clearly distinguish modern and ancestral populations. This is necessary to 
give a clear description of admixed descendants such as Melanesians whose genetic make-up may not 
correspond to observed cultural traits. 
 
  
Population Description 
  
Taiwan aboriginal and other Asian including 
Filipino, Malay and Indonesian 
 
Austronesian-speaking Mongoloid (A-SM) 
Australian Aborigine and Papuan interior 
 
Papuan-speaking Australoid (P-SA) 
Coastal PNG plus islands and other Melanesians 
 
~50:50 (A-SM: P-SA)ab 
Polynesian including Maori 70:30 to 87:13 (A-SM: P-SA)ac 
  
 
aWollstein et al. (2010), bFriedlaender et al. (2008), cKimura et al. (2008) 
 
Discussion 
 
From the discovery of the ABO blood groups in the early 20
th
 century, phenotyping remains 
as a fundamental element in transfusion medicine.  Currently, molecular methods have begun 
to emerge as a new technique for blood typing.  The molecular bases of many blood groups 
have been characterized, including those associated with null variants – see Patnaik et al. 
(2012) for details.  As a consequence, many molecular methods have since been designed for 
blood group typing, with most of them aiming at multiple blood group loci (see Montpetit et 
al., 2006; Hashmi et al., 2007;  Karpasitou et al., 2008; Avent et al., 2009).   
 
     Previously, we have demonstrated the consistency of molecular diagnostics (i.e. SNP 
array and PCR-SSP) for human platelet loci (Edinur et al., 2013).   Here, we further 
characterized the same sets of samples in the larger study of blood group polymorphism using 
a combination of commercial PCR-SSP kits, BLOODchip and SBT (see Figs. 1 and 2), plus 
comparison with serological references.  Throughout this study, we have shown the reliability 
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of these three molecular methods (i.e. PCR-SSP, SBT and SNP arrays) for blood group 
genotyping and thus our work reflects findings from other studies (Beiboer et al., 2005; 
Hashmi et al., 2007; Kappler-Gratias et al., 2011; Jungbauer et al., 2012).  Generally, antigen 
expression can be predicted by genotyping and any discrepancy between serology and 
molecular typing is usually associated with new mutations, which may be cryptic to antibody 
probes.  Therefore, the capability of molecular methods to show actual serological expression 
is only dependent on the number of known variants included in the genotyping platform.   For 
example, the JK*IVS5-1g>a SNP is not available in the commercial PCR-SSP kit used in the 
present survey, but is a common JKnull [Jk(a-b-)] variant in A-SM and Polynesian populations 
(see Irshaid et al., 2000; Lin and Yu, 2008 and below for values).  Subsequently, the 
genotype profile obtained from this kit alone will lead to false positive prediction of Jk(a-b+) 
or Jk(a+b+) phenotypes (see Table S5).  Comparison of phenotype predictions based on 
PCR-SSP alone and in combination with SBT (JK*IVS5-1g>a) shows 19% discordant 
results. This concern is made evident by the high frequency of JK*IVS5-1g>a observed in 
this study (0.09, 0.11 and 0.14 in TM, MFA and PFA, respectively).  Several other molecular 
bases of the JKnull variant have also been reported:  single nucleotide polymorphism 
(202C>T, 222C>A, 582C>G, 871T>C, 896G>A, 956C>T), 723delA, deletion of intron 3 to 
intron 5 and 5‟-donor splice site of intron 7 (Lucien et al., 1998; Irshaid et al., 2000; Wester 
et al., 2008; Liu et al., 2009).  These variants were not tested in the present survey and are 
uncommon in A-SM and Polynesians (see Irshaid et al., 2000; Lin and Yu, 2008).   However, 
we cannot conclusively exclude their occurrence in Polynesians.  Other blood group variants 
such as Di(a+b-) and Gp.Mur are not included in PCR-SSP kits, but are available via 
BLOODchip service (see Table S1).  These variants were not observed in the present survey, 
but were reported for their putative ancestral populations (see Daniels, 2008; Lin and 
Broadberry, 1998).  We cannot exclude the possibility of their existence in other Polynesians, 
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and future studies using larger sample sizes could yet reveal these phenotypes.  Therefore, we 
feel that inclusion of as many known SNPs as possible related to serological expression will 
help to improve accuracy of molecular blood group genotyping.  Nonetheless, molecular 
method is already superior to serology in many respects and circumstances; e.g. fetal blood 
group diagnosis, determination of blood group types in multi-transfused patients and 
resolution of ABO and RHD serological discrepancies (Hustinx et al., 2009).   
 
     The obvious barriers for application of blood group genotyping are operational and related 
to cost and turnaround time (Hustinx et al., 2009; Storry and Olsson, 2009; Schonitzer, 2009; 
Wagner, 2009 and Table S6 for parameters and comments).  Routine serological matching is 
only required for ABO and RhD and may in certain cases be extended to RhCE and Kell 
antigens (Wagner, 2009; Hustinx et al., 2009; Storry and Olsson, 2009).  This may be one 
reason why the traditional serological approach in transfusion medicine appears to be cheaper 
than molecular genotyping.  The question of costs remains an issue that merits further 
exploration.  The overall costs of tests are given in Table S6 for the panels detailed in Table 
S1.  In short, test for six blood groups plus six HPA loci by PCR-SSP kits is much cheaper (c. 
€128 than testing nine blood groups and twelve HPA loci via BLOODchip (c. €350).  
However, these figures do not take proper account of cost per test, technician time and 
clinical priority. There are several clinical applications where RBC genotyping has 
advantages over agglutination tests for the provision of safe blood. These include: (a) patients 
who are recently transfused, (b) patients who have a positive direct antiglobulin test because 
of antibodies bound to RBCs: such as in haemolytic anemia, (c) presence of autoantibodies 
hinders serological RBC typing but not genotyping, or (d) patient with a pre-existing 
clinically significant RBC antibody.  Genotyping is also extremely useful to clarify equivocal 
results or where there is evidence of weakly expressed antigens. In addition, there are 
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worldwide shortages of „traditional‟ grouping antisera that is leading to escalating test costs. 
Recently, genotyping has been used to assess the Rh type of the fetus in cases where the fetus 
is at risk of haemolytic disease. A real-time polymerase chain reaction method has been 
developed using the mother‟s circulating blood rather than amniotic cells as source of fetal 
DNA, and this method is now in widespread use (Finning et al., 2008).  
 
At present, the output from high-throughput molecular methods such as BLOODchip 
more than matches the routine requirements of transfusion centres and can be used to screen 
not only for ABO, Rhesus, MNS, Kell, Kidd and Duffy, but extended to Colton, Dombrock, 
Diego and 12 HPA loci (see Table S1).  Recently, the Lutheran blood group system has also 
been included in the new generation of BLOODchip analysis (BLOODchip
®
 v4.1; 
http://www.progenika.com).  Overall, molecular genotyping does seem to offer the 
opportunity to improve the efficiency of high quality transfusion services and in our opinion 
high throughput blood genotyping might become an ideal platform in the near future. 
 
     Blood group data generated from the present survey suggest that successful blood donor 
recruitment in New Zealand is dependent on public support through blood donations from 
both, major and minor ethnic groups living in New Zealand.  The genepool of Polynesian and 
Maori people is significantly different from those of Europeans, who are the majority in New 
Zealand (see Table S4 plus other references).   The match probabilities shown in Table 2 
demonstrated that blood groups are highly variable, not only between populations of 
geographically unrelated region (e.g. Europeans and Polynesians), but also within the 
populations themselves.  For instance, even if patient and donor are compatible for ABO, 
Rhesus and Kell blood groups, the probability of mismatch is remains high for other blood 
groups (e.g. MNS, Kidd and Duffy), regardless of ethnic group.  Therefore, it is important to 
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emphasize that getting a match for as many blood group antigens as possible between donor 
and recipient would significantly reduced risk of alloimmunization.   
 
     Patterns and processes involved during migration of A-SM speakers to Polynesia 
particularly gene flow from P-SA populations are demonstrated using NJ tree (Fig. 3) and 
PCO plot (Fig. 4).  The tree and plot were constructed using only ABO, Rhesus and MNS 
phenotype frequencies, since only limited data are available for other blood groups.  These 
blood group loci are the most polymorphic, the ones of greatest medical significance and, 
therefore, the ones for which most data exist.  The tree and plot were unable to fully 
distinguish populations (e.g. Polynesians and A-SM) and show varying degrees of A-SM and 
P-SA genetic contribution to Polynesians, perhaps due to less discriminative genetic 
information being used than in earlier studies.  Our previous findings on HLA loci showed a 
fairly wide range (55:45 to 90:10) of A:SM and P:SA proportions in Polynesian and Maori 
populations (see Edinur et al., 2012).  Therefore, the inability of blood group data to show 
A:SM:P-SA ancestral fractions might also be due to founder effects and natural selection, as 
previously observed for HLA loci (see Mourant et al., 1978; Chambers and Edinur, 2013; 
Edinur et al., 2012).  Differences between PFA and MFA on the plots might be due to high 
frequencies of ABO B and Rhesus DCCee phenotype frequencies in the former, compared 
with MFA (see Table 2).   To better illustrate this point, we have plotted ABO and Rhesus 
phenotype frequency spectra for Polynesian, A-SM and P-SA populations in Figs. 5 and 6, 
respectively.  We observed reduced genetic variation and frequencies of B, AB and DCCee 
phenotypes from the original base of settlement movements (i.e. Taiwan) to the most remote 
corners of Polynesia (i.e. Easter Island and New Zealand).  In contrast, there are increased of 
DCcEe and DccEE phenotype frequencies with distance from Island of South East Asia and 
Melanesia.  These observations support the presence of selective pressure and/or longer-term 
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bottleneck as the genepool of Polynesian sub-populations were repeatedly refined by founder 
effects due to multiple re-settlements.  In addition, inferences made based on ABO and 
Rhesus frequencies are unable to link Maori (i.e. MFA and RFA) to any populations with 
absolute certainty, since only limited data available for other Polynesian sub-populations.  
Nonetheless, location of Polynesian populations at the lower right axis of the plot (Fig. 4) is 
evidence of their close genetic relationship to Asian populations, rather than Europeans and 
African.  In contrast, differences observed between MFA and TM or Maori NZ is due to 
contemporary gene flow from Europeans as TM and Maori NZ (Woodfield et al., 1987) were 
recruited from samples that are known to have European admixture.  Therefore, the 
molecular blood group data from MFA provides good reference standard for the wider un-
admixed Maori group, as this Maori sub-group is also matched well with the serological data 
for RFA (see Table S3).   
 
     As a conclusion, the present survey provides the first molecular blood group genotyping 
data for the Maori and Polynesian population living in New Zealand.  Our validation using 
three different blood group genotyping methods gave 100% concordance and thus reflects the 
possibility of applying a range of molecular platforms in transfusion medicine.  In addition, 
the collected blood group data are in general account accord with the of Polynesian origins 
(Chambers, 2008; Bellwood et al., 2011; Chambers and Edinur, 2013; Chambers, 2013), 
although not as conclusive as those provided by genome-wide SNP, HLA and autosomal 
microsatellites markers (Hagelberg et al., 1999; Zimdahl et al., 1999; Friedlaender et al., 
2008; Kimura et al., 2008; Wollstein et al., 2010; Edinur et al., 2012). 
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Fig. 5:  ABO blood group phenotype frequency spectra in various Polynesian sub-populations. Reference populations were obtained from Nigg, 1930; Shapiro, 1940; Sanger 
et al., 1951; Simmons et al., 1955; Simmons and Graydon, 1957; Stavely and Douglas, 1958; Stavely and Douglas, 1959; Nakajima et al., 1971; Lai and Bloom, 1982; 
Windhof and Walter, 1983. 
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Fig. 6: Rhesus blood group phenotype frequency spectra in various Polynesian sub-populations. Reference populations were obtained from Sanger et al., 1951; Simmons et 
al., 1955; Stavely and Douglas, 1958; Stavely and Douglas, 1959; Nakajima et al., 1971; Lai and Bloom, 1982; Windhof and Walter, 1983. 
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Supplementary information 
 
Table S1: Blood group variants captured by DNA-SSP and BLOODchip technology. 
 
Blood group variants 
 
BAGene DNA-SSP 
 
Progenika SNP 
     
ABO  
 
ABO-TYPE variant 
       A 
B 
O 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
     
     Rhesus  
 
RH-TYPE 
       RhD+ 
RhD- 
Weak D 
Partial D 
C 
c 
E 
E 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
     MNS   
 
MNS-TYPE  
       M 
N 
S 
s 
U 
Mia 
 
+ 
+ 
+ 
+ 
- 
 
+ 
+ 
+ 
+ 
+ 
+ 
     
     Kell   
 
KKD-TYPE 
       
K 
k 
Kpa 
Kpb 
Kpc 
Jsa 
Jsb 
Kmod 
 
+ 
+ 
- 
- 
- 
- 
- 
- 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
     
     Kidd   
         Jka 
Jkb 
IVS5-1g>a   
 
+ 
+ 
- 
 
+ 
+ 
+ 
     
     Duffy   
         Fya 
Fyb 
FyGATA 
Fyx 
 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
     
     Diego   
 
- 
       Dia 
Dib 
 
- 
- 
 
+ 
+ 
     
     Colton   
 
- 
       
Coa 
 
- 
 
+ 
Cob 
 
- 
 
+ 
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 Table S1, cont. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood group variants 
 
BAGene DNA-SSP 
 
Progenika SNP 
     
Dombrock   
 
- 
       Doa 
Dob 
 
- 
- 
 
+ 
+ 
     
HPA  
 
HPA-TYPE 
       HPA-1a 
HPA-1b 
HPA-2a 
HPA-2b 
HPA-3a 
HPA-3b 
HPA-4a 
HPA-4b 
HPA-5a 
HPA-5b 
HPA-6a 
HPA-6b 
HPA-7a 
HPA-7b 
HPA-8a 
HPA-8b 
HPA-9a 
HPA-9b 
HPA-10a 
HPA-10b 
HPA-11a 
HPA-11b 
HPA-15a 
HPA-15b 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
+ 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Chapter 3.3 
 
192 
 
Table S2: PCR protocols for SBT of Kell, IVS5-1 and Duffy variants 
Locus Primers  PCR reaction set-up PCR cycling condition 
   
Step Temp  Time  Cycles 
IVS5-1A>G F: CAAGTGCAACCAAAGCTCAC  Template = 2ul (15ng/ul) P.denaturation 94 7min 1 
 
R: CTGCCATATAACAACTCCCATTC (Wester et al., 2008)  Forward primer = 1ul (10uM) Denaturation 96 30s 
35 
  
Reverse primer = 1ul (10uM) Annealing  58 30s 
  
MyTaqTM Red Mix (Bioline) =12.5ul  Extension 72 60s 
  
Distilled water = 9.5ul Final extension 72 7min 1 
    
   
Locus Primers  PCR reaction set-up PCR cycling condition 
   
Step Temp  Time  Cycles 
Kell F: TTTAGTCCTCACTCCCATGCTTCC  Template = 2ul (15ng/ul) P.denaturation 94 5min 1 
 
R: TATCACACAGGTGTCCTCTCTTCC  (Lee et al., 1995) Forward primer = 1ul (10uM) Denaturation 94 20s 
35 
  
Reverse primer = 1ul (10uM) Annealing  62 15s 
  
MyTaqTM Red Mix (Bioline) =12.5ul  Extension 72 20s 
  
Distilled water = 9.5ul Final extension 72 10min 1 
       
Locus Primers  PCR reaction set-up  PCR cycling condition  
   
Step Temp  Time  Cycles 
Duffy F: TCCCCCTCAACTGAGAACTC (Rios et al., 1999) Template = 2ul (15ng/ul) P.denaturation 94 5min 1 
 
R: AAGGCTGAGCCATAYYAGAC (this study) Forward primer = 1ul (10uM) Denaturation 94 20s 
35 
  
Reverse primer = 1ul (10uM) Annealing  62 15s 
  
MyTaqTM Red Mix (Bioline) =12.5ul  Extension 72 20s 
  
Distilled water = 9.5ul Final extension 72 10min 1 
       
All amplified products were sequenced using ABI3730 DNA Analyzer (Applied Biosystems) by Massey Genome Service (Massey University, New Zealand) 
Chapter 3.3 
 
193 
 
Table S3:  Exact tests on Maori datasets 
 
ABO 
    
 
TR  TM  RFA  
TR  
TM  
RFA  
MFA 
~ 
0.14 
0.67 
0.50 
~ 
~ 
0.05 
0.74 
~ 
~ 
~ 
0.30 
    
Rhesus 
    
 
TR  TM  RFA  
TR  
TM  
RFA  
MFA 
~ 
0.16 
0.18 
0.37 
~ 
~ 
0.01 
0.08 
~ 
~ 
~ 
1 
 
Abbreviations: TR: Total RakaiPaaka, TM: Total Maori, RFA: RakaiPaaka with Full Ancestry, MFA: Maori 
with Full Ancestry 
 
 
Table S4:  Exact tests on Polynesian and European datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Euro = Europeans, TM =Total Maori, MFA= Maori with Full Ancestry, PFA = Polynesians with 
Full Ancestry 
 
ABO 
 
Rhesus 
         
 
TM MFA PFA 
  
TM MFA PFA 
TM 
MFA 
PFA 
Euro 
~ 
0.73 
0.00 
0.02 
~ 
~ 
0.01 
0.06 
~ 
~ 
~ 
0.11 
 
TM 
MFA 
PFA 
Euro 
~ 
0.83 
0.00 
0.00 
~ 
~ 
0.00 
0.00 
~ 
~ 
~ 
0.00 
         
MNS 
 
Kell 
         
 
TM MFA PFA 
  
TM MFA PFA 
TM 
MFA 
PFA 
Euro 
~ 
1.00 
0.82 
0.00 
~ 
~ 
0.84 
0.00 
~ 
~ 
~ 
0.02 
 
TM 
MFA 
PFA 
Euro 
~ 
1.00 
1.00 
0.11 
~ 
~ 
1.00 
0.30 
~ 
~ 
~ 
0.74 
         
Kidd 
 
Duffy 
         
 
TM MFA PFA 
  
TM MFA PFA 
TM 
MFA 
PFA 
Euro 
~ 
0.30 
0.27 
0.00 
~ 
~ 
0.04 
0.00 
~ 
~ 
~ 
0.17 
 
TM 
MFA 
PFA 
Euro 
~ 
1.00 
0.03 
0.00 
~ 
~ 
0.05 
0.02 
~ 
~ 
~ 
0.00 
         
Dombrock 
              
 
TM MFA PFA 
     TM 
MFA 
PFA 
Euro 
~ 
0.67 
0.41 
0.01 
~ 
~ 
0.21 
0.01 
~ 
~ 
~ 
0.91 
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Table S5: Comparison of phenotype predictions based on PCR-SSP and combination of PCR-SSP and SBT (JK*IVS5-1g>a). 
 
Kidd  PCR-SSP (N) 
 
PCR-SSP plus JK*IVS5-1g>a (N) 
 
Discordant results (N) 
 
 
     
Jk(a+b-) 
Jk(a-b+) 
Jk(a+b+) 
 21 
5 
33 
 
32 
5 
22 
 
11 (19%) 
 
 
     
 
Abbreviations:  N = sample size 
 
 
 
 
Table S6: Summary of the costs associated with the three molecular methods used in the present survey. 
 
 
* The overall cost is given for the blood group tests covered by each technology, excluding technician time and other related cost.
Methods 
 
 Blood groups 
 
HPA 
 
DNA  Cost 
 
Time 
 
Comments 
      
  
     PCR-SSP 
 
 
 
ABO, Rhesus, Kell, Kidd, Duffy and 
MNS 
 
 
1 to -5 and -
15 
 
 
65ul 
(50ng/ul) 
 c. €128 
per sample 
 
 
3h/samples/ 
blood group 
 
 
Labour extensive, time  consuming  
and  require lots of DNA template 
 
      
  
     BLOODchip 
 
 
 
ABO, Rhesus, Kell, Kidd, Duffy, MNS, 
Dombrock, Diego  and Colton 
 
 
 1 to -11 and -
15 
 
 
40 ul 
(50ng/μl) 
 
 c. €350 
per sample 
 
 
20 samples, 
10h 
 
 
Expensive but cover multiple 
number of antigens and short 
turnaround time 
      
  
     SBT 
  
Kell and Duffy 
  
HPA-6 
  
6ul 
(15ng/ul) 
 
c. €10 per 
sample  
2-3 days 
  
Accurate but laborious, costly and 
time-consuming 
      
  
     
Chapter 3.4 
 
195 
 
Human platelet antigens frequencies in Maori and Polynesian populations  
 
 
 
H.A. Edinur
*
, P.P.J. Dunn
§
,
 
R.A. Lea
†
 and G.K. Chambers
*
 
 
*
School of Biological Sciences, Victoria University of Wellington, New Zealand 
§
Tissue Typing Laboratory, New Zealand Blood Service, Auckland 
†
School of Medical
 
Sciences, Griffith University, Australia 
 
 
 
 
 
Status:  Transfusion Medicine, 23, 330-337. 
 
 
 
 
 
 
Key words: Platelet, alloimmunization, Polynesia, Polynesians, Maori  
Correspondence:  Dr Geoffrey K. Chambers, School of Biological Sciences, Victoria 
University of Wellington, PO Box 600, Wellington 6140, New Zealand. Ph: +64-(0)4-463-
6091, Fax:  +64-(0)4-463-5331, e-mail: Geoff.Chambers@vuw.ac.nz 
Chapter 3.4 
196 
 
SUMMARY 
 
Background:  Allele frequencies of human platelet antigens (HPA) reflect population history 
and possibility of platelet-specific alloimmunization.  Here, we report on screening of 
variants at HPA loci for Polynesian and Maori subjects. 
Objectives:  Our aims are to evaluate new HPA genotyping methods, compile and analyse 
new HPA datasets for these subjects, use HPA data for tracing ancestry, migration patterns, 
genetic admixture and its  potential influence on health. 
Materials and Methods:  A total of 75 Maori and 25 Polynesian DNA samples were 
genotyped using commercial BAGene HPA-TYPE DNA-SSP kits, BLOODchip 
hybridization SNP assays and DNA sequence based typing.  
Results:  Genotyping was successful and cross validation of PCR-SSP and BLOODchip gave 
100% agreement.  Among the HPA loci tested, only 6 are dimorphic (HPA-1 to -3, -5, -6 and 
-15) and all others are monomorphic.  The Polynesians and Maori have the „a‟ allele form as 
the most common for all loci except HPA-15. 
Conclusions:  The newly observed HPA data as well as PCO analysis clearly indicate genetic 
contributions from both, Asia and Australasia in Maori and Polynesian populations together 
with recent admixture with Europeans.  In addition, different prevalences of HPA alleles 
among Polynesian, Maori and European populations contribute towards different risk profiles 
for platelet specific alloimmunization.  This is the first report for these populations and our 
findings are of direct practical relevance for blood transfusion centres, the management of 
pregnancies, assessment of NAIT and management of multi-transfused patients.   
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INTRODUCTION 
 
Human platelet antigens (HPA) are immunogenic transmembrane glycoprotein antigens 
expressed on the surface of anucleate platelets (Robinson et al., 2010 and Rozman, 2002).  
Neonatal alloimmune thrombocytopenia (NAIT), post transfusion purpura (PTP) and platelet 
transfusion refractoriness are among clinical consequences of alloantibodies against HPA that 
develop during pregnancy and after blood or platelet transfusion (see Lubenow et al., 2000; 
Ohto et al., 2000; Spencer and Burrows, 2001; Engelfriet and Reesink, 2003; Metcalfe et al., 
2003), although there is evidence that PTP is autoantibody rather than alloantibody induced 
(Watkins et al., 2012).  The molecular basis of 22 serologically defined HPA (see Robinson 
et al., 2010) have been assigned and approved according to guidelines set up by The Platelet 
Nomenclature Committee (Metcalfe et al., 2003).  Alloantibodies against both, high and low 
frequency alleles (designated as a and b, respectively) are only recorded for six HPA systems 
(i.e. HPA-1 to -5, and -15).   
 
Population genetic studies have shown that distributions of HPA alleles reflect ancestry and 
the potential prevalence of alloimunization (e.g. see Feng et al., 2006; De La Vega Elena et 
al., 2008).  We are now investigating this proposition by undertaking a new study on 
previously uncharacterized populations of New Zealand Maori and Polynesians.  Previous 
studies on genes, language and culture have thrown up contrasting theories that each account 
for parts of the patterns and some of the processes involved during diffusion of Austronesian-
speaking Mongoloid (A-SM) peoples to Remote Oceania.  These ideas are known by various 
exotic names; Slow Boats, Fast Trains, Out of Taiwan etc.  This competition has been further 
reinforced by apparently conflicting data from genetic studies of mtDNA vs. Y-chromosome 
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vs. autosomal markers, only recently resolved by adding in gender biased gene flow in 
matrilineal societies (Chambers, 2006).  
 
The emergent consensus is captured by the following updated version of our „Synthetic Total 
Evidence Model (STEM)‟ as an extension to the one first proposed Chambers (2006).  This 
comprehensive model combines all previous ideas and data relating to the origins of 
Polynesian peoples (see also Chambers and Edinur, 2012 and Chambers, 2013 for the 
updated version of STEM).  The model involves greater or lesser blending of the genepools of 
two distinct peoples; A-SM (ex-Taiwanese Aboriginals) and Papuan-speaking Australoid (P-
SA: ex-coastal Melanesia and islands of the Bismarck Archipelago).  It is thus a reticulated 
history of human evolution in the Pacific, rather than an exclusively branching one.  Under 
this model, A-SM people migrated south from Taiwan (Bellwood et al., 2011) via Island 
South East Asia (ISEA) and engaged in gender biased genetic exchange with P-SA people in 
the Bismarck Archipelago creating Lapita culture and displacing local Papuan languages.  
Low levels of genetic introgression from P-SA to A-SM created Proto-Polynesians and later 
gave rise to those now known as Melanesians (Friedlaender et al., 2008; Kayser, 2010) via 
continued directional admixture. 
 
Movement into the oceanic islands of Near Oceania by Proto-Polynesians was the next step 
carrying Lapita pottery skills with them.  They were later followed as far as Fiji by 
Melanesians who spoke Austonesian languages and displaced most, but not all of the Proto-
Polynesians from Vanuatu, New Caledonia etc. (Bellwood, 1978).  The Proto-Polynesians 
moved on to occupy Remote Oceania reaching a core area in Eastern Polynesia and then 
rapidly expanding to fill up the Polynesian Triangle (Hawaii, Easter Island and New 
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Zealand).  In New Zealand, Maori remained as an isolated people from around 650ybp until 
the arrival of Europeans over the last 150 years. 
 
This recently extended version of the basic STEM model is supported by multiple lines of 
evidence and subsumes all previous partial pattern and process models (see above and 
Bellwood et al., 2011), except for those that exclude Taiwan as the origin of the A-SM 
component.  It makes testable predictions with respect to populations of origin, the gender-
biased reticulated admixture process leading to differentiation of male and female lineages 
and genepool refinement via bottlenecks and founder effects.  The aims of present study are 
to evaluate new molecular HPA genotyping (i.e. sequence specific primers vs. single 
nucleotide polymorphism array), compile and analyse new HPA datasets for Polynesian and 
Maori subjects, use HPA data from this study for tracing ancestry, migration patterns and 
genetic admixture and to evaluate their  potential influence on health.  To the best of our 
knowledge, this is the first molecular genetics study of HPA for Maori and the only available 
HPA data for Polynesians are those from Ma‟ohis individuals, the native population of the 
Tuamotu Archipelago reported by Halle et al. (2004).  These data complement our recent 
study of HLA in Maori and Polynesians and its relevance to transplantation and autoimmune 
diseases (Edinur et al., 2012) and provide valuable information on frequencies of HPA 
antigens, important in transfusion sciences.   
 
MATERIALS AND METHODS 
Samples  
A total of 75 Maori (Total Maori = TM) and 25 Polynesian with Full Ancestry (PFA) 
genomic DNA samples obtained with informed consent and ethical approval were drawn 
from the Victoria University of Wellington DNA Bank.  The larger Maori group was then 
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divided into a pair of smaller sub-groups based on self-defined pedigree: Maori with Full 
Ancestry (MFA: N = 47) + Maori with Admixed History (MAH: N = 28).   
HPA genotyping 
The genomic DNA were screened for HPA variants using commercial (BAGene DNA-SSP 
HPA-TYPE kit; BAG Health Care GmbH, Lich, Germany) polymerase chain reaction (PCR)-
sequence specific primer (SSP) kit and hybridization single nucleotide polymorphism (SNP) 
assay service (BLOODchip; Progenika Biopharma S.A., Spain) for genotyping of HPA-1 to -
5 and-15, and HPA-1 to -11 and -15, respectively.  A total of 60 and 50 samples were 
genotyped using these methods, respectively.  In order to cross validate molecular typing 
methods used in this study, ten of these samples were typed using both, PCR-SSP kits and 
BLOODchip analysis service.  We also performed sequence based typing (SBT) for HPA-6 
on the samples which were genotyped using the commercial SSP kits.  Our pair of forward 
and reverse primers and PCR protocol for HPA-6 genotyping is based on Tanaka et al. 
(1996).  The PCR products were sequenced using ABI3730 DNA Analyzer (Applied 
Biosystems) by Massey Genome Service (Massey University, Palmerston North, New 
Zealand).   
Statistical analysis 
Allele and genotype frequencies were estimated by direct counting.  Chi-squared tests (SPSS 
Inc., Chicago, IL) were used to test for Hardy-Weinberg equilibrium (HWE) and to compare 
HPA genotype frequencies between pairs of our Maori and Polynesian study groups and sub-
groups.  Principal coordinate (PCO) analysis was performed using Multivariate Statistical 
Software Package 3 (Kovach Computing Services, UK; http://www.kovcomp.com/mvsp).  
Neighbor-joining (NJ) phylogenetic tree was constructed from Nei‟s genetic distances using 
PHYLIP software package, version 3.6 (Felsenstein, 2004) and the topology of the tree was 
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visualized using TreeView program (Page, 1996).  Probabilities of transfusion and pregnancy 
alloimmunization were calculated according to De La Vega Elena et al. (2008). 
 
RESULTS 
 
The HPA alleles and frequencies at each locus observed in Maori and Polynesian study 
groups and sub-groups are listed in Table 1 and see Fig. 1 in Discussion.  Together with our 
newly collected data in Table 1 are HPA data (HPA-1 to 11 from Jones et al., 2003 and HPA-
15 from Ertel et al., 2005) from reference (EUR) European populations (see later for 
population comparison and estimation of transfusion and gestation incompatibility).  Most of 
the HPA loci tested are polymorphic, except for HPA-4, and -7 to -11. In addition, only 
homozygous HPA-5a and -6a individuals were observed in the MFA sub-group.  All HPA 
genotype profiles for the polymorphic HPA systems in Maori and Polynesian study groups 
and sub-groups are in HWE (see Table S1; non-polymorphic HPA systems are removed for 
simplicity).  Chi-squared tests on genotype frequencies (Table S2) show no significant 
differences between pairs of study population groups and sub-groups except for PFA vs. 
MFA at HPA-3, -5 and -6 and TM vs. PFA at HPA-6.  Admixture effects in our TM and 
MAH were then shown by plotting them on a bar diagram (Fig. 2) where polymorphic HPA 
alleles in TM and MAH are usually intermediate between MFA and our reference Europeans 
populations (Jones et al., 2003 and Ertel et al., 2005).   
 
Genetic relationships between Polynesians and Melanesians and their putative Mongoloid 
and Australoid ancestors from elsewhere in Asia and Australasia were probed by building 
HPA-1 to -5 allele frequency PCO plots (Fig. 3) and NJ phylogenetic tree (Fig. 4).  In these 
figures, A-SM and P-SA are the ancestral types who have contributed to the genepool of 
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Polynesians and Maori.  The PCO plots show more clear separation of populations; A-SM, P-
SA and Europeans.  In the plots, the PFA group is well separated and fall between A-SM 
populations and Australian aborigines compared with MFA which tends to cluster more 
closely with their A-SM relatives.  As might be expected, our admixed sub-group, MAH, is 
plotted as displaced toward European populations in the lower right corner of Fig. 3, 
reflecting recent European admixture. 
 
We also calculated probabilities of transfusion and foetomaternal incompatibility for Maori 
and Polynesian datasets and used reference European (EUR) populations (Jones et al., 2003 
for HPA-1, -2, -3, -5, -6 and Ertel et al., 2005 for HPA-15) to represent the majority 
European ethnic group in New Zealand (see Table S3 for details and how the data can be 
interpreted).  For all datasets, HPA-4 and -7 to -11 are monomorphic.  Thus, it is unlikely for 
alloimunization to develop for these HPA loci and, therefore, they have been removed from 
Table S3. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3.4 
203 
 
Table 1: HPA allele frequencies in Polynesian and Maori study groups and sub-groups and 
reference European
§
 (EUR) populations  
       
HPA-  TM (N=75) MAH (N=28) MFA (N=47) PFA (N=25) EUR* 
 
 
     
1a 
1b 
 0.960 
0.040 
0.946 
0.054 
0.968 
0.032 
0.980 
0.020 
0.840 
0.161 
       
2a 
2b 
 0.933 
0.067 
0.911 
0.089 
0.947 
0.053 
0.920 
0.080 
0.925 
0.0075 
       
3a 
3b 
 0.580 
0.420 
0.607 
0.393 
0.564 
0.436 
0.720 
0.280 
0.627 
0.373 
       
4a 
4b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
5a 
5b 
 0.987 
0.013 
0.964 
0.036 
1.000 
0.000 
0.940 
0.060 
0.914 
0.086 
       
6a 
6b 
 0.987 
0.013 
0.964 
0.036 
1.000 
0.000 
0.900 
0.100 
1.000 
0.000 
       
7a  
7b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
8a 
8b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
9a 
9b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
10a 
10b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
11a 
11b 
 1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
1.000 
0.000 
       
15a 
15b 
 0.340 
0.660 
0.304 
0.696 
0.362 
0.638 
0.300 
0.700 
0.512 
0.488 
 
 
     
 
HPA: human platelet antigen, N = sample size, TM: Total Maori, MAH: Maori with Admixed History, MFA: 
Maori with Full Ancestry and PFA: Polynesians with Full Ancestry, § = HPA data for Europeans (EUR) 
obtained from Jones et al., 2003 (HPA-1 to -6) and is Ertel et al.,2005 (HPA-15) and * = sample size for HPA-1 
to -6 is 134 and 407 for HPA-15. 
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Fig. 1:  Agarose gel electrophoresis of the HPA allele specific products amplified using BAGene DNA-SSP HPA-TYPE kit. 
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Fig. 2: Bar graph for polymorphic HPA loci show that our MAH is intermediate between MFA, TM and Europeans (EUR).  HPA data for EUR were obtained from Jones et 
al., 2003 (HPA-1 to -3, -5 and -6) and is Ertel et al., 2005 (HPA-15). 
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Fig. 3: PCO plots constructed using HPA-1 to -5 allele frequencies.  Reference populations for Europeans (grey), Austronesian-speaking Mongoloid (blue font), Papuan-
speaking Australoid (red) and Polynesians (green) obtained from Seller et al., 1999; Chu et al., 2001; Bennet et al., 2002; Jones et al., 2003, Shih et al., 2003; Halle et al., 
2004; Robinson et al., 2010; Tan et al., 2012.  Abbreviations: TM: Total Maori, MAH: Maori with Admixed History, MFA: Maori with Full Ancestry and PFA: Polynesians 
with Full Ancestry. 
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Fig. 4: Position of Polynesians and Maori in N-J phylogenetic tree constructed using HPA-1 to -5 allele 
frequencies compared to those probed in Fig. 3. Abbreviations and references are as assigned for Fig. 3.  
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DISCUSSION 
 
Serological typing has been integral to platelet phenotyping until the early 1990s (Norton et 
al., 2004).  However, the serological assays have certain well known limitations, especially 
with limited supply of antisera.  Introduction of molecular techniques has contributed toward 
a better understanding of the genetic and morphological variation of HPA alleles.  
Differences between the HPA alleles are mostly due to single nucleotide polymorphism 
leading to a single amino acid substitution (see Metcalfe et al., 2003 for molecular basis of 
HPA alleles).  With the elucidation of the molecular basis of HPA, many DNA-based 
methods are now available for HPA characterization, including regular PCR-based (PCR-SSP 
and PCR-RFLP; restriction fragment length polymorphism) and high-throughput (SNP array 
and Luminex) genotyping platform; see also Veldhuisen et al., 2009; Wu and Csako, 2006; 
Avent, 2007 for reviews on molecular techniques available for HPA typing.  
 
Genotyping of all samples was successful and cross validation using 10 samples gave 100% 
agreement.  The Progenika Biopharma service is simple and convenient.  DNA samples (with 
minimum concentration and amount of 50 ng/μl and 2 μg, respectively) are sent via courier to 
facilities in Derio, Spain.  It takes about 2 weeks and data reports are returned as electronic 
spreadsheets.  We conducted our tests as part of a wider blood group screening exercise (128 
SNPs for 9 blood groups and 12 HPA loci; Edinur, unpublished) and cost c. €350 per sample.  
The Progenika Biopharma does offer platelet only assay using a combination of multiplex 
PCR and Luminex technology (i.e. IDHPA).  Genotyping of HPA using BAGene DNA-SSP 
HPA-TYPE kit was done in-house.  The SSP method requires PCR followed by 
determination of product size by using agarose gel electrophoresis – see Fig. 1.  Gel is easily 
interpreted „by eye‟ or with manufacturer‟s software.  The PCR-SSP kits use a simple 
Chapter 3.4 
209 
 
procedure, work well, require 14μƖ (50-100ng/μƖ) of DNA, relatively inexpensive but 
restricted to limited number of HPA specificities (i.e. without HPA-6 to -11 variants).   
 
There were no inconsistencies among the ten samples genotyped using both, PCR-SSP kits 
and BLOODchip and this indicates the accuracy of molecular diagnostics.  However, we 
needed to perform SBT for HPA-6 locus on those samples genotyped using the commercial 
PCR-SSP kits, because this locus is polymorphic in Maori and Polynesians and is not 
included in their kit (see later).  The service provided by Progenika Biopharma is more 
expensive compared with BAGene PCR-SSP kits or any PCR-based typing, but some may 
judge the price to be worthwhile when one considers the total number of SNPs (i.e 128 SNPs 
for full detailed coverage of 9 blood groups and 12 HPA systems) included on the 
BLOODchip.  Several PCR-SSP kits or PCR protocols are needed to genotype larger number 
of antigens which in turn are costly, laborious, time consuming and require lots of DNA 
template.  Overall, DNA-based methods provide the best option for accurate and specific 
characterization of HPA and are superior to serogical phenotyping for prenatal diagnostic and 
management of multi-transfusion patients (see Wu and Csako, 2006; Avent, 2007).  
Nonetheless, a high-throughput molecular method such as BLOODchip would be preferable 
for mass screening of donors with rare genotypes at multiple HPA loci.  There is a single 
caveat.  All DNA markers show potential for expression of a particular marker type, but 
serology shows the actual expression.  Thus, molecular analysis of DNA SNP may not reveal 
a variant mutation that affects expression or modification of this allele.  Serological tests are 
unlikely to miss novel null variant in individual except in the sense that they will appear as 
homozygote.  Novel variant present different problem as they may cross react weakly or not 
at all with antibody-based reagent. 
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Visual comparisons on the distributions of HPA allele frequencies (Table 1) and statistical 
analysis on genotype frequencies (see Table S2) show no large contrast between MFA and 
MAH/TM, except for evidence of reduced variability in MFA.  Among the 12 HPA loci 
tested, only 4 are dimorphic in MFA, compared with 6 in both, TM and MAH.  This finding 
of reduced diversity in MFA is consistent with factors associated with founder effects and 
longer-term bottlenecks which are known to reduce allelic diversity, specifically via the 
preferential loss of rare alleles (i.e. HPA-5b and -6b in MFA).   Nonetheless, we are able to 
show the effect of recent European admixture with confidence as can be readily seen in Fig. 2 
where in almost every case the length of each bar representing the MAH sub-group is 
intermediate between those for TM, MFA and EUR.  Therefore, we use HPA data from MFA 
for tracing Maori lineage and history.  In contrast, HPA data from TM is very important for 
platelet alloimunization estimation, because they represent the genepool of present day Maori 
living in New Zealand due to its combination of MFA and MAH components.  
 
Differences between PFA and MFA (see Table 1 and S2) are really only obvious for HPA-3, 
-5 and -6.  These are due to the particularly low occurrence of HPA-3b in PFA (0.28 vs. 0.44 
in MFA) and monomorphic nature of the HPA-5 and -6 systems in MFA.  Small differences 
between PFA and MFA might be due to factors associated with sample collection and 
population histories.  Higher diversity observed in PFA compared with MFA is related to the 
nature of our PFA subjects, which are combination of Pacific Islanders from different 
geographical sources living in New Zealand.  
 
Allele frequencies for the HPA-1, -2, -5 and -6 loci in PFA and MFA (see Table 1) are 
similar to those observed in Asian populations, particularly those for Taiwan aboriginals (Seo 
et al., 1998; Chu et al., 2001; Shih et al., 2003; Halle et al., 2004; Feng et al., 2006; Tan et 
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al., 2012), rather than Europeans (Seller et al., 1999; Bennet et al., 2002; Jones et al., 2003; 
Robinson et al., 2010).  In addition, the presence of the HPA-6b allele in PFA reflects close 
genetic relationship with populations in East Asia as this allele is only observed among Asian 
populations (see Chu et al., 2001; Shih et al., 2003; Feng et al., 2006) and in the one previous 
study on Polynesians (Halle et al., 2004).  
 
However, allele frequencies for HPA-3 locus in PFA are not only different to MFA but also 
to those previously reported for Ma‟ohis Polynesians (Halle et al., 2004).  The PFA study 
group has a low frequency of HPA-3b (0.28), which is similar to indigenous Taiwanese Tsou 
(0.25; see Chu et al., 2001), but not anywhere near as low as to those recorded for aboriginal 
communities (0.07-0.06) from Australia (Chen et al., 1997; Bennet et al., 2002).  Both, PFA 
and MFA were observed to have relatively low frequencies of HPA-15a (0.36 and 0.30, 
respectively) compared with other populations from Asia, Africa and European populations, 
who often have almost equal values for HPA-15a and -b or higher frequencies of HPA-15a 
than HPA-15b (see Robinson et al., 2005 for wider comparisons).  Allele frequencies at the 
HPA-15 locus have not been studied for many populations.  Hence, we presently lack 
important reference data for ancestral groups; Taiwan aborigines and P-SA populations.  The 
HPA-15a and -b allele frequencies reported for our PFA group are respectively the lowest 
and highest values for any characterized population. 
 
We believe that genetic relationships between Polynesians and their putative Mongoloid and 
Australoid ancestors from elsewhere in Asia and Australasia as well as recent admixture with 
Europeans are best demonstrated by using PCO plots (Fig. 3), rather than by using methods 
such as NJ (see Fig. 4), that assume a tree-like evolutionary process.  This is shown by 
occasional inability of NJ procedure to group particular populations into their geographic 
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localities and known population labels, besides showing low bootstrap values.  Our PCO 
analysis shows that Polynesians (i.e. PFA) are distinct from other A-SM populations (Taiwan 
aborigines, Malays and Filipinos) and their position reflects their degree of shared A-SM/P-
SA ancestry.  Slight differences between PFA and other Polynesian populations (i.e. MFA 
and Ma‟ohis) on the plots might appear to reflect different proportions of genetic inputs from 
their ancestors, but more likely arise from genepool refinement via founder effects after 
multiple re-settlements and long term isolation.  In addition, the PCO plots also show 
evidence for gene flow in MAH as it lies closer to European populations.  Overall, the new 
data collected for PFA and MFA are consistent with the hybrid origin of Polynesians (Kimura 
et al., 2008; Wollstein et al., 2010; Bellwood et al., 2011) and European admixture in present 
day Maori is shown by our TM group.  
 
The findings from the present survey show how important it is to recognize that New Zealand 
is a heterogeneous multi-ethnic country.  This is of particular importance because it may have 
medical consequences.  Different prevalence of HPA alleles among Polynesian, Maori and 
European populations will contribute towards different risk profiles for platelet specific 
alloimmunization.  For instance, mismatch probability of random transfusion is quite high for 
HPA-1b and -15a among Europeans and HPA-3b and -6b among pairs of PFA individuals 
(see Table S3).  These calculated population specific mismatch probabilities will influence 
medical thinking regarding the risk of random platelet transfusion.  In addition, if one 
considers Europeans as major blood donors, HPA alloimmunization will only increase for 
HPA-1b, -5b and -15a in TM, MAH, PFA, MFA and only for HPA-3b in PFA.  In contrast, 
mismatch probability for Europeans will be slightly reduced for any of these HPA systems 
when transfused with platelets from Maori and Polynesian donors, regardless of group.  In 
addition, alloimmunization against HPA-6b is also potentially developed if platelets from 
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PFA are transfused to Europeans and Maori (TM/MAH/MFA).  Datasets in Table S3 also 
suggest high probability of developing anti- HPA-3b and -15a antibodies during pregnancy in 
all groups and sub-groups.    We note that the probability of developing antibodies against 
HPA gene products depends not only on the relative frequencies of the alleles, but also the 
immunogenicity of the antigens.  The possibility of alloimunization during pregnancy is also 
particularly high for HPA-1b, -5b and -15b among Europeans, for HPA-2b among MAH, for 
HPA-3a among MFA and for HPA-6b among PFA.  For inter-group marriages, the 
theoretical occurrence of NAIT increases for mixed couples of Europeans with others 
(TM/MAH/MFA/PFA) for HPA-1b and -15a, Maori (TM/MAH/MFA) and Europeans with 
PFA for HPA-3b and mixed couples of PFA with others (TM/MAH/MFA/Europeans) for 
HPA-6b.  The probability of transfusion and fetomaternal incompatibility is also supported 
by the presence of rare HPA genotypes; HPA-1bb, HPA-3bb, and HPA-5bb among 
Europeans (reviewed in Steffensen et al., 1996; Bennet et al., 2002; Ertel et al., 2005; Hauck-
Dlimi et al., 2012) and HPA-6bb in PFA.  At first sight, the high incidence of HPA-1a 
observed in this study means that NAIT caused by maternal antibodies against a mismatched 
HPA-1a on foetal platelets is likely to be a rare occurrence in Maori and Polynesians, but 
noting at the same time that blood group O frequency in the range (0.40-0.48) and HLA-
DRB3*01 allele is 0.40-0.45, which may reduce one‟s optimism in this respect (present 
author unpublished data).  This is because HPA-1a alloimmunization is strongly associated 
with HLA-DRB3*01:01, but not with blood group 0 phenotype (see Williamson et al., 1998; 
Ahlen et al., 2012). 
  
Overall, data generated from this study have shown the value and ability of DNA-based 
methods for HPA typing, the prevalence of HPA alleles in Maori and Polynesians and 
allowed us to use these data for studying ancestry, admixture and to evaluate their clinical 
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consequences.  Our findings are of practical relevance for blood transfusion centre protocols 
and management of pregnancies.  Transfusion centres may now wish to recruit HPA- and 
HLA- typed donors and the use high-throughput molecular methods such as BLOODchip, 
would be a good way to conduct mass donor screening and typing.  Knowledge of the 
incidence of HPA in different populations helps in the management of possible NAIT.  
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Supplementary information 
 
Table S1:  List of polymorphic HPA genotype profiles and Hardy-Weinberg analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPA: human platelet antigen, N = sample size, HWE: Hardy-Weinberg equilibrium, O: Observed frequency, E: Expected frequencies, X2: Chi-squared test, n.a: not 
applicable, p = significant value (p<0.05), TM: Total Maori, MAH: Maori with Admixed History, MFA: Maori with Full Ancestry and PFA: Polynesians with Full Ancestry. 
 TM (N=75)  MAH (N=28)  MFA (N=47)  PFA (N=25) 
                
HPA O E HWE  O E HWE  O E HWE  O E HWE 
genotype   analysis    analysis    analysis    analysis 
                
1a/1a 
1a/1b 
1b/1b 
0.920 
0.080 
0.000 
0.922 
0.077 
0.002 
X2 = 0.130 
P = 0.718 
 0.893 
0.107 
0.000 
0.896 
0.101 
0.003 
X2 = 0.090 
P = 0.764 
 0.936 
0.064 
0.000 
0.937 
0.062 
0.001 
X2 = 0.050 
P = 0.823 
 0.960 
0.040 
0.000 
0.960 
0.039 
0.000 
X2 = 0.010 
P = 0.920 
                
2a/2a 
2a/2b 
2b/2b 
0.880 
0.107 
0.013 
0.871 
0.124 
0.004 
X2 = 1.530 
P = 0.216 
 0.857 
0.107 
0.036 
0.829 
0.163 
0.008 
X2 = 3.260 
P = 0.071 
 0.894 
0.106 
0 
0.896 
0.101 
0.003 
X2 = 0.150 
P = 0.699 
 0.760 
0.240 
0.000 
0.774 
0.211 
0.014 
X2 = 0.460 
P = 0.498 
                
3a/3a 
3a/3b 
3b/3b 
0.320 
0.520 
0.160 
0.336 
0.487 
0.176 
X2 = 0.340 
P = 0.560 
 0.393 
0.429 
0.179 
0.369 
0.477 
0.154 
X2 = 0.290 
P = 0.590 
 0.277 
0.574 
0.149 
0.318 
0.492 
0.190 
X2 = 1.330 
P = 0.249 
 0.560 
0.320 
0.120 
0.518 
0.403 
0.078 
X2 = 1.064 
P = 0.302 
                
5a/5a 
5a/5b 
5b/5b 
0.973 
0.027 
0.000 
0.973 
0.026 
0.000 
X2 = 0.010 
P = 0.920 
 0.929 
0.071 
0.000 
0.930 
0.069 
0.001 
X2 = 0.040 
P = 0.841 
 1.000 
0.000 
0.000 
1.000 
0.000 
0.000 
n.a 
 
 
 0.880 
0.120 
0.000 
0.884 
0.113 
0.004 
X2 = 0.100 
P = 0.752 
                
6a/6a 
6a/6b 
6b/6b 
0.973 
0.027 
0.000 
0.973 
0.026 
0.000 
X2 = 0.010 
P = 0.920 
 0.929 
0.071 
0.000 
0.930 
0.069 
0.001 
X2 = 0.040 
P = 0.841 
 1.000 
0.000 
0.000 
1.000 
0.000 
0.000 
n.a 
 
 
 0.840 
0.120 
0.040 
0.810 
0.180 
0.010 
X2 = 2.780 
P = 0.095 
                
15a/15a 
15a/15b 
15b/15b 
0.093 
0.493 
0.413 
0.116 
0.449 
0.436 
X2 = 0.740 
P = 0.390 
 0.071 
0.464 
0.464 
0.092 
0.423 
0.485 
X2 = 0.270 
P = 0.603 
 0.106 
0.511 
0.383 
0.131 
0.462 
0.407 
X2 = 0.530 
P = 0.467 
 0.120 
0.360 
0.520 
0.090 
0.420 
0.490 
X2 = 0.510 
P = 0.475 
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Table S2: Homogeneity tests on genotype frequencies of polymorphic HPA loci observed in 
Maori and Polynesian study group and sub-groups 
 
HPA: human platelet antigen, TM: Total Maori, MAH: Maori with Admixed History, MFA: Maori with Full 
Ancestry and PFA: Polynesians with Full Ancestry, p = significant value (p<0.05). 
 
 
 
 
 
  HPA-1     HPA-2  
         
 TM MAH MFA   TM MAH MFA 
         
TM *    TM *   
         
MAH 
X2 = 0.188,  
P = 0.701 *   MAH 
X2 =  0.538,  
P = 1.000 *  
         
MFA 
X2 = 0.111,  
P = 1.000 
X2 = 0.447,  
P = 0.665 *  MFA 
X2 =  0.633,  
P = 1.000 
X2 = 1.705,  
P = 0.527  * 
         
PFA 
X2 = 0.461, 
 P = 0.677 
X2 = 0.853,  
P = 0.613 
X2 = 0.177,  
P = 1.000  PFA 
X2 =  3.032,  
P = 0.385 
X2 = 2.419,  
P = 0.278 
X2 =  2.251,  
P = 0.173 
         
  HPA-3     HPA-5  
         
 TM MAH MFA   TM MAH MFA 
         
TM *    TM *   
         
MAH 
X2 = 0.705,  
P = 0.728 *   MAH 
X2 = 1.094,  
P = 0.572 *  
         
MFA 
X2 = 0.361,  
P = 0.846  
X2 = 1.556, 
 P = 0.471 *  MFA 
X2 = 1.274,  
P = 0.522 
X2 = 3.449,  
P = 0.136 * 
         
PFA 
X2 = 6.222,  
P = 0.045 
X2 = 2.539,  
P = 0.283 
X2 = 7.183,  
P = 0.026  PFA 
X2 = 3.439,  
P = 0.098 
X2 = 0.365,  
P = 0.658 
X2 = 5.885,  
P = 0.039 
         
  HPA-6     HPA-15  
         
 TM MAH MFA   TM MAH MFA 
         
TM *    TM *   
         
MAH 
X2 = 1.094,  
P = 0.572 *   MAH 
X2 = 0.271,  
P = 0.898 *  
         
MFA 
X2 = 1.274,  
P = 0.522 
X2 = 3.449,  
P = 0.136 *  MFA 
X2 = 0.134 ,  
P = 0.964 
X2 = 0.587,  
P = 0.776 * 
         
PFA 
X2 = 6.621,  
P = 0.033 
X2 = 1.567,  
P = 0.493 
X2 = 7.962,  
P = 0.012  PFA 
X2 = 0.675,  
P = 0.745 
X2 = 0.463,  
P = 0.789 
X2 = 0.819,  
P = 0.682 
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Table S3: Probability of transfusion and gestation mismatch for Maori, Polynesian and 
reference European
§
 (EUR) populations. 
 
  Transfusion  Gestation 
    
HPA- TM>TM/MAH/MFA/PFA/EUR  TM>TM/MAH/MFA/PFA/EUR 
    
1a 
1b 
2a 
2b 
3a 
3b 
5a 
5b 
6a 
6b 
15a 
15b 
0.002/0.003/0.001/0.000/0.026 
0.072/0.070/0.073/0.075/0.055 
0.004/0.008/0.003/0.006/0.006 
0.112/0.107/0.116/0.109/0.110 
0.145/0.127/0.157/0.065/0.115 
0.223/0.245/0.211/0.344/0.261 
0.000/0.001/0.000/0.004/0.007 
0.026/0.025/0.026/0.023/0.022 
0.000/0.001/0.000/0.010/0.000 
0.026/0.025/0.026/0.021/0.026 
0.246/0.274/0.230/0.277/0.134 
0.102/0.082/0.116/0.080/0.232 
 0.002/0.003/0.001/0.000/0.025 
0.037/0.036/0.037/0.038/0.028 
0.004/0.007/0.003/0.006/0.005 
0.058/0.055/0.060/0.056/0.057 
0.102/0.090/0.110/0.045/0.081 
0.141/0.155/0.134/0.218/0.165 
0.000/0.001/0.000/0.004/0.007 
0.013/0.012/0.013/0.012/0.011 
0.000/0.001/0.000/0.010/0.000 
0.013/0.012/0.013/0.011/0.013 
0.148/0.165/0.139/0.167/0.081 
0.076/0.061/0.086/0.059/0.173 
    
HPA- MAH>TM/MAH/MFA/PFA/EUR  MAH>TM/MAH/MFA/PFA/EUR 
    
1a 
1b 
2a 
2b 
3a 
3b 
5a 
5b 
6a 
6b 
15a 
15b 
0.002/0.003/0.001/0.000/0.026 
0.096/0.093/0.098/0.100/0.073 
0.004/0.008/0.003/0.006/0.006 
0.149/0.141/0.153/0.144/0.146 
0.149/0.131/0.161/0.066/0.118 
0.212/0.233/0.201/0.327/0.248 
0.000/0.001/0.000/0.004/0.007 
0.068/0.065/0.070/0.062/0.059 
0.000/0.001/0.000/0.010/0.000 
0.068/0.065/0.070/0.057/0.070 
0.224/0.250/0.210/0.252/0.123 
0.105/0.084/0.119/0.082/0.238 
 0.002/0.003/0.001/0.000/0.024 
0.049/0.048/0.050/0.051/0.038 
0.004/0.007/0.003/0.006/0.005 
0.078/0.074/0.080/0.076/0.076 
0.107/0.094/0.116/0.048/0.084 
0.132/0.145/0.125/0.204/0.154 
0.000/0.001/0.000/0.003/0.007 
0.035/0.033/0.036/0.032/0.030 
0.000/0.001/0.000/0.010/0.000 
0.035/0.033/0.036/0.029/0.036 
0.132/0.147/0.124/0.149/0.072 
0.081/0.064/0.091/0.063/0.183 
    
HPA- MFA>TM/MAH/MFA/PFA/EUR  MFA>TM/MAH/MFA/PFA/EUR 
1a 
1b 
2a 
2b 
3a 
3b 
5a 
5b 
6a 
6b 
15a 
15b 
0.002/0.003/0.001/0.000/0.026 
0.058/0.056/0.059/0.060/0.044 
0.004/0.008/0.003/0.006/0.006 
0.090/0.086/0.093/0.088/0.089 
0.143/0.125/0.154/0.063/0.113 
0.229/0.251/0.217/0.354/0.268 
0.000/0.001/0.000/0.004/0.007 
0.000/0.000/0.000/0.000/0.000 
0.000/0.001/0.000/0.010/0.000 
0.000/0.000/0.000/0.000/0.000 
0.258/0.287/0.241/0.290/0.141 
0.100/0.080/0.114/0.078/0.228 
 0.002/0.003/0.001/0.000/0.025 
0.029/0.029/0.030/0.031/0.022 
0.004/0.008/0.003/0.006/0.005 
0.046/0.044/0.048/0.045/0.046 
0.099/0.087/0.107/0.044/0.078 
0.147/0.161/0.139/0.266/0.171 
0.000/0.001/0.000/0.004/0.007 
0.000/0.000/0.000/0.000/0.000 
0.000/0.001/0.000/0.010/0.000 
0.000/0.000/0.000/0.000/0.000 
0.158/0.175/0.147/0.177/0.086 
0.074/0.059/0.084/0.057/0.167 
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Table S3, cont. 
 
 
 Transfusion  Gestation 
    
HPA- PFA>TM/MAH/MFA/PFA/EUR  PFA>TM/MAH/MFA/PFA/EUR 
1a 
1b 
2a 
2b 
3a 
3b 
5a 
5b 
6a 
6b 
15a 
15b 
0.002/0.003/0.001/0.000/0.026 
0.036/0.035/0.037/0.038/0.028 
0.004/0.008/0.003/0.006/0.006 
0.134/0.127/0.138/0.130/0.131 
0.163/0.142/0.175/0.072/0.189 
0.162/0.178/0.153/0.250/0.189 
0.000/0.001/0.000/0.004/0.007 
0.113/0.108/0.116/0.103/0.097 
0.000/0.001/0.000/0.010/0.000 
0.185/0.177/0.190/0.154/0.190 
0.222/0.247/0.208/0.250/0.121 
0.105/0.084/0.119/0.082/0.239  
0.002/0.003/0.001/0.000/0.025 
0.018/0.018/0.019/0.019/0.014 
0.004/0.007/0.003/0.006/0.005 
0.070/0.066/0.072/0.068/0.068 
0.127/0.111/0.137/0.056/0.100 
0.094/0.103/0.089/0.145/0.110 
0.000/0.001/0.000/0.003/0.007 
0.058/0.056/0.060/0.053/0.050 
0.000/0.001/0.000/0.009/0.000 
0.097/0.093/0.100/0.081/0.100 
0.131/0.146/0.122/0.147/0.071 
0.081/0.065/0.092/0.063/0.184 
    
HPA- EUR>TM/MAH/MFA/PFA/EUR  EUR>TM/MAH/MFA/PFA/EUR 
    
1a 
1b 
2a 
2b 
3a 
3b 
5a 
5b 
6a 
6b 
15a 
15b 
0.002/0.003/0.001/0.000/0.025 
0.273/0.265/0.277/0.284/0.208 
0.004/0.008/0.003/0.006/0.006 
0.126/0.120/0.129/0.122/0.124 
0.152/0.133/0.164/0.067/0.120 
0.204/0.224/0.193/0.315/0.239 
0.000/0.001/0.000/0.004/0.007 
0.160/0.153/0.165/0.145/0.138 
0.000/0.001/0.000/0.010/0.000 
0.000/0.000/0.000/0.000/0.000 
0.332/0.370/0.310/0.373/0.181 
0.085/0.068/0.097/0.066/0.193 
 0.001/0.002/0.001/0.000/0.022 
0.148/0.144/0.151/0.155/0.113 
0.004/0.007/0.003/0.006/0.005 
0.065/0.062/0.067/0.063/0.064 
0.111/0.097/0.119/0.049/0.087 
0.125/0.137/0.119/0.193/0.147 
0.000/0.001/0.000/0.003/0.007 
0.084/0.080/0.086/0.076/0.072 
0.000/0.001/0.000/0.010/0.000 
0.000/0.000/0.000/0.000/0.000 
0.223/0.248/0.209/0.251/0.122 
0.056/0.045/0.064/0.044/0.128 
 
HPA: human platelet antigen, TM: Total Maori, MAH: Maori with Admixed History, MFA: Maori with Full 
Ancestry and PFA: Polynesians with Full Ancestry, § = HPA data for Europeans (EUR) obtained from Jones et 
al., 2003 (HPA-1 to -6) and Ertel et al., 2005 (HPA-15), >: donor to recipient for transfusion and father to 
mother populations for gestation. 
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Abstract 
 
The KIR gene region is highly polymorphic and variability is shown in both haplotype-gene 
content and at the allelic level.  In this respect, the KIR system variations reflect that 
observed for the highly polymorphic HLA class I loci, where products are ligands for KIR.  
In the present study, we examine KIR gene content in a set of Polynesian and Maori 
individuals previously genotyped for HLA loci.  The haplotype A homozygote was the most 
common KIR genotype profile observed which is consistent with high frequencies (0.87-
1.00) of individual KIR genes that make up the A haplotype.  Other profiles observed were 
AB heterozygote haplotypes involving mostly combinations of centromeric (KIR2DL2-
2DS2) and telomeric (2DL5-2DS1, 2DS1-3DS1 and 2DS5-3DS1) B pairs of loci, which were 
in strong positive association.  A principal component plot constructed using KIR carrier 
frequency shows that geographically proximal populations tend to cluster together fairly well 
reflecting the shared history among populations.  However, KIR variation at the population 
level may also reflect adaptation to local selective forces.  Therefore, we compared 
correlations of KIR and HLA ligand frequencies in order to avoid potential issues of non-
independence due to the shared genetic history among the populations.  There were 
significant positive correlations between KIR3DLI and HLA-Bw4/Bw4-80I and significant 
negative correlations for pairs of 3DSI-Bw4/Bw4-80I, 2DL2-C1 and 2DS1-C2.  Overall, our 
research findings together with subsequent analyses provide a valuable perspective on 
Polynesian immunogenetics and support the view that global patterns of KIR and HLA 
diversity are shaped by both population history and adaptation by natural selection.   
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Introduction 
 
Killer cell immunoglobulin-like receptors (KIR) are transmembrane glycoproteins expressed 
by natural killer cells.  These receptor proteins are classified based on the number of 
extracellular immunoglobulin domains (either 2D; 2 domains or 3D; 3 domains) and the 
characteristics of their cytoplasmic domain (S; short or L; long).  KIR with the long 
cytoplasmic domains contain an immunoreceptor tyrosine-based inhibition motif and 
transduce inhibitory signals, while those with the short cytoplasmic domain transmit an 
activating signal through association with DAP-12 molecule (Wilson et al. 1997; Carrington 
and Norman 2003). 
 
The KIR glycoproteins are encoded by genes on human chromosome 19q13.4 (Suto et al. 
1998).  The KIR genes are highly polymorphic and variability is shown in both, haplotype 
gene content and at the allelic level (reviewed by Middleton and Gonzelez 2010).  A total of 
16 KIR genes have been identified and can be divided into two haplotype groups, known as 
A and B.  The four framework KIR genes (KIR3DL3, 3DP1, 2DL4 and 3DL2) are common 
to both haplotypes.  The A haplotype consists of KIR2DL3, 2DP1, 2DL1, 3DL1 and 2DS4 
genes whereas haplotype B is assigned based on the present of KIR3DS1, 2DL5, 2DS1, 
2DS5, 2DL2, 2DS2 and 2DS3 genes (Rajalingam et al. 2008).  To date, there are more than 
600 different alleles that have been reported across all of the 16 KIR loci (see Robinson et al. 
2010; Gonzalez-Galarza et al. 2011).  In this respect, the observed diversity in the KIR 
system is similar to that observed for the highly polymorphic human leukocyte antigen 
(HLA) class I, ligand for KIR.  The high polymorphism of KIR and HLA class I loci are 
thought to have co-evolved with distinct KIR-HLA ligand combinations being associated in 
pathogenesis of autoimmune diseases, virus infections, tumours, fertility and the success of 
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transplantation (see Ruggeri et al., 2002; Yawata et al. 2006; Single et al. 2007; Ahlenstiel et 
al. 2008; Kurkani et al. 2008; Moesta and Parham, 2012; Parham et al. 2012a,b; Parham and 
Moffett 2013).  Therefore, evolutionary forces acting effectively at the population level may 
simultaneously influence allele and haplotype frequency for HLA class I and KIR loci.   
 
In recent years, several large scale studies have been conducted to explore worldwide patterns 
of KIR variation.  These provide exceptional value for authenticating population history (e.g. 
see Hollenbach et al. 2010; Hollenbach et al. 2012).  This study is the first KIR gene content 
screening in Maori.  To date, the only KIR data available for Polynesian sub-populations 
(Cook Islands, Tonga, Samoa and Tokelau) are those reported by Velickovic et al. (2006).  
The present study is intended to examine gene content polymorphism in previously HLA 
genotyped Polynesian and Maori individuals (see Edinur et al. 2012).  The newly collected 
KIR data will be used for ancestry study and can also be used as reference medical standard 
for disease association studies in Maori and Polynesians.   
 
Materials and Methods 
Study population group and sub-groups 
Genomic DNA samples from 108 unrelated Maori (Total Maori = TM) and 48 Polynesian 
(TP = Total Polynesians) unrelated individuals were drawn from the Victoria University of 
Wellington DNA Bank.  The larger Maori and Polynesian groups were then divided into a 
pair of smaller sub-groups based on a self-defined pedigree: Maori with Full Ancestry (MFA: 
N = 50) and Polynesians with Full Ancestry (PFA: N = 34), after Edinur et al. (2012).  
Ethical approvals were obtained from New Zealand Central Region Ethics Committee and 
VUW Human Ethics Committee. 
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KIR and HLA genotyping 
KIR genotyping was carried out using polymerase chain reaction-sequence specific 
oligonucleotides (PCR-SSO) using Luminex (LABType
®
 SSO KIR Typing Test, One 
Lambda
®
, CA, USA).  HLA genotyping was performed using Luminex and sequence based 
typing as previously described and data was presented in Edinur et al. (2012) and Edinur et 
al. (2013). 
Statistical analysis 
Observed carrier frequency (F) was determined by direct counting. Gene frequency (GF) was 
calculated using the formula .  Group A and B haplotypes were predicted 
according to Rajalingam et al. (2008). Chi-squared tests (SPSS Inc., Chicago, IL) were used 
to test for Hardy-Weinberg equilibrium (HWE) while linkage disequilibrium between pairs of 
KIR genes were estimated using Wn or Cramer‟s V statistic, as previously described by 
Single et al. (2008).  The correlation coefficient is equivalent to Wn, the summary of 
relationship between two loci.  The Wn has a range from -1 to +1, which depends on the 
direction of association.  The statistical significance of LD between a pair of loci was then 
estimated using Fisher‟s exact test.  Differences in carrier KIR frequencies between 
Polynesian datasets were evaluated using Chi-squared tests with Yate‟s continuity correction 
available in the Graphpad software 
(http://www.graphpad.com/quickcalcs/contingency1.cfm). A principal component analysis 
(PCA) was performed using Multivariate Statistical Software Package 3 (Kovach Computing 
Services, UK; http://www.kovcomp.com/mvsp).  Correlations between KIR and HLA ligand 
carrier frequencies were examined using T-tests on transformed correlation coefficients.  We 
performed the labels for the KIR genes and calculated the correlation between the HLA and 
KIR genes for each random permutation.  A total of 10,000 permutations were applied.  The 
p-value for each correlation was calculated as a percentage of the 10,000 correlation runs.  
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Thus calculated values that were as large as or larger than the one observed.  This p-value is a 
two-tailed permutation p-value.   
 
Results 
 
Genotype profiles and haplotype assignments for study population groups and sub-groups are 
illustrated in Fig. 1.  A total of 38 different genotype profiles were observed in the present 
study; 33 in TM, 21 in MFA, 19 in TP and 14 profiles for PFA and no significant departure 
from HWE was observed for these study population groups and sub-groups.  Thirty of these 
profiles have previously been reported in allele frequency net database 
(www.allelefrequencies.net).  For each genotype, there are more inhibitory than stimulatory 
genes.  The homozygous haplotype A genotype is the most common form and the highest 
frequency was observed in PFA (0.50).   All the 16 previously known types of KIR genes 
were detected in the present study and their observed carrier and estimated gene frequencies 
are listed in Table 1.  Overall, frequencies of inhibitory (KIR2DL1, 2DL3, 3DL1, 2DL4, 
3DL3) and pseudo-genes (KIR2DP1 and 3DP1) are higher than stimulatory genes (KIR2DS1, 
2DS2, 2DS3, DS5 and 3DS1), except for KIR2DS4 which was present in more than 97% of 
individuals.  As expected, the framework genes (KIR3DL3, 2DL4, 3DP1 and 3DL2) were 
present in almost all of the individuals tested.  Linkage disequilibrium (LD) analysis shows 
strong positive associations for the gene pairs KIR2DS2-2DL2, 2DL5-2DS1, 2DS5-3DS1 
and 2DS1-3DS1 (see Table S1a-d).  The framework genes were excluded from the LD 
analysis because they are present in all samples.  In addition, KIR2DP1 and 2DL1 were 
present in all TP group and PFA sub-group individuals and also excluded from LD analysis.   
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The KIR carrier frequencies and genotype profiles obtained in the present study were 
compared with those of previously studied Polynesian sub-populations; see Table S2 and 
Velickovic et al. (2006) for details.  The four Polynesian sub-populations are generally not 
significantly different between each other except for the KIR2DS4 gene.  Nonetheless, their 
pool gene frequency as Velickovic Total Polynesians (VTP) is perfectly matched with our 
new collected data for PFA (see Table S3a-g).  Therefore, we combined PFA with VTP, 
forming a larger dataset, PMD (Polynesian meta dataset) for wider population comparisons.  
Statistical tests showed our MFA is similar to PFA but is different with VTP only for 
frequency of KIR2DS4.  Although our TM group is only different with MFA for KIR3DS1, 
the former is significantly different with VTP and PFA (see Table S3a-g).  In addition, 
comparisons of the KIR profiles showed quite a marked differences between our partially 
admixed groups (i.e. TP and TM) and the full ancestry sub-groups (i.e. PFA and MFA).  Only 
21 and 14 KIR gene profiles observed in MFA and PFA (respectively), compared with 33 and 
19 in TM and TP (respectively).  We believe this reflects European admixture effects in TP 
and TM.  Admixture effects are not so obvious in TP compared with TM.  This might be due 
to the smaller sample size of the former group.  Therefore, we used PMD and MFA to 
represent the genepools of Polynesians and Maori (respectively) for tracing history, while 
those from TP and TM represent modern day Polynesians and Maori living in New Zealand.  
We used PCA for a wider comparison of KIR distribution in Polynesians and other 
populations. The PCA plot constructed using KIR carrier frequencies (see Fig.2) 
demonstrated that most populations cluster together according to their geographic locations.   
 
Finally, we examined the correlation between each combination of KIR-HLA ligands using 
reference populations (see Table S4) reported by Single et al. (2007).  We observed 
significant positive correlation between KIR3DLI and HLA-Bw4/ Bw4-80I and significant 
Chapter 3.5 
232 
 
negative correlation for pairs of KIR3DSI and HLA-Bw4/Bw4-80I, KIR2DL2 and HLA-C 
group 1 ligand and KIR2DS1 and HLA-C group 2 (see Table 2, Fig. S1a-i).    
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ID 
 
HG 
 
Framework and pseudogens Haplotyp A genes Haplotype B genes 
TP 
 
PFA 
 
TM 
 
MFA 
 3D 
L2 
3D 
L3 
2D 
L4 
3D 
P1 
2D 
P1 
2D 
L1 
2D 
L3 
3D 
L1 
2D 
S4 
2D 
S1 
2D 
S2 
2D 
S3 
2D 
S5 
2D 
L2 
2D 
L5 
3D 
S1 
1 AA 
                
22 17 37 18 
N6 AA 
                
0 0 1 0 
200 AB 
                
0 0 1 1 
433 AB 
                
1 1 0 0 
267 AB 
                
1 0 0 0 
55 AB 
                
0 0 1 0 
4 AB 
                
3 0 20 6 
31 AB 
                
2 2 1 1 
5 AB 
                
2 1 3 2 
22 AB 
                
0 0 2 1 
33 AB 
                
1 0 2 0 
2 AB 
                
2 2 3 1 
8 AB 
                
2 2 4 4 
28 AB 
                
0 0 1 1 
381 AB 
                
0 0 2 0 
9 AB 
                
0 0 1 0 
3 AB 
                
2 2 7 3 
11 AB 
                
1 1 0 0 
7 AB 
                
1 1 1 1 
6 AB 
                
2 1 2 1 
242 AB 
                
0 0 1 1 
 
Fig. 1: Genotype profile observed in the study population groups and sub-groups. Haplotype ID was assigned according to allele frequency net database (Gonzalez-Galarza et 
al. 2011). Abbreviations: HG: haplogroup, TM = Total Maori, TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry. 
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Fig. 1 cont. 
 
ID 
 
HG 
 
Framework and pseudogens Haplotyp A genes Haplotype B genes 
TP 
 
PFA 
 
TM 
 
MFA 
 3D 
L2 
3D 
L3 
2D 
L4 
3D 
P1 
2D 
P1 
2D 
L1 
2D 
L3 
3D 
L1 
2D 
S4 
2D 
S1 
2D 
S2 
2D 
S3 
2D 
S5 
2D 
L2 
2D 
L5 
3D 
S1 
N4 AB 
                
1 0 0 0 
N3 AB 
                
1 1 0 0 
N2 AB 
                
0 0 1 1 
N1 AB 
                
0 0 1 1 
N5 AB 
                
0 0 1 0 
81 BB 
                
0 0 2 1 
176 BB 
                
0 0 1 0 
71 BB 
                
0 0 2 1 
90 BB 
                
0 0 1 0 
73 BB 
                
2 1 1 1 
75 BB 
                
1 1 0 0 
87 BB 
                
1 1 1 0 
74 BB 
                
0 0 1 1 
N9 BB 
                
0 0 1 0 
N7 BB 
                
0 0 2 1 
76 BB 
                
0 0 2 2 
172 BB 
                
0 0 1 0 
Total number of individuals 48 34 108 50 
Frequencies of haplotype A 0.69 0.71 0.61 0.61 
Frequencies of haplotype B 0.31 0.29 0.39 0.39 
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Table 1: Phenotype and genotype frequencies in study population groups and sub-groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TM = Total  Maori, TP = Total Polynesians, MFA = Maori  
with Full Ancestry, PFA = Polynesians with Full Ancestry, N = sample number. 
 
 
 
 
 
   
  
KIR 
 
TP 
(N=48) 
PFA 
(N=34) 
TM 
(N=108) 
MFA 
(N=50) 
   
  
   
  
Phenotype frequency 
 3DL3 
2DS2 
2DL2 
2DL3 
2DL5 
2DS3 
2DS5 
2DP1 
2DL1 
3DP1 
2DL4 
3DL1 
3DS1 
2DS1 
2DS4 
3DL2 
1 
0.38 
0.38 
0.96 
0.48 
0.29 
0.23 
1 
1 
0.96 
1 
0.96 
0.31 
0.31 
0.98 
1 
1 
0.32 
0.32 
0.97 
0.50 
0.29 
0.24 
1 
1 
0.97 
1 
0.94 
0.29 
0.35 
0.97 
1 
1 
0.54 
0.54 
0.87 
0.44 
0.20 
0.25 
0.91 
0.94 
0.97 
1 
0.95 
0.64 
0.34 
0.99 
1 
1 
0.50 
0.50 
0.86 
0.52 
0.28 
0.28 
0.88 
0.92 
0.98 
1 
0.96 
0.42 
0.40 
0.98 
1 
   
  
 
Genotype frequency  
   
  
3DL3 
2DS2 
2DL2 
2DL3 
2DL5 
2DS3 
2DS5 
2DP1 
2DL1 
3DP1 
2DL4 
3DL1 
3DS1 
2DS1 
2DS4 
3DL2 
1 
0.21 
0.21 
0.80 
0.28 
0.16 
0.12 
1 
1 
0.80 
1 
0.80 
0.17 
0.17 
0.86 
1 
1 
0.18 
0.18 
0.83 
0.29 
0.16 
0.13 
1 
1 
0.83 
1 
0.76 
0.16 
0.20 
0.83 
1 
1 
0.32 
0.32 
0.64 
0.26 
0.11 
0.13 
0.70 
0.76 
0.83 
1 
0.79 
0.40 
0.19 
0.90 
1 
1 
0.29 
0.29 
0.63 
0.31 
0.15 
0.15 
0.65 
0.72 
0.86 
1 
0.80 
0.24 
0.23 
0.86 
1 
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Fig. 2: PCA constructed using KIR2DL1-5, 3DL1-3, 2DS1-5 and 3DS1 carrier frequencies.  Reference populations were obtained from  
Hollenbach et al. (2010), Hollenbach et al. (2012), Gonzalez-Galarza et al. (2011), Taniguchi and Kawabata (2009), Velickovic et al.  
(2006), Velickovic et al. (2008) and Velickovic et al. (2010). 
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Table 2: Correlation between KIR and HLA carrier frequencies 
KIR and HLA pair 
 
Correlation (r) 
 
Permutation p-value  
     
 
3DL1-Bw4 
 
0.36 
 
0.02  
3DL1-Bw480I 
 
0.40 
 
0.01  
3DS1-Bw4 
 
-0.53 
 
0  
3DS1-Bw480I 
 
-0.60 
 
0  
2DL1-C group 02 
 
0.05 
 
0.77  
2DL2-C group C1 
 
-0.35 
 
0.04  
2DL3-C group C1 
 
0.23 
 
0.18  
2DS1-C group 02 
 
-0.45 
 
0.01  
2DS2-C group C1 
 
-0.33 
 
0.06  
     
 
 
 
Discussion 
 
A detailed account of Polynesian origins and a chronology of their associated archaeology is 
presented by Bellwood et al. (2011).  In short, the Austronesian-speaking Mongoloids (A-
SM) from Taiwan voyaged to Melanesia via the Philippines and Borneo.  Gender-biased 
genetic admixture occurred between A-SM and residents of coastal Papua New Guinea and 
the islands of the Bismarck Archipelago (i.e. Papuan-speaking Australoid: PSA), before the 
first moved outwards to Remote Oceania (Polynesia) and occupied New Zealand from 650 
ybp.  The general account above has received independent confirmation from a Bayesian 
phylogenetic analysis of Pacific and East Asian languages (Gray et al., 2009) and large-scale 
independent molecular phylogenetic studies (Kimura et al. 2008 and Woolstein et al. 2010).   
 
We have previously shown evidence for the hybrid origin of Polynesian populations by using 
HLA data (Edinur et al. 2012 and Edinur et al. 2013) and thus support the account (Chambers 
2006; Bellwood et al. 2011).  Here, we extend this research and characterize KIR loci in the 
same sets of samples (see Table 1 and Fig. 1).  Statistical analyses (see Table S3a-g) of the 
KIR data showed a close genetic relationship between our Polynesians full ancestry sub-
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group (i.e. PFA) and the previous study on the four (Cook Island, Samoa, Tonga and 
Tokelau) Polynesian sub-populations (Zlatibor et al. 2006).  Therefore, we combined them to 
create a larger dataset (i.e. PMD) for Polynesians.  In contrast, there are significant 
differences between our Maori full ancestry sub-group (i.e. MFA) and the larger admixed 
group (i.e. TM).  This might be due to European admixture in TM as previously discovered 
(Edinur et al. 2012).   The admixture is not so obvious in TP and this might reflect the effects 
of smaller sample size represented by this study group.  All things considered, we used MFA 
and PMD for genealogical studies while those represented by TP and TM represented the 
genepools of modern day Polynesians and Maori living in New Zealand.    
 
In wider context, distribution of KIR genotypes among Maori and Polynesians is most similar 
to Asian populations.  These have been often reported to have slightly higher frequency of 
haplotype A and genotype AA homozygote profiles, compared with Europeans, African and 
P-SA populations (see Yawata et al. 2002; Whang et al. 2005; Rajalingam et al. 2008; 
Ashouri et al. 2009; Hollenbach et al. 2010; Hollenbach et al. 2012; John et al. 2012).  
Positions of Polynesian and Maori KIR datasets in a wider geographical context are shown in 
Fig. 2.  In the PCA plot, geographically proximal populations tend to cluster together fairly 
well.  As expected, Oceanian populations form two well separated groups which represent at 
least two different lineages of people; A-SM and P-SA plus others (Polynesians and 
Melanesians) who have greater or lesser influence from these two putative ancestral 
populations.  Here, Maori and Polynesians are close to Asian populations and reflect more A-
SM influence than P-SA/Melanesians.  Some of the HLA loci also showed a greater A-SM 
ancestral fraction (i.e. HLA-B and -DRB1) in Polynesians (~100:0 genetic proportions of 
ASM:P-SA ancestral fractions) compared with 60:40 for HLA-A and -C loci (Edinur et al. 
2012).  Overall, KIR gene content frequency may appear to be rather less directly informative 
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compared with HLA or SNP data for historical reconstructions, but it may also reflect natural 
selection (see later).  In addition, it is hard to make an effective comparison because most 
KIR population data are not reported for all the 16 KIR genes and few studies are reported at 
the allelic level.   
 
Population level variation of KIR may reflect local adaptation especially for these medically 
important genes.  Studies have shown selective forces on both KIR gene content and allelic 
variants (Single et al. 2007; Norman et al. 2007).  However, testing for natural selection may 
be confounded by issues such as non-independence and shared history among populations, as 
demonstrated above (see Fig. 2).  This difficulty can be resolved by application of two 
unlinked loci (e.g. KIR and HLA) and using a permutation-based approach (refer Single et al. 
2008 for details).  Based on this statistical method, the two unlinked loci are assumed to have 
experienced the same demographic history and the permutation-based method is used to 
generate a null hypothesis of no functional relationship between the two loci.  We therefore 
examined correlation between frequencies of KIR and their HLA ligand (see Table 2, Fig. 
S1a-i).  Generally, there is evidence of a positive correlation between inhibitory KIR-HLA 
ligand combinations and negative correlation between activating KIR-HLA ligands in 
worldwide populations.  This might be due to selection pressures that favour more inhibitory 
KIR-HLA complex to avoid auto-reactivity.  The significant negative correlation observed 
between the KIR2DL2 and HLA-C group 1 ligand is conflicting with a positive correlation of 
other inhibitory KIR-HLA complexes.  The HLA-C group 1 is also a ligand for the more 
common inhibitory KIR2DL3 and negative correlation between KIR2DL2 and HLA-C group 
1 ligand might be compromised by the positive correlation of KIR2DL3 and HLA-C group 1 
(see also Single et al. 2007 and Hollenbach et al. 2012).  Functional study has shown that the 
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presence of one inhibitory KIR-HLA complex is sufficient for self-tolerance (Valiante et al. 
1997).   
 
In Polynesians and Maori, each individual has at least one inhibitory KIR that recognize self 
HLA class I molecule.  This is evident from the predominance of haplotype A (0.61-0.71) 
among Polynesians and Maori (see Fig. 1).  Thus, selection in favour of inhibitory KIR genes 
and their ligands may provide protection from autoimmune diseases (e.g. psoriasis, and 
rheumatoid vasculitis) in Polynesians and Maori.   This observation reflects our inference 
based on the HLA data (see Edinur et al. 2013).  Nonetheless, high frequencies of haplotype 
A homozygote individuals (0.36 - 0.50) among Maori and Polynesians may mean that they 
are vulnerable to infectious diseases, cancer and have decreased rate of reproduction success.  
These individuals possibly possess no stimulatory KIR (due to the predominance of null 
2DS4 allele), which are implicated with reduced risk of infectious (e.g. human 
immunodeficiency virus, tuberculosis and human cytomegalovirus) and reproductive (e.g. 
preeclampsia) diseases (reviewed in Kulkarni et al. 2008).   Hiby et al. (2004) have shown 
that a combination of maternal homozygote for haplotype A and fetal with HLA-group C2 is 
associated with an occurrence of preeclampsia.  They hypothesized that an inverse 
relationship between the KIR AA genotype and HLA-group C2 frequencies in various 
populations as a mechanism of selective pressures for maintaining reproductive success.  
However, haplotype A homozygote and HLA-C2 frequencies are in balance among 
Polynesians (0.35-0.50 vs 0.39-0.52), as compared with Australian aborigines (0.02 vs 0.60) 
and Asian populations (0.35-0.60 vs 0.10-0.20).  Evolutionary processes due to natural 
selection might be violated in Polynesians due their A-SM:PSA dual origin and the clinical 
consequences of this admixture could be an important subject of disease association study 
(see Edinur et al. 2012).  In addition, KIR has been shown to be of relevance in 
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transplantation medicine as the success rate is also dependent on the degree of KIR matching 
between donor and recipient.  The Maori and Polynesians seem to share a number of common 
and unique KIR gene content profiles and this could facilitate the search of donors for 
allograft transplantation, but see Ruggeri et al. (2002).   
 
Overall, our research findings together with subsequent analyses support the view that global 
patterns of KIR and HLA diversity are shaped by migration patterns, demographic history as 
well as human adaptation toward episodes of natural selection (Sanchez-Mazas et al. 2011).  
We believe that the KIR data reported in this study provides increased understanding of 
Polynesian immunogenetics and could be used as a medical reference standard for 
Polynesians and Maori living in New Zealand.   
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Supplementary information 
 
Table S1a: Linkage disequilibrium analysis of KIR genes in TP group 
 
 
Wn 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 3DP1 3DL1 3DS1 2DS1 2DS4 
2DS2 ~ 1 -0.27 0.55 0.45 0.29 -0.27 -0.05 0.22 0.31 0.11 
2DL2 0 ~ -0.27 0.55 0.45 0.29 -0.27 -0.05 0.22 0.31 0.11 
2DL3 0.14 0.14 ~ -0.22 -0.32 -0.38 -0.04 -0.04 -0.31 -0.31 -0.03 
2DL5 0 0 0.22 ~ 0.67 0.57 -0.22 -0.22 0.70 0.70 -0.15 
2DS3 0 0 0.08 0 ~ 0.41 -0.10 -0.32 0.46 0.56 -0.23 
2DS5 0.07 0.07 0.05 0 0.01 ~ 0.11 -0.38 0.70 0.70 -0.27 
3DP1 0.14 0.14 1 0.22 0.50 1 ~ -0.04 0.14 0.14 -0.03 
3DL1 1 1 1 0 0.08 0.05 1 ~ -0.31 -0.31 0.70 
3DS1 0.20 0.20 0.09 0 0 0 1 0.09 ~ 0.90 -0.22 
2DS1 0.05 0.05 0.09 0 0 0 1 0.09 0 ~ -0.22 
2DS4 1 1 1 0.48 0.29 0.23 1 0.04 0.31 0.31 ~ 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 3DP1 3DL1 3DS1 2DS1 2DS4 
 
p-value 
 
Linkage between pairs of loci is considered significant at p-value < 0.05. The correlation coefficient is equivalent to Wn, the summary of relationship between two loci.  The 
Wn has a range from -1 to +1, which depend on the direction of association.   
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Table S1b: Linkage disequilibrium analysis of KIR genes in PFA sub-group 
 
 
Wn 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 3DP1 3DL1 3DS1 2DS1 2DS4 
2DS2 ~ 1 -0.25 0.69 0.52 0.36 -0.25 -0.09 0.28 0.41 0.12 
2DL2 0 ~ -0.25 0.69 0.52 0.36 -0.25 -0.09 0.28 0.41 0.12 
2DL3 0.32 0.32 ~ -0.17 -0.27 -0.31 -0.03 -0.04 -0.24 -0.24 -0.03 
2DL5 0 0 1 ~ 0.65 0.55 -0.17 -0.25 0.74 0.74 -0.17 
2DS3 0 0 0.29 0 ~ 0.25 -0.27 -0.39 0.47 0.60 -0.27 
2DS5 0.08 0.08 0.24 0 0.19 ~ 0.10 -0.45 0.75 0.75 -0.31 
3DP1 0.32 0.32 1 1 0.29 1 ~ -0.04 0.13 0.13 -0.03 
3DL1 1 1 1 0.48 0.08 0.05 1 ~ -0.34 -0.34 0.70 
3DS1 0.14 0.14 0.35 0 0.02 0 1 0.12 ~ 0.87 -0.24 
2DS1 0.03 0.03 0.35 0 0 0 1 0.12 0 ~ -0.24 
2DS4 1 1 1 1 0.29 0.24 1 0.06 0.35 0.35 ~ 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 3DP1 3DL1 3DS1 2DS1 2DS4 
 
p-value 
 
Linkage between pairs of loci is considered significant at p-value < 0.05. The correlation coefficient is equivalent to Wn, the summary of relationship between two loci.  The 
Wn has a range from -1 to +1, which depend on the direction of association.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3.5 
251 
 
Table S1c: Linkage disequilibrium analysis of KIR genes in TM group  
 
 
Wn 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 2DP1 2DL1 3DP1 3DL1 3DS1 2DS1 2DS4 
2DS2 ~ 1 -0.36 0.38 0.19 0.32 -0.30 -0.23 -0.04 -0.20 0.27 0.28 -0.09 
2DL2 0 ~ -0.36 0.38 0.19 0.32 -0.30 -0.23 -0.04 -0.20 0.27 0.28 -0.09 
2DL3 0 0 ~ -0.38 -0.22 -0.22 0.54 0.63 -0.07 0.44 -0.28 -0.30 0.25 
2DL5 0 0 0 ~ 0.57 0.65 -0.23 -0.27 0.04 -0.25 0.84 0.81 -0.11 
2DS3 0.06 0.06 0.04 0 ~ 0.24 0.08 0.12 0.09 -0.22 0.43 0.31 0.05 
2DS5 0 0 0.04 0 0.02 ~ -0.18 -0.23 -0.03 -0.38 0.72 0.66 -0.17 
2DP1 0 0 0 0.02 0.68 0.12 ~ 0.76 0.14 0.23 -0.29 -0.31 0.30 
2DL1 0.03 0.03 0 0.01 0.34 0.03 0.00 ~ -0.04 0.33 -0.32 -0.34 0.40 
3DP1 1 1 1 1 1 1 0.26 1 ~ -0.04 0.01 0.00 -0.02 
3DL1 0.06 0.06 0 0.02 0.06 0 0.07 0.02 1 ~ -0.29 -0.31 0.44 
3DS1 0.01 0.01 0.01 0 0 0 0 0 1 0.01 ~ 0.92 -0.13 
2DS1 0 0 0 0 0 0 0 1 1 0 0 ~ -0.13 
2DS4 1 1 0.13 0.44 1 0.25 0.09 0.06 1 0.05 0.36 0.34 ~ 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 2DP1 2DL1 3DP1 3DL1 3DS1 2DS1 2DS4 
 
p-value 
 
Linkage between pairs of loci is considered significant at p-value < 0.05. The correlation coefficient is equivalent to Wn, the summary of relationship between two loci.  The 
Wn has a range from -1 to +1, which depend on the direction of association.   
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Table S1d: Linkage disequilibrium analysis of KIR genes in MFA sub-group  
 
 
 
Wn 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 2DP1 2DL1 3DP1 3DL1 3DS1 2DS1 2DS4 
2DS2 ~ 1 -0.40 0.48 0.18 0.45 -0.37 -0.25 -0.14 -0.20 0.36 0.33 -0.14 
2DL2 0 ~ -0.40 0.48 0.18 0.45 -0.37 -0.25 -0.14 -0.20 0.36 0.33 -0.14 
2DL3 0.01 0.01 ~ -0.39 -0.13 -0.39 0.56 0.63 -0.06 0.51 -0.36 -0.38 0.35 
2DL5 0 0 0.01 ~ 0.60 0.60 -0.35 -0.24 -0.14 -0.20 0.82 0.78 -0.14 
2DS3 0 0.35 0.38 0 ~ 0.11 0.09 0.16 0.09 -0.10 0.46 0.40 0.09 
2DS5 0 0 0.01 0 0.50 ~ -0.32 -0.41 -0.23 -0.33 0.73 0.67 -0.23 
2DP1 0.02 0.02 0 0.02 0.66 0.04 ~ 0.68 -0.05 0.24 -0.43 -0.45 0.39 
2DL1 0.23 0.23 0 0.24 0.55 0.02 0 ~ -0.04 0.38 -0.30 -0.31 0.57 
3DP1 1 1 1 1 1 0.28 1 1 ~ -0.03 -0.17 -0.17 -0.02 
3DL1 0.49 0.49 0.02 0.49 0.49 0.07 0.23 0.12 1 ~ -0.24 -0.25 0.70 
3DS1 0.02 0.02 0.03 0 0 0 0 0.07 0.42 0.17 ~ 0.96 -0.17 
2DS1 0.04 0.04 0.01 0 0.01 0.00 0 0.06 0.40 0.16 0 ~ -0.17 
2DS4 1 1 0.14 1.00 1 0.28 0.12 0.06 1 0.04 0.42 1 ~ 
 
2DS2 2DL2 2DL3 2DL5 2DS3 2DS5 2DP1 2DL1 3DP1 3DL1 3DS1 2DS1 2DS4 
 
p-value 
 
Linkage between pairs of loci is considered significant at p-value < 0.05. The correlation coefficient is equivalent to Wn, the summary of relationship between two loci.  The 
Wn has a range from -1 to +1, which depend on the direction of association.   
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Table S2: Comparison of KIR carrier frequencies between various Polynesian datasets 
 
 
 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, TM = Total Maori, 
TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = Samoa, CI = Cook Islands, VTP = 
combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies of VTP and PFA.  
 
 
 
 
 
 
Population N 3DL1 2DL1 2DL3 2DS4 2DL2 2DL5 3DS1 2DS1 2DS2 2DS3 2DS5 2DL4 3DL2 3DL3 2DP1 3DP1 
 
 
                
TM  108 0.95 0.94 0.87 0.99 0.54 0.44 0.64 0.34 0.54 0.20 0.25 1 1 1 0.91 0.97 
TP 48 0.96 1 0.96 0.98 0.38 0.48 0.31 0.31 0.38 0.29 0.23 1 1 1 1 0.96 
MFA 50 0.96 0.92 0.86 0.98 0.50 0.52 0.42 0.40 0.50 0.28 0.28 1 1 1 0.88 0.98 
PFA 34 0.94 1 0.97 0.97 0.32 0.50 0.29 0.35 0.32 0.29 0.24 1 1 1 1 0.97 
TOK 47 0.85 0.89 0.96 0.96 0.40 0.57 0.32 0.36 0.43 0.34 0.26 1 1 0.98 0.96 0.96 
TON 49 0.84 1 0.94 0.73 0.51 0.53 0.35 0.29 0.49 0.35 0.39 1 1 1 1 0.96 
SA 50 0.92 0.98 0.98 0.94 0.38 0.48 0.38 0.34 0.40 0.34 0.22 1 1 1 0.98 0.98 
CI 48 0.90 0.92 0.92 0.77 0.58 0.44 0.29 0.40 0.56 0.15 0.35 1 1 1 0.94 0.94 
VTP 194 0.88 0.95 0.95 0.85 0.47 0.51 0.34 0.35 0.47 0.29 0.30 1 1 1 0.97 0.96 
PMD 228 0.89 0.96 0.95 0.87 0.45 0.51 0.33 0.35 0.45 0.29 0.29 1 1 1 0.97 0.96 
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Table S3a: Homogeneity tests for Polynesian datasets (KIR2DS4 and 3DS1) 
 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, TM = Total Maori, 
TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = Samoa, CI = Cook Islands, VTP = 
combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies of VTP and PFA.   
 
 
 
 
 
 
 
 
 
 
 
 
  
2DS4 
  
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP 
 
~ 0.80 0.55 0.98 0 0.99 0.01 0.64 0.03 0.05 
PFA 
 
0.86 ~ 0.97 0.78 0.01 0.76 0.03 0.90 0.10 0.15 
TM 
 
0.00 0.00 ~ 0.57 0 0.45 0 0.18 0 0 
MFA 
 
0.37 0.35 0.02 ~ 0 0.96 0 0.61 0.02 0.04 
TON 
 
0.88 0.79 0 0.59 ~ 0.01 0.86 0.01 0.09 0.03 
TOK 
 
0.94 0.81 0 0.41 0.94 ~ 0.02 0.70 0.09 0.14 
CI 
 
0.82 0.98 0 0.27 0.71 0.95 ~ 0.04 0.27 0.13 
SA 
 
0.62 0.56 0 0.84 0.89 0.68 0.48 ~ 0.15 0.24 
VTP 
 
0.85 0.74 0 0.38 0.93 0.92 0.64 0.72 ~ 0.70 
PMD 
 
0.91 0.80 0 0.32 0.99 0.99 0.70 0.64 0.96 ~ 
  
TP PFA TM MFA TON TOK CI SA VTP PMD 
  
3DS1 
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Table S3b: Homogeneity tests for Polynesian datasets (KIR3DL1 and 2DL1) 
 
  
3DL1 
  
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP 
 
~ 0.72 0.90 0.97 0.10 0.15 0.43 0.71 0.19 0.24 
PFA 
 
NA ~ 0.77 0.69 0.27 0.36 0.75 0.71 0.46 0.54 
TM 
 
0.22 0.36 ~ 0.86 0.03 0.06 0.31 0.63 0.06 0.09 
MFA 
 
0.14 0.24 0.81 ~ 0.09 0.13 0.40 0.67 0.17 0.21 
TON 
 
NA NA 0.22 0.13 ~ 0.85 0.58 0.34 0.55 0.42 
TOK 
 
0.06 0.13 0.43 0.92 0.06 ~ 0.73 0.45 0.75 0.61 
CI 
 
0.13 0.23 0.76 0.95 0.12 0.97 ~ 0.95 0.98 0.91 
SA 
 
0.32 0.41 0.55 0.36 0.32 0.18 0.33 ~ 0.60 0.71 
VTP 
 
0.23 0.37 0.88 0.67 0.22 0.29 0.62 0.56 ~ 0.89 
PMD 
 
0.29 0.44 0.84 0.48 0.28 0.17 0.44 0.70 0.89 ~ 
  
TP PFA TM MFA TON TOK CI SA VTP PMD 
  
2DL1 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, NA = not 
applicable, TM = Total Maori, TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = 
Samoa, CI = Cook Islands, VTP = combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies 
of VTP and PFA. 
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Table S3c: Homogeneity tests for Polynesian datasets (KIR2DL5 and 2DS1) 
 
 
2DL5 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP ~ 0.77 0.17 0.18 0.66 0.98 0.67 0.97 0.78 0.85 
PFA 0.81 ~ 0.18 0.19 0.89 0.76 0.78 0.78 0.90 0.96 
TM 0.09 0.05 ~ 0.86 0.32 0.18 0.57 0.06 0.03 0.02 
MFA 0.30 0.17 0.79 ~ 0.33 0.19 0.57 0.07 0.06 0.04 
TON 0.26 0.14 0.89 0.92 ~ 0.68 0.98 0.60 0.79 0.99 
TOK 0.93 0.61 0.18 0.46 0.40 ~ 0.69 0.96 0.80 0.87 
CI 0.07 0.04 0.72 0.53 0.60 0.12 ~ 0.33 0.62 0.53 
SA 0.96 0.77 0.10 0.31 0.27 0.97 0.07 ~ 0.56 0.61 
VTP 0.31 0.17 0.31 0.82 0.72 0.52 0.21 
 
~ 0.88 
PMD 0.45 0.24 0.16 0.60 0.52 0.70 0.12 0.48 0.73 ~ 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
 
2DS1 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, TM = Total Maori, 
TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = Samoa, CI = Cook Islands, VTP = 
combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies of VTP and PFA. 
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Table S3d: Homogeneity tests for Polynesian datasets (KIR2DS2 and 2DS3) 
 
 
2DS2 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP ~ 0.96 0.05 0.21 0.25 0.62 0.07 0.80 0.20 0.31 
PFA 0.98 ~ 0.05 0.17 0.20 0.48 0.06 0.63 0.17 0.24 
TM 0.32 0.39 ~ 0.79 0.71 0.27 0.90 0.15 0.31 0.16 
MFA 0.90 0.89 0.39 ~ 0.92 0.60 0.68 0.42 0.82 0.60 
TON 0.71 0.79 0.05 0.62 ~ 0.67 0.61 0.49 0.92 0.70 
TOK 0.77 0.84 0.34 0.67 0.95 ~ 0.26 0.96 0.71 0.91 
CI 0.14 0.18 0.53 0.17 0.04 0.05 ~ 0.16 0.32 0.20 
SA 0.77 0.84 0.10 0.67 0.94 1.00 0.05 ~ 0.47 0.65 
VTP 0.97 0.95 0.14 0.90 0.53 0.60 0.07 0.59 ~ 0.20 
PMD 0.98 0.96 0.12 0.89 0.53 0.60 0.06 0.59 0.99 ~ 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
 
2DS3 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, TM = Total Maori, 
TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = Samoa, CI = Cook Islands, VTP = 
combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies of VTP and PFA. 
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Table S3e: Homogeneity tests for Polynesian datasets (KIR2DS5 and 3DL3) 
 
 
2DS5 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP ~ 0.95 0.94 0.73 0.14 0.95 0.26 0.91 0.44 0.50 
PFA NA ~ 0.86 0.84 0.23 0.84 0.36 0.87 0.58 0.65 
TM NA NA ~ 0.84 0.12 0.94 0.25 0.83 0.44 0.53 
MFA NA NA NA ~ 0.36 0.96 0.57 0.74 0.93 0.89 
TON NA NA NA NA ~ 0.24 0.89 0.11 0.31 0.24 
TOK 0.99 0.39 0.67 0.98 0.98 ~ 0.41 0.87 0.68 0.77 
CI NA NA NA NA NA 0.99 ~ 0.21 0.57 0.47 
SA NA NA NA NA NA 0.98 NA ~ 0.35 0.41 
VTP 0.62 0.67 0.45 0.61 0.61 0.84 0.62 0.61 ~ 0.92 
PMD 0.65 
 
0.49 0.64 0.64 0.77 0.65 0.64 0.91 ~ 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
 
3DL3 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, NA = not 
applicable, TM = Total Maori, TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = 
Samoa, CI = Cook Islands, VTP = combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies 
of VTP and PFA. 
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Table S3f: Homogeneity tests for Polynesian datasets (KIR2DP1 and 3DP1) 
 
 
2DP1 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP ~ NA 0.07 0.04 NA 0.47 0.24 0.32 0.47 0.55 
PFA 0.77 ~ 0.15 0.10 NA 0.62 0.37 0.41 0.65 0.73 
TM 0.65 0.96 ~ 0.80 0.06 0.46 0.75 0.18 0.04 0.02 
MFA 0.97 0.78 0.77 ~ 0.04 0.31 0.53 0.12 0.03 0.01 
TON 0.98 0.78 0.67 0.99 ~ 0.46 0.23 0.32 0.46 0.54 
TOK 0.98 0.76 0.63 0.96 0.97 ~ 0.66 0.96 0.69 0.90 
CI 0.65 0.87 0.56 0.58 0.98 0.66 ~ 0.58 0.54 0.40 
SA 0.97 0.78 0.77 1.00 0.99 0.96 0.58 ~ 0.68 0.80 
VTP 0.99 0.74 0.78 0.77 0.99 0.97 0.81 0.77 ~ 0.78 
PMD 0.94 0.78 0.82 0.80 0.97 0.92 0.75 0.80 0.93 ~ 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
 
3DP1 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, NA= not 
applicable, TM = Total Maori, TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = 
Samoa, CI = Cook Islands, VTP = combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies 
of VTP and PFA. 
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Table S3g: Homogeneity tests for Polynesian datasets (KIR2DL3 and KIR2DL2) 
 
 
2DL3 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
TP ~ 0.77 0.17 0.18 0.66 0.98 0.67 0.97 0.78 0.85 
PFA 0.81 ~ 0.18 0.19 0.89 0.76 0.59 0.78 0.90 0.96 
TM 0.09 0.05 ~ 0.86 0.32 0.18 0.57 0.06 0.03 0.02 
MFA 0.30 0.17 0.79 ~ 0.33 0.19 0.57 0.07 0.06 0.04 
TON 0.26 0.14 0.89 0.92 ~ 0.68 0.98 0.60 0.79 0.99 
TOK 0.93 0.61 0.18 0.46 0.40 ~ 0.69 0.96 0.80 0.87 
CI 0.07 0.04 0.72 0.53 0.60 0.12 ~ 0.33 0.62 0.53 
SA 0.96 0.77 0.10 0.31 0.27 0.97 0.07 ~ 0.56 0.61 
VTP 0.31 0.17 0.31 0.82 0.72 0.52 0.21 0.33 ~ 0.88 
PMD 0.45 0.24 0.16 0.60 0.52 0.70 0.12 0.48 0.73 ~ 
 
TP PFA TM MFA TON TOK CI SA VTP PMD 
 
2DL2 
 
KIR data for the four Polynesian sub-populations (TOK, TON, SA and CI) were obtained from Zlatibor et al. (2006). Abbreviations:  N = sample number, TM = Total Maori, 
TP = Total Polynesians, MFA = Maori with Full Ancestry, PFA = Polynesians with Full Ancestry, TOK = Tokelau, TON = Tonga, SA = Samoa, CI = Cook Islands, VTP = 
combined carrier frequencies for the four Polynesian sub-populations (TOK, TON, SA and CI) and PMD = combined carrier frequencies of VTP and PFA.   
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Table S4: KIR2DL1, 2DL2, 2DL3, 3DL1, 2DS1, 2DS2, 3DS1 and HLA-C1, -C2 and -Bw4 
carrier frequencies 
 
Population ID C1 C2 Bw4 
Bw4- 
80I 
2D 
L1 
2D 
L2 
2D 
L3 
3D 
L1 
2D 
S1 
2D 
S2 
3D 
S1 
Biaka 1 0.69 0.73 0.79 0.49 0.97 0.58 0.80 1 0.01 0.57 0.03 
Ethiopian 2 0.72 0.76 0.80 0.77 0.90 0.81 0.77 0.97 0.26 0.77 0.23 
Hausa 3 0.64 0.85 0.79 0.67 1 0.37 0.97 1 0.14 0.32 0.03 
Ibo 4 0.63 0.83 0.78 0.75 0.96 0.61 0.76 1 0.08 0.58 0.06 
Mbuti 5 0.68 0.70 0.73 0.46 0.94 0.66 0.62 0.97 0.28 0.66 0.11 
Yoruba 6 0.67 0.84 0.65 0.56 1 0.38 0.92 0.99 0.15 0.35 0.12 
Adygei 7 0.72 0.79 0.78 0.57 1 0.50 0.93 0.98 0.35 0.50 0.35 
CEPH_UT 8 0.84 0.54 0.62 0.26 0.97 0.57 0.89 0.94 0.40 0.59 0.39 
Danish 9 0.83 0.61 0.50 0.20 0.98 0.52 0.96 0.98 0.37 0.52 0.38 
European 10 0.82 0.66 0.56 0.26 0.98 0.46 0.92 0.93 0.38 0.47 0.40 
Finns 11 0.77 0.63 0.51 0.26 1 0.39 0.97 0.91 0.55 0.39 0.53 
Irish 12 0.88 0.59 0.66 0.20 0.99 0.52 0.92 0.97 0.28 0.52 0.32 
Russian 13 0.85 0.61 0.67 0.26 0.94 0.44 0.86 0.98 0.23 0.44 0.21 
Druze 14 0.74 0.80 0.69 0.57 0.97 0.72 0.78 0.97 0.24 0.72 0.31 
Yemenites 15 0.84 0.81 0.69 0.59 0.98 0.47 0.95 0.98 0.31 0.50 0.36 
Ami 16 0.98 0.33 0.05 0.00 0.92 0.63 0.85 1 0.38 0.60 0.33 
Atayal 17 1 0.10 0 0.00 1 0 1 1 0.33 0.00 0.34 
Cambodian 18 0.89 0.61 0.69 0.13 0.91 0.45 0.86 0.95 0.43 0.43 0.48 
Hakka 19 1 0.30 0.55 0.32 1 0.33 0.97 0.98 0.50 0.33 0.53 
Han_SF 20 1 0.38 0.68 0.40 1 0.14 1 0.98 0.37 0.14 0.36 
Han_Taiwan 21 1 0.38 0.79 0.51 0.98 0.19 0.94 0.98 0.35 0.19 0.37 
Japan 22 0.96 0.18 0.60 0.38 1 0.09 1 0.96 0.48 0.09 0.49 
Micronesian 23 0.53 0.89 0.09 0.03 0.97 0.43 0.97 0.97 0.50 0.43 0.51 
Nasioi 24 0.95 0.24 0.25 0.00 0.91 0.96 0.59 0.59 0.91 0.91 0.73 
Yakut 25 0.92 0.75 0.88 0.46 0.98 0.28 0.92 0.96 0.46 0.37 0.42 
Maya 26 0.89 0.38 0.09 0.07 0.94 0.38 0.94 0.94 0.62 0.38 0.56 
Pima 27 0.93 0.60 0.23 0.14 0.88 0.64 0.88 0.77 0.77 0.64 0.72 
Katritiana 28 0.80 0.52 0 0 0.86 0.67 0.86 0.82 0.80 0.67 0.80 
Surui 29 0.91 0.55 0.07 0.07 0.98 0.26 0.98 0.91 0.48 0.26 0.30 
Ticuna 30 0.92 0.54 0.31 0.19 0.94 0.39 0.94 0.94 0.62 0.39 0.46 
TP 31 0.87 0.49 0.23 0.02 1 0.39 0.95 0.96 0.39 0.36 0.32 
PFA 32 0.89 0.52 0.18 0.03 1 0.33 0.96 0.94 0.44 0.30 0.36 
TM 33 0.94 0.47 0.22 0.06 0.95 0.54 0.88 0.95 0.34 0.55 0.36 
MFA 34 0.96 0.39 0.14 0 0.91 0.50 0.85 0.96 0.39 0.50 0.43 
 
Reference populations obtained from Single et al. (2007). 
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Fig. S1a: Correlation between KIR3DL1 and HLA-Bw4 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1b: Correlation between KIR3DL1 and and HLA-Bw4-80I carrier frequencies.  Reference populations 
were obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1c: Correlation between KIR3DS1 and HLA-Bw4 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding population ID in Table S4.   
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Fig. S1d: Correlation between KIR3DS1 and HLA-Bw4-80I carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1e: Correlation between KIR2DL1 and HLA-C group 2 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1f: Correlation between KIR2DL2 and HLA-C group 1 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1g: Correlation between KIR2DL3 and HLA-C group 1 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1h: Correlation between KIR2DS1 and HLA-C group 2 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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Fig. S1i: Correlation between KIR2DS2 and HLA-C group 1 carrier frequencies.  Reference populations were 
obtained from Single et al. (2008).  Numbers are corresponding to population ID in Table S4.   
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General Discussion and Conclusion  
 
My PhD work has been focussed on using recently developed molecular technologies to 
survey immune system (i.e. HLA, KIR and MICA), blood group and HPA genes in 
Polynesian and Maori subjects.  It began with a bioinformatics study of low (Chapter 3.1) and 
high (Chapter 3.2) resolution HLA and MICA data and followed by my laboratory based 
analyses of blood groups (Chapter 3.3) and HPA (Chapter 3.4).  The systematic study on KIR 
(Chapter 3.5) adds extra information on the analysis of high resolution HLA data because 
both genes are shaped by their shared histories of pathogen encounters.   
 
Overall, the present study has successfully compiled new HLA, MICA, blood group, HPA 
and KIR datasets for Polynesian and Maori subjects [Objective: A – refer to General 
Introduction].  These genetic markers are are highly diverse, reflecting their roles in 
immunity and/or as markers of tissue identity.  I would like to note that the present survey 
provides the first ever blood group, HPA and MICA molecular data for Polynesians and 
Maori.  I have also compared my data with those from previous genetic studies of KIR and 
HLA for four Polynesian sub-populations (Velickovic, 2001 and Velickovic et al., 2006) and 
HLA for Maori (Tracey, 2001) [Objective: B].  Statistical tests on the HLA and KIR datases 
generally show no significant differences between our Polynesians full ancestry sub-group 
(i.e. PFA: Polynesians with Full Ancestry) and the four individual Polynesian sub-
populations (Cook Island, Tokelau, Tonga and Samoa) reported earlier.  Therefore, they were 
combined to make larger dataset, PMD (Polynesians meta dataset) for geneaological study.  
This was not the case for our Maori group where the HLA data collected for present study on 
our Maori full ancestry sub-group (MFA: Maori with Full Ancestry) is significantly different 
from those reported by Tracey (2001).  The difference can be attributed to European 
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admixture in the latter.  Therefore, HLA data from MFA was used for ancestry study while 
those reported by Tracey (2011) were combined with Maori admixed study group (TM: Total 
Maori) to represent genepool of Modern day Maori. 
 
The new HLA, KIR, blood group, MICA and HPA datasets/meta datasets were also 
compared with other those from Asia Pacific populations [Objectives: C.i. and C.ii].  
Phylogenetic and principal component/coordinate analyses show that Polynesian sub-
populations are closely related to another, as compared with those from other Asia Pacific 
populations.  Estimations made based on HLA-A, -B, -C and -DRB1 allele frequencies show 
wide range (55:45 to 90:10) of ASM:P-SA ancestral fractions in Maori and other 
Polynesians.  The same phenomenon was also observed for blood group, HPA and KIR data 
(see Chapters 3.1 – 3.5).  Inability of these data to show A:SM:P-SA ancestral fractions 
clearly might appear to reflect different proportions of genetic inputs from their ancestors, but 
more likely associated with population histories, which include founder effects and local 
selection forces.   
 
Overall, findings from the present study are entirely consistent with the expectation that both, 
Polynesians and Maori are intermediate between A-SM and P-SA populations (Kimura et al., 
2008 and Wollstein et al., 2010).  In particular, Polynesian sub-populations share a common 
Taiwanese ancestor and have experienced gender-biased admixture with P-SA populations.  
These observations thus support the account that emerges from other disciplines, particularly 
from anthropology, archaeology and linguistics (see Chambers and Edinur, 2013 and 
Chamber, 2013).  Genetic data collected for Polynesians over the years contribute significant 
support for key elements of the Synthetic Total Evidence Model of Pacific Settlement.  This 
thesis brings them together for the first time since Chambers (2006) and extends the 
Chapter 4 
 
273 
 
Bellwood et al. (2011) and Chambers (2013) accounts which are focussed on support for the 
Out of Taiwan component.  Today, the genepools of Polynesians and Maori are expanding 
through opportunities for intermarriage with members of other ethnic group (i.e. Europeans) 
that form significant part of domestic population.  Genetic data collected from admixed 
Maori and Polynesian study groups are significantly different from that full ancestry study 
groups and show the significant effect of recent admixture following the arrival of Europeans 
settlers in New Zealand [Objective: C.ii].   
 
Nature of loci tested also bear more or less directly on questions of health [Objective C. iii].  
This is particularly important because my thesis is largely concerned with finding efficient 
new ways to score these markers for transplantation and transfusion medicine.  Tissue 
matching of HLA, MICA, KIR, blood group and HPA is a fundamental element in 
transfusion and transplant surgery and it is vital that these technologies take accurate account 
of the ethnic origins of both donor and recipient (see Chapters 3.1 - 3.5).  This is due to 
significant differences between Polynesians and those of European origin, who form the 
majority segment of the modern day multi-ethnic country of New Zealand.  For example, 
different prevalence of blood groups (e.g. ABO and Rhesus) and HPA alleles (e.g. HPA-1b, -
5b and -15a) between Polynesian and European populations were shown to increase risk of 
alloimunization (see Chapters 3.3 and 3.4).  In general, feasibility of finding suitable donors 
for Polynesian and Maori patients is higher within their own ethnic groups as they share 
common and unique genepools.  Nonetheless, Polynesian and Maori genepools are today 
becoming more diverse due to inter-group marriage with those from the European lineages.  
As a consequence, the numbers of available donors for un-admixed Polynesian and Maori 
patients become smaller, but increase the number of potential donor and recipient pairs that 
belong to the admixed group.  Therefore, I have argued in Chapters 3.2 to 3.4 that it should 
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become a policy for transfusion and transplant centres to perform a pre-
transfusion/transplantation cross-match and recruit increased numbers of donors with rare 
phenotype profiles. 
 
The prevalence of HLA, MICA and KIR data deposited in this thesis were also discussed for 
their wider potential influence on the health of modern day Maori and Polynesians.  In 
general, Polynesians and Maori are unaffected by autoimmune diseases such as type I 
diabetes, psoriasis, rheumatoid vasculitis and coeliac disease, which are associated with 
particular types of HLA, MICA and KIR that are common to Europeans.  However, 
increasing admixture with Europeans may mean that “European autoimmune diseases” such 
as ankylosing spondylitis and coeliac disease may become common in Maori and Polynesians.  
In addition, there are several autoimmune diseases (e.g. subacute cutaneous lupus 
erythematosus and diabetes) that are common to Polynesians and their genetic associations 
are still to be determined.   
 
My laboratory work on blood group and HPA (see Chapters 3.3 and 3.4) was also designed to 
assess the new molecular blood group typing methods in Polynesian and Maori populations 
[Objective D.i.-iii].  Scores for the other loci are based on the application of the pre-existing 
and established screening technologies (e.g. Luminex vs. SBT for HLA and KIR typing).  
Validation using three different blood group and HPA genotyping methods (i.e. PCR-SSP, 
SBT and SNP assay) gave 100% concordance and thus reflects the accuracy of DNA-based 
methods.  However, each genotyping method should try to include all known variants that are 
associated with serological expression.  For example, commercial PCR-SSP kits used in the 
present survey does not include Jknull and HPA-6 which are common/polymorphic in 
Polynesians and Maori.  Thus, routine uncritical application of these kits would lead to false 
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predictions and will subsequently increase risk of alloimunization.  Overall, there is 
compelling evidence for the wider application of molecular approaches for HLA, KIR, MICA, 
blood group and HPA typing.  Molecular methods show exact variations in particular genes 
and have shown to improve resolution of polymorphic loci to a precision that could not 
previously be achieved using serological approaches (see also Patnaik et al., 2012 and 
Robinson et al., 2013).  In addition, molecular methods are already superior in many ways to 
the traditional phenotyping and have solved problem of unavaibility of reliable antisera, poor 
cell expression and cross reactivity (see Chapter 3.3 and 3.4).  Currently, molecular methods 
as simple as PCR-SSP to rapid and high-throughput PCR-SSOP based platforms such as 
Luminex and SNP genotyping assay have been tested and used by others for HLA, MICA, 
KIR, blood group and HPA typing (reviewed by Middleton, 2005, and Wu and Csako, 2006, 
Veldhuisen et al., 2009 and Dunn, 2011).  At present, several different commercial kits/SNP 
genotyping are used to genotype HLA, MICA, KIR, blood group and HPA loci, individually.  
Nonetheless, it is expected that these loci could be genotyped simultaneously in near future, 
probably by designing mega DNA chip.  All looks promising for the application of molecular 
approaches in clinical settings and to the extend that never been achieved using serological 
approaches.  
 
In conclusion, the present molecular genetics study has successfully compiled new HLA, 
MICA, blood groups, HPA and KIR datasets for Polynesians and Maori, used the datasets for 
dual analyses of ancestry and health, demonstrated the reliability of current genotyping 
platforms that would suit well the needs of transfusion and transplantation centers and 
provide test of the hypotheses presented in the Introduction on p. 30: 
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Chapter 3.1: that HLA data will provide a way to test the claim of the STEM model that 
Polynesians have unequal genetic contributions from A-SM and P-SA ancestors. 
 
Accepted: The HLA allele frequencies in Polynesians and Maori are intermediate between 
those for reference A-SM and P-SA populations and thus our data are entirely consistent with 
STEM model.  Ancestral fractions are generally around 60:40 (Fig.S4-S8, pp. 105-109).  But 
HLA-B and -DRB1 loci are exceptional being around 100% A-SM. 
 
Chapter 3.2: that high resolution HLA and MICA data will help to explain differences in the 
rates of occurrence of auto-immune diseases and infection diseases between that Polynesians 
and Europeans. 
 
Accepted: Differences in HLA and MICA distributions between Europeans and Polynesians 
help to explain why the latter are unaffected by autoimmune diseases and infection diseases 
that are common among Europeans; e.g. ankylosing spondylitis and uveitis are associated 
with HLA-B*27 which is a low frequency allele group in Polynesians: see Table 1, p. 121 and 
discussion on pp.134-137.   
 
Chapter 3.3: that molecular techniques provide a reliable alternative technology for 
determining  blood groups in Polynesian subjects. 
 
Accepted: There is compelling evidence for the application of molecular blood grouping in 
Polynesians, but should include all known variants that are associated with serological 
expression.   Both PCR-SSP and BLOODchip technologies proved accurate and effective.   
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Chapter 3.4: that Maori and Polynesians will show difference in HPA allelic distribution 
from Europeans due to population history. 
 
Rejected: Distribution of HPA in Polynesians is only significantly different from Europeans 
for some loci, e.g. HPA-3 and HPA-15 – see Table 1 on p. 203.   
 
Chapter 3.5: that Polynesians will display a unique repertoire of KIR haplotypes and 
different from those previously reported in Europeans. 
 
Accepted: Polynesians do have many unique KIR haplotypes compared with Europeans – see 
Fig. 1 on pp. 233-234 and discussion on pp. 237-239 which explains that Polynesians are 
most closely related to Asians in this respect. 
 
In addition, novel information gained and deposited in this thesis has strongly endorsed the 
indigenous biomedicine approach, and will be particularly also valuable to Asia-Pacific 
populations of Austronesian peoples.  In the view of present study, future study and analysis 
of high resolution HLA and KIR data (to be reported later) will further help to inform 
ancestry and health in Polynesian and Maori people and will be wide interest to the 
biomedical community.  
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Abstract 
 
Malay and Maori people are both end populations of the great Austronesian Diaspora.  Under 
multidisciplinary received wisdom of this model they represent closely related but divergent 
descendants of Taiwanese farmers who became transoceanic voyagers from around 5000 ybp.  
The greater part of today‟s Malay sub-ethnic groups represent this ancestral stock.  They 
arrived relatively recently via Borneo and Indonesia and are now a major component of the 
modern multicultural population of today‟s Malaysia.  
 
In contrast, Maori are a geographically and culturally distinct element of the widespread 
Polynesian people.  This larger group arose around 2500 ybp via limited gender-biased 
geneflow between Austronesian voyagers and Papuan residents of coastal Papua New Guinea 
and the islands of the Bismarck Archipelago.  Maori themselves are now a substantial 
minority component of the largely European population of modern New Zealand. 
 
In this presentation we will survey genetic evidence collected from Maori and Malay 
volunteers which inform the above account.  Thus it can be said with confidence that Malays 
and Maori spring from the same original source and remain closely related today. The data to 
hand include maternal (mitochondrial DNA haplotypes), paternal (Y chromosome nucleotide 
polymorphisms and microsatellites), and biparental (Human Leucocyte Antigen) systems.  
Our data are of significance for better understanding of health issues in these populations and 
endorse the emergent picture from linguistics and archaeology.  They also underline our 
assertion that studies on either one of these two populations have value for the other and 
indeed for people all across the Pacific Regions of Near and Remote Oceania. 
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Introduction: The emergent model of Malay, Maori and Pacific genetic 
history 
 
The developing deep time story of Polynesian genetic history has been presented by one of 
the present authors in Chambers (2006, 2008) and later phases described in detail by Kayser 
(2010).  In short, the now more or less standard reconstruction features three ancient lineages; 
(1) island South-East Asians (Austronesian-speaking Mongaloids, A-SM), (2) ancient 
peoples including the various Negrito groups, Australian Aborigines and New Guineans 
(Papuan-speaking Australoids, P-SA) and (3) Europeans (Caucasoids) – and see Box 1 for 
more on terminology.  It has previously been the prevailing view that these lineages arose by 
multiple dispersals out of Africa (Lahr and Foley, 1994).  Thus, it has been held that Lineages 
(1) and (2) separated shortly after anatomically modern humans first left Africa (Figure 1).  
Lineage (1) people were believed to have travelled to eastern Asia via the central Asian 
Steppe vs. Lineage (2) ancestors who went by a southern coastal route via India.  The ancient 
Europeans, Lineage (3) simply turned to the North.  While much of the available genetic data 
are consistent with this established view, it has recently been challenged (see Stoneking and 
Krause, 2011) by extensive single nucleotide polymorphism (SNP) surveys (e.g. by Wollstein 
et al, 2010).  The data are argued to provide a best fit to a model with a single dispersal which 
gave rise to all the three lineages.  Similar doubts have been expressed based on a study of 
the Aboriginal genome (Rasmussen et al, 2011).  These authors suggest later separation of 
Lineage (1) and (2) and/or extensive geneflow between them – see Gibbons (2011) for 
commentary.  Oppenheimer (2009) seems to endorse the single out of Africa origin for 
Lineages (1) and (2), but often seems to be in two minds regarding just when the split 
between them occurred.  Recent microbiological data concerning the stomach bacterium, 
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Helicobacter pylori, from Moodley et al. (2009) and Bayesian dating of Austronesian 
language trees by Gray et al. (2007) support the idea (Bellwood et al., 2011) that A-SM from 
Taiwan moved south via the Philippines (Bellwood and Dizon, 2005) and Borneo with a 
western branch going on to Malaysia and Indonesia and an eastern branch heading for the 
Pacific (Figure 2). Proto-Polynesian populations were formed when descendants of Lineage 
(1) voyagers above were re-united with Lineage (2) somewhere in the Bismarck Archipelago 
off the northern coast of what is today‟s Papua New Guinea (PNG).  There is one caveat 
which now renders this older orthodox view provisional; i.e. that the HUGO Pan-Asian SNP 
Consortium (2009) has recently presented an extensive data set and claimed that the Asian 
Lineage (1) may be of much greater significance than those who followed the putative 
southern coastal route leading to Lineage (2); see above and discussions in Stoneking and 
Krause (2011).  We note that this view has received some recent support from Reich et al. 
(2011) who show that the Melanesian genepool in Bourgainville contains relict signals from 
admixture with the ancient and enigmatic Denisovian people who are presently only known 
from their remains in Siberian caves. The Bouganville Islanders tested are dark skinned 
Papuan speakers and thus it seems relatively unlikely that they obtained their Denisovian 
DNA via contact with Austronesians. However, one should probably suspend judgement on 
this question as there is no present extended evidence for or against Denisovian genes in any 
Asian population.  Finally, the original Polynesian settlers of New Zealand (Maori) and the 
various Malay sub-ethnic groups in Peninsula Malaysia now find themselves living amongst 
more recent settlers. In New Zealand the majority of these people belong to the European 
Lineage (3). The potential pharmacogenomic consequences of this contemporary admixture 
have been explored by Lea and Chambers (2007).  While in Malaysia historic immigrant 
populations have come from India, China and Europe.  Hence, the contemporary population 
is a sophisticated multicultural melange consisting of ancient indigenous groups, such as the 
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Orang Asli, Malay sub-ethnic groups who are predominantly, but perhaps not exclusively, 
Austronesian arrivals old and new (see Edinur et al., 2009 for an account) plus immigrants 
old and new. 
 
 
 
 
Figure 1: Diagram showing the conventional Out of Africa Model with multiple dispersals (lilac arrows) giving 
rise to Lineage (1) shown in pink, Lineage (2) in blue and European Lineage (3) in green. This figure is 
reproduced from Chambers, 2008 (with permission requested). 
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Figure 2: Settlement of Island South East Asia, Near and Remote Oceania based on archaeological dating.  The 
directions of movements are inferred from sequential chronology and lingusitic evidence. This figure is 
reproduced from Bellwood et al., 2008 (with permission requested). 
 
The supporting evidence 
 
The most recent chapter in this history dates starting from around 4,500 ybp (see Chambers, 
2006) and forms part of the greater „Austronesian Diaspora‟ (Simanjuntak et al., 2006). The 
common Austronesian ancestors of Malays and all Polynesians (i.e. including Maori) are hill 
tribe aboriginal people of Taiwan (Amis, Atayal, Paiwan etc.) who migrated southwards via 
the Batanes Islands and Philippines etc. according to the „Out of Taiwan‟ archaeological 
hypothesis (Bellwood and Dizon, 2005).  Recent molecular studies (Delfin et al., 2011, 
Gunnarsdóttir et al., 2011 and Tabbada et al. 2010) document the passage of maternal and 
paternal genetic markers across this „populated viaduct‟ and gives confidence to those who 
hold this view. A fully detailed current account of the evidence supporting this pathway and 
its associated chronology is presented by Bellwood et al. (2011). The onward migration 
process was dubbed „The Express Train to Polynesia‟ by Diamond (1988), but is perhaps 
better captured by the „Slow Boat Model‟ (see Kayser et al., 2000) and later elaborations such 
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as the „Slow Boat from Asia Model‟ (Kayser et al., 2006 and 2008). It is important that this 
latter model should not be confused with a less orthodox version (Richards et al., 1988) 
which confusingly still goes under the same title (e.g. as recently presented in Soares et al., 
2008). Nonetheless, one must acknowledge that to the minds of some investigators this 
competing idea may have gained some support with the publication of the recent report from 
the HUGO Pan-Asian SNP Consortium (2009). However, the present authors caution that the 
new data point to a significantly earlier chronology for these hypothetical population 
movements and that there is archaeological support for neither (see later). 
 
Further southward movement brought the voyagers to Borneo and Sulawesi.  From here they 
split with one branch going west and eventually reaching Malaysia and even Madagascar.  
The other branch went east towards the Pacific (see later).  The origins of Proto- and 
Deutero-Malays have been fully described by Edinur et al. (2009).  In brief this episode 
began between 4500 and 3500 ybp as Austronesian speakers moved on to Central Java and 
Eastern Indonesia.  The Proto-Malay population formed in Peninsula Malaysia via migration 
across the Straits of Malacca 3500 to 2500 ybp.  They were joined by a wide range of local 
immigrant groups, Thai, Chinese etc. to form a Deutero-Malay population that displaced the 
ancient indigenous peoples into mountain forests, apparently without significant admixture.  
More recently new Austronesian people have arrived in Malaysia from neighbouring 
countries and have formed more or less easily recognisable sub-ethnic groups; e.g. 
Minangkabau from Sumatra moved to Negeri Sembilan (c14th) and Bugis to Johor and 
Selangor from Makasar (c17th) – see Edinur et al. (2009) and references therein for a more 
complete account. 
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Continued south and westward movement eventually (by c. 3300 ybp) brought the other 
branch of the Austronesian voyagers into contact with the Papuan language-speaking 
descendants of Lineage (2). These were people who had been resident in the general PNG 
area for more than 20,000 years. In contrast with events in Malaysia, the result of this 
interaction was widespread genetic and linguistic replacement in the settled indigenous 
populations in situ. This gives rise to the long-recognised differences between coastal and 
highland peoples in PNG (Stoneking et al., 1990) and has left clear signals in their 
descendant gene pools (Friedlaender et al., 2008 and Kayser et al., 2008). For instance, 
Soares et al. (2011) show that the famous Polynesian CCG mtDNA motif first arose in the 
Bismarck Archipelago. These new findings are entirely consistent with the account we have 
presented here and can also be found in much the same form and described at length by 
Wollstein et al. (2010) and by Kayser (2010). The study by Soares et al. (2011) presents 
molecular clock dates that are at odds with our chronology derived using extensive evidence 
from other disciplines. Their new calculations are based on more extensive whole 
mitochondrial genome data and do allow for the effects of natural selection to accommodate 
earlier shortcomings as recognised by the same authors (Soares et al., 2009). This helps to 
bring their dates forward and reduce the confidence intervals around them, but not 
sufficiently to bring them into line with received wisdom. Once again this leads the present 
authors to urge a prudent approach when interpreting molecular clock estimates which 
depend on in-built assumptions, both implicit and explicit. There is a fascinating asymmetry 
between maternal (mtDNA haplotypes) and paternal (Y-chromosome SNPs and 
microsatellite loci) markers.  This is clearly a result of gender-biased geneflow (see 
Chambers, 2006 and 2008 and Kayser et al., 2008). Hence, these differences are attributed to 
matrilocal marriage practice (men move to join their wife‟s family on their ancestral land) 
coupled with matrilineal inheritance of property and social status among Austronesian 
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groups.  This behavioural culture is in marked contrast to the patrilocal practices of Papuan 
groups in the same area (Hage and Marck, 2003).  A detailed picture of the evidence upon 
which this reconstruction stands has been presented recently by Kasyer (2010) and 
informatively placed in a wider regional and cultural context by Donohue and Denham 
(2010). 
 
Spreading out from this original base, new settlement movements proceeded to fill up 
dispersed habitable space and extending to Central Polynesia (Marquesas Is) by 1300 ybp and 
reaching the most remote corners of the Polynesian Triangle; Hawaii (by 1100 ybp), Easter 
Island (1100 ybp) and New Zealand (700 ybp). A recent review of available 14-C dating 
evidence by Wilmshurst et al. (2010) suggests that this phase took place over a much more 
condensed time period. Caution is presently advised regarding their interpretations as the 
work has yet to receive wider scrutiny from the academic community. Evidence supporting 
the general account above has been presented by Bellwood et al. (2011) and receives 
independent confirmation from the large-scale independent molecular study of Friedlaender 
et al. (2008). Further, and as noted earlier, a molecular phylogenetic study (Moodley et al., 
2009) of H. pylori (an obligate human commensal responsible for the development of 
stomach ulcers) together with Bayesian analysis of Pacific and East Asian languages (Gray et 
al., 2009) makes a compelling case for the pathway linking Taiwan with the far distant 
reaches of Remote Oceania and the directionality of migration. The latter study also reveals 
sharp temporal discontinuities which are co-incident with major geographical boundaries 
(Figures 3A and 3B). In contrast, and as also noted above, the SNP study by the HUGO Pan-
Asian Consortium (2009) might be interpreted as support for the alternate „Out of Island SE 
Asia‟ aka „Slow Boat from Melanesia‟ (Kayser, 2010) hypothesis, which is in such marked 
conflict with the well established position taken by Bellwood et al. (2011). It will clearly take 
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quite some time before this new information can be accommodated into a single unified 
mainstream theory. The empirical virtues of the HUGO study (large scale with many loci) are 
balanced by its failure to account for the manifest differences between Melanesian and 
Austronesian gene pools (see Kayser et al., 2008 and references) and lack of congruence with 
a now extensive archaeological chronology (Bellwood et al., 2010).  One possibility is that 
the data analysis methods used by the HUGO team seem to necessarily constrain the data to 
fit a divaricating (tree-like) process. So, if the actual historical pattern includes reverse 
migration and/or reticulation, then such methods are prone to converge on a misleading, but 
otherwise convincing, result.  
 
Recently it has become possible (and affordable) to carry out really large scale genetic 
screening exercises which are capable of partitioning modern genepools into ancestral 
fractions (see Box 1).  Here we note Kimura et al.'s (2008) initial estimate based on extensive 
nuclear SNP data that the genepool of Polynesians in Tonga is comprised 70% Asian 
Austronesian and just 30% Papuan. Their reference group for Papuan-speaking Australoids is 
drawn from the Gidra people who come from the Western Province lowlands of mainland 
Papua New Guinea and would not be expected to have admixture from Austronesian –
speaking Mongoloids coming down the migration route from Taiwan etc.  The admixture 
estimates of Kimura et al. (2008) are rather higher than those of Wollstein et al. (2010). But 
nonetheless taken together these studies do serve to show that a significant historical 
exchange of genes did indeed take place, but never to the extent of complete 
admixture.  They call their model the „Slow Train‟. The sex biased nature of this process as 
explained here and by Wollstein et al. (2010) is not apparent in the earlier study due to the 
nature of their data.  This later report by Wollstein et al. (2010) covers similar ground with 
two important differences.  First, their analysis of their SNP survey data includes a 
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comparison between rates of polymorphism on X-chromosome loci and those on autosomes 
confirming directional gender biased admixture as discussed above. Second, their estimate 
for admixture proportions is 87:13 for East Asian:Near Oceanian (i.e. A-SM:P-SA). Such 
proportions suggest rather more limited admixture than has conventionally been accepted and 
is more in keeping with the original Fast Train Model rather than any version of the Slow 
Boat Model. But perhaps of even greater fascination is Wollstein et al.‟s (2010) finding that a 
Melanesian population in Fiji has much greater Near Oceanian gene content than typical 
Polynesian populations in the central Pacific islands (Remote Oceania). They quote figures of 
65:35 Polynesian:Near Oceanian for their Fijian subjects. This ratio extrapolates to 57:43 
East Asian:Near Oceanian using the split above. In our view, this is of key significance in 
explaining the persistent differences between typical present day Melanesian and Polynesian 
populations. It also goes a long way towards reconciling the difference in admixture estimates 
between their study and that of Kimura et al. (2008) i.e. that the latter study included 
authentic Melanesian type subjects. Hence, it is now apparent that a second wave of migrants 
left Near Oceania following the Proto-Polynesians and subsequently largely replaced them in 
the Vanuatu archipelago, New Caledonia and Fiji, but did not extend further.  We know 
nothing about the geographical source(s) of these second wave migrants, or about the reasons 
why they set out. We can only speculate about the timing of these events, but it seems likely 
that they correspond to the demise of Lapita culture in these sites. It has long been clear 
(Marshall, et al., 2005 and Chambers, 2006) that all of the above mentioned models only 
capture part(s) of the pattern or process.  For instance Trejaut et al. (2011) now agree and 
recognise that: 
 
 “Express train”, “Slow boat” and “Out of Taiwan” models are all components of a 
single phenomenon.   
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However, our own „Synthetic Total Evidence Model‟ as first advanced in Chambers (2006) 
does encompass most features including: Out of Taiwan, admixture in Near Oceania with 
gender biased geneflow plus Proto-Polynesian Diaspora with Bottlenecks (actually founder 
effects) – see Figure 4. It must now be extended to include the later expansion of Melanesians 
across Near Oceania as originally described by Bellwood (1978), Chapter 9 pp. 233-280, but 
adding in  a modern view of the genetic make up of these voyagers according to Wollstein et 
al. (2010). 
 
 
 
 
Figure 3A: Map showing locations where Austronesian languages are spoken and showing the distribution of 
various language groups colour coded to match the tree in Figure 3B. This figure is reproduced from Gray et al., 
2009 (with permission requested). 
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Figure 3B Evolutionary tree of Austronesian langueages. Tree showing ancestor-descendant relationships 
between Austronesian languages.  The inferred locations of the pauses in linguistic evolution are shown in 
Figure 3A and match discontinuities in the archaeological record. This figure is reproduced from Gray et al., 
2009 (with permission requested). 
 
 
 
 
 
 
Figure 4:  The Synthetic Total Evidence Model shown in diagrammatic form.  Movements of the Lineage (1) A-
SM people is shown in green and Lineage (2) P-SA populations in orange.  The dispersal of Proto-Polynesians 
is shown by purple arrows. This figure is reproduced from The Dominion Post newspaper (with permission 
requested). 
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Box 1 Note on nomenclature of Asian and Pacific peoples.  
We have adopted the system below to clearly distinguish modern and ancestral populations. This is necessary to 
give a clear description of admixed descendants such as Melanesians whose genetic make-up may not 
correspond to observed cultural traits. 
 
 
Population 
 
Description 
Taiwan aboriginal and other Asian including 
Filipino, Malay and Indonesian 
 
Austronesian-speaking Mongoloid (A-SM) 
Australian Aborigine and Papuan interior 
 
Papuan-speaking Australoid (P-SA) 
Coastal PNG plus islands and other 
Melanesians 
 
~50:50 (A-SM: P-SA)
ab
 
Polynesian including Maori 
 
70:30 to 87:13 (A-SM: P-SA)
ac
 
 
aWollstein et al. (2010), bFriedlaender et al. (2008), cKimura et al. (2008) 
 
 
 
A short history of research contributions from USM and VUW 
 
Some of information generated in these two centres has already been referenced among the 
evidence which today supports the emergent model and the work of scientists at VUW has 
been presented in greater detail and in temporal context by Marshall et al. (2005) and by 
Chambers (2006).  Nonetheless, we have judged it appropriate to give a further brief account 
of this rather diverse set of studies stressing their natures, lessons learned along the way and 
showing how they are integrated to motivate the present programme which is being carried 
out by a USM scholar at VUW.  This new initiative forms the subject of the final section of 
this article. 
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We begin around 1988 with an era of forensic science projects at VUW intended to develop 
DNA profiling technology for case work.  Technology progressed through multi- and single-
locus minisatellite probes (Hamilton, 1994) to multiplex PCR amplification of microsatellite 
loci using fluorescent labels (Watson, 2000).  Analysis of these data (Clark et al., 1995) 
confirmed that the Maori (and Polynesian) genepool was both different from that of 
Europeans and less variable – a manifestation of the „population bottleneck in Polynesia‟ as 
according to Flint et al. (1989).  As might well be expected, these effects were most marked 
in Maori, being the population right at the end of the series of island hopping migrations.  
Most importantly this early work secured our set of banked DNA samples together with 
reliable data on the ethnic groups of the volunteer contributors. 
 
Our next project involved a survey of SNPs in genes for alcohol metabolism.  These had been 
implicated as protective factors in a series of studies on Japanese, Korean and Chinese 
populations.  These markers were known as ADH2*2 and ALDH 2*2 (todays revised 
nomenclature is ADH1B*2 for the former).  Our study confirmed the presence (allele 
frequency = 0.42) and protective effect of ADH2*2 in young male Maori (Chambers et al., 
2002).  This gene variant is very rare (frequency generally below 0.02) in Caucasians.  Unlike 
many Asian populations the even more protective ALDH2*2 variant is not found in Maori of 
Polynesians.  This is something that they have in common with Taiwanese aboriginals and 
lends support to the „Out of Taiwan‟ idea. 
 
Our next two studies looked at one matrilineal marker (mtDNA: mitochondrial DNA) and 
one set of paternal markers (Y-chromosome SNPs) as potential contributors to a missing 
persons database.  Low levels of variability turned out to make both of these of limited utility 
for Maori and Polynesian subjects in New Zealand.  However, the ancestry of these systems 
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proved to be very interesting.  The mtDNA markers tracked back somewhat unconvincingly 
to Taiwan (Whyte, Marshall and Chambers, 2005).  But later work by Benton (2010) 
produced full mtDNA sequences for the first time in our laboratory and his phylogenetic 
analysis shows how they can be traced back to Taiwanese ancestors (Figure 5). The Y-
chromosomes point to PNG (Underhill et al., 2001).  This may seem to offer a contradiction 
with respect to the mtDNA data, but is entirely in line with previous observations, as can be 
appreciated by examining the wider picture obtained by others (Figure 6).  This is a striking 
illustration of the consequences of previous episodes of gender-biased geneflow.  Because 
there were pre-existing databases of Maori and Polynesian mtDNA haplotypes, Whyte, 
Marshall and Chambers (2005) were also able to estimate the number of founding females 
who first settled Aotearoa (later to become known as New Zealand) returning values in the 
range 40-380, depending on what assumptions are built into the calculations.  The fact that all 
of these are relatively large numbers suggested to us that the settlement process that took 
place around 700-650 ybp was well planned and deliberate.   
 
More recently we had a chance to collaborate with the Marshfield Clinic programme in the 
USA (Friedlaender et al., 2008).  This allowed our collaborators to score a large number of 
loci including microsatellites and insertion/deletion polymorphisms (indels).  Extensive 
analysis of this very large dataset including external reference populations helped to build a 
strong case that Polynesians arose via admixture between A-SM (ex-Taiwan) and P-SM 
(northern PNG residents); see Figure 7 for an illustration.  Hence, taken together these new 
data plus those from the proceeding work at VUW may fairly be said to illuminate many 
features of the emergent model presented earlier. These include and A-SM origin in Taiwan, 
formation of Proto-Polynesians via gender biased admixture with P-SA followed by 
refinement of the gene pool during colonisation of the Pacific to the most distant islands of 
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Remote Oceania.  Together they go to build the platform upon which the Synthetic Total 
Evidence Model stands. 
 
Before moving on to describe our present programme at VUW which is focussed on 
developing an indigenous approach to transplant and transfusion medicine, we need to 
consider foundation work done at USM which motivates this new venture.  Edinur et al. 
(2009) used molecular methods to examine Class I and II HLA (Human Leucocyte Antigen) 
systems (see Figure 8 for an explanatory diagram).  These markers, HLA-A, -B, -C (formerly 
Cw), class I and HLA-DRB1 and -DQB1, Class II are important antigens in tissue matching 
for transplant surgery.  They are also extremely diverse and so it is important to survey them 
widely across big samples drawn from potential donor and recipient pools.  The same 
properties make them excellent tools for detecting population subdivision and ancestral 
relationships.  The study looked at six sub-ethnic groups from various geographic locations 
within Peninsula Malaysia (Figure 9).  As mentioned previously, many of these had only 
recently (within the past 2-300 years) arrived in Malaysia from neighbouring territories.  
These include Banjar, Bugis and Jawa who proved to be particularly closely related and who 
all come from islands around the Java Sea (Java, Kalimantan, and Sulawesi).   Equally, 
Minangkabau and Rawa (both originally from Sumatra) were found to group together.  
 
The outlier population is Kelantan Malays.  This is not surprising as they do show cultural 
and historical links to northern populations Thai and perhaps even further to Vietnam and/or 
China.  However, this does not show clearly in the phylogenetic trees or principal coordinate 
plots.  There may be historic or technical reasons for these observations. 
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However, the experience gained in the above project does provide an incentive to collect the 
same information for the VUW DNA Bank samples and will more or less complete delivery 
of our analytical contract with the original participants.  There are precedents (see below for 
full references) for this type of study in New Zealand, but these lacked clearly defined 
ancestry records.  Hence, one cannot say if they represent modern admixed populations (the 
health focus) or original genepool representatives (as required for accurate ancestry 
determination).  Thus our new programme not only offers to expand the datasets, but also to 
better determine how they may best be understood.  Groups with full ancestry can then be 
used to reconstruct patterns of relationship across the Pacific and out to Asia and Australia 
following the methodology established by Edinur et al. (2009). 
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Figure 5A: Genetic relationships between Maori and Taiwanese Aboriginals as revealed through studies of 
complete mtDNA sequences. The phylogenetic tree of Maori and Taiwanese mtDNA sequences. Maori 
sequences (marked as RHAS = Rakaipaaka Health and Ancestry Study) are nested inside those from Amis, 
Atayal, Paiwan and Tao.  Note that various Polynesian mtDNA sequences are also included inside the Maori 
group. This figure is reproduced from Benton (2010). 
Appendix 1 
 
300 
 
 
 
Figure 5B: Map of the homelands of Taiwanese Aboriginal Hill Tribes. B: Map of Taiwan showing where the 
various tribes live. This figure is reproduced from Trejaut et al., 2005 (with permission requested). 
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Figure 6:  Map showing distributions of Y-chromosome haplotypes in A-SM and P-SA populations. This figure 
is reproduced from Kayser et al., 2003 (with permission requested). 
 
 
 
 
Figure 7: Phylogenetic and Structure analysis of data from many nuclear loci showing the relationship of 
Polynesians to other population groups worldwide. The branch leading to Polynesians and Maori lies at the 
intersection of the regions covered by Taiwanese (light blue) and Melanesians (grey). This figure is reproduced 
from Friedlaender et al., 2008 (with permission requested). 
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Figure 8:  Genetic map of human chromosome 6 showing the locations of class I and II HLA loci together with 
experimental procedures for low- and high-resolution typing. 
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Figure 9:  Diagram of locations of six Malay sub-ethnic groups who participated in the HLA study by Edinur et 
al. (2009).  The figure is reproduced from this source with permission (requested). 
 
 
The new HLA screening programme at VUW 
 
Throughout the development of the Synthetic Total Evidence Model and its predecessors, 
data from HLA loci have played a significant part (Sarjeantson et al., 1982) especially in 
dealing with inconsistent findings between mtDNA and Y-chromosome markers (see 
Hagelberg et al., 1999, Lie et al., 2006, Mack et al., 2000, and Ohashi et al., 2006). However, 
interpretation of these HLA data has not had the opportunity to take into consideration the 
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hybrid origin of Proto-Polynesians via gender-biased gene flow between Austronesian-
speaking Mongoloids and Papuan-speaking Australoids. Therefore, we are now returning to 
examine HLA loci in light of new understanding.  As explained above we are using and 
developing the approach employed by Edinur et al. (2009) and will also have the added 
advantage of being able to incorporate data from their study of extra Austronesian people, the 
six Malay sub-ethnic groups. 
 
Several screening studies have already been done on Polynesians (see Zimdahl et al., 1999, 
Mack et al., 2000, Velickovic and Carter 2001,  Velickovic et al., 2002 and Gonzalez-
Galarza et al., 2011), but they focus mostly on  HLA Class II markers. There are also 
unpublished data for HLA Class I (Velickovic, 2001) from the same samples first used for 
HLA Class II typing in Velickovic et al. (2001). However, these samples too contain 
individuals who are nominally Polynesians, but who are known to have some Caucasian 
and/or Asian admixture.  
 
Our present study examines DNA samples that have been classified according to reported 
admixture (e.g. MFA = Maori with Full Ancestry vs. MAH = Maori with Admixed Heritage 
etc.). Hence, this new work includes the only individuals ever examined where some 
participants can be clearly identified as lacking genetic input from Caucasian ancestors. This 
design allows comparisons that were not previously possible. The new work represents an 
independent re-sampling of these populations, and thus has comparative value too.  In brief, 
we find that those Polynesian populations (VTP = Velickovic Total Polynesians) examined 
by Velickovic (2001) best match our PFA (Polynesian with Full Ancestry subgroup) and thus 
represent the ancestral genepool.  In contrast, the data (Tracey and Carter, 2006) obtained 
from Maori samples (TTM = Tracey Total Maori) collected by Tracey (2007) are a much 
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better match to our pooled TM group (Total Maori = MFA + MAH) or to MAH than they are 
to MFA.  This indicates to us that the earlier study was indeed compromised to some extent 
by undisclosed admixture.   However, our new data can now be combined effectively with 
previous data for small scale meta-analyses.  Thus PMD (combines VTP + PFA) provides a 
large (2n = 448) sample for ancestry analysis and MMD (combines TTM + TM) provides an 
increased group size representing the current Maori population in New Zealand.  Importantly, 
our MFA subgroup becomes the best representative of the original Maori genepool for 
comparison with PMD and data from external source P-SA and A-SM populations, the latter 
including Malays.  The effect of present day admixture with Europeans on the Maori 
genepool is illustrated in Figure 10.  This shows the relative frequencies of HLA-C alleles.  
Consider, for example HLA-C*01.  Here we see that this allele is present in around 37% of 
MFA genes examined, but only in about 3% of the European reference group.  The 
corresponding value for the admixed MAH subgroup is intermediate at 19%.  There are many 
other examples in the diagram and we have corresponding pictures for all the other loci too. 
 
We can now proceed to historical reconstructions of relationships between populations.  We 
will also compare principal coordinate analysis (PCO) and neighbour-joining (NJ) 
methodologies along the way. The HLA data are examined in the light of the Total Synthetic 
Evidence Model of Pacific settlement and include tests for historical geneflow with a 70:30 
ratio (A-SM-P-SA) as a null hypothesis based on the SNP data of Kimura et al. (2008) versus 
the 87:13 estimate of Wollstein et al. (2010). Wider comparisons have also been made in a 
new and more appropriate context recognising other Austronesian populations (e.g. Malay 
and Taiwanese Aboriginals) as being distinct from Polynesians and as representing “the pure 
ancestral type Austronesian-speaking Mongoloid” lineages.  These plots are for the class I 
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HLA data alone and shown for illustration in Figures 11 (NJ) and 12 (PCO).  They are taken 
from our new report on this work (Edinur et al., 2012). 
 
The NJ analysis (Figure 11) has a fairly conventional outcome and groups Maori with 
Polynesians closest to Cook Islanders.  The PCO plot (Figure 12) is more informative and 
includes both A-SM and P-SA populations (shown as ellipses that encompass the metadata 
collections gleaned from the literature and online databases).  Here one can clearly see that 
that the Polynesian populations all lie intermediate between A-SM and P-SA reflecting this 
hybrid origin.  We have done mathematical simulations to estimate A-SM: P-SA fractions in 
these populations (not shown).  This type of exercise typically returns values around 60:40 
for most HLA loci – rather lower than those reported for the big SNP surveys (see earlier).  
However, some individual loci such as HLA-B show close to 100% A-SM ancestry content.  
We think this is a very exciting finding and interpret it to reflect past episodes of natural 
selection.  This seems to be a reasonable conclusion given that HLA loci have been 
implicated in defensive responses against a wide range of pathogens (see references in figure 
legends for more details).  The admixed groups like MAH are displaced towards the 
European reference as might be expected.  The MFA group lies closer to the main body of 
Polynesian data points, again notably closest to Cook Islanders.  Melanesian populations 
represented by Madang and Rabaul show greater affinity with the P-SA group as might be 
expected.  Interestingly the Island South East Asia group (ISEA) which includes Malays lies 
away from the body of the source A-SM populations from Taiwan and in our view reflects 
historic changes in HLA allele frequency rather than bulk P-SA input.  This view is supported 
by the fact that the Malay sub-ethnic groups reported on by Edinur et al. (2009) do not seem 
to have HLA alleles or overall allelic profiles that are in any way similar to those of P-SA 
populations (data not shown). 
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Figure 10: Allele frequency spectrum for MFA and MAH compared with a standard European reference 
population (ELAN).  The histogram bars are colour coded according to the key on the diagram. This figure is 
reproduced from Edinur et al., 2012 (with permission requested). 
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Figure 11: A neighbour joining tree for combined HLA class I data.  Those branches with the greatest statistical 
support are shown as darker lines according to the key in the diagram.  Names of populations are also colour 
coded as to type (A-SM etc.) for easy reference.  
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Figure 12: A principal coordinates plot for combined HLA class I data. The colour coding scheme is as for 
Figure 11.  The data for this diagram come from many published sources, but principally those referenced in the 
text plus others (includes Bhatia et al., 1998, Bugawan et al., 1999, Chen et al., 2007, Chu et al., 2001, Edinur 
et al., 2009, Gonzalez-Galarza et al., 2010, Lie et al., 2006, Shaw et al., 1999, Main et al., 2001, Lin et al., 
2001, Velickovic, 2001).  
 
 
Concluding observations 
 
The genetic data we have collected over the years contribute significant support for key 
elements of the Synthetic Total Evidence Model of Pacific Settlement.  This article brings 
them together for the first time since Chambers (2006) and extends the Bellwood et al. (2011) 
account which is focussed on support for the Out of Taiwan component.  As previously we 
hold that our data support accounts that emerge from other disciplines, particularly from 
anthropology, archaeology, linguistics and indigenous oral histories.  Together they provide 
an enriched worldview of the Austronesian Diaspora which gave rise to both Malays and 
Maori.  Here we show how Austronesian-speaking voyagers have spread round the globe to 
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reach an estimated population size of more than 250 million in dispersed populations 
stretching from Madagascar to Easter Island, Hawaii and New Zealand.  We have shown that 
Malays and Maori are closely related via their Taiwanese ancestors and differ in that the 
Polynesian genetic trail includes restricted and gender-biased admixture with Papuan-
speaking Australoids.  Today the genepools of both Malays and Maori are expanding through 
opportunities for intermarriage with members of other ethnic groups that form significant 
parts of their respective domestic populations. Thus it can be said with confidence that 
Malays and Maori spring from the same original source and remain closely related. 
 
From a philosophical perspective it is instructive for us to note that the VUW laboratory 
never consciously engaged in any attempt to investigate this area of scholarship through the 
design of our experiments.  Each new investigation had a strongly applied focus such as 
designing forensic databases or improving medical outcomes.  However, the genetic basis of 
all of our work means that the data collected do also bear more or less directly on questions 
of ancestry.  Hence, we have taken every opportunity to present our research findings 
together with analyses and interpretation in this context both via the scientific literature, 
public talks and the popular media.  In doing so we are conscious of an ethical obligation to 
share this information and its potential significance with those who supported the work and 
contributed samples. 
 
Our more recent work on pharmacogenomics and HLA screening are anticipated to have 
medical benefits.  Further the recognition of the close relationships between Maori and 
Malays teaches us that studies carried out on one population can have relevance for the other 
and indeed for the wider Asia-Pacific community.  We seek to further this symbiosis via the 
present USM and VUW collaboration as described here.  
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Summary 
 
We present here the results of the Analysis of HLA Population Data (AHPD) project of the 
16th International HLA and Immunogenetics Workshop (16IHIW) held in Liverpool in May–
June 2012. Thanks to the collaboration of 25 laboratories from 18 different countries, HLA 
genotypic data for 59 new population samples (either well-defined populations or donor 
registry samples) were gathered and 55 were analysed statistically following HLA-NET 
recommendations. The new data included, among others, large sets of well defined 
populations from north-east Europe and West Asia, as well as many donor registry data from 
European countries. The GENE[RATE] computer tools were combined to create a 
GENE[RATE] computer pipeline to automatically (i) estimate allele frequencies by an 
expectation-maximization algorithm accommodating ambiguities, (ii) estimate heterozygosity, 
(iii) test for Hardy–Weinberg equilibrium (HWE), (iv) test for selective neutrality, (v) 
generate frequency graphs and summary statistics for each sample at each locus and (vi) plot 
multidimensional scaling (MDS) analyses comparing the new samples with previous IHIW 
data. Intrapopulation analyses show that HWE is rarely rejected, while neutrality tests often 
indicate a significant excess of heterozygotes compared with neutral expectations. The 
comparison of the 16IHIW AHPD data with data collected during previous workshops (12th–
15th) shows that geography is an excellent predictor of HLA genetic differentiations for 
HLA-A, -B and -DRB1 loci but not for HLA-DQ, whose patterns are probably more 
influenced by natural selection. In Europe, HLA genetic variation clearly follows a north to 
south-east axis despite a low level of differentiation between European, North African and 
West Asian populations. Pacific populations are genetically close to Austronesian-speaking 
South-East Asian and Taiwanese populations, in agreement with current theories on the 
peopling of Oceania. Thanks to this project, HLA genetic variation is more clearly defined 
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worldwide and better interpreted in relation to human peopling history and HLA molecular 
evolution. 
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Introduction 
 
The Analysis of HLA Population Data (AHPD) component of the 16IHIW held in Liverpool 
(UK) in May–June 2012 was set up as a continuation of the AHPD component of the 15th 
IHIW held in Buzios (Brazil) in September 2008 (Nunes et al., 2010). The main objectives of 
the project were to analyse statistically new HLA molecular data for different collections of 
individuals (mostly population samples and bone marrow donor registries) provided by 
participating laboratories, to update the results of previous IHIW population studies and to 
discuss them in relation to the history of human genetic differentiations. Another aim of the 
project was to improve the statistical methods and computer programs, which were developed 
within the frame of both the European network HLA-NET 
(http://www.cost.eu/domains_actions/bmbs/Actions/BM0803) and different research projects 
supported by the Swiss FNS (Nunes et al., 2011; Buhler et al., 2012) to handle the huge sets 
of complex HLA data submitted to the AHPD team during this workshop. 
 
Materials and methods 
 
Collection of new population data 
Thanks to several announcements made at the European Federation for Immunogenetics (EFI) 
and the American Society of Histocompatibility and Immunogenetics meetings, through the 
EFI mailing list and Newsletter and on the 16IHIW website, tissue typing laboratories were 
invited to participate first by filling the Population Questionnaire recommended by HLA-
NET (http://geneva.unige.ch/ahpd/ahpd_form. php) (Sanchez-Mazas et al., 2012b) and then 
by sending electronically the HLA data of population or donor samples to the AGP 
(Anthropology, Genetics and Peopling history) team at the University of Geneva 
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(Switzerland). By May 2012, a total of 55 samples totalizing up to 67 623 individuals were 
submitted by 23 teams from 17 different countries (Table 1). These data included 32 samples 
from well-defined populations (i.e. populations sampled on purpose for an anthropological 
study and well characterized geographically and linguistically) and 23 samples from donor 
registries (typed for either one or several loci, in majority HLA-DRB1). Four additional 
samples were submitted by 2 teams (from 2 countries, including 1 new) joining the AHPD 
project during the workshop, bringing the total number of submitted samples to 59 (36 from 
well-defined populations and 23 from donor registries, see Table 1). These last data could not 
be included in time for the population comparisons of the present report, but will be used in 
further analyses.  
 
     One to 7 HLA loci were typed by sequence-based typing (SBT), sequence-specific 
oligoprobes (SSO) and/or sequence-specific primer (SSP) molecular techniques in the 
submitted samples. Overall, the 16IHIW AHPD data thus represent 166 series of HLA single-
locus genotypic data. A detailed description of all data sets including population names, 
geographic locations, linguistic information, loci typed, sample sizes per locus, molecular 
techniques used to type the samples and resolution levels, as well as the rules adopted to 
classify populations into geographic regions (Sanchez-Mazas, 2012) can be found on the 
AHPD website (http://geneva.unige.ch/ahpd/).  
 
      For interpopulation analyses, the new data collected within the scope of the 16IHIW 
AHPD project were analysed jointly with the population data collected during the last 
workshops (12th–15th IHIWs). Overall, these data include a total of 116, 113, 75, 56, 57, 97 
and 153 samples tested for HLA-A, -B, -C, -DPB1, -DQA1, -DQB1 and -DRB1, respectively 
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(after removing samples not in Hardy–Weinberg equilibrium (HWE), see below). Their 
geographic distribution is shown in Fig. 1. 
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Table 1: List of participants (alphabetical order) who submitted data to the AHPD project of 
the 16th IHIW.  
   Number of submitted 
samples 
     
No. Participant(s) name Country Population Registry 
     
1 Marco Andreani & Manuela Testi Italy 3a  
2 Margarita Boldyreva Russia 18  
3 Geoffrey Chambers, Paul Dunn & Hisham 
Atan Edinur 
New Zealand 1  
4 Jacques Chiaroni, Julie Di Cristofaro, 
Jean-Marie Tiercy, Barbara Kervaire 
& Alicia Sanchez-Mazas‟ AGP team 
France & 
Switzerland 
5  
5 Chris Darke UK  1 
6 Valerie Dubois France  1 
7 Paul Dunn New Zealand  5 
8 Nadra Elamin Germany  1 
9 Jean-Francois Eliaou France  1 
10 Zorana Grubic Croatia 1  
11 Taina Jaatinen Finland  2 
12 Marja Liisa Lokki, Annika Wennerstrom 
& Riitta Paakkanen 
Finland 1b  
13 Narinder Mehra India  1 
14 Dia Papaioannou Voniatis 
& Agathi Varnavidou 
Cyprus  1 
15 Chryssa Papasteriades Greece 1  
16 Francesca Poli Italy  1 
17 Lucie Richard Quebec  1 
18 Inigo Romon Alonso Spain  1 
19 Antonij Slavcev & Libor Kolesar Czech Republic  1 
20 Genc Sulcebe Albania 1  
21 Tatiana Suslova & Maria Chernova Russia  3 
22 Jean-Marie Tiercy & Grazia Nicoloso Switzerland  1 
 23 Blanka Vidan-Jeras Slovenia 1 2 
Total 1 32 23 
24 Uma Kanga India 3  
25 Warunee Kunachiwa Thailand 1  
Total 2 36 36 23 
 
aSamples of patient families (unrelated father and mother of the patient); bA sample of controls 
Total 1: data submitted by May 2012 and included in the present analyses 
Total 2: total data including additional samples submitted during the 16th AHPD (not included in the analyses).      
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Statistical analyses 
 
During the preparation of the 16IHIW AHPD project, recommendations were given to all 
participants on how to report typing data, ambiguities and standard formats before sending 
the data. The data received by the AHPD team were then screened carefully to check allele 
names according to the new nomenclature adopted since the last IHIW (Marsh et al., 2010). 
When present, NMDP codes were expanded to the corresponding lists of alleles. The data 
were also converted from Text, Excel or LUMINEX output formats to UNIFORMAT 
(extension .unif), the standard input format for using the GENE[RATE] computer tools 
(http://geneva.unige.ch/generate/) recommended by HLANET (Sanchez-Mazas et al., 
2012a,b). After that, the following analyses were performed for each population thanks to the 
GENE[RATE] programs: 
 • Estimation of allele frequencies at each HLA locus at different levels of resolution: first 
field (in all cases, except HLA-DPB1 see hereafter), second field (when possible) and mixed 
resolution levels (to keep the maximum information available). To estimate allele frequencies, 
GENE[RATE] uses an expectation-maximization algorithm under a model of HWE and 
specifically adapted to take into account all genotyping ambiguities (Nunes et al., 2010, 
2011). 
• Test for HWE at each HLA locus. To perform this test, GENE[RATE] compares the log 
likelihood for frequency estimates obtained under a HWE model with that  btained under an 
inbreeding model (Nunes et al., 2010). Populations tested at several HLA loci were 
considered to deviate significantly from HWE when a significant deviation (5% level) was 
found for at least one locus after Bonferroni‟s correction for the number of loci typed in each 
population. In such cases, the estimated frequencies were not used for interpopulation 
analyses. 
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• Estimation of population heterozygosity and test of selective neutrality. The GENE[RATE] 
tool used here is an adaptation of the classical Ewens–Watterson (Ewens, 1972; Watterson, 
1978) and Slatkin (Slatkin, 1994) tests for analysing data with ambiguities. This procedure 
was first described by Nunes et al. (2010) and improved by Nunes et al. (2011).  
 
      The „summary statistics‟ described above were generated together with a colour-coded 
graph of allele frequencies at each locus and for each population, as was made for the 
15IHIW AHPD report (Nunes et al., 2010).  
 
     Following intrapopulation analyses, interpopulation analyses comparing the data 
submitted to the present and previous (i.e. 12th–16th) IHIW were carried out. These analyses 
included the following: 
• Estimation of pairwise Reynolds‟ genetic distances (Reynolds et al., 1983) between 
populations. 
• Multidimensional scaling (MDS) analyses (Kruskal, 1964) using Reynolds‟ genetic 
distances. To better evaluate the genetic relationships between populations, which are 
sometimes difficult to assess in MDS when numerous populations are included, four data sets 
were considered successively: (i) the whole set of populations, (ii) the whole set of  minus 
Amerindians, Australian Aborigines, Melanesians, populations from the Pacific area and 
Taiwanese (all these populations except Amerindians and Taiwanese are called Oceanians 
hereafter), (iii) Oceanians and Austronesian-speaking populations from South-East Asia 
(including Taiwanese) and (iv) Europeans and West Asians for data considered at the second 
field level of resolution.  
• Mantel tests (Mantel, 1967) to assess the correlation between genetic and great circle 
geographic distances (Ray, 2002). 
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     The GENE[RATE] computer tools were improved to perform automatically genetic 
distance and two- and three-dimensional MDS analyses on a set of data (GENE[RATE] 
pipeline). This was performed by integrating R facilities to the ARLEQUIN (Excoffier et al., 
2005) program. GNU/Linux scripts and the R software were used to perform Mantel tests. 
The analyses described above were performed at each HLA locus by considering the first 
field level of resolution to include a maximum number of populations. Additional analyses 
were further performed on a lower number of populations from Europe and West Asia by 
considering the second field level of resolution. 
 
 
 
 
Figure 1: Geographic location of the population samples submitted to the 12th to 16th International HLA and 
Immunogenetics Workshops and analyzed in this study. The 16IHIW samples are shown in red. 
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Results 
 
For all population or donor registry samples submitted to the 16IHIW AHPD project, colour-
coded graphs of allele frequencies (at the maximum resolution available) and summary 
statistics estimated at all loci tested were generated and can be found on the AHPD website 
(http://geneva.unige.ch/ahpd/). Synthesis of the results obtained by considering the data at the 
first field of resolution (and second field for HLA-DPB1, as alleles at this locus are not 
subdivided into allele families) is presented in Table 2. Note that some samples, which were 
initially tested at a medium level of resolution, were recorded at the first field level because 
of an excessive degree of complexity in the initial data. This applies to the six samples from 
the Pacific islands and the samples from the Czech Republic, Quebec and France Montpellier 
(only HLA-B data in the latter case).  
 
     As shown in Table 2, the most numerous data set is that for the HLA-DRB1 locus (55 
samples representing almost 70 000 individuals), with more well-defined populations than 
donor registry samples. Many samples have also been tested for HLA-A and -B (32 
populations representing more than 40 000 individuals), but this time the proportion of donor 
registry samples is higher. As expected, mean sample sizes are much larger for donor registry 
data (up to about 2700 individuals for HLA-DRB1). However, well-defined populations are 
very satisfactorily represented by sample sizes of about 100-200 individuals. Mean 
heterozygosities at the first field level of resolution are lower for HLA-DQA1 and -DQB1 
(around 70%) compared with HLA-A, -B, -C and -DRB1 (around 85–95%). HLA-DPB1 is 
close to the latter loci with mean heterozygosities between 80% and 85% at the second field 
level of resolution. Well-defined population samples do not differ remarkably from donor 
registry samples with this respect. Very few rejections from HWE are observed (9.6% on all 
Appendix 2 
333 
 
series of data, and 4.8% after Bonferroni‟s correction for the number of loci typed in each 
population, see Table 2). Interestingly, these rejections principally affect donor registry 
samples: apart from Belorussians from Vitebsk and Kalmyks-El-Mari tested exclusively at 
HLA-DRB1, HWE is rejected for French, French from Montpellier, Maori, Tongans, 
Sudanese, Quebecers, Swiss and Slovenians donor, all of them being represented by donor 
registries. Moreover, after Bonferroni‟s correction on the number of loci, significant 
rejections are only observed for donor registries: French (at the second field but not first field 
level of resolution), Sudanese (at first and second fields), Quebecers (at both fields, with 
second field only available for HLA-DRB1) and Swiss (at first and mixed first-second fields). 
These data were thus not included in the interpopulation analyses. Note that for the Swiss, the 
data for most regional recruitment centres (11 of 13 regional centres) were in HWE, although 
the whole national registry was not (Buhler et al., 2012), as discussed below. 
 
     In contrast with HWE tests, for a high number of samples tested for HLA-B, -C and -
DRB1 (much less for HLA-A and -DPB1, and none for HLA-DQA1 and -DQB1), the 
frequency distributions do not match neutrality expectations, showing an excess of 
heterozygotes both in well-defined population and donor registry samples (Table 2). For this 
analysis, some discrepancies are observed between the results obtained at the first and second 
field levels of resolution, but not systematically in the same way (i.e. rejected at first field and 
not at second field or the reverse, data not shown).  
 
     Correlation coefficients (r) between genetic and geographic distances and their 
significance are given in Table 3. On the left part of the table, the coefficients shown were 
computed on data taken at the first field level of resolution, first for all samples and then for 
all samples minus Amerindians, Taiwanese and Oceanians to clarify the relationships among 
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the other populations. All coefficients are highly significant (P <0.001). However, at all loci 
except DQB1, r is much greater when Amerindian, Taiwanese and Oceanian populations are 
removed from the analysis. On the right part of the table, the coefficients were computed on 
data taken at the second field level of resolution, first for all populations from Europe and 
West Asia taken together, then for Europeans and West Asians taken separately (the analyses 
at second field level of resolution were limited to geographic regions for which new 16IHIW 
data were available). Most coefficients are significant (P < 0.001 or P < 0.01) except for 
Europeans at loci HLA-A and HLA-DPB1, West Asians at locus HLA-C, and Europeans plus 
West Asians at locus HLA-DQB1.  
 
 
     The MDS analyses (for the different data sets described above) are given in Supporting 
Information S1–S19 and S20–S29, except (to show an example) the plots for HLA-A that are 
also presented in Fig. 2 for the total data set and in Fig. 3 for the total data set minus 
Amerindians, Taiwanese and Oceanians (first field in both cases). Good Stress values, around 
0.1, were obtained for both analyses. Amerindian, Taiwanese and Oceanian populations are 
widely scattered on the plot shown in Fig. 2, which suggests a high level of differentiation 
(high FST), probably due to rapid genetic drift. By contrast, Fig. 3 reveals a very close 
relationship between genetic and geographic distances when the latter populations are 
removed, in agreement with the high and highly significant correlation coefficient found (r = 
0.539). On the whole, similar patterns are observed for the HLA-B and -DRB1 loci. On the 
other hand, the results found for HLA-DQA1 and HLA-DQB1 indicate a greater deviation 
between genetic and geographic distances (r = 0.418 and 0.390, respectively, for the data set 
excluding Amerindians, Taiwanese and Oceanians), a discrepancy which is also visible on 
the MDS. The results found for HLA-C are intermediate (r = 0.445). 
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     Considering the new populations tested for HLADRB1, which are the most numerous (55), 
the main observations are the following: the inclusion of more new European samples to the 
analyses allows confirming previous results indicating that European populations are 
genetically differentiated along a North–West/Central/South-East axis (Nunes et al., 2010; 
Buhler et al., 2012). Indeed, the Saami and Finns are plotted at one end of the MDS 
(Supporting Information S18) and are rather close to North-East Asians (among which the 
new Nenet, Buriat, Tuvinian and Bashkir populations tested in this study); the Greeks, 
Kosovo Albanians and Italians are plotted at the other end of the MDS and are closer to West 
Asians (among which the new Iraqi Kurdistan and Syrian populations); and the other 
Europeans (among which the new populations from the Russian area) are plotted in between. 
Similar results are found for HLA-A and -B, showing, for example, that Cypriots make a 
genetic link between South-EastEuropeans and West Asians. The MDS for HLA-DRB1 also 
shows that, while the Nenets, Buriats, Tuvinians and Bashkirs cluster with other Altaic-
speaking populations from north-east Asia (as mentioned earlier), the Udmurts and the Tatars 
are much more distant. Among the new populations from Afghanistan, the Pashtuns and to a 
lesser extent the Hazara are genetically closer to the Indians than the Tajiks, Uzbeks and 
Turkmens. Besides these main trends, the MDS plots show some overlap between European, 
West Asian, North African and, to a lesser extent, North-East Asian populations, while the 
populations from the other geographic areas (sub-Saharan Africa and South-East Asia) are 
more discriminated, in agreement with their geographic location. 
 
     As said above, Oceanian and Taiwanese (plus Amerindian) populations are widely 
scattered on the MDS plots (first series with all data). This is the reason why additional MDS 
analyses including the new populations from the Pacific together with other Oceanian and 
Austronesian-speaking populations from South-East Asia have been performed (Supporting 
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Information S4, S7, S10, S13, S16 and S19). A remarkable result is that for the 3 loci HLA-A, 
-B and -DRB1 (because among the 16IHIW data only one Pacific population was tested for 
HLA-C, -DQA1 and -DQB1 and none for HLA-DPB1), the new Pacific populations tested 
(i.e. Cook Islanders, Maori, Maori-Polynesians, Niueans, Samoans and Tongas) are 
genetically close to each other and to Austronesian-speaking populations from South-East 
Asia and Taiwan. 
      
The analyses performed with data considered at the second field level of resolution are given 
in Supporting Information S20–29. 
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Table 2: Summary statistics at each HLA locus (first field level of resolution, except HLA-DPB1 at second field) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
wd; well-defined populations; dr, donor registry samples.aSamples rejecting HWE are not considered. 
 
 
 
 
 
 
Locus Collection Number of 
populations 
tested 
Number of 
individuals 
tested 
Mean sample 
size (± s.d) 
Mean 
Heterozygositya 
(± s.d) 
HWE rejection 
(%) at 5% level 
HWE rejection (5%) 
after Bonferroni's 
correction 
Neutrality 
rejection (%) at 
5% level 
A Total set 32 46 797 1462(±2813 ) 0.838(±0.049 ) 3 (9.4) 1 3 (10) 
 wd 10 1768 177(±90) 0.842(± 0.052) 0 0 2 (25) 
 dr 22 45029 2047(±3246 ) 0.837(±0.049) 3 (13.6) 1 1 (4.5) 
B Total set 32 44375 1387(2618±  ) 0.907(±0.031 ) 6 (18.8) 4 21 (67.7) 
 wd 10 1761 176(± 90) 0.913(±0.022 ) 0 0 6 (75) 
 dr 22 42614 1937(±3017) 0.904(±0.034 ) 6 (27.3) 4 15 (65.2) 
C Total set 16 13962 873(±1220 ) 0.858(±0.022 ) 3 (18.8) 1 10 (62.5) 
 wd 7 911 130(±56 ) 0.865(±0.015 ) 0 0 3 (60) 
 dr 9 13051 1450(±1390) 0.0852(±0.027 ) 3 (33.3) 1 7 (77.8) 
DPB1 Total set 8 2041 255(±341) 0.838(±0.047 ) 0 0 1 (12.5) 
 wd 6 726 121(±60) 0.851(±0.042 ) 0 0 1 (16.7) 
 dr 2 1315 658(± 605) 0.801(±0.051 ) 0 0 0 
DQA1 Total set 5 1306 261(±231) 0.701(±0.024 ) 0 0 0 
 wd 1 146 - - 0 0 0 
 dr 4 1160 290(±257 ) 0.703(±0.027 ) 0 0 0 
DQB1 Total set 18 8745 486(±552) 0.721(±0.046 ) 1 (5.6) 1 0 
 wd 8 1502 188(±98) 0.703(±0.055 ) 0 0 0 
 dr 10 7243 724(±652) 0.735(±0.035 ) 1 (9.1) 1 0 
DRB1 Total set 55 67623 1230(±3553) 0.874(±0.018 ) 3 (5.5) 1 29 (52.7) 
 wd 32 4348 136(±65) 0.875(±0.018 ) 2 (6.5) 0 16 (51.6) 
 dr 23 63275 2751(±5180) 0.872(±0.018 ) 1 (4.2) 1 13 (54.2) 
All loci Total set  166   16 (9.6) 8 (4.8) 64 (38) 
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Table 3: Correlation analyses between genetic and geographic distances 
 
 
k, number of populations; r, Mantel correlation coefficient; EUR, Europeans; WASI, West Asians; AME, Amerindians; OCE, Oceanians (see text). aBased on 9999 
permutations.
 First field resolution     Second field resolution    
          
Locus Collection k r P-valuea  Collection k r P-valuea 
          
A All samples 116 0.288 0.0001  EUR & WASI 28 0.436 0.0001 
 All samples minus AME, Taiwanese and OCE 76 0.539 0.0001  EUR 17 0.124 0.2148 
      WASI 11 0.163 0.0292 
B All samples 113 0.340 0.0001  EUR & WASI 30 0.424 0.0001 
 All samples minus AME, Taiwanese and OCE 75 0.540 0.0001  EUR 15 0.549 0.0001 
      WASI 15 0.321 0.0002 
C All samples 75 0.284 0.0001  EUR & WASI 23 0.327 0.0001 
 All samples minus AME, Taiwanese and OCE 50 0.445 0.0001  EUR 14 0.441 0.0006 
      WASI 9 0.211 0.0578 
DPB1      All samples 56 0.395 0.0001 
      All samples minus AME, Taiwanese and OCE 39 0.551 0.0001 
      EUR & WASI 24 0.287 0.0007 
      EUR 17 0.122 0.1240 
      WASI 7 0.405 0.0190 
          
DQA1 All samples 57 0.364 0.0001      
 All samples minus AME, Taiwanese and OCE 35 0.418 0.0001      
DQB1 All samples 97 0.435 0.0001  EUR & WASI 35 0.154 0.0705 
 All samples minus AME, Taiwanese and OCE 72 0.390 0.0001  EUR 34 0.203 0.0131 
      WASI 1 - - 
DRB1 All samples 153 0.422 0.0001  EUR & WASI 40 0.331 0.0001 
 All samples minus AME, Taiwanese and OCE 104 0.504 0.0001  EUR 28 0.374 0.0001 
      WASI 12 0.421 0.0001 
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Figure 2: Two-dimensional multidimensional scaling analysis for the total data set at HLA-A (first field of 
resolution). The three-dimensional plot and legend with population numbers are provided in Supporting 
Information S2. 
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Figure 3: Two-dimensional multidimensional scaling analysis for the total data set minus Amerindians, 
Taiwanese and Oceanians at HLA-A (first field of resolution). The three-dimensional plot and legend with 
population numbers are provided in Supporting Information S3. 
 
 
Discussion and conclusion 
 
The new data submitted to the 16IHIW AHPD component considerably improve the 
population data set brought together during previous HLA workshops (Imanishi et al., 1992; 
Clayton et al., 1997; Mack et al., 2007; Nunes et al., 2010). This time, Europe is particularly 
well represented, including an important set of populations from the Russian area, a region 
which was almost completely unknown for HLA before. A significant improvement was also 
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the inclusion of several samples from West Asia. Finally, a novelty of the 16IHIW AHPD 
project was to gather a large set of donor registry data (mostly from European countries) in 
addition to well-defined population samples. 
 
     The first remarkable result of the analyses performed in this study is that almost all 
populations tested are in HWE, despite many rejections of selective neutrality. This means 
that, although evidence is shown of an excess of HLA heterozygotes compared with neutral 
expectations, probably due to their selective advantage against pathogens (Meyer & Thomson, 
2001; Prugnolle et al., 2005; Solberg et al., 2008; Buhler & Sanchez-Mazas, 2011; Sanchez-
Mazas et al., 2012a,b), this likely natural selection did not create deviations from HWE. In 
addition to the fact that the Hardy–Weinberg law is very robust (i.e. almost always verified), 
any significant deviation from HWE should then be considered seriously as an indicator of 
either inaccurate population sampling (and typing errors, but this should be considered as less 
and less likely with current typing methods) or strong deviation from equilibrium due to 
demographic or selective factors. Interestingly, HWE was rejected for some donor registry 
samples analysed in this study (French, Sudanese, Quebecers and Swiss), suggesting that 
such samples are too heterogeneous (in regard to the origin of the individuals tested) to be 
used for population comparisons. However, as recently found for the Swiss stem cell registry 
(Buhler et al., 2012), samples collected within regional recruitment centres may be at 
equilibrium, although the national registry is not. This may reflect genetic variation among 
regions within the corresponding country and indicate that regional instead of national data 
can sometimes be used for anthropological studies. The HLA data of bone marrow donor 
(BMD) registries ought to be analysed more thoroughly in this perspective. 
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     The significant improvement in the HLA-typed population data set resulting from the 
16IHIW AHPD project also allows preparing more detailed HLA genetic maps of human 
populations, which are very useful to investigate human migrations‟ history. Continental or 
regional maps are particularly relevant as the huge amount of existing data now make global 
maps difficult to read. East Asia has recently been described in detail for HLA genetic 
variation, and a challenging model of human migrations in this part of the world has been 
proposed (Di & Sanchez-Mazas, 2011). Africa still needs to be explored, as, unfortunately, 
very few HLA-typed population samples are available for such a large continent (see Fig. 1) 
whose history seems to be particularly complex (Excoffier et al., 1987; Poloni et al., 2009; 
Tishkoff et al., 2009). By contrast, Europe is now very well represented by HLA population 
data, and a clear genetic variation (yet with still unexplained discrepancies between loci, 
probably due to selection) is observed, mainly along a north to south-east geographic axis 
(Buhler et al., 2006, 2012). Although neighbouring populations such as North Africans and 
West Asians overlap to some extent to Europeans, possibly as a signature of past immune 
adaptations to pathogen-rich environments (Currat et al., 2010; Sanchez-Mazas et al., 
2012a,b), the observed pattern may easily be related to the demic diffusion of Neolithic 
farmers from Anatolia advocated by many scholars based on other genetic results 
(Ammerman & Cavalli-Sforza, 1984; Chikhi et al., 1998, 2002; Barbujani & Bertorelle, 2001; 
Barbujani, 2006; Balaresque et al., 2010). Finally, as several samples from the Pacific area 
(„Polynesians‟ taken in a broad sense) have been submitted to the present project (Cook 
Islanders, Maori, Maori-Polynesians, Niueans, Samoans and Tongas), our new results can 
also be interpreted in relation to population genetic relationships in Oceania. Being in HWE, 
these donor registry samples may be considered as representative of their corresponding local 
populations. However, the results show that they are much less differentiated among them 
and from South-East Asian populations than would be predicted from the large geographic 
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distances separating the different Pacific islands from where they originate. Of course, we 
cannot rule out some admixture effect as except for the Maori-Polynesian (well-defined 
population sampled around Wellington in New Zealand), the individuals are taken from 
donor registries, which recruit people from all over Polynesia. On the other hand, the position 
of the Polynesian samples on the MDS close to Austronesian-speaking South-East Asian and 
Taiwanese is congruent with the widely supported „out of- Taiwan‟ hypothesis of the 
peopling history of Oceania (Diamond & Bellwood, 2003; Bellwood & Dizon, 2008). 
Additional analyses on the new HLA data submitted to the AHPD 16IHIW component are 
currently in progress. 
 
     Last but not least, we would like to emphasize that the 16IHIW AHPD project also 
promoted the development of very useful computer tools now combined into a pipeline for 
automatic population genetics‟ analyses. Thanks to this workshop and the impulse of the 
HLA-NET project, the GENE[RATE] pipeline will soon be available to the scientific 
community to automatically perform basic HLA analyses starting from laboratory typing 
outputs to ending with population genetic comparisons. We hope that this fundamental 
contribution will catalyse HLA population genetic studies, most useful for immunogenetic, 
epidemiological andanthropological studies. 
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